CA2711703A1 - Sensation modifying topical composition foam - Google Patents
Sensation modifying topical composition foam Download PDFInfo
- Publication number
- CA2711703A1 CA2711703A1 CA2711703A CA2711703A CA2711703A1 CA 2711703 A1 CA2711703 A1 CA 2711703A1 CA 2711703 A CA2711703 A CA 2711703A CA 2711703 A CA2711703 A CA 2711703A CA 2711703 A1 CA2711703 A1 CA 2711703A1
- Authority
- CA
- Canada
- Prior art keywords
- agent
- composition
- sensation
- weight
- foam
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 594
- 230000035807 sensation Effects 0.000 title claims abstract description 336
- 239000006260 foam Substances 0.000 title claims abstract description 241
- 230000000051 modifying effect Effects 0.000 title claims abstract description 98
- 230000000699 topical effect Effects 0.000 title claims description 31
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 346
- 239000003380 propellant Substances 0.000 claims abstract description 104
- 238000010792 warming Methods 0.000 claims abstract description 81
- 239000002826 coolant Substances 0.000 claims abstract description 39
- 239000000443 aerosol Substances 0.000 claims abstract description 38
- 230000002459 sustained effect Effects 0.000 claims abstract description 33
- 230000002040 relaxant effect Effects 0.000 claims abstract description 29
- 230000004936 stimulating effect Effects 0.000 claims abstract description 25
- 239000004094 surface-active agent Substances 0.000 claims description 155
- 239000002904 solvent Substances 0.000 claims description 79
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 78
- 238000001816 cooling Methods 0.000 claims description 74
- -1 N-substituted-p-menthane-3-carboxamide Chemical class 0.000 claims description 73
- 230000000694 effects Effects 0.000 claims description 72
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 claims description 67
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 claims description 65
- 239000013543 active substance Substances 0.000 claims description 63
- 239000003974 emollient agent Substances 0.000 claims description 55
- 239000003921 oil Substances 0.000 claims description 51
- 235000019198 oils Nutrition 0.000 claims description 50
- 229920000642 polymer Polymers 0.000 claims description 45
- 239000000839 emulsion Substances 0.000 claims description 44
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 44
- 229940060184 oil ingredients Drugs 0.000 claims description 41
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 38
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 38
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 34
- 229940041616 menthol Drugs 0.000 claims description 34
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 33
- 235000017663 capsaicin Nutrition 0.000 claims description 32
- 229960002504 capsaicin Drugs 0.000 claims description 32
- 239000000126 substance Substances 0.000 claims description 32
- 239000007957 coemulsifier Substances 0.000 claims description 28
- 229960004063 propylene glycol Drugs 0.000 claims description 28
- 239000003381 stabilizer Substances 0.000 claims description 28
- ILCOCZBHMDEIAI-UHFFFAOYSA-N 2-(2-octadecoxyethoxy)ethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCOCCO ILCOCZBHMDEIAI-UHFFFAOYSA-N 0.000 claims description 27
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 claims description 26
- 239000003961 penetration enhancing agent Substances 0.000 claims description 26
- 229940098760 steareth-2 Drugs 0.000 claims description 25
- 230000002209 hydrophobic effect Effects 0.000 claims description 24
- 239000001525 mentha piperita l. herb oil Substances 0.000 claims description 23
- 235000019477 peppermint oil Nutrition 0.000 claims description 23
- 239000002537 cosmetic Substances 0.000 claims description 22
- ICIDSZQHPUZUHC-UHFFFAOYSA-N 2-octadecoxyethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCO ICIDSZQHPUZUHC-UHFFFAOYSA-N 0.000 claims description 21
- 239000000284 extract Substances 0.000 claims description 21
- 239000002671 adjuvant Substances 0.000 claims description 20
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 20
- 229920001285 xanthan gum Polymers 0.000 claims description 20
- 239000002798 polar solvent Substances 0.000 claims description 19
- 150000002191 fatty alcohols Chemical class 0.000 claims description 18
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 claims description 18
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 18
- 229920000053 polysorbate 80 Polymers 0.000 claims description 18
- 229940100458 steareth-21 Drugs 0.000 claims description 18
- 235000010493 xanthan gum Nutrition 0.000 claims description 18
- 239000000230 xanthan gum Substances 0.000 claims description 18
- 229940082509 xanthan gum Drugs 0.000 claims description 18
- 239000000194 fatty acid Substances 0.000 claims description 17
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical group CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 17
- 230000003389 potentiating effect Effects 0.000 claims description 17
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 16
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 16
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 16
- 229940088594 vitamin Drugs 0.000 claims description 16
- 229930003231 vitamin Natural products 0.000 claims description 16
- 235000013343 vitamin Nutrition 0.000 claims description 16
- 239000011782 vitamin Substances 0.000 claims description 16
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 15
- 229930195729 fatty acid Natural products 0.000 claims description 15
- 229940075507 glyceryl monostearate Drugs 0.000 claims description 15
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims description 15
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 15
- 229940068968 polysorbate 80 Drugs 0.000 claims description 15
- 241000208690 Hamamelis Species 0.000 claims description 14
- 239000008365 aqueous carrier Substances 0.000 claims description 14
- 239000011280 coal tar Substances 0.000 claims description 14
- 229920002545 silicone oil Polymers 0.000 claims description 14
- 229920002701 Polyoxyl 40 Stearate Polymers 0.000 claims description 13
- 235000021302 avocado oil Nutrition 0.000 claims description 13
- 239000008163 avocado oil Substances 0.000 claims description 13
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 12
- 229940057004 coal tar extract Drugs 0.000 claims description 12
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 claims description 11
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 11
- 239000004166 Lanolin Substances 0.000 claims description 11
- ZBJCYZPANVLBRK-UHFFFAOYSA-N Menthone 1,2-glyceryl ketal Chemical compound CC(C)C1CCC(C)CC11OC(CO)CO1 ZBJCYZPANVLBRK-UHFFFAOYSA-N 0.000 claims description 11
- 239000004909 Moisturizer Substances 0.000 claims description 11
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 11
- 235000019388 lanolin Nutrition 0.000 claims description 11
- 229940039717 lanolin Drugs 0.000 claims description 11
- 230000001333 moisturizer Effects 0.000 claims description 11
- 239000008177 pharmaceutical agent Substances 0.000 claims description 11
- 239000003755 preservative agent Substances 0.000 claims description 11
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 11
- 241000723346 Cinnamomum camphora Species 0.000 claims description 10
- 229920002125 Sokalan® Polymers 0.000 claims description 10
- 229920002472 Starch Polymers 0.000 claims description 10
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims description 10
- 239000002246 antineoplastic agent Substances 0.000 claims description 10
- 229930008380 camphor Natural products 0.000 claims description 10
- 239000002738 chelating agent Substances 0.000 claims description 10
- 238000006243 chemical reaction Methods 0.000 claims description 10
- 150000004665 fatty acids Chemical class 0.000 claims description 10
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 10
- 230000002335 preservative effect Effects 0.000 claims description 10
- 239000008107 starch Substances 0.000 claims description 10
- 235000019698 starch Nutrition 0.000 claims description 10
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 9
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 9
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 9
- 235000006679 Mentha X verticillata Nutrition 0.000 claims description 9
- 235000002899 Mentha suaveolens Nutrition 0.000 claims description 9
- 235000001636 Mentha x rotundifolia Nutrition 0.000 claims description 9
- 230000032683 aging Effects 0.000 claims description 9
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 9
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 9
- 239000000739 antihistaminic agent Substances 0.000 claims description 9
- 239000003963 antioxidant agent Substances 0.000 claims description 9
- 235000006708 antioxidants Nutrition 0.000 claims description 9
- 230000003139 buffering effect Effects 0.000 claims description 9
- 229960000846 camphor Drugs 0.000 claims description 9
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 9
- 125000002091 cationic group Chemical group 0.000 claims description 9
- 239000010649 ginger oil Substances 0.000 claims description 9
- 239000003906 humectant Substances 0.000 claims description 9
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 9
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 9
- 229960001047 methyl salicylate Drugs 0.000 claims description 9
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 8
- LVYLCBNXHHHPSB-UHFFFAOYSA-N 2-hydroxyethyl salicylate Chemical compound OCCOC(=O)C1=CC=CC=C1O LVYLCBNXHHHPSB-UHFFFAOYSA-N 0.000 claims description 8
- 235000002961 Aloe barbadensis Nutrition 0.000 claims description 8
- 244000144927 Aloe barbadensis Species 0.000 claims description 8
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims description 8
- 235000004357 Mentha x piperita Nutrition 0.000 claims description 8
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 claims description 8
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims description 8
- UJNOLBSYLSYIBM-WISYIIOYSA-N [(1r,2s,5r)-5-methyl-2-propan-2-ylcyclohexyl] (2r)-2-hydroxypropanoate Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OC(=O)[C@@H](C)O UJNOLBSYLSYIBM-WISYIIOYSA-N 0.000 claims description 8
- 235000011399 aloe vera Nutrition 0.000 claims description 8
- KVYGGMBOZFWZBQ-UHFFFAOYSA-N benzyl nicotinate Chemical compound C=1C=CN=CC=1C(=O)OCC1=CC=CC=C1 KVYGGMBOZFWZBQ-UHFFFAOYSA-N 0.000 claims description 8
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims description 8
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 8
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 claims description 8
- 239000003205 fragrance Substances 0.000 claims description 8
- 229940088597 hormone Drugs 0.000 claims description 8
- 239000005556 hormone Substances 0.000 claims description 8
- 229920000136 polysorbate Polymers 0.000 claims description 8
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims description 8
- 229940005550 sodium alginate Drugs 0.000 claims description 8
- 235000010413 sodium alginate Nutrition 0.000 claims description 8
- 239000000661 sodium alginate Substances 0.000 claims description 8
- 239000011787 zinc oxide Substances 0.000 claims description 8
- 235000014692 zinc oxide Nutrition 0.000 claims description 8
- 206010020649 Hyperkeratosis Diseases 0.000 claims description 7
- 208000000260 Warts Diseases 0.000 claims description 7
- 235000006886 Zingiber officinale Nutrition 0.000 claims description 7
- 229940007061 capsicum extract Drugs 0.000 claims description 7
- 239000001943 capsicum frutescens fruit extract Substances 0.000 claims description 7
- 229940082500 cetostearyl alcohol Drugs 0.000 claims description 7
- 239000006184 cosolvent Substances 0.000 claims description 7
- 235000008397 ginger Nutrition 0.000 claims description 7
- 229950008882 polysorbate Drugs 0.000 claims description 7
- 201000010153 skin papilloma Diseases 0.000 claims description 7
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 claims description 7
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims description 6
- 241000208680 Hamamelis mollis Species 0.000 claims description 6
- 235000005865 Symphytum officinale Nutrition 0.000 claims description 6
- 240000002299 Symphytum officinale Species 0.000 claims description 6
- 229910052782 aluminium Inorganic materials 0.000 claims description 6
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 6
- 230000000202 analgesic effect Effects 0.000 claims description 6
- 230000001387 anti-histamine Effects 0.000 claims description 6
- 235000010980 cellulose Nutrition 0.000 claims description 6
- 229920002678 cellulose Polymers 0.000 claims description 6
- 239000001913 cellulose Substances 0.000 claims description 6
- 239000003086 colorant Substances 0.000 claims description 6
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 claims description 6
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 claims description 6
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 claims description 6
- 239000000499 gel Substances 0.000 claims description 6
- 239000012676 herbal extract Substances 0.000 claims description 6
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 6
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 6
- 239000000077 insect repellent Substances 0.000 claims description 6
- 239000002917 insecticide Substances 0.000 claims description 6
- 239000011707 mineral Substances 0.000 claims description 6
- 235000010755 mineral Nutrition 0.000 claims description 6
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 6
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 6
- 239000007800 oxidant agent Substances 0.000 claims description 6
- 230000004526 pharmaceutical effect Effects 0.000 claims description 6
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 6
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 6
- 239000001993 wax Substances 0.000 claims description 6
- 229940118846 witch hazel Drugs 0.000 claims description 6
- WEEGYLXZBRQIMU-UHFFFAOYSA-N 1,8-cineole Natural products C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 claims description 5
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 5
- CKNYEUXAXWTAPK-UHFFFAOYSA-N 4-octoxy-4-oxobutanoic acid Chemical compound CCCCCCCCOC(=O)CCC(O)=O CKNYEUXAXWTAPK-UHFFFAOYSA-N 0.000 claims description 5
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims description 5
- WEEGYLXZBRQIMU-WAAGHKOSSA-N Eucalyptol Chemical compound C1C[C@H]2CC[C@]1(C)OC2(C)C WEEGYLXZBRQIMU-WAAGHKOSSA-N 0.000 claims description 5
- 108010010803 Gelatin Proteins 0.000 claims description 5
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 5
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 5
- 108090000189 Neuropeptides Proteins 0.000 claims description 5
- 239000004264 Petrolatum Substances 0.000 claims description 5
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 5
- 229930003316 Vitamin D Natural products 0.000 claims description 5
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 5
- 230000000895 acaricidal effect Effects 0.000 claims description 5
- 239000000642 acaricide Substances 0.000 claims description 5
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 5
- 150000004347 all-trans-retinol derivatives Chemical class 0.000 claims description 5
- 229960000458 allantoin Drugs 0.000 claims description 5
- 239000013566 allergen Substances 0.000 claims description 5
- 239000002269 analeptic agent Substances 0.000 claims description 5
- 239000000058 anti acne agent Substances 0.000 claims description 5
- 239000003242 anti bacterial agent Substances 0.000 claims description 5
- 230000003712 anti-aging effect Effects 0.000 claims description 5
- 230000000844 anti-bacterial effect Effects 0.000 claims description 5
- 230000003501 anti-edematous effect Effects 0.000 claims description 5
- 230000002402 anti-lipaemic effect Effects 0.000 claims description 5
- 230000001857 anti-mycotic effect Effects 0.000 claims description 5
- 230000001166 anti-perspirative effect Effects 0.000 claims description 5
- 230000001028 anti-proliverative effect Effects 0.000 claims description 5
- 230000001139 anti-pruritic effect Effects 0.000 claims description 5
- 230000002682 anti-psoriatic effect Effects 0.000 claims description 5
- 230000002421 anti-septic effect Effects 0.000 claims description 5
- 230000002579 anti-swelling effect Effects 0.000 claims description 5
- 230000001153 anti-wrinkle effect Effects 0.000 claims description 5
- 230000000656 anti-yeast Effects 0.000 claims description 5
- 229940124340 antiacne agent Drugs 0.000 claims description 5
- 239000000043 antiallergic agent Substances 0.000 claims description 5
- 239000000935 antidepressant agent Substances 0.000 claims description 5
- 229940005513 antidepressants Drugs 0.000 claims description 5
- 239000004599 antimicrobial Substances 0.000 claims description 5
- 239000002543 antimycotic Substances 0.000 claims description 5
- 230000003078 antioxidant effect Effects 0.000 claims description 5
- 239000003213 antiperspirant Substances 0.000 claims description 5
- 239000003908 antipruritic agent Substances 0.000 claims description 5
- 239000003443 antiviral agent Substances 0.000 claims description 5
- 239000006172 buffering agent Substances 0.000 claims description 5
- 239000002327 cardiovascular agent Substances 0.000 claims description 5
- 229940125692 cardiovascular agent Drugs 0.000 claims description 5
- 239000003246 corticosteroid Substances 0.000 claims description 5
- 229940127089 cytotoxic agent Drugs 0.000 claims description 5
- 239000002781 deodorant agent Substances 0.000 claims description 5
- 239000007854 depigmenting agent Substances 0.000 claims description 5
- 239000000645 desinfectant Substances 0.000 claims description 5
- 239000000417 fungicide Substances 0.000 claims description 5
- 239000008273 gelatin Substances 0.000 claims description 5
- 229920000159 gelatin Polymers 0.000 claims description 5
- 235000019322 gelatine Nutrition 0.000 claims description 5
- 235000011852 gelatine desserts Nutrition 0.000 claims description 5
- 239000003630 growth substance Substances 0.000 claims description 5
- 230000003779 hair growth Effects 0.000 claims description 5
- 239000012051 hydrophobic carrier Substances 0.000 claims description 5
- 150000001261 hydroxy acids Chemical class 0.000 claims description 5
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 5
- 229940071826 hydroxyethyl cellulose Drugs 0.000 claims description 5
- 230000004957 immunoregulator effect Effects 0.000 claims description 5
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 5
- 239000003018 immunosuppressive agent Substances 0.000 claims description 5
- 239000003410 keratolytic agent Substances 0.000 claims description 5
- 150000003951 lactams Chemical class 0.000 claims description 5
- 239000003589 local anesthetic agent Substances 0.000 claims description 5
- 229910052751 metal Inorganic materials 0.000 claims description 5
- 239000002184 metal Substances 0.000 claims description 5
- 229910044991 metal oxide Inorganic materials 0.000 claims description 5
- 150000004706 metal oxides Chemical class 0.000 claims description 5
- 229920000609 methyl cellulose Polymers 0.000 claims description 5
- 235000010981 methylcellulose Nutrition 0.000 claims description 5
- 239000001923 methylcellulose Substances 0.000 claims description 5
- 239000003002 pH adjusting agent Substances 0.000 claims description 5
- 239000002304 perfume Substances 0.000 claims description 5
- 229940066842 petrolatum Drugs 0.000 claims description 5
- 235000019271 petrolatum Nutrition 0.000 claims description 5
- 238000002428 photodynamic therapy Methods 0.000 claims description 5
- 229920000058 polyacrylate Polymers 0.000 claims description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 5
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 5
- 150000003180 prostaglandins Chemical class 0.000 claims description 5
- 239000005526 vasoconstrictor agent Substances 0.000 claims description 5
- 229940124549 vasodilator Drugs 0.000 claims description 5
- 239000003071 vasodilator agent Substances 0.000 claims description 5
- 235000019155 vitamin A Nutrition 0.000 claims description 5
- 239000011719 vitamin A Substances 0.000 claims description 5
- 235000019166 vitamin D Nutrition 0.000 claims description 5
- 239000011710 vitamin D Substances 0.000 claims description 5
- 229940045997 vitamin a Drugs 0.000 claims description 5
- 229940046008 vitamin d Drugs 0.000 claims description 5
- 239000003357 wound healing promoting agent Substances 0.000 claims description 5
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 claims description 4
- ZYTMANIQRDEHIO-AEJSXWLSSA-N (1s,2r,5s)-5-methyl-2-prop-1-en-2-ylcyclohexan-1-ol Chemical compound C[C@H]1CC[C@H](C(C)=C)[C@@H](O)C1 ZYTMANIQRDEHIO-AEJSXWLSSA-N 0.000 claims description 4
- 239000001500 (2R)-6-methyl-2-[(1R)-4-methyl-1-cyclohex-3-enyl]hept-5-en-2-ol Substances 0.000 claims description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 4
- AJBZENLMTKDAEK-UHFFFAOYSA-N 3a,5a,5b,8,8,11a-hexamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-4,9-diol Chemical compound CC12CCC(O)C(C)(C)C1CCC(C1(C)CC3O)(C)C2CCC1C1C3(C)CCC1C(=C)C AJBZENLMTKDAEK-UHFFFAOYSA-N 0.000 claims description 4
- 240000000073 Achillea millefolium Species 0.000 claims description 4
- 235000007754 Achillea millefolium Nutrition 0.000 claims description 4
- 229920001817 Agar Polymers 0.000 claims description 4
- 240000006054 Agastache cana Species 0.000 claims description 4
- 235000019489 Almond oil Nutrition 0.000 claims description 4
- 241001474374 Blennius Species 0.000 claims description 4
- 235000003880 Calendula Nutrition 0.000 claims description 4
- 240000001432 Calendula officinalis Species 0.000 claims description 4
- 102000011632 Caseins Human genes 0.000 claims description 4
- 108010076119 Caseins Proteins 0.000 claims description 4
- 240000003538 Chamaemelum nobile Species 0.000 claims description 4
- 235000007866 Chamaemelum nobile Nutrition 0.000 claims description 4
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 claims description 4
- 229920001661 Chitosan Polymers 0.000 claims description 4
- 235000001258 Cinchona calisaya Nutrition 0.000 claims description 4
- 239000011703 D-panthenol Substances 0.000 claims description 4
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 claims description 4
- 235000004866 D-panthenol Nutrition 0.000 claims description 4
- 244000004281 Eucalyptus maculata Species 0.000 claims description 4
- 239000005770 Eugenol Substances 0.000 claims description 4
- 229920002907 Guar gum Polymers 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 claims description 4
- 235000010650 Hyssopus officinalis Nutrition 0.000 claims description 4
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims description 4
- 241000207923 Lamiaceae Species 0.000 claims description 4
- 229920000161 Locust bean gum Polymers 0.000 claims description 4
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 4
- 235000007232 Matricaria chamomilla Nutrition 0.000 claims description 4
- 244000246386 Mentha pulegium Species 0.000 claims description 4
- 235000016257 Mentha pulegium Nutrition 0.000 claims description 4
- 241001479543 Mentha x piperita Species 0.000 claims description 4
- KNVPMEZIMFVWMD-UHFFFAOYSA-N Menthyl pyrrolidone carboxylate Chemical compound CC(C)C1CCC(C)CC1OC(=O)N1C(=O)CCC1 KNVPMEZIMFVWMD-UHFFFAOYSA-N 0.000 claims description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 4
- 239000004368 Modified starch Substances 0.000 claims description 4
- 229920000881 Modified starch Polymers 0.000 claims description 4
- 108010058846 Ovalbumin Proteins 0.000 claims description 4
- 229920002845 Poly(methacrylic acid) Polymers 0.000 claims description 4
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 4
- 229920001328 Polyvinylidene chloride Polymers 0.000 claims description 4
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 claims description 4
- 244000178231 Rosmarinus officinalis Species 0.000 claims description 4
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 4
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims description 4
- 229920001615 Tragacanth Polymers 0.000 claims description 4
- 244000273928 Zingiber officinale Species 0.000 claims description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 4
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 claims description 4
- 229960004373 acetylcholine Drugs 0.000 claims description 4
- 239000008272 agar Substances 0.000 claims description 4
- 235000010443 alginic acid Nutrition 0.000 claims description 4
- 229920000615 alginic acid Polymers 0.000 claims description 4
- 239000000783 alginic acid Substances 0.000 claims description 4
- 229960001126 alginic acid Drugs 0.000 claims description 4
- 150000004781 alginic acids Chemical class 0.000 claims description 4
- 239000008168 almond oil Substances 0.000 claims description 4
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 claims description 4
- 150000001412 amines Chemical group 0.000 claims description 4
- 239000002216 antistatic agent Substances 0.000 claims description 4
- 239000003125 aqueous solvent Substances 0.000 claims description 4
- 239000000305 astragalus gummifer gum Substances 0.000 claims description 4
- 229950004580 benzyl nicotinate Drugs 0.000 claims description 4
- 239000002981 blocking agent Substances 0.000 claims description 4
- 239000004067 bulking agent Substances 0.000 claims description 4
- 229960001948 caffeine Drugs 0.000 claims description 4
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims description 4
- 229940105847 calamine Drugs 0.000 claims description 4
- 229920003090 carboxymethyl hydroxyethyl cellulose Polymers 0.000 claims description 4
- 235000010418 carrageenan Nutrition 0.000 claims description 4
- 229920001525 carrageenan Polymers 0.000 claims description 4
- 229940045110 chitosan Drugs 0.000 claims description 4
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 claims description 4
- 229960005233 cineole Drugs 0.000 claims description 4
- 229960003949 dexpanthenol Drugs 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- KNFXXAGQEUUZAZ-UHFFFAOYSA-N ethyl ethaneperoxoate Chemical compound CCOOC(C)=O KNFXXAGQEUUZAZ-UHFFFAOYSA-N 0.000 claims description 4
- 229960002217 eugenol Drugs 0.000 claims description 4
- 229960002389 glycol salicylate Drugs 0.000 claims description 4
- 235000010417 guar gum Nutrition 0.000 claims description 4
- 239000000665 guar gum Substances 0.000 claims description 4
- 229960002154 guar gum Drugs 0.000 claims description 4
- 229910052864 hemimorphite Inorganic materials 0.000 claims description 4
- 229960001340 histamine Drugs 0.000 claims description 4
- 235000001050 hortel pimenta Nutrition 0.000 claims description 4
- 229920002674 hyaluronan Polymers 0.000 claims description 4
- 229960003160 hyaluronic acid Drugs 0.000 claims description 4
- 229920013818 hydroxypropyl guar gum Polymers 0.000 claims description 4
- 235000015110 jellies Nutrition 0.000 claims description 4
- 239000008274 jelly Substances 0.000 claims description 4
- 235000010420 locust bean gum Nutrition 0.000 claims description 4
- 239000000711 locust bean gum Substances 0.000 claims description 4
- 239000001771 mentha piperita Substances 0.000 claims description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 4
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 4
- 235000019426 modified starch Nutrition 0.000 claims description 4
- 239000003158 myorelaxant agent Substances 0.000 claims description 4
- 239000002858 neurotransmitter agent Substances 0.000 claims description 4
- 229920002689 polyvinyl acetate Polymers 0.000 claims description 4
- 239000011118 polyvinyl acetate Substances 0.000 claims description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 4
- 239000004800 polyvinyl chloride Substances 0.000 claims description 4
- 229920000915 polyvinyl chloride Polymers 0.000 claims description 4
- 239000005033 polyvinylidene chloride Substances 0.000 claims description 4
- 239000001651 pyrus cydonia seed extract Substances 0.000 claims description 4
- 229960000948 quinine Drugs 0.000 claims description 4
- ZMQAAUBTXCXRIC-UHFFFAOYSA-N safrole Chemical compound C=CCC1=CC=C2OCOC2=C1 ZMQAAUBTXCXRIC-UHFFFAOYSA-N 0.000 claims description 4
- 229960001860 salicylate Drugs 0.000 claims description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 claims description 4
- 229910052711 selenium Inorganic materials 0.000 claims description 4
- 239000011669 selenium Substances 0.000 claims description 4
- 235000011649 selenium Nutrition 0.000 claims description 4
- 229940076279 serotonin Drugs 0.000 claims description 4
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 4
- 229940080237 sodium caseinate Drugs 0.000 claims description 4
- 230000000475 sunscreen effect Effects 0.000 claims description 4
- 239000000516 sunscreening agent Substances 0.000 claims description 4
- CPYIZQLXMGRKSW-UHFFFAOYSA-N zinc;iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+3].[Fe+3].[Zn+2] CPYIZQLXMGRKSW-UHFFFAOYSA-N 0.000 claims description 4
- 235000010210 aluminium Nutrition 0.000 claims description 3
- 230000000845 anti-microbial effect Effects 0.000 claims description 3
- 230000003115 biocidal effect Effects 0.000 claims description 3
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 claims description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- 229960000890 hydrocortisone Drugs 0.000 claims description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 3
- 230000000149 penetrating effect Effects 0.000 claims description 3
- 150000004492 retinoid derivatives Chemical class 0.000 claims description 3
- 229960004889 salicylic acid Drugs 0.000 claims description 3
- MDVYIGJINBYKOM-UHFFFAOYSA-N 3-[[5-Methyl-2-(1-methylethyl)cyclohexyl]oxy]-1,2-propanediol Chemical compound CC(C)C1CCC(C)CC1OCC(O)CO MDVYIGJINBYKOM-UHFFFAOYSA-N 0.000 claims description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 2
- 208000001126 Keratosis Diseases 0.000 claims description 2
- 102000003797 Neuropeptides Human genes 0.000 claims description 2
- 230000003444 anaesthetic effect Effects 0.000 claims description 2
- 230000001430 anti-depressive effect Effects 0.000 claims description 2
- 239000007979 citrate buffer Substances 0.000 claims description 2
- 230000000855 fungicidal effect Effects 0.000 claims description 2
- 230000001861 immunosuppressant effect Effects 0.000 claims description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 2
- 229940099259 vaseline Drugs 0.000 claims description 2
- 244000303965 Cyamopsis psoralioides Species 0.000 claims 1
- 238000009472 formulation Methods 0.000 description 79
- 229920001223 polyethylene glycol Polymers 0.000 description 37
- 230000000087 stabilizing effect Effects 0.000 description 37
- 238000011282 treatment Methods 0.000 description 35
- 239000003995 emulsifying agent Substances 0.000 description 34
- 239000002202 Polyethylene glycol Substances 0.000 description 30
- 239000004615 ingredient Substances 0.000 description 30
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 29
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 28
- 239000007788 liquid Substances 0.000 description 25
- NNPPMTNAJDCUHE-UHFFFAOYSA-N isobutane Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 description 24
- 238000000034 method Methods 0.000 description 24
- 150000003077 polyols Chemical class 0.000 description 24
- 229920005862 polyol Polymers 0.000 description 23
- 235000013772 propylene glycol Nutrition 0.000 description 23
- 239000012071 phase Substances 0.000 description 22
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 21
- 239000002736 nonionic surfactant Substances 0.000 description 20
- 239000002480 mineral oil Substances 0.000 description 18
- 235000010446 mineral oil Nutrition 0.000 description 18
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 18
- 230000002829 reductive effect Effects 0.000 description 18
- 150000001298 alcohols Chemical class 0.000 description 17
- 239000001273 butane Substances 0.000 description 17
- 230000035597 cooling sensation Effects 0.000 description 17
- 239000007787 solid Substances 0.000 description 17
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 15
- 238000010438 heat treatment Methods 0.000 description 15
- 230000000670 limiting effect Effects 0.000 description 15
- 239000001294 propane Substances 0.000 description 14
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 13
- 230000001965 increasing effect Effects 0.000 description 13
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 12
- 235000011187 glycerol Nutrition 0.000 description 12
- 229960005150 glycerol Drugs 0.000 description 12
- 239000001282 iso-butane Substances 0.000 description 12
- 230000002035 prolonged effect Effects 0.000 description 12
- 239000003981 vehicle Substances 0.000 description 12
- 229930195733 hydrocarbon Natural products 0.000 description 11
- 150000002430 hydrocarbons Chemical class 0.000 description 11
- 230000035515 penetration Effects 0.000 description 11
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 10
- 208000002874 Acne Vulgaris Diseases 0.000 description 10
- 235000002566 Capsicum Nutrition 0.000 description 10
- 239000004215 Carbon black (E152) Substances 0.000 description 10
- 206010000496 acne Diseases 0.000 description 10
- 239000004480 active ingredient Substances 0.000 description 10
- 230000001668 ameliorated effect Effects 0.000 description 10
- 239000001390 capsicum minimum Substances 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 230000001976 improved effect Effects 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 10
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 9
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical class OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 9
- 240000008574 Capsicum frutescens Species 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- 238000010521 absorption reaction Methods 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 208000035475 disorder Diseases 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 239000001301 oxygen Substances 0.000 description 9
- 229910052760 oxygen Inorganic materials 0.000 description 9
- 150000005846 sugar alcohols Polymers 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- VQTUBCCKSQIDNK-UHFFFAOYSA-N Isobutene Chemical compound CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 description 8
- 238000002156 mixing Methods 0.000 description 8
- 206010040872 skin infection Diseases 0.000 description 8
- 238000005406 washing Methods 0.000 description 8
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 7
- NMSBTWLFBGNKON-UHFFFAOYSA-N 2-(2-hexadecoxyethoxy)ethanol Chemical compound CCCCCCCCCCCCCCCCOCCOCCO NMSBTWLFBGNKON-UHFFFAOYSA-N 0.000 description 7
- CTPDSKVQLSDPLC-UHFFFAOYSA-N 2-(oxolan-2-ylmethoxy)ethanol Chemical compound OCCOCC1CCCO1 CTPDSKVQLSDPLC-UHFFFAOYSA-N 0.000 description 7
- 208000002193 Pain Diseases 0.000 description 7
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 7
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 7
- 235000021355 Stearic acid Nutrition 0.000 description 7
- 229930006000 Sucrose Natural products 0.000 description 7
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 230000000368 destabilizing effect Effects 0.000 description 7
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 7
- 150000002148 esters Chemical class 0.000 description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 7
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 7
- 208000014674 injury Diseases 0.000 description 7
- 239000004973 liquid crystal related substance Substances 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 230000003020 moisturizing effect Effects 0.000 description 7
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 239000008117 stearic acid Substances 0.000 description 7
- 239000005720 sucrose Substances 0.000 description 7
- MEJYDZQQVZJMPP-ULAWRXDQSA-N (3s,3ar,6r,6ar)-3,6-dimethoxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan Chemical compound CO[C@H]1CO[C@@H]2[C@H](OC)CO[C@@H]21 MEJYDZQQVZJMPP-ULAWRXDQSA-N 0.000 description 6
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical compound CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 6
- KOCVACNWDMSLBM-UHFFFAOYSA-N 4-(Ethoxymethyl)-2-methoxyphenol Chemical compound CCOCC1=CC=C(O)C(OC)=C1 KOCVACNWDMSLBM-UHFFFAOYSA-N 0.000 description 6
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 6
- 201000004384 Alopecia Diseases 0.000 description 6
- 206010007134 Candida infections Diseases 0.000 description 6
- 201000004624 Dermatitis Diseases 0.000 description 6
- 241000282414 Homo sapiens Species 0.000 description 6
- AKDLSISGGARWFP-UHFFFAOYSA-N Homodihydrocapsaicin Chemical compound COC1=CC(CNC(=O)CCCCCCCC(C)C)=CC=C1O AKDLSISGGARWFP-UHFFFAOYSA-N 0.000 description 6
- 208000003251 Pruritus Diseases 0.000 description 6
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 6
- WPMWEFXCIYCJSA-UHFFFAOYSA-N Tetraethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCO WPMWEFXCIYCJSA-UHFFFAOYSA-N 0.000 description 6
- 208000027418 Wounds and injury Diseases 0.000 description 6
- 150000005215 alkyl ethers Chemical class 0.000 description 6
- 229940088710 antibiotic agent Drugs 0.000 description 6
- 201000003984 candidiasis Diseases 0.000 description 6
- 229940105329 carboxymethylcellulose Drugs 0.000 description 6
- 150000002009 diols Chemical class 0.000 description 6
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 6
- 239000003623 enhancer Substances 0.000 description 6
- 239000007789 gas Substances 0.000 description 6
- 229960003943 hypromellose Drugs 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 239000002563 ionic surfactant Substances 0.000 description 6
- FBUKVWPVBMHYJY-UHFFFAOYSA-N nonanoic acid Chemical compound CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 235000011067 sorbitan monolaureate Nutrition 0.000 description 6
- 230000007480 spreading Effects 0.000 description 6
- 238000003892 spreading Methods 0.000 description 6
- 229940114926 stearate Drugs 0.000 description 6
- 150000003445 sucroses Chemical class 0.000 description 6
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 5
- MDVYIGJINBYKOM-IBSWDFHHSA-N 3-[(1r,2s,5r)-5-methyl-2-propan-2-ylcyclohexyl]oxypropane-1,2-diol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OCC(O)CO MDVYIGJINBYKOM-IBSWDFHHSA-N 0.000 description 5
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 5
- 229920002884 Laureth 4 Polymers 0.000 description 5
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 5
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical compound ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 5
- 229940035676 analgesics Drugs 0.000 description 5
- 239000000730 antalgic agent Substances 0.000 description 5
- 229940125715 antihistaminic agent Drugs 0.000 description 5
- 239000003212 astringent agent Substances 0.000 description 5
- 229940051250 hexylene glycol Drugs 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 229940061515 laureth-4 Drugs 0.000 description 5
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 210000000664 rectum Anatomy 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 229940035044 sorbitan monolaurate Drugs 0.000 description 5
- NFLGAXVYCFJBMK-RKDXNWHRSA-N (+)-isomenthone Natural products CC(C)[C@H]1CC[C@@H](C)CC1=O NFLGAXVYCFJBMK-RKDXNWHRSA-N 0.000 description 4
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 4
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 4
- FDCJDKXCCYFOCV-UHFFFAOYSA-N 1-hexadecoxyhexadecane Chemical compound CCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC FDCJDKXCCYFOCV-UHFFFAOYSA-N 0.000 description 4
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 4
- OSCILYIQKAVULO-UHFFFAOYSA-N 2-hydroxyethyl hydrogen carbonate;5-methyl-2-propan-2-ylcyclohexan-1-ol Chemical compound OCCOC(O)=O.CC(C)C1CCC(C)CC1O OSCILYIQKAVULO-UHFFFAOYSA-N 0.000 description 4
- DISYHRKLFBBFAS-UHFFFAOYSA-N 3-(1-methyl-4-propan-2-ylcyclohexyl)oxypropane-1,2-diol Chemical compound CC(C)C1CCC(C)(OCC(O)CO)CC1 DISYHRKLFBBFAS-UHFFFAOYSA-N 0.000 description 4
- 241000222122 Candida albicans Species 0.000 description 4
- 206010012442 Dermatitis contact Diseases 0.000 description 4
- 206010017533 Fungal infection Diseases 0.000 description 4
- 241000701806 Human papillomavirus Species 0.000 description 4
- 244000245214 Mentha canadensis Species 0.000 description 4
- 235000016278 Mentha canadensis Nutrition 0.000 description 4
- NFLGAXVYCFJBMK-UHFFFAOYSA-N Menthone Chemical compound CC(C)C1CCC(C)CC1=O NFLGAXVYCFJBMK-UHFFFAOYSA-N 0.000 description 4
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 239000008118 PEG 6000 Substances 0.000 description 4
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 4
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 4
- 229920001214 Polysorbate 60 Polymers 0.000 description 4
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 description 4
- 208000018777 Vulvar intraepithelial neoplasia Diseases 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 229940073669 ceteareth 20 Drugs 0.000 description 4
- 208000010247 contact dermatitis Diseases 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 238000002788 crimping Methods 0.000 description 4
- MWKFXSUHUHTGQN-UHFFFAOYSA-N decan-1-ol Chemical compound CCCCCCCCCCO MWKFXSUHUHTGQN-UHFFFAOYSA-N 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 230000003676 hair loss Effects 0.000 description 4
- MLJGZARGNROKAC-VQHVLOKHSA-N homocapsaicin Chemical compound CCC(C)\C=C\CCCCC(=O)NCC1=CC=C(O)C(OC)=C1 MLJGZARGNROKAC-VQHVLOKHSA-N 0.000 description 4
- JKIHLSTUOQHAFF-UHFFFAOYSA-N homocapsaicin Natural products COC1=CC(CNC(=O)CCCCCC=CC(C)C)=CC=C1O JKIHLSTUOQHAFF-UHFFFAOYSA-N 0.000 description 4
- JZNZUOZRIWOBGG-UHFFFAOYSA-N homocapsaicin-II Natural products COC1=CC(CNC(=O)CCCCC=CCC(C)C)=CC=C1O JZNZUOZRIWOBGG-UHFFFAOYSA-N 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 239000002085 irritant Substances 0.000 description 4
- ZYTMANIQRDEHIO-KXUCPTDWSA-N isopulegol Chemical compound C[C@@H]1CC[C@@H](C(C)=C)[C@H](O)C1 ZYTMANIQRDEHIO-KXUCPTDWSA-N 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 239000006210 lotion Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 201000001441 melanoma Diseases 0.000 description 4
- 229930007503 menthone Natural products 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 229960002900 methylcellulose Drugs 0.000 description 4
- 208000008588 molluscum contagiosum Diseases 0.000 description 4
- 150000002772 monosaccharides Chemical class 0.000 description 4
- 230000002956 necrotizing effect Effects 0.000 description 4
- OQILCOQZDHPEAZ-UHFFFAOYSA-N octyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OCCCCCCCC OQILCOQZDHPEAZ-UHFFFAOYSA-N 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- LSTDYDRCKUBPDI-UHFFFAOYSA-N palmityl acetate Chemical compound CCCCCCCCCCCCCCCCOC(C)=O LSTDYDRCKUBPDI-UHFFFAOYSA-N 0.000 description 4
- 229940100460 peg-100 stearate Drugs 0.000 description 4
- 229920002523 polyethylene Glycol 1000 Polymers 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000001953 sensory effect Effects 0.000 description 4
- 230000008591 skin barrier function Effects 0.000 description 4
- 235000011069 sorbitan monooleate Nutrition 0.000 description 4
- 239000001593 sorbitan monooleate Substances 0.000 description 4
- 229940035049 sorbitan monooleate Drugs 0.000 description 4
- 229950011392 sorbitan stearate Drugs 0.000 description 4
- 235000012424 soybean oil Nutrition 0.000 description 4
- 239000003549 soybean oil Substances 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 229940098465 tincture Drugs 0.000 description 4
- 208000000143 urethritis Diseases 0.000 description 4
- 239000000341 volatile oil Substances 0.000 description 4
- 239000001871 (1R,2R,5S)-5-methyl-2-prop-1-en-2-ylcyclohexan-1-ol Substances 0.000 description 3
- OEGPRYNGFWGMMV-UHFFFAOYSA-N (3,4-dimethoxyphenyl)methanol Chemical class COC1=CC=C(CO)C=C1OC OEGPRYNGFWGMMV-UHFFFAOYSA-N 0.000 description 3
- POEDHWVTLBLWDA-UHFFFAOYSA-N 1-butylindole-2,3-dione Chemical compound C1=CC=C2N(CCCC)C(=O)C(=O)C2=C1 POEDHWVTLBLWDA-UHFFFAOYSA-N 0.000 description 3
- BPIUIOXAFBGMNB-UHFFFAOYSA-N 1-hexoxyhexane Chemical compound CCCCCCOCCCCCC BPIUIOXAFBGMNB-UHFFFAOYSA-N 0.000 description 3
- IFUIILQWHYHIEK-UHFFFAOYSA-N 2-Ethoxy-4-(4-methyl-1,3-dioxolan-2-yl)phenol Chemical class C1=C(O)C(OCC)=CC(C2OC(C)CO2)=C1 IFUIILQWHYHIEK-UHFFFAOYSA-N 0.000 description 3
- RFGCVZIIIHRESZ-UHFFFAOYSA-N 2-Methoxy-4-(4-methyl-1,3-dioxolan-2-yl)phenol Chemical class C1=C(O)C(OC)=CC(C2OC(C)CO2)=C1 RFGCVZIIIHRESZ-UHFFFAOYSA-N 0.000 description 3
- XMVBHZBLHNOQON-UHFFFAOYSA-N 2-butyl-1-octanol Chemical compound CCCCCCC(CO)CCCC XMVBHZBLHNOQON-UHFFFAOYSA-N 0.000 description 3
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 3
- VLDFMKOUUQYFGF-UHFFFAOYSA-N 4-(butoxymethyl)-2-methoxyphenol Chemical compound CCCCOCC1=CC=C(O)C(OC)=C1 VLDFMKOUUQYFGF-UHFFFAOYSA-N 0.000 description 3
- LSKFRYMLGSVAPL-UHFFFAOYSA-N 4-[(4-hydroxy-3-methoxyphenyl)methoxymethyl]-2-methoxyphenol Chemical compound C1=C(O)C(OC)=CC(COCC=2C=C(OC)C(O)=CC=2)=C1 LSKFRYMLGSVAPL-UHFFFAOYSA-N 0.000 description 3
- HBTAOSGHCXUEKI-UHFFFAOYSA-N 4-chloro-n,n-dimethyl-3-nitrobenzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 HBTAOSGHCXUEKI-UHFFFAOYSA-N 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 3
- 244000007835 Cyamopsis tetragonoloba Species 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- VUNOFAIHSALQQH-UHFFFAOYSA-N Ethyl menthane carboxamide Chemical compound CCNC(=O)C1CC(C)CCC1C(C)C VUNOFAIHSALQQH-UHFFFAOYSA-N 0.000 description 3
- 239000001338 FEMA 3805 Substances 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- LMXFTMYMHGYJEI-UHFFFAOYSA-N Menthoglycol Natural products CC1CCC(C(C)(C)O)C(O)C1 LMXFTMYMHGYJEI-UHFFFAOYSA-N 0.000 description 3
- RWAXQWRDVUOOGG-UHFFFAOYSA-N N,2,3-Trimethyl-2-(1-methylethyl)butanamide Chemical compound CNC(=O)C(C)(C(C)C)C(C)C RWAXQWRDVUOOGG-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 229920000604 Polyethylene Glycol 200 Polymers 0.000 description 3
- 201000004681 Psoriasis Diseases 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 206010042496 Sunburn Diseases 0.000 description 3
- 208000024780 Urticaria Diseases 0.000 description 3
- 241000234314 Zingiber Species 0.000 description 3
- UJNOLBSYLSYIBM-SGUBAKSOSA-N [(1r,2s,5r)-5-methyl-2-propan-2-ylcyclohexyl] 2-hydroxypropanoate Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OC(=O)C(C)O UJNOLBSYLSYIBM-SGUBAKSOSA-N 0.000 description 3
- FOLJTMYCYXSPFQ-CJKAUBRRSA-N [(2r,3s,4s,5r,6r)-6-[(2s,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-(octadecanoyloxymethyl)oxolan-2-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methyl octadecanoate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)CCCCCCCCCCCCCCCCC)O[C@@H]1O[C@@]1(COC(=O)CCCCCCCCCCCCCCCCC)[C@@H](O)[C@H](O)[C@@H](CO)O1 FOLJTMYCYXSPFQ-CJKAUBRRSA-N 0.000 description 3
- 239000008186 active pharmaceutical agent Substances 0.000 description 3
- 239000003524 antilipemic agent Substances 0.000 description 3
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 3
- 238000000222 aromatherapy Methods 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 235000019445 benzyl alcohol Nutrition 0.000 description 3
- 229960004217 benzyl alcohol Drugs 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 230000002026 carminative effect Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 229960001334 corticosteroids Drugs 0.000 description 3
- 150000001991 dicarboxylic acids Chemical class 0.000 description 3
- 229940031578 diisopropyl adipate Drugs 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 150000002170 ethers Chemical class 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 230000009969 flowable effect Effects 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 235000020708 ginger extract Nutrition 0.000 description 3
- 229940002508 ginger extract Drugs 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 125000005456 glyceride group Chemical group 0.000 description 3
- 230000005484 gravity Effects 0.000 description 3
- 208000014617 hemorrhoid Diseases 0.000 description 3
- GOBFKCLUUUDTQE-UHFFFAOYSA-N homodihydrocapsaicin-II Natural products CCC(C)CCCCCCC(=O)NCC1=CC=C(O)C(OC)=C1 GOBFKCLUUUDTQE-UHFFFAOYSA-N 0.000 description 3
- 239000008240 homogeneous mixture Substances 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 229940095045 isopulegol Drugs 0.000 description 3
- 229960005015 local anesthetics Drugs 0.000 description 3
- 230000002535 lyotropic effect Effects 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 150000002739 metals Chemical class 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- RGOVYLWUIBMPGK-UHFFFAOYSA-N nonivamide Chemical compound CCCCCCCCC(=O)NCC1=CC=C(O)C(OC)=C1 RGOVYLWUIBMPGK-UHFFFAOYSA-N 0.000 description 3
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 3
- 210000002345 respiratory system Anatomy 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 229960002920 sorbitol Drugs 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 238000013112 stability test Methods 0.000 description 3
- 229940100459 steareth-20 Drugs 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 description 3
- KJIOQYGWTQBHNH-UHFFFAOYSA-N undecanol Chemical compound CCCCCCCCCCCO KJIOQYGWTQBHNH-UHFFFAOYSA-N 0.000 description 3
- 210000001215 vagina Anatomy 0.000 description 3
- ZENOXNGFMSCLLL-UHFFFAOYSA-N vanillyl alcohol Natural products COC1=CC(CO)=CC=C1O ZENOXNGFMSCLLL-UHFFFAOYSA-N 0.000 description 3
- 229940078465 vanillyl butyl ether Drugs 0.000 description 3
- WQFGPARDTSBVLU-UHFFFAOYSA-N (1R,2S,3S,4R)-p-Menthane-2,3-diol Chemical compound CC(C)C1CCC(C)C(O)C1O WQFGPARDTSBVLU-UHFFFAOYSA-N 0.000 description 2
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 2
- NPNPZTNLOVBDOC-UHFFFAOYSA-N 1,1-difluoroethane Chemical compound CC(F)F NPNPZTNLOVBDOC-UHFFFAOYSA-N 0.000 description 2
- UENOQWSWMYJKIW-UHFFFAOYSA-N 1,2,2-trimethylcyclohexan-1-ol Chemical compound CC1(C)CCCCC1(C)O UENOQWSWMYJKIW-UHFFFAOYSA-N 0.000 description 2
- ARXKVVRQIIOZGF-UHFFFAOYSA-N 1,2,4-butanetriol Chemical compound OCCC(O)CO ARXKVVRQIIOZGF-UHFFFAOYSA-N 0.000 description 2
- WAYINTBTZWQNSN-UHFFFAOYSA-N 11-methyldodecyl 3,5,5-trimethylhexanoate Chemical compound CC(C)CCCCCCCCCCOC(=O)CC(C)CC(C)(C)C WAYINTBTZWQNSN-UHFFFAOYSA-N 0.000 description 2
- XFOQWQKDSMIPHT-UHFFFAOYSA-N 2,3-dichloro-6-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=CC=C(Cl)C(Cl)=N1 XFOQWQKDSMIPHT-UHFFFAOYSA-N 0.000 description 2
- KWVPFECTOKLOBL-KTKRTIGZSA-N 2-[(z)-octadec-9-enoxy]ethanol Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCO KWVPFECTOKLOBL-KTKRTIGZSA-N 0.000 description 2
- MGYUQZIGNZFZJS-KTKRTIGZSA-N 2-[2-[(z)-octadec-9-enoxy]ethoxy]ethanol Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCOCCO MGYUQZIGNZFZJS-KTKRTIGZSA-N 0.000 description 2
- URDCARMUOSMFFI-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(2-hydroxyethyl)amino]acetic acid Chemical compound OCCN(CC(O)=O)CCN(CC(O)=O)CC(O)=O URDCARMUOSMFFI-UHFFFAOYSA-N 0.000 description 2
- CAYHVMBQBLYQMT-UHFFFAOYSA-N 2-decyltetradecan-1-ol Chemical compound CCCCCCCCCCCCC(CO)CCCCCCCCCC CAYHVMBQBLYQMT-UHFFFAOYSA-N 0.000 description 2
- LTPZLDNFECOIQY-UHFFFAOYSA-N 2-methyl-3-(1-methyl-4-propan-2-ylcyclohexyl)oxypropane-1,2-diol Chemical compound CC(C)C1CCC(C)(OCC(C)(O)CO)CC1 LTPZLDNFECOIQY-UHFFFAOYSA-N 0.000 description 2
- JYZLSYFPFQTNNO-UHFFFAOYSA-N 2-octyldecan-1-ol Chemical compound CCCCCCCCC(CO)CCCCCCCC JYZLSYFPFQTNNO-UHFFFAOYSA-N 0.000 description 2
- UIVPNOBLHXUKDX-UHFFFAOYSA-N 3,5,5-trimethylhexyl 3,5,5-trimethylhexanoate Chemical compound CC(C)(C)CC(C)CCOC(=O)CC(C)CC(C)(C)C UIVPNOBLHXUKDX-UHFFFAOYSA-N 0.000 description 2
- AYERSDHOTKHEDA-UHFFFAOYSA-N 3-(1-methyl-4-propan-2-ylcyclohexyl)oxybutan-1-ol Chemical compound CC(C)C1CCC(C)(OC(C)CCO)CC1 AYERSDHOTKHEDA-UHFFFAOYSA-N 0.000 description 2
- DCNFPFNLHFFBFM-UHFFFAOYSA-N 3-(1-methyl-4-propan-2-ylcyclohexyl)oxypropan-1-ol Chemical compound CC(C)C1CCC(C)(OCCCO)CC1 DCNFPFNLHFFBFM-UHFFFAOYSA-N 0.000 description 2
- RCEFMOGVOYEGJN-UHFFFAOYSA-N 3-(2-hydroxyphenyl)-6-(3-nitrophenyl)-1,4-dihydropyrimidin-2-one Chemical compound OC1=CC=CC=C1N1C(=O)NC(C=2C=C(C=CC=2)[N+]([O-])=O)=CC1 RCEFMOGVOYEGJN-UHFFFAOYSA-N 0.000 description 2
- DARSINVAIIMSIF-UHFFFAOYSA-N 3-methyl-4-pyrrolidin-1-yl-2h-furan-5-one Chemical compound O=C1OCC(C)=C1N1CCCC1 DARSINVAIIMSIF-UHFFFAOYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- 206010063409 Acarodermatitis Diseases 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- 206010000501 Acne conglobata Diseases 0.000 description 2
- 206010049141 Acne fulminans Diseases 0.000 description 2
- 208000002485 Adiposis dolorosa Diseases 0.000 description 2
- 206010048946 Anal abscess Diseases 0.000 description 2
- 208000031093 Anal and rectal disease Diseases 0.000 description 2
- 206010061424 Anal cancer Diseases 0.000 description 2
- 206010002153 Anal fissure Diseases 0.000 description 2
- 206010068172 Anal pruritus Diseases 0.000 description 2
- 206010059313 Anogenital warts Diseases 0.000 description 2
- 206010073941 Anorectal human papilloma virus infection Diseases 0.000 description 2
- 208000007860 Anus Neoplasms Diseases 0.000 description 2
- 208000016583 Anus disease Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000004926 Bacterial Vaginosis Diseases 0.000 description 2
- 206010004146 Basal cell carcinoma Diseases 0.000 description 2
- 208000027496 Behcet disease Diseases 0.000 description 2
- 208000009137 Behcet syndrome Diseases 0.000 description 2
- 206010004265 Benign familial pemphigus Diseases 0.000 description 2
- 208000003643 Callosities Diseases 0.000 description 2
- 240000004160 Capsicum annuum Species 0.000 description 2
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 2
- 235000007862 Capsicum baccatum Nutrition 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 2
- 206010007882 Cellulitis Diseases 0.000 description 2
- 208000007190 Chlamydia Infections Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 206010008642 Cholesteatoma Diseases 0.000 description 2
- 241000252203 Clupea harengus Species 0.000 description 2
- 208000000907 Condylomata Acuminata Diseases 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- 206010012468 Dermatitis herpetiformis Diseases 0.000 description 2
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 2
- 208000004483 Dyspareunia Diseases 0.000 description 2
- 208000004145 Endometritis Diseases 0.000 description 2
- 201000000297 Erysipelas Diseases 0.000 description 2
- 206010015218 Erythema multiforme Diseases 0.000 description 2
- 206010015226 Erythema nodosum Diseases 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical group C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- 208000034347 Faecal incontinence Diseases 0.000 description 2
- 208000037574 Familial benign chronic pemphigus Diseases 0.000 description 2
- 206010016334 Feeling hot Diseases 0.000 description 2
- 208000009531 Fissure in Ano Diseases 0.000 description 2
- 206010016936 Folliculitis Diseases 0.000 description 2
- 201000001678 Frey syndrome Diseases 0.000 description 2
- 206010017543 Fungal skin infection Diseases 0.000 description 2
- 206010017553 Furuncle Diseases 0.000 description 2
- 206010017711 Gangrene Diseases 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 206010018612 Gonorrhoea Diseases 0.000 description 2
- 206010018693 Granuloma inguinale Diseases 0.000 description 2
- 208000004041 Gustatory Sweating Diseases 0.000 description 2
- 208000027655 Hailey-Hailey disease Diseases 0.000 description 2
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 208000008454 Hyperhidrosis Diseases 0.000 description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
- 206010021531 Impetigo Diseases 0.000 description 2
- 208000006877 Insect Bites and Stings Diseases 0.000 description 2
- 206010022998 Irritability Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 208000007766 Kaposi sarcoma Diseases 0.000 description 2
- 206010066295 Keratosis pilaris Diseases 0.000 description 2
- 208000004204 Larva Migrans Diseases 0.000 description 2
- 235000018978 Mentha arvensis Nutrition 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 229920003096 Methocel™ K100M Polymers 0.000 description 2
- 241001448624 Miliaria Species 0.000 description 2
- 201000002481 Myositis Diseases 0.000 description 2
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 2
- 208000000175 Nail-Patella Syndrome Diseases 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 206010028885 Necrotising fasciitis Diseases 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 2
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 2
- 206010034277 Pemphigoid Diseases 0.000 description 2
- 241000721454 Pemphigus Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 206010034972 Photosensitivity reaction Diseases 0.000 description 2
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 description 2
- 229920002582 Polyethylene Glycol 600 Polymers 0.000 description 2
- 239000004721 Polyphenylene oxide Substances 0.000 description 2
- 208000037062 Polyps Diseases 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 208000009544 Pruritus Ani Diseases 0.000 description 2
- 206010037549 Purpura Diseases 0.000 description 2
- 241001672981 Purpura Species 0.000 description 2
- 208000004680 Rectal Fistula Diseases 0.000 description 2
- 208000021326 Ritter disease Diseases 0.000 description 2
- 241001303601 Rosacea Species 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 208000007893 Salpingitis Diseases 0.000 description 2
- 241000447727 Scabies Species 0.000 description 2
- 206010039710 Scleroderma Diseases 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- 206010040943 Skin Ulcer Diseases 0.000 description 2
- 206010040954 Skin wrinkling Diseases 0.000 description 2
- 239000004141 Sodium laurylsulphate Substances 0.000 description 2
- 206010064127 Solar lentigo Diseases 0.000 description 2
- 206010041929 Staphylococcal scalded skin syndrome Diseases 0.000 description 2
- 235000019486 Sunflower oil Nutrition 0.000 description 2
- 206010044223 Toxic epidermal necrolysis Diseases 0.000 description 2
- 231100000087 Toxic epidermal necrolysis Toxicity 0.000 description 2
- 241000159241 Toxicodendron Species 0.000 description 2
- 241000159243 Toxicodendron radicans Species 0.000 description 2
- 208000005448 Trichomonas Infections Diseases 0.000 description 2
- 206010044620 Trichomoniasis Diseases 0.000 description 2
- 241000209140 Triticum Species 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 208000006374 Uterine Cervicitis Diseases 0.000 description 2
- 208000037009 Vaginitis bacterial Diseases 0.000 description 2
- 206010065173 Viral skin infection Diseases 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 206010047642 Vitiligo Diseases 0.000 description 2
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 2
- 208000003728 Vulvodynia Diseases 0.000 description 2
- 206010047791 Vulvovaginal dryness Diseases 0.000 description 2
- 206010069055 Vulvovaginal pain Diseases 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- OFUHPGMOWVHNPN-QWZFGMNQSA-N [(2r)-2,5,7,8-tetramethyl-2-[(4r,8r)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl] (9z,12z)-octadeca-9,12-dienoate Chemical compound O1[C@](C)(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CCC2=C(C)C(OC(=O)CCCCCCC\C=C/C\C=C/CCCCC)=C(C)C(C)=C21 OFUHPGMOWVHNPN-QWZFGMNQSA-N 0.000 description 2
- OCKWAZCWKSMKNC-UHFFFAOYSA-N [3-octadecanoyloxy-2,2-bis(octadecanoyloxymethyl)propyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(COC(=O)CCCCCCCCCCCCCCCCC)(COC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC OCKWAZCWKSMKNC-UHFFFAOYSA-N 0.000 description 2
- 206010000269 abscess Diseases 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 231100000360 alopecia Toxicity 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 206010002156 anal fistula Diseases 0.000 description 2
- 229940035674 anesthetics Drugs 0.000 description 2
- 208000025009 anogenital human papillomavirus infection Diseases 0.000 description 2
- 201000004201 anogenital venereal wart Diseases 0.000 description 2
- 201000011165 anus cancer Diseases 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229940070312 arachidyl propionate Drugs 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- ISAOCJYIOMOJEB-UHFFFAOYSA-N benzoin Chemical compound C=1C=CC=CC=1C(O)C(=O)C1=CC=CC=C1 ISAOCJYIOMOJEB-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- YZXZAUAIVAZWFN-UHFFFAOYSA-N bis(5-methyl-2-propan-2-ylcyclohexyl) butanedioate Chemical compound CC(C)C1CCC(C)CC1OC(=O)CCC(=O)OC1C(C(C)C)CCC(C)C1 YZXZAUAIVAZWFN-UHFFFAOYSA-N 0.000 description 2
- 235000021324 borage oil Nutrition 0.000 description 2
- 239000010474 borage seed oil Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 208000000594 bullous pemphigoid Diseases 0.000 description 2
- VIHAEDVKXSOUAT-UHFFFAOYSA-N but-2-en-4-olide Chemical compound O=C1OCC=C1 VIHAEDVKXSOUAT-UHFFFAOYSA-N 0.000 description 2
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 2
- WERYXYBDKMZEQL-UHFFFAOYSA-N butane-1,4-diol Chemical compound OCCCCO WERYXYBDKMZEQL-UHFFFAOYSA-N 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 235000019519 canola oil Nutrition 0.000 description 2
- 239000000828 canola oil Substances 0.000 description 2
- 239000001728 capsicum frutescens Substances 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- ULDHMXUKGWMISQ-UHFFFAOYSA-N carvone Chemical compound CC(=C)C1CC=C(C)C(=O)C1 ULDHMXUKGWMISQ-UHFFFAOYSA-N 0.000 description 2
- 206010008323 cervicitis Diseases 0.000 description 2
- 229940081620 ceteth-2 Drugs 0.000 description 2
- 229940049297 cetyl acetate Drugs 0.000 description 2
- 229940048851 cetyl ricinoleate Drugs 0.000 description 2
- 201000004308 chancroid Diseases 0.000 description 2
- 239000003240 coconut oil Substances 0.000 description 2
- 235000019864 coconut oil Nutrition 0.000 description 2
- 235000012716 cod liver oil Nutrition 0.000 description 2
- 239000003026 cod liver oil Substances 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 235000005687 corn oil Nutrition 0.000 description 2
- 239000002285 corn oil Substances 0.000 description 2
- BMCQMVFGOVHVNG-TUFAYURCSA-N cortisol 17-butyrate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)CO)(OC(=O)CCC)[C@@]1(C)C[C@@H]2O BMCQMVFGOVHVNG-TUFAYURCSA-N 0.000 description 2
- 239000008406 cosmetic ingredient Substances 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 239000002385 cottonseed oil Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 2
- 229940086555 cyclomethicone Drugs 0.000 description 2
- DTPCFIHYWYONMD-UHFFFAOYSA-N decaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO DTPCFIHYWYONMD-UHFFFAOYSA-N 0.000 description 2
- PDYOTPOJFZAOIS-UHFFFAOYSA-N decanoic acid;2,2-dimethylpropane-1,3-diol;octanoic acid Chemical compound OCC(C)(C)CO.CCCCCCCC(O)=O.CCCCCCCCCC(O)=O PDYOTPOJFZAOIS-UHFFFAOYSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- SASYSVUEVMOWPL-NXVVXOECSA-N decyl oleate Chemical compound CCCCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC SASYSVUEVMOWPL-NXVVXOECSA-N 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 2
- 150000005690 diesters Chemical class 0.000 description 2
- 229940008099 dimethicone Drugs 0.000 description 2
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 description 2
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 201000010582 ecthyma Diseases 0.000 description 2
- 208000002169 ectodermal dysplasia Diseases 0.000 description 2
- 208000031068 ectodermal dysplasia syndrome Diseases 0.000 description 2
- 230000002497 edematous effect Effects 0.000 description 2
- 208000004000 erythrasma Diseases 0.000 description 2
- SYCXJIPGDBATKA-UHFFFAOYSA-N ethyl (5-methyl-2-propan-2-ylcyclohexyl) carbonate Chemical compound CCOC(=O)OC1CC(C)CCC1C(C)C SYCXJIPGDBATKA-UHFFFAOYSA-N 0.000 description 2
- 239000010642 eucalyptus oil Substances 0.000 description 2
- 229940044949 eucalyptus oil Drugs 0.000 description 2
- 239000010475 evening primrose oil Substances 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000010408 film Substances 0.000 description 2
- 230000003890 fistula Effects 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical group 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 239000003193 general anesthetic agent Substances 0.000 description 2
- 210000004392 genitalia Anatomy 0.000 description 2
- 150000002334 glycols Chemical class 0.000 description 2
- 208000001786 gonorrhea Diseases 0.000 description 2
- 208000024963 hair loss Diseases 0.000 description 2
- 239000010460 hemp oil Substances 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 235000019514 herring Nutrition 0.000 description 2
- XAMHKORMKJIEFW-AYTKPMRMSA-N hexadecyl (z,12r)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCCCC\C=C/C[C@H](O)CCCCCC XAMHKORMKJIEFW-AYTKPMRMSA-N 0.000 description 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
- 208000002557 hidradenitis Diseases 0.000 description 2
- 201000007162 hidradenitis suppurativa Diseases 0.000 description 2
- 239000006266 hydroalcoholic foam Substances 0.000 description 2
- 229960001524 hydrocortisone butyrate Drugs 0.000 description 2
- 230000037315 hyperhidrosis Effects 0.000 description 2
- 206010021198 ichthyosis Diseases 0.000 description 2
- OPEHDFRKFVXKNP-UHFFFAOYSA-N icosyl propanoate Chemical compound CCCCCCCCCCCCCCCCCCCCOC(=O)CC OPEHDFRKFVXKNP-UHFFFAOYSA-N 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 231100000021 irritant Toxicity 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 229940100554 isononyl isononanoate Drugs 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 229940093629 isopropyl isostearate Drugs 0.000 description 2
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 2
- 229940075495 isopropyl palmitate Drugs 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 239000000832 lactitol Substances 0.000 description 2
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 2
- 235000010448 lactitol Nutrition 0.000 description 2
- 229960003451 lactitol Drugs 0.000 description 2
- 238000013532 laser treatment Methods 0.000 description 2
- 208000028454 lice infestation Diseases 0.000 description 2
- 201000011486 lichen planus Diseases 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- 239000000944 linseed oil Substances 0.000 description 2
- 235000021388 linseed oil Nutrition 0.000 description 2
- 206010025135 lupus erythematosus Diseases 0.000 description 2
- 201000003265 lymphadenitis Diseases 0.000 description 2
- 206010025226 lymphangitis Diseases 0.000 description 2
- 235000010449 maltitol Nutrition 0.000 description 2
- 239000000845 maltitol Substances 0.000 description 2
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 2
- 229940035436 maltitol Drugs 0.000 description 2
- 230000000873 masking effect Effects 0.000 description 2
- 239000001683 mentha spicata herb oil Substances 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 229940042472 mineral oil Drugs 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 229940035363 muscle relaxants Drugs 0.000 description 2
- 229940078812 myristyl myristate Drugs 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 201000007970 necrotizing fasciitis Diseases 0.000 description 2
- ZYTMANIQRDEHIO-UHFFFAOYSA-N neo-Isopulegol Natural products CC1CCC(C(C)=C)C(O)C1 ZYTMANIQRDEHIO-UHFFFAOYSA-N 0.000 description 2
- 230000009826 neoplastic cell growth Effects 0.000 description 2
- 210000001640 nerve ending Anatomy 0.000 description 2
- 230000001722 neurochemical effect Effects 0.000 description 2
- 231100000344 non-irritating Toxicity 0.000 description 2
- ZWRUINPWMLAQRD-UHFFFAOYSA-N nonan-1-ol Chemical compound CCCCCCCCCO ZWRUINPWMLAQRD-UHFFFAOYSA-N 0.000 description 2
- SJWFXCIHNDVPSH-UHFFFAOYSA-N octan-2-ol Chemical compound CCCCCCC(C)O SJWFXCIHNDVPSH-UHFFFAOYSA-N 0.000 description 2
- OEIJHBUUFURJLI-UHFFFAOYSA-N octane-1,8-diol Chemical compound OCCCCCCCCO OEIJHBUUFURJLI-UHFFFAOYSA-N 0.000 description 2
- 229940055577 oleyl alcohol Drugs 0.000 description 2
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 208000005963 oophoritis Diseases 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- CFJYNSNXFXLKNS-UHFFFAOYSA-N p-menthane group Chemical group C1(CCC(CC1)C(C)C)C CFJYNSNXFXLKNS-UHFFFAOYSA-N 0.000 description 2
- 230000003071 parasitic effect Effects 0.000 description 2
- 229940086560 pentaerythrityl tetrastearate Drugs 0.000 description 2
- 238000000819 phase cycle Methods 0.000 description 2
- 229940057874 phenyl trimethicone Drugs 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 230000036211 photosensitivity Effects 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 206010035114 pityriasis rosea Diseases 0.000 description 2
- 206010035116 pityriasis rubra pilaris Diseases 0.000 description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
- 229920000570 polyether Polymers 0.000 description 2
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 2
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 229940113124 polysorbate 60 Drugs 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- BFZNCPXNOGIELB-UHFFFAOYSA-N propan-2-yl 10-[5,6-dihexyl-2-(8-oxo-8-propan-2-yloxyoctyl)cyclohex-3-en-1-yl]dec-9-enoate Chemical compound CCCCCCC1C=CC(CCCCCCCC(=O)OC(C)C)C(C=CCCCCCCCC(=O)OC(C)C)C1CCCCCC BFZNCPXNOGIELB-UHFFFAOYSA-N 0.000 description 2
- NEOZOXKVMDBOSG-UHFFFAOYSA-N propan-2-yl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OC(C)C NEOZOXKVMDBOSG-UHFFFAOYSA-N 0.000 description 2
- YPFDHNVEDLHUCE-UHFFFAOYSA-N propane-1,3-diol Chemical compound OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- WBHHMMIMDMUBKC-QJWNTBNXSA-M ricinoleate Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC([O-])=O WBHHMMIMDMUBKC-QJWNTBNXSA-M 0.000 description 2
- 229940066675 ricinoleate Drugs 0.000 description 2
- 201000004700 rosacea Diseases 0.000 description 2
- 229940119224 salmon oil Drugs 0.000 description 2
- 208000005687 scabies Diseases 0.000 description 2
- 230000037390 scarring Effects 0.000 description 2
- 238000005204 segregation Methods 0.000 description 2
- 230000001235 sensitizing effect Effects 0.000 description 2
- 239000003352 sequestering agent Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 230000037384 skin absorption Effects 0.000 description 2
- 231100000274 skin absorption Toxicity 0.000 description 2
- 231100000075 skin burn Toxicity 0.000 description 2
- 231100000019 skin ulcer Toxicity 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229940083542 sodium Drugs 0.000 description 2
- 235000015424 sodium Nutrition 0.000 description 2
- CRPCXAMJWCDHFM-UHFFFAOYSA-M sodium;5-oxopyrrolidine-2-carboxylate Chemical compound [Na+].[O-]C(=O)C1CCC(=O)N1 CRPCXAMJWCDHFM-UHFFFAOYSA-M 0.000 description 2
- 230000007928 solubilization Effects 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- 235000011071 sorbitan monopalmitate Nutrition 0.000 description 2
- 239000001570 sorbitan monopalmitate Substances 0.000 description 2
- 229940031953 sorbitan monopalmitate Drugs 0.000 description 2
- 235000011076 sorbitan monostearate Nutrition 0.000 description 2
- 239000001587 sorbitan monostearate Substances 0.000 description 2
- 229940035048 sorbitan monostearate Drugs 0.000 description 2
- 235000019721 spearmint oil Nutrition 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 239000002600 sunflower oil Substances 0.000 description 2
- 230000005062 synaptic transmission Effects 0.000 description 2
- 239000011269 tar Substances 0.000 description 2
- 230000002277 temperature effect Effects 0.000 description 2
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 2
- BORJONZPSTVSFP-UHFFFAOYSA-N tetradecyl 2-hydroxypropanoate Chemical compound CCCCCCCCCCCCCCOC(=O)C(C)O BORJONZPSTVSFP-UHFFFAOYSA-N 0.000 description 2
- DZKXJUASMGQEMA-UHFFFAOYSA-N tetradecyl tetradecanoate Chemical compound CCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCC DZKXJUASMGQEMA-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000006264 topical foam Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 2
- 150000005691 triesters Chemical class 0.000 description 2
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 2
- LINXHFKHZLOLEI-UHFFFAOYSA-N trimethyl-[phenyl-bis(trimethylsilyloxy)silyl]oxysilane Chemical compound C[Si](C)(C)O[Si](O[Si](C)(C)C)(O[Si](C)(C)C)C1=CC=CC=C1 LINXHFKHZLOLEI-UHFFFAOYSA-N 0.000 description 2
- COXJMKGEQAWXNP-UHFFFAOYSA-N tris(14-methylpentadecyl) 2-hydroxypropane-1,2,3-tricarboxylate Chemical compound CC(C)CCCCCCCCCCCCCOC(=O)CC(O)(C(=O)OCCCCCCCCCCCCCC(C)C)CC(=O)OCCCCCCCCCCCCCC(C)C COXJMKGEQAWXNP-UHFFFAOYSA-N 0.000 description 2
- 208000013139 vaginal neoplasm Diseases 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 208000015317 vulvar disease Diseases 0.000 description 2
- 201000006669 vulvar dystrophy Diseases 0.000 description 2
- 239000007762 w/o emulsion Substances 0.000 description 2
- 239000010497 wheat germ oil Substances 0.000 description 2
- 239000008256 whipped cream Substances 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- NOOLISFMXDJSKH-AEJSXWLSSA-N (+)-menthol Chemical compound CC(C)[C@H]1CC[C@H](C)C[C@@H]1O NOOLISFMXDJSKH-AEJSXWLSSA-N 0.000 description 1
- KONGRWVLXLWGDV-BYGOPZEFSA-N (-)-cubebol Chemical compound CC(C)[C@@H]([C@H]12)CC[C@@H](C)[C@]32[C@@H]1[C@@](C)(O)CC3 KONGRWVLXLWGDV-BYGOPZEFSA-N 0.000 description 1
- NFLGAXVYCFJBMK-BDAKNGLRSA-N (-)-menthone Chemical compound CC(C)[C@@H]1CC[C@@H](C)CC1=O NFLGAXVYCFJBMK-BDAKNGLRSA-N 0.000 description 1
- CFOQKXQWGLAKSK-KTKRTIGZSA-N (13Z)-docosen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCCO CFOQKXQWGLAKSK-KTKRTIGZSA-N 0.000 description 1
- ULJXKUJMXIVDOY-OPRDCNLKSA-N (1r,2r,5r)-2-methyl-5-propan-2-ylcyclohexan-1-ol Chemical compound CC(C)[C@@H]1CC[C@@H](C)[C@H](O)C1 ULJXKUJMXIVDOY-OPRDCNLKSA-N 0.000 description 1
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
- WJTCHBVEUFDSIK-NWDGAFQWSA-N (2r,5s)-1-benzyl-2,5-dimethylpiperazine Chemical compound C[C@@H]1CN[C@@H](C)CN1CC1=CC=CC=C1 WJTCHBVEUFDSIK-NWDGAFQWSA-N 0.000 description 1
- GSTSUZHIVMCRLR-RVZXSAGBSA-N (2s)-2,6-diaminohexanoic acid;(2s)-5-oxopyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCC(=O)N1.NCCCC[C@H](N)C(O)=O GSTSUZHIVMCRLR-RVZXSAGBSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- JXNPEDYJTDQORS-HZJYTTRNSA-N (9Z,12Z)-octadecadien-1-ol Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCO JXNPEDYJTDQORS-HZJYTTRNSA-N 0.000 description 1
- MINDHVHHQZYEEK-UHFFFAOYSA-N (E)-(2S,3R,4R,5S)-5-[(2S,3S,4S,5S)-2,3-epoxy-5-hydroxy-4-methylhexyl]tetrahydro-3,4-dihydroxy-(beta)-methyl-2H-pyran-2-crotonic acid ester with 9-hydroxynonanoic acid Natural products CC(O)C(C)C1OC1CC1C(O)C(O)C(CC(C)=CC(=O)OCCCCCCCCC(O)=O)OC1 MINDHVHHQZYEEK-UHFFFAOYSA-N 0.000 description 1
- 239000001124 (E)-prop-1-ene-1,2,3-tricarboxylic acid Substances 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 description 1
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 description 1
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 1
- NSGXIBWMJZWTPY-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropane Chemical compound FC(F)(F)CC(F)(F)F NSGXIBWMJZWTPY-UHFFFAOYSA-N 0.000 description 1
- YAXKTBLXMTYWDQ-UHFFFAOYSA-N 1,2,3-butanetriol Chemical compound CC(O)C(O)CO YAXKTBLXMTYWDQ-UHFFFAOYSA-N 0.000 description 1
- ZWVMLYRJXORSEP-UHFFFAOYSA-N 1,2,6-Hexanetriol Chemical compound OCCCCC(O)CO ZWVMLYRJXORSEP-UHFFFAOYSA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- WDQFELCEOPFLCZ-UHFFFAOYSA-N 1-(2-hydroxyethyl)pyrrolidin-2-one Chemical compound OCCN1CCCC1=O WDQFELCEOPFLCZ-UHFFFAOYSA-N 0.000 description 1
- XFRVVPUIAFSTFO-UHFFFAOYSA-N 1-Tridecanol Chemical compound CCCCCCCCCCCCCO XFRVVPUIAFSTFO-UHFFFAOYSA-N 0.000 description 1
- CMCBDXRRFKYBDG-UHFFFAOYSA-N 1-dodecoxydodecane Chemical compound CCCCCCCCCCCCOCCCCCCCCCCCC CMCBDXRRFKYBDG-UHFFFAOYSA-N 0.000 description 1
- CJPDBKNETSCHCH-UHFFFAOYSA-N 1-methylsulfinyldodecane Chemical compound CCCCCCCCCCCCS(C)=O CJPDBKNETSCHCH-UHFFFAOYSA-N 0.000 description 1
- HBXWUCXDUUJDRB-UHFFFAOYSA-N 1-octadecoxyoctadecane Chemical compound CCCCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCCCC HBXWUCXDUUJDRB-UHFFFAOYSA-N 0.000 description 1
- NQDZCRSUOVPTII-UHFFFAOYSA-N 10-methylundecan-1-ol Chemical compound CC(C)CCCCCCCCCO NQDZCRSUOVPTII-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- XUJLWPFSUCHPQL-UHFFFAOYSA-N 11-methyldodecan-1-ol Chemical compound CC(C)CCCCCCCCCCO XUJLWPFSUCHPQL-UHFFFAOYSA-N 0.000 description 1
- CFOQKXQWGLAKSK-UHFFFAOYSA-N 13-docosen-1-ol Natural products CCCCCCCCC=CCCCCCCCCCCCCO CFOQKXQWGLAKSK-UHFFFAOYSA-N 0.000 description 1
- WFKIBYWRUUICEX-UHFFFAOYSA-N 2,3-dimethyl-4-pyrrolidin-1-yl-2h-furan-5-one Chemical compound CC1OC(=O)C(N2CCCC2)=C1C WFKIBYWRUUICEX-UHFFFAOYSA-N 0.000 description 1
- QNMCWJOEQBZQHB-UHFFFAOYSA-N 2-Hexyl-1-octanol Chemical compound CCCCCCC(CO)CCCCCC QNMCWJOEQBZQHB-UHFFFAOYSA-N 0.000 description 1
- HMFKFHLTUCJZJO-OQUNMALSSA-N 2-[(2R)-2-[(2R,3R,4R)-3,4-bis(2-hydroxyethoxy)oxolan-2-yl]-2-(2-hydroxyethoxy)ethoxy]ethyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCOC[C@@H](OCCO)[C@H]1OC[C@@H](OCCO)[C@H]1OCCO HMFKFHLTUCJZJO-OQUNMALSSA-N 0.000 description 1
- MQFYRUGXOJAUQK-UHFFFAOYSA-N 2-[2-[2-(2-octadecanoyloxyethoxy)ethoxy]ethoxy]ethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCOCCOCCOCCOC(=O)CCCCCCCCCCCCCCCCC MQFYRUGXOJAUQK-UHFFFAOYSA-N 0.000 description 1
- KGULFLCOPRYBEV-KTKRTIGZSA-N 2-[2-[2-[(z)-octadec-9-enoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCOCCOCCO KGULFLCOPRYBEV-KTKRTIGZSA-N 0.000 description 1
- DWHIUNMOTRUVPG-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCO DWHIUNMOTRUVPG-UHFFFAOYSA-N 0.000 description 1
- HNUQMTZUNUBOLQ-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-(2-octadecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO HNUQMTZUNUBOLQ-UHFFFAOYSA-N 0.000 description 1
- NLMKTBGFQGKQEV-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-hexadecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO NLMKTBGFQGKQEV-UHFFFAOYSA-N 0.000 description 1
- OIALAIQRYISUEV-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]e Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO OIALAIQRYISUEV-UHFFFAOYSA-N 0.000 description 1
- FAOVRYZLXQUFRR-UHFFFAOYSA-N 2-butyldecan-1-ol Chemical compound CCCCCCCCC(CO)CCCC FAOVRYZLXQUFRR-UHFFFAOYSA-N 0.000 description 1
- ZVUNTIMPQCQCAQ-UHFFFAOYSA-N 2-dodecanoyloxyethyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCOC(=O)CCCCCCCCCCC ZVUNTIMPQCQCAQ-UHFFFAOYSA-N 0.000 description 1
- JQJGGMZIMBGQQY-UHFFFAOYSA-N 2-hexadecylicosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCC(CO)CCCCCCCCCCCCCCCC JQJGGMZIMBGQQY-UHFFFAOYSA-N 0.000 description 1
- XULHFMYCBKQGEE-UHFFFAOYSA-N 2-hexyl-1-Decanol Chemical compound CCCCCCCCC(CO)CCCCCC XULHFMYCBKQGEE-UHFFFAOYSA-N 0.000 description 1
- LOIMOHMWAXGSLR-UHFFFAOYSA-N 2-hexyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCC LOIMOHMWAXGSLR-UHFFFAOYSA-N 0.000 description 1
- QWGRWMMWNDWRQN-UHFFFAOYSA-N 2-methylpropane-1,3-diol Chemical compound OCC(C)CO QWGRWMMWNDWRQN-UHFFFAOYSA-N 0.000 description 1
- QPILHXCDZYWYLQ-UHFFFAOYSA-N 2-nonyl-1,3-dioxolane Chemical compound CCCCCCCCCC1OCCO1 QPILHXCDZYWYLQ-UHFFFAOYSA-N 0.000 description 1
- XNIHZNNZJHYHLC-UHFFFAOYSA-N 2-oxohexanoic acid Chemical compound CCCCC(=O)C(O)=O XNIHZNNZJHYHLC-UHFFFAOYSA-N 0.000 description 1
- HVTNWJPMARCVBP-UHFFFAOYSA-N 2-tetradecylicosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCC(CO)CCCCCCCCCCCCCC HVTNWJPMARCVBP-UHFFFAOYSA-N 0.000 description 1
- RTXVDAJGIYOHFY-UHFFFAOYSA-N 2-tetradecyloctadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCC(CO)CCCCCCCCCCCCCC RTXVDAJGIYOHFY-UHFFFAOYSA-N 0.000 description 1
- MRBKEAMVRSLQPH-UHFFFAOYSA-N 3-tert-butyl-4-hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1 MRBKEAMVRSLQPH-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 description 1
- JZVYOOSYROCPHU-UHFFFAOYSA-N 5-methyl-4-pyrrolidin-1-ylfuran-3-one Chemical compound O=C1COC(C)=C1N1CCCC1 JZVYOOSYROCPHU-UHFFFAOYSA-N 0.000 description 1
- LIFHMKCDDVTICL-UHFFFAOYSA-N 6-(chloromethyl)phenanthridine Chemical compound C1=CC=C2C(CCl)=NC3=CC=CC=C3C2=C1 LIFHMKCDDVTICL-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- ONAIRGOTKJCYEY-XXDXYRHBSA-N CCCCCCCCCCCCCCCCCC(O)=O.O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 Chemical compound CCCCCCCCCCCCCCCCCC(O)=O.O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 ONAIRGOTKJCYEY-XXDXYRHBSA-N 0.000 description 1
- 101100235626 Caenorhabditis elegans hlb-1 gene Proteins 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- 241000208293 Capsicum Species 0.000 description 1
- ULJXKUJMXIVDOY-UHFFFAOYSA-N Carvomenthol Natural products CC(C)C1CCC(C)C(O)C1 ULJXKUJMXIVDOY-UHFFFAOYSA-N 0.000 description 1
- 241001340526 Chrysoclista linneella Species 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241000640882 Condea Species 0.000 description 1
- 241000723368 Conium Species 0.000 description 1
- IELOKBJPULMYRW-NJQVLOCASA-N D-alpha-Tocopheryl Acid Succinate Chemical compound OC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C IELOKBJPULMYRW-NJQVLOCASA-N 0.000 description 1
- CIWBSHSKHKDKBQ-DUZGATOHSA-N D-isoascorbic acid Chemical compound OC[C@@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-DUZGATOHSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- PSMFFFUWSMZAPB-UHFFFAOYSA-N Eukalyptol Natural products C1CC2CCC1(C)COCC2(C)C PSMFFFUWSMZAPB-UHFFFAOYSA-N 0.000 description 1
- 208000035874 Excoriation Diseases 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- MBPTXJNHCBXMBP-PWSCQACJSA-N Galanolactone Natural products O=C1/C(=C\C[C@@H]2[C@@]3(C)[C@H](C(C)(C)CCC3)CC[C@@]32OC3)/CCO1 MBPTXJNHCBXMBP-PWSCQACJSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 229920001908 Hydrogenated starch hydrolysate Polymers 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- KLDXJTOLSGUMSJ-JGWLITMVSA-N Isosorbide Chemical class O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 KLDXJTOLSGUMSJ-JGWLITMVSA-N 0.000 description 1
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 1
- 229940124091 Keratolytic Drugs 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 239000004976 Lyotropic liquid crystal Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 1
- RJUFJBKOKNCXHH-UHFFFAOYSA-N Methyl propionate Chemical compound CCC(=O)OC RJUFJBKOKNCXHH-UHFFFAOYSA-N 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- ALQSHHUCVQOPAS-UHFFFAOYSA-N Pentane-1,5-diol Chemical compound OCCCCCO ALQSHHUCVQOPAS-UHFFFAOYSA-N 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- QPFYXYFORQJZEC-FOCLMDBBSA-N Phenazopyridine Chemical compound NC1=NC(N)=CC=C1\N=N\C1=CC=CC=C1 QPFYXYFORQJZEC-FOCLMDBBSA-N 0.000 description 1
- 206010050661 Platelet aggregation inhibition Diseases 0.000 description 1
- 229920002535 Polyethylene Glycol 1500 Polymers 0.000 description 1
- 229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920001219 Polysorbate 40 Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 description 1
- 101000611641 Rattus norvegicus Protein phosphatase 1 regulatory subunit 15A Proteins 0.000 description 1
- 208000018569 Respiratory Tract disease Diseases 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 244000028419 Styrax benzoin Species 0.000 description 1
- 235000000126 Styrax benzoin Nutrition 0.000 description 1
- ONAIRGOTKJCYEY-UHFFFAOYSA-N Sucrose monostearate Chemical compound CCCCCCCCCCCCCCCCCC(O)=O.OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(CO)O1 ONAIRGOTKJCYEY-UHFFFAOYSA-N 0.000 description 1
- 235000008411 Sumatra benzointree Nutrition 0.000 description 1
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 1
- UWHCKJMYHZGTIT-UHFFFAOYSA-N Tetraethylene glycol, Natural products OCCOCCOCCOCCO UWHCKJMYHZGTIT-UHFFFAOYSA-N 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- BAECOWNUKCLBPZ-HIUWNOOHSA-N Triolein Natural products O([C@H](OCC(=O)CCCCCCC/C=C\CCCCCCCC)COC(=O)CCCCCCC/C=C\CCCCCCCC)C(=O)CCCCCCC/C=C\CCCCCCCC BAECOWNUKCLBPZ-HIUWNOOHSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
- 241001135917 Vitellaria paradoxa Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- IJCWFDPJFXGQBN-RYNSOKOISA-N [(2R)-2-[(2R,3R,4S)-4-hydroxy-3-octadecanoyloxyoxolan-2-yl]-2-octadecanoyloxyethyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCCCCCCCCCCCC IJCWFDPJFXGQBN-RYNSOKOISA-N 0.000 description 1
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
- GCSPRLPXTPMSTL-IBDNADADSA-N [(2s,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)O[C@@]1([C@]2(CO)[C@H]([C@H](O)[C@@H](CO)O2)O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GCSPRLPXTPMSTL-IBDNADADSA-N 0.000 description 1
- ZPVGIKNDGJGLCO-VGAMQAOUSA-N [(2s,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)O[C@@]1([C@]2(CO)[C@H]([C@H](O)[C@@H](CO)O2)O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O ZPVGIKNDGJGLCO-VGAMQAOUSA-N 0.000 description 1
- JBPUGFODGPKTDW-SFHVURJKSA-N [(3s)-oxolan-3-yl] n-[[3-[[3-methoxy-4-(1,3-oxazol-5-yl)phenyl]carbamoylamino]phenyl]methyl]carbamate Chemical compound C=1C=C(C=2OC=NC=2)C(OC)=CC=1NC(=O)NC(C=1)=CC=CC=1CNC(=O)O[C@H]1CCOC1 JBPUGFODGPKTDW-SFHVURJKSA-N 0.000 description 1
- RRUDCFGSUDOHDG-UHFFFAOYSA-N acetohydroxamic acid Chemical compound CC(O)=NO RRUDCFGSUDOHDG-UHFFFAOYSA-N 0.000 description 1
- 229960001171 acetohydroxamic acid Drugs 0.000 description 1
- 229940091181 aconitic acid Drugs 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000005456 alcohol based solvent Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 150000007933 aliphatic carboxylic acids Chemical class 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229940099583 aluminum starch octenylsuccinate Drugs 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- JINBYESILADKFW-UHFFFAOYSA-N aminomalonic acid Chemical compound OC(=O)C(N)C(O)=O JINBYESILADKFW-UHFFFAOYSA-N 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000000326 anti-hypercholesterolaemic effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001705 anti-serotonergic effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000006265 aqueous foam Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 239000008122 artificial sweetener Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 229960002130 benzoin Drugs 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- SNHRLVCMMWUAJD-SUYDQAKGSA-N betamethasone valerate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O SNHRLVCMMWUAJD-SUYDQAKGSA-N 0.000 description 1
- 229960004311 betamethasone valerate Drugs 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- OZCRKDNRAAKDAN-UHFFFAOYSA-N but-1-ene-1,4-diol Chemical compound O[CH][CH]CCO OZCRKDNRAAKDAN-UHFFFAOYSA-N 0.000 description 1
- BMRWNKZVCUKKSR-UHFFFAOYSA-N butane-1,2-diol Chemical compound CCC(O)CO BMRWNKZVCUKKSR-UHFFFAOYSA-N 0.000 description 1
- OWBTYPJTUOEWEK-UHFFFAOYSA-N butane-2,3-diol Chemical compound CC(O)C(C)O OWBTYPJTUOEWEK-UHFFFAOYSA-N 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 239000010624 camphor oil Substances 0.000 description 1
- 229960000411 camphor oil Drugs 0.000 description 1
- 239000004204 candelilla wax Substances 0.000 description 1
- 235000013868 candelilla wax Nutrition 0.000 description 1
- 229940073532 candelilla wax Drugs 0.000 description 1
- 239000001722 capsicum frutescens oleoresin Substances 0.000 description 1
- 229940050948 capsicum oleoresin Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- NPAXBRSUVYCZGM-UHFFFAOYSA-N carbonic acid;propane-1,2-diol Chemical compound OC(O)=O.CC(O)CO NPAXBRSUVYCZGM-UHFFFAOYSA-N 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229920006184 cellulose methylcellulose Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000011153 ceramic matrix composite Substances 0.000 description 1
- 229940056318 ceteth-20 Drugs 0.000 description 1
- 238000012710 chemistry, manufacturing and control Methods 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 230000002279 cholagogic effect Effects 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- RFFOTVCVTJUTAD-UHFFFAOYSA-N cineole Natural products C1CC2(C)CCC1(C(C)C)O2 RFFOTVCVTJUTAD-UHFFFAOYSA-N 0.000 description 1
- GTZCVFVGUGFEME-IWQZZHSRSA-N cis-aconitic acid Chemical compound OC(=O)C\C(C(O)=O)=C\C(O)=O GTZCVFVGUGFEME-IWQZZHSRSA-N 0.000 description 1
- 238000004581 coalescence Methods 0.000 description 1
- MRUAUOIMASANKQ-UHFFFAOYSA-N cocamidopropyl betaine Chemical compound CCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC([O-])=O MRUAUOIMASANKQ-UHFFFAOYSA-N 0.000 description 1
- 229940073507 cocamidopropyl betaine Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- KONGRWVLXLWGDV-UHFFFAOYSA-N cubebol Natural products C12C(C(C)C)CCC(C)C32C1C(C)(O)CC3 KONGRWVLXLWGDV-UHFFFAOYSA-N 0.000 description 1
- 229940099418 d- alpha-tocopherol succinate Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 231100000223 dermal penetration Toxicity 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- GYZLOYUZLJXAJU-UHFFFAOYSA-N diglycidyl ether Chemical compound C1OC1COCC1CO1 GYZLOYUZLJXAJU-UHFFFAOYSA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- DFQOCHPHORLRID-UHFFFAOYSA-N dodecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCCCCCCCCCCCC DFQOCHPHORLRID-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000000613 ear canal Anatomy 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000006267 emulsion-based foam Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 235000010350 erythorbic acid Nutrition 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 125000004387 flavanoid group Chemical group 0.000 description 1
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 235000019256 formaldehyde Nutrition 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- MBPTXJNHCBXMBP-IGOJNLFMSA-N galanolactone Chemical compound C([C@@H]1[C@@]2(C)CCCC([C@@H]2CC[C@]11OC1)(C)C)\C=C1\CCOC1=O MBPTXJNHCBXMBP-IGOJNLFMSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- RBNPOMFGQQGHHO-UHFFFAOYSA-N glyceric acid Chemical compound OCC(O)C(O)=O RBNPOMFGQQGHHO-UHFFFAOYSA-N 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 235000019382 gum benzoic Nutrition 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000000025 haemostatic effect Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- IUJAMGNYPWYUPM-UHFFFAOYSA-N hentriacontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC IUJAMGNYPWYUPM-UHFFFAOYSA-N 0.000 description 1
- 150000002386 heptoses Chemical class 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- ACCCMOQWYVYDOT-UHFFFAOYSA-N hexane-1,1-diol Chemical compound CCCCCC(O)O ACCCMOQWYVYDOT-UHFFFAOYSA-N 0.000 description 1
- ISSPZNCHBPXIKN-UHFFFAOYSA-N hexane-1,6-diol;hexane-2,3-diol Chemical compound CCCC(O)C(C)O.OCCCCCCO ISSPZNCHBPXIKN-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229960000443 hydrochloric acid Drugs 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- NBZBKCUXIYYUSX-UHFFFAOYSA-N iminodiacetic acid Chemical compound OC(=O)CNCC(O)=O NBZBKCUXIYYUSX-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000011016 integrity testing Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229940026239 isoascorbic acid Drugs 0.000 description 1
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 1
- 229940113096 isoceteth 20 Drugs 0.000 description 1
- 229960005280 isotretinoin Drugs 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 230000001530 keratinolytic effect Effects 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 229940031674 laureth-7 Drugs 0.000 description 1
- 229960003639 laurocapram Drugs 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- JXNPEDYJTDQORS-UHFFFAOYSA-N linoleyl alcohol Natural products CCCCCC=CCC=CCCCCCCCCO JXNPEDYJTDQORS-UHFFFAOYSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960001929 meloxicam Drugs 0.000 description 1
- JSEFYOBABBXEJJ-UHFFFAOYSA-N menthol propylene glycol carbonate Chemical compound CC(O)COC(=O)OC1CC(C)CCC1C(C)C.CC(C)C1CCC(C)CC1OC(=O)OC(C)CO JSEFYOBABBXEJJ-UHFFFAOYSA-N 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 201000003152 motion sickness Diseases 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229960003128 mupirocin Drugs 0.000 description 1
- 229930187697 mupirocin Natural products 0.000 description 1
- DDHVILIIHBIMQU-YJGQQKNPSA-L mupirocin calcium hydrate Chemical compound O.O.[Ca+2].C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1.C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1 DDHVILIIHBIMQU-YJGQQKNPSA-L 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 229940043348 myristyl alcohol Drugs 0.000 description 1
- SLCVBVWXLSEKPL-UHFFFAOYSA-N neopentyl glycol Chemical compound OCC(C)(C)CO SLCVBVWXLSEKPL-UHFFFAOYSA-N 0.000 description 1
- 229940117969 neopentyl glycol Drugs 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 239000002840 nitric oxide donor Substances 0.000 description 1
- MGFYIUFZLHCRTH-UHFFFAOYSA-N nitrilotriacetic acid Chemical compound OC(=O)CN(CC(O)=O)CC(O)=O MGFYIUFZLHCRTH-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- YYZUSRORWSJGET-UHFFFAOYSA-N octanoic acid ethyl ester Natural products CCCCCCCC(=O)OCC YYZUSRORWSJGET-UHFFFAOYSA-N 0.000 description 1
- 239000006268 oleaginous foam Substances 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229940099570 oleth-2 Drugs 0.000 description 1
- 229940095127 oleth-20 Drugs 0.000 description 1
- 229940075643 oleth-3 Drugs 0.000 description 1
- 229940093446 oleth-5 Drugs 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Polymers 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 229940116315 oxalic acid Drugs 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 229930004008 p-menthane Natural products 0.000 description 1
- 229930006948 p-menthane-3,8-diol Natural products 0.000 description 1
- 150000002936 p-menthane-3,8-diol derivatives Chemical class 0.000 description 1
- LBIYNOAMNIKVKF-FPLPWBNLSA-N palmitoleyl alcohol Chemical compound CCCCCC\C=C/CCCCCCCCO LBIYNOAMNIKVKF-FPLPWBNLSA-N 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 229940031709 peg-30-dipolyhydroxystearate Drugs 0.000 description 1
- 229940032066 peg-4 dilaurate Drugs 0.000 description 1
- UWJJYHHHVWZFEP-UHFFFAOYSA-N pentane-1,1-diol Chemical compound CCCCC(O)O UWJJYHHHVWZFEP-UHFFFAOYSA-N 0.000 description 1
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 description 1
- RUOPINZRYMFPBF-UHFFFAOYSA-N pentane-1,3-diol Chemical compound CCC(O)CCO RUOPINZRYMFPBF-UHFFFAOYSA-N 0.000 description 1
- GLOBUAZSRIOKLN-UHFFFAOYSA-N pentane-1,4-diol Chemical compound CC(O)CCCO GLOBUAZSRIOKLN-UHFFFAOYSA-N 0.000 description 1
- XLMFDCKSFJWJTP-UHFFFAOYSA-N pentane-2,3-diol Chemical compound CCC(O)C(C)O XLMFDCKSFJWJTP-UHFFFAOYSA-N 0.000 description 1
- GTCCGKPBSJZVRZ-UHFFFAOYSA-N pentane-2,4-diol Chemical compound CC(O)CC(C)O GTCCGKPBSJZVRZ-UHFFFAOYSA-N 0.000 description 1
- 229960003330 pentetic acid Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 229960004838 phosphoric acid Drugs 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- KASDHRXLYQOAKZ-ZPSXYTITSA-N pimecrolimus Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](Cl)[C@H](OC)C1 KASDHRXLYQOAKZ-ZPSXYTITSA-N 0.000 description 1
- 229960005330 pimecrolimus Drugs 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229940113116 polyethylene glycol 1000 Drugs 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 229940104257 polyglyceryl-6-dioleate Drugs 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 description 1
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 description 1
- 229940101027 polysorbate 40 Drugs 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229940070891 pyridium Drugs 0.000 description 1
- 150000004040 pyrrolidinones Chemical class 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 239000003507 refrigerant Substances 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 239000008257 shaving cream Substances 0.000 description 1
- 229940057910 shea butter Drugs 0.000 description 1
- 235000021309 simple sugar Nutrition 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 230000037075 skin appearance Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- BTURAGWYSMTVOW-UHFFFAOYSA-M sodium dodecanoate Chemical compound [Na+].CCCCCCCCCCCC([O-])=O BTURAGWYSMTVOW-UHFFFAOYSA-M 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940082004 sodium laurate Drugs 0.000 description 1
- 229940048109 sodium methyl cocoyl taurate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- IZWPGJFSBABFGL-GMFCBQQYSA-M sodium;2-[methyl-[(z)-octadec-9-enoyl]amino]ethanesulfonate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC(=O)N(C)CCS([O-])(=O)=O IZWPGJFSBABFGL-GMFCBQQYSA-M 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 229950006451 sorbitan laurate Drugs 0.000 description 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 235000011078 sorbitan tristearate Nutrition 0.000 description 1
- 239000001589 sorbitan tristearate Substances 0.000 description 1
- 229960004129 sorbitan tristearate Drugs 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000003655 tactile properties Effects 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- REZOIPSCCRVWNN-UHFFFAOYSA-N tetratriacontan-17-ol Chemical compound CCCCCCCCCCCCCCCCCC(O)CCCCCCCCCCCCCCCC REZOIPSCCRVWNN-UHFFFAOYSA-N 0.000 description 1
- 210000003051 thermoreceptor Anatomy 0.000 description 1
- 108091008689 thermoreceptors Proteins 0.000 description 1
- 230000001331 thermoregulatory effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- 235000019505 tobacco product Nutrition 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- 229940042130 topical foam Drugs 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- GTZCVFVGUGFEME-UHFFFAOYSA-N trans-aconitic acid Natural products OC(=O)CC(C(O)=O)=CC(O)=O GTZCVFVGUGFEME-UHFFFAOYSA-N 0.000 description 1
- 238000005809 transesterification reaction Methods 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 229940087291 tridecyl alcohol Drugs 0.000 description 1
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 1
- 229940117972 triolein Drugs 0.000 description 1
- 150000003641 trioses Chemical class 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 229940057402 undecyl alcohol Drugs 0.000 description 1
- 229940045136 urea Drugs 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000002888 zwitterionic surfactant Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
- A01N25/16—Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/046—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/42—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9706—Algae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A61K9/122—Foams; Dry foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
- A61K2800/24—Thermal properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
- A61K2800/24—Thermal properties
- A61K2800/242—Exothermic; Self-heating; Heating sensation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
- A61K2800/24—Thermal properties
- A61K2800/244—Endothermic; Cooling; Cooling sensation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Dispersion Chemistry (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Pest Control & Pesticides (AREA)
- Environmental Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Dentistry (AREA)
- Toxicology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Plant Pathology (AREA)
- Agronomy & Crop Science (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
Abstract
This invention relates to foamable compositions that are capable of producing a sensation or sensation modifying effect upon application on a body surface. More particularly the invention relates to a composition that provides to a subject at least one sensation for a sustained period of time following application to the skin. The composition includes (a) at least one sensation or sensation modifying agent, comprising one or more of a cooling agent, a warming agent, a relaxing or soothing agent, and a stimulating or refreshing agent; (b) a foamable carrier; and (c) a propellant having a concentration about 3% to about 45%
by weight of the total composition. The composition is stored in an aerosol container and upon release expands to form a non-crackling short term stable foam.
by weight of the total composition. The composition is stored in an aerosol container and upon release expands to form a non-crackling short term stable foam.
Description
SENSATION MODIFYING TOPICAL COMPOSITION FOAM
BACKGROUND
[0001] Compositions of various types have incorporated within them components or agents which provide a sensation to mucosal membranes and/or to skin. The sensation may be a warming, cooling, relaxation stimulation or refreshing feeling or a combination of two or more feelings. The sensation or feeling may be real or artificial.
BACKGROUND
[0001] Compositions of various types have incorporated within them components or agents which provide a sensation to mucosal membranes and/or to skin. The sensation may be a warming, cooling, relaxation stimulation or refreshing feeling or a combination of two or more feelings. The sensation or feeling may be real or artificial.
[0002] Compositions which include a sensation agent include, inter alia, toothpastes, mouthwashes, perfumes, lotions, shaving cream, shampoos, antiperspirants, deodorants, beverages, chewing gum, tobacco products, and pharmaceutical products.
[0003] Most compositions known to date, comprising one or more sensation agents, cannot retain the sensation at the site of application thereof in a subject over extended periods of time. Typically, topical formulations do not retain the sensational effect for more than a few seconds. Additionally, the sensation agent may be volatile, such as menthol, used for providing a topical cooling effect, and the formulation may not retain the active agent for more than a few seconds.
[0004] The mechanism of cooling and warming sensation or sensation modification for example is poorly understood at present. It has been suggested that, among other options, the action of menthol and other cooling agents and capsaicin, camphor and other heat compounds occurs via "thermoreceptors" that register "cool" and "hot"
sensation, respectively. It has been suggested that the 'cooling' effect of menthol is a physiological effect due to the direct action of menthol on the nerve endings of the human body responsible for the detection of hot or cold and is not due to latent heat of evaporation such that menthol acts as a direct stimulus on the cold receptors at the nerve endings which, in turn, stimulate the central nervous system.
sensation, respectively. It has been suggested that the 'cooling' effect of menthol is a physiological effect due to the direct action of menthol on the nerve endings of the human body responsible for the detection of hot or cold and is not due to latent heat of evaporation such that menthol acts as a direct stimulus on the cold receptors at the nerve endings which, in turn, stimulate the central nervous system.
[0005] Substances which are known to provide a sensation of warmth or warmth modulation on application and are called "warming agents" include polyhydric alcohols, capsicum (red pepper) powder, a capsicum tincture, capsicum extract, capsaicin, homocapsaicin, homodihydrocapsaicin, nonanoyl vanillyl amide, nonanoic acid vanillyl ether, vanillyl alcohol alkyl ether derivatives, such as vanillyl ethyl ether, vanillyl butyl ether, vanillyl pentyl ether, and vanillyl hexyl ether, isovanillyl alcohol alkyl ethers, ethylvanillyl alcohol alkyl ethers, veratryl alcohol derivatives, substituted benzyl alcohol derivatives, substituted benzyl alcohol alkyl ethers, vanillin propylene glycol acetal, ethylvanillin propylene glycol acetal, ginger extract, ginger oil, gingeol, and gingeron.
[0006] Foams are considered a more convenient vehicle for topical delivery of active agents. There are several types of topical foams, including aqueous foams, such as commonly available shaving foams; hydroalcoholic foams, emulsion-based foams, comprising oil and water components and oleaginous foams, which consist of high oil content, and which are foamable compositions having a specific surfactant selected from the group consisting of ethoxylated lanolin oil, propoxylated lanolin oil, and mixtures thereof and high levels of water that produce fast breaking foams that disappears rapidly into the skin with cooling sensation is described. Some formulations make a sound or crackling effect when foam is dispensed. Dimethyl ether is a substance which evaporates very rapidly and its use with an aqueous non emollient gel composition, lotion composition and a solution in producing a cooling effect (as opposed to mere sensation without cooling). High levels of propellant have also been used to provide a solid or semi ointment deposit with a temperature between minus to plus 5 C.
[0007] Foam forming refrigerant compositions, suitable for emergency treatment of burns have also been described.
[0008] Foams and, in particular, foam emulsions are complicated systems which do not form under all circumstances. Changes in foam emulsion composition, such as by the addition of active ingredients may destabilize the foam. There is, therefore, a need for a foam composition, which provides desirable properties to the skin and can remain stable whilst accommodating a variety of sensation agents or active ingredients.
[0009] Formulations based on oil or ointment or emollients have a number of useful attributes making them suitable candidates for topical pharmaceutical and cosmetic compositions including foamable compositions. They are inherently stable and inert which are clearly desirable characteristics. They are able to moisturize and soften the skin and in appropriate amounts can act as a protective or barrier layer and can form a barrier to water. By appropriate formulation they can act to improve agent delivery to the skin and yet remain resistant to being washed off. On the other hand they are by their nature greasy materials and can be difficult to formulate particularly into a topical foamable composition that can deliver substantially uniform and stable composition or foam that ameliorates or overcomes the look and feel of a greasy material, especially where that composition is waterless or substantially so. It is further a problem to incorporate into such a vehicle, effective amounts of one or more active sensation and/or pharmaceutical ingredients such that they are uniformly present throughout the formulation and are effectively delivered without the use of a lower alcohol in the formulation.
[0010] On one level it is far from simple or obvious to produce waterless foamable compositions that when released produce foams of quality suitable for sensation, pharmaceutical or cosmetic application. On a further level having realized a carrier that will produce a waterless foam of quality there is an additional difficulty to be overcome, namely how to adapt the formula and achieve a formulation, which can accept a range of various active sensation, pharmaceutical and cosmetic agents such that the composition and active agent are stable and the foam produced remains of quality.
Specifically, one of the challenges in preparing such waterless or substantially waterless foamable compositions is ensuring that the one or more active sensation, pharmaceutical or therapeutic agents does not react, isomerize or otherwise break down to any significant extent during is storage and use. Particularly, there remains an unmet need for improved, easy to use, stable and non-irritating foam formulations, with unique sensation, therapeutic or beneficial properties containing a stable or stabilized active sensation, pharmaceutical or cosmetic agent.
Specifically, one of the challenges in preparing such waterless or substantially waterless foamable compositions is ensuring that the one or more active sensation, pharmaceutical or therapeutic agents does not react, isomerize or otherwise break down to any significant extent during is storage and use. Particularly, there remains an unmet need for improved, easy to use, stable and non-irritating foam formulations, with unique sensation, therapeutic or beneficial properties containing a stable or stabilized active sensation, pharmaceutical or cosmetic agent.
[0011] There remains an unmet need for improved, easy to use, stable and non-irritating topical foam formulations containing a stable or stabilized active sensation, pharmaceutical or cosmetic agent having a therapeutic or beneficial effect, intended for treatment of dermal and mucosal tissues.
[0012] There is still a need to provide stable aqueous and non-aqueous compositions comprising one or more sensation agents for sustained provision of at least one sensation from the sensation agent(s).
SUMMARY
SUMMARY
[0013] The application relates to aqueous foamable vehicles capable of delivering one or more sensation agents to a body surface in a breakable foam of quality.
The aqueous vehicles may be emulsion or gel vehicles. The application also relates to non aqueous foamable vehicles capable of delivering one or more sensation agents to a body surface in a breakable foam of quality. Upon contact with the body surface an effective amount of one or more sensory agents are capable of causing a perceived sensory effect.
The aqueous vehicles may be emulsion or gel vehicles. The application also relates to non aqueous foamable vehicles capable of delivering one or more sensation agents to a body surface in a breakable foam of quality. Upon contact with the body surface an effective amount of one or more sensory agents are capable of causing a perceived sensory effect.
[0014] In one or more embodiments the formulations are resistant to aging as indicated by their ability to withstand centrifugation. In other embodiments the formulations have a significant and suitable collapse time of 300 or more seconds.
[0015] In one or more embodiments the formulations are considered to be pleasant for use.
[0016] There is provided a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface.
[0017] There is further provided a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, where the sensation is primarily a cooling or warming sensation over a sustained period of time. The sustained period of time is at least five minutes, more preferably, at least 15 minutes, yet more preferably, at least 30 minutes, still more preferably, at least one hour. According to some embodiments the sensation may be felt for up to two hours or more.
[0018] There is further provided a stable foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, where the sensation is primarily a relaxing, soothing, stimulating or refreshing sensation.
[0019] There is provided a stable foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, where the sensation is a combination of two or more sensations.
[0020] There is provided a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, in which the sensation is caused by a sensation agent and the sensation is further modulated, potentiated, increased, reduced, or ameliorated by the presence of a sensation modifying agent.
[0021] There is provided a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, in which the sensation is caused by a sensation agent and the sensation is complementary, supplementary or in addition to or superimposed on a cosmetic, therapeutic or pharmaceutical effect.
[0022] There is provided a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, wherein the foamable composition comprises a substantially non aqueous carrier.
[0023] There is provided a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, wherein the foamable composition comprises a substantially aqueous emollient carrier.
[0024] This invention relates to foamable compositions that are capable of producing a sensation or sensation modifying effect upon application on a body surface.
More particularly the invention relates to foamable pharmaceutical and cosmetic compositions, containing an active agent, having a sensation or sensation modifying affect on a body surface, upon application.
More particularly the invention relates to foamable pharmaceutical and cosmetic compositions, containing an active agent, having a sensation or sensation modifying affect on a body surface, upon application.
[0025] There is provided a stable foamable composition that is stable on a surface at the delivery site for at least one minute, more preferably, at least two minutes, yet more preferably, for at least five minutes.
[0026] There is thus provided according to some aspects of the present invention, a composition that provides to a subject at least one sensation for a sustained period of time following application to the skin. The composition includes:
a. at least one sensation or sensation modifying agent, including one or more of a cooling agent, a warming agent, a relaxing or soothing agent, and a stimulating or refreshing agent;
b. a foamable carrier; and c. a propellant having a concentration about 3% to about 45% by weight of the total composition.
The composition is stored in an aerosol container and upon release expands to form a non-crackling short term stable foam.
a. at least one sensation or sensation modifying agent, including one or more of a cooling agent, a warming agent, a relaxing or soothing agent, and a stimulating or refreshing agent;
b. a foamable carrier; and c. a propellant having a concentration about 3% to about 45% by weight of the total composition.
The composition is stored in an aerosol container and upon release expands to form a non-crackling short term stable foam.
[0027] According to some embodiments, the sensation effect is provided at a delivery site of the subject.
[0028] According to some embodiments, upon contact at a delivery site the sustained sensation is not primarily due to the propellant or an exothermic reaction.
[0029] According to some embodiments, 4 the foamable carrier is resistant to aging and/or suitable for delivery of at least one sensation or sensation modifying agent.
[0030] According to some embodiments, the relaxing or soothing agent includes a herb extract, an astringent, a sea weed extract, an oat extract; an oil, a waxy or unctuous substance, a mineral, a vitamin, a pharmaceutical agent, menthol, camphor, eugenol, eucalyptol, safrol, methyl salicylate, menthyl lactate, menthyl ethoxyacetate, menthone glycerinacetal, 3-I-menthoxypropane-1,2-diol, ethyl 1-menthyl carbonate, (1 S,3S,4R)-p-menth-8-en-3-ol, menthyl pyrrolidone carboxylate, an N-substituted-p-menthane-carboxamide, hamamelis extract, ginger oil, or any mixture of two or more thereof.
[0031]
[0032] According to some embodiments, the herb extract comprises one or more of aloe vera, alpha bisabolol, D-panthenol, allantoin, hamamelis, chamomile, and yarrow.
[0033] According to some embodiments, the astringent comprises one or more of calendula, comfrey, and witch hazel.
[0034] According to some embodiments, the oil includes one or more of almond oil, avocado oil, cardamone, eucalyptus, mentha piperita (peppermint), hyssop, and rosemary.
[0035] According to some embodiments, the waxy or unctuous substance includes one or more of lanolin and petrolatum (e.g., vaseline jelly).
[0036] According to some embodiments, the mineral includes one or more of zinc oxide, calamine and selenium.
[0037] According to some embodiments, the vitamin includes tocopheryl acetate.
[0038] According to some embodiments, the pharmaceutical agent includes one or more of an analgesic, an anesthetic, an anti-inflammatory agent, an antihistamine, and a muscle relaxant.
[0039] According to some embodiments, the stimulating or refreshing agent includes an alcohol, L-menthol, camphor, menthe oil, capsicum extract, capsaicin, benzyl nicotinate, salicylate, glycol salicylate, acetyl choline, serotonin, histamine, a prostaglandin, a neurotransmitter; a CNS stimulant, caffeine, quinine, or any mixture of two or more thereof.
[0040] According to some embodiments, the foamable carrier inclues about 40%
to about 99% by weight of the total composition, excluding the propellant, and is an aqueous emulsion, an aqueous gel, or a non-aqueous carrier.
to about 99% by weight of the total composition, excluding the propellant, and is an aqueous emulsion, an aqueous gel, or a non-aqueous carrier.
[0041] According to some embodiments, the foamable carrier includes:
i. at least one surface active agent at a concentration of about 0.1 % to about 10% by weight of the carrier;
ii. at least one polymeric agent at a concentration of about 0.1 % to about 5%
by weight of the total composition; and iii. at least one non-aqueous solvent.
i. at least one surface active agent at a concentration of about 0.1 % to about 10% by weight of the carrier;
ii. at least one polymeric agent at a concentration of about 0.1 % to about 5%
by weight of the total composition; and iii. at least one non-aqueous solvent.
[0042] According to some embodiments, the foamable carrier further includes one or more of:
i. a co-emulsifier or foam stabilizer at a concentration of about 0.1 % to about 5%
by weight of the total composition;
ii. a wax, viscosity, bulking or firming agent at a concentration of about 0.1 % to about 15% by weight of the total composition;
iii. a co-solvent at a concentration of about 0.1 % to about 20% by weight of the total composition;
iv. a penetration enhancer or potent solvent at a concentration of about 0.1 %
to about 25% by weight of the total composition;
v. a foam adjuvant agent, comprising a fatty alcohol having 15 or more carbons in the carbon chain, or a fatty acid having 16 or more carbons in the carbon chain, at a concentration of about 0.1 % to about 25% by weight of the total composition;
vi. a stabilizer at a concentration of about 5% to about 30% by weight of the total composition; and vii. an agent providing an occlusive effect, at a concentration of about 5% to about 30% by weight of the total composition.
i. a co-emulsifier or foam stabilizer at a concentration of about 0.1 % to about 5%
by weight of the total composition;
ii. a wax, viscosity, bulking or firming agent at a concentration of about 0.1 % to about 15% by weight of the total composition;
iii. a co-solvent at a concentration of about 0.1 % to about 20% by weight of the total composition;
iv. a penetration enhancer or potent solvent at a concentration of about 0.1 %
to about 25% by weight of the total composition;
v. a foam adjuvant agent, comprising a fatty alcohol having 15 or more carbons in the carbon chain, or a fatty acid having 16 or more carbons in the carbon chain, at a concentration of about 0.1 % to about 25% by weight of the total composition;
vi. a stabilizer at a concentration of about 5% to about 30% by weight of the total composition; and vii. an agent providing an occlusive effect, at a concentration of about 5% to about 30% by weight of the total composition.
[0043] According to some embodiments, the composition further includes at least one additional active agent, which is a cosmetic active agent or a pharmaceutical active agent having a cosmetic or pharmaceutical effect other than a sensation or sensation modifying effect.
[0044] According to some embodiments the at least one additional active agent comprises at least one of an active herbal extract, an acaricide, an age spot and keratosis removing agent, an allergen, an analgesic, a local anesthetic, an antiacne agent, an antiallergic agent, an antiaging agent, an antibacterial, an antibiotic, an antiburn agent, an anticancer agent, an antidandruff agent, an antidepressant, an antidermatitis agent, an antiedemic, an antihistamine, an antihelminth, an antihyperkeratolytic agent, an antiinflammatory agent, an antiirritant, an antilipemic, an antimicrobial, an antimycotic, an antiproliferative agent, an antioxidant, an anti-wrinkle agent, an antipruritic, an antipsoriatic agent, an antirosacea agent, an antiseborrheic agent, an antiseptic, an antiswelling agent, an antiviral agent, an anti-yeast agent, an astringent, a topical cardiovascular agent, a chemotherapeutic agent, coal tar or an extract thereof, a corticosteroid, a dicarboxylic acid, a disinfectant, a fungicide, a hair growth regulator, a hormone, a hydroxy acid, an immunosuppressant, an immunoregulating agent, an insecticide, an insect repellent, a keratolytic agent, a lactam, a metal, a metal oxide, a mitocide, a neuropeptide, a non-steroidal anti-inflammatory agent, an oxidizing agent, a pediculicide, a photodynamic therapy agent, a retinoid, a sanative, a scabicide, a self tanning agent, a skin whitening agent, a vasoconstrictor, a vasodilator, a vitamin, a vitamin derivative, vitamin A or a derivative thereof, vitamin D or a derivative thereof, a wound healing agent, and a wart remover.
[0045] According to some embodiments, the composition further includes an additional component, which is an anti-perspirant, an anti-static agent, a buffering agent, a bulking agent, a chelating agent, a colorant, a conditioner, a deodorant, a diluent, a dye, an emollient, fragrance, a humectant, a moisturizer, an occlusive agent, a penetration enhancer, a perfuming agent, a permeation enhancer, a pH-adjusting agent, a preservative, a skin penetration enhancer, a sunscreen, a sun blocking agent, a sunless tanning agent, a vitamin, or a mixture of any two or more thereof.
[0046] According to some embodiments, the polymeric agent comprises at least one of locust bean gum, sodium alginate, sodium caseinate, egg albumin, gelatin agar, carrageenin gum, sodium alginate, xanthan gum, quince seed extract, tragacanth gum, guar gum, a cationic guar, hydroxypropyl guar gum, starch, an amine-bearing polymer, chitosan, alginic acid, hyaluronic acid, a chemically modified starch, a carboxyvinyl polymer, a polyvinylpyrrolidone, a polyvinyl alcohol, a polyacrylic acid polymer, a polymethacrylic acid polymer, a polyvinyl acetate, a polyvinyl chloride polymer, a polyvinylidene chloride polymer, a methylcellulose, a hydroxypropyl cellulose, a hydroxypropyl methylcellulose, a hydroxyethyl cellulose, a hydroxypropyl methyl cellulose, a methylhydroxyethylcellulose, a methylhydroxypropylcellulose, a hydroxyethylcarboxymethylcellulose, a carboxymethyl cellulose, a carboxymethylcellulose, a carboxymethylhydroxyethylcellulose, a cationic cellulose, a ployethylene glycol, xanthan gum, a sodium carboxymethylcellulose, microcrystalline-cellulose, aluminum starch octyl succinate, and a polyacrylate.
[0047] According to some embodiments, upon dispensing as a foam, the composition has a density of about 0.01 to about 0.2 g/ml.
[0048] According to some embodiments, the compositions described herein contain a sensation or sensation modifying including at least one of:
a combination of a cooling and a warming agent;
a combination of a cooling and a soothing or relaxing agent;
a combination of a cooling and a stimulating or refreshing agent;
a combination of a warming and a stimulating or refreshing agent;
a combination of a warming and a soothing or relaxing agent;
a combination of a cooling, a warming and a soothing or relaxing agent; and a combination of a cooling, a warming and stimulating or refreshing agent.
a combination of a cooling and a warming agent;
a combination of a cooling and a soothing or relaxing agent;
a combination of a cooling and a stimulating or refreshing agent;
a combination of a warming and a stimulating or refreshing agent;
a combination of a warming and a soothing or relaxing agent;
a combination of a cooling, a warming and a soothing or relaxing agent; and a combination of a cooling, a warming and stimulating or refreshing agent.
[0049] According to some embodiments, the compositions described herein contain:
a. a sensation or sensation modifying agent including menthol at a concentration of 0.5 to about 3% by weight of the composition;
b. at least one additional active agent including:
i. coal tar or coal tar extract at a concentration of about 2% to about 20% by weight of the composition; and ii. at least one other active agent comprising salicylic acid, hydrocortisone, or both, in a concentration of about 0.5% to about 10% by weight of the composition.
a. a sensation or sensation modifying agent including menthol at a concentration of 0.5 to about 3% by weight of the composition;
b. at least one additional active agent including:
i. coal tar or coal tar extract at a concentration of about 2% to about 20% by weight of the composition; and ii. at least one other active agent comprising salicylic acid, hydrocortisone, or both, in a concentration of about 0.5% to about 10% by weight of the composition.
[0050] There is further provided according to some embodiments of the present invention, a composition for providing a subject with at least one sensation for a sustained period of time. The composition includes:
a. coal tar or coal tar extract;
b. a mixture of mint and peppermint oil;
c. a silicone oil;
d. a surfactant;
e. a buffering system; and f. a propellant at a concentration of about 3% to about 45% by weight of the total composition.
The composition is stored in an aerosol container and upon release expands to form a short term stable foam.
a. coal tar or coal tar extract;
b. a mixture of mint and peppermint oil;
c. a silicone oil;
d. a surfactant;
e. a buffering system; and f. a propellant at a concentration of about 3% to about 45% by weight of the total composition.
The composition is stored in an aerosol container and upon release expands to form a short term stable foam.
[0051] There is is provided according to some embodiments of the present invention, a composition for providing a subject with at least one sensation for a sustained period of time. The composition includes:
a. coal tar or coal tar extract;
b. a mixture of mint and peppermint oil;
c. a triglyceride;
d. a surfactant;
e. a buffering system; and f. a propellant at a concentration of about 3% to about 45% by weight of the total composition.
The composition is stored in an aerosol container and upon release expands to form a short term stable foam.
a. coal tar or coal tar extract;
b. a mixture of mint and peppermint oil;
c. a triglyceride;
d. a surfactant;
e. a buffering system; and f. a propellant at a concentration of about 3% to about 45% by weight of the total composition.
The composition is stored in an aerosol container and upon release expands to form a short term stable foam.
[0052] There is further provided according to some embodiments of the present invention, a composition for providing a subject with at least one sensation for a sustained period of time. The composition includes:
a. coal tar or coal tar extract;
b. a mixture of mint and peppermint oil;
c. a silicone oil and a triglyceride;
d. a surfactant;
e. a buffering system; and f. a propellant at a concentration of about 3% to about 45% by weight of the total composition.
The composition is stored in an aerosol container and upon release expands to form a short term stable foam. According to some embodiments, the buffering system comprises an EDTA, a citrate buffer, or a mixture thereof. According to some embodiments, the compositions described herein further includes a polymeric agent, a foam adjuvant, or a combination thereof. According to some embodiments, the compositions described herein further includes a penetrating agent, a humectant, or a combination thereof. According to some embodiments, the coal tar or coal tar extract is present in the compositions described herein at a concentration of about 2% to about 20% by weight. According to some embodiments, the surfactant is present in the compositions described herein at a concentration of about 2% to about 8.5% by weight.
a. coal tar or coal tar extract;
b. a mixture of mint and peppermint oil;
c. a silicone oil and a triglyceride;
d. a surfactant;
e. a buffering system; and f. a propellant at a concentration of about 3% to about 45% by weight of the total composition.
The composition is stored in an aerosol container and upon release expands to form a short term stable foam. According to some embodiments, the buffering system comprises an EDTA, a citrate buffer, or a mixture thereof. According to some embodiments, the compositions described herein further includes a polymeric agent, a foam adjuvant, or a combination thereof. According to some embodiments, the compositions described herein further includes a penetrating agent, a humectant, or a combination thereof. According to some embodiments, the coal tar or coal tar extract is present in the compositions described herein at a concentration of about 2% to about 20% by weight. According to some embodiments, the surfactant is present in the compositions described herein at a concentration of about 2% to about 8.5% by weight.
[0053] There is further provided according to some embodiments of the present invention, a composition for providing a subject with at least one sensation at a delivery site for a sustained period of time. The composition includes:
a. about 10% by weight of a cooling agent;
b. about 81 % to about 83% by weight of a glycol;
c. about 6% by weight of one or more surfactants;
d. about 1 % by weight of a polymeric agent; and e. a propellant at a concentration of about 3% to about 45% by weight of the total composition.
The composition is stored in an aerosol container and upon release expands to form a short term stable foam. According to some embodiments, the cooling agent is peppermint oil or menthol crystals. According to some embodiments, the glycol is propylene glycol. According to some embodiments, the surfactant includes steareth 2, polysorbate 80, glyceryl monostearate, or mixtures thereof. According to some embodiments, the polymeric agent is hydroxypropyl cellulose. According to some embodiments, the composition further includes a foam adjuvant. According to some embodiments, the foam adjuvant is cetostearyl alcohol.
a. about 10% by weight of a cooling agent;
b. about 81 % to about 83% by weight of a glycol;
c. about 6% by weight of one or more surfactants;
d. about 1 % by weight of a polymeric agent; and e. a propellant at a concentration of about 3% to about 45% by weight of the total composition.
The composition is stored in an aerosol container and upon release expands to form a short term stable foam. According to some embodiments, the cooling agent is peppermint oil or menthol crystals. According to some embodiments, the glycol is propylene glycol. According to some embodiments, the surfactant includes steareth 2, polysorbate 80, glyceryl monostearate, or mixtures thereof. According to some embodiments, the polymeric agent is hydroxypropyl cellulose. According to some embodiments, the composition further includes a foam adjuvant. According to some embodiments, the foam adjuvant is cetostearyl alcohol.
[0054] There is further provided according to some embodiments of the present invention, a waterless composition for providing a subject with at least one sensation at a delivery site for a sustained period of time. The composition includes:
a. about 0.03% by weight of a warming agent;
b. about 97.97% by weight of a glycol;
c. about 2% by weight of one or more surfactants; and d. a propellant at a concentration of about 3% to about 45% by weight of the total composition.
The composition is stored in an aerosol container and upon release expands to form a short term stable foam. According to some embodiments, the warming agent is capsaicin. According to some embodiments, the glycol is propylene glycol.
According to some embodiments, the surfactant is steareth 2.
a. about 0.03% by weight of a warming agent;
b. about 97.97% by weight of a glycol;
c. about 2% by weight of one or more surfactants; and d. a propellant at a concentration of about 3% to about 45% by weight of the total composition.
The composition is stored in an aerosol container and upon release expands to form a short term stable foam. According to some embodiments, the warming agent is capsaicin. According to some embodiments, the glycol is propylene glycol.
According to some embodiments, the surfactant is steareth 2.
[0055] There is further provided according to some embodiments of the present invention, a composition for providing a subject with at least one sensation at a delivery site for a sustained period of time. The composition includes:
a. about 10% by weight of a warming agent comprising ginger;
b. about 81 % to about 85% by weight of water;
c. about 4.5% to about 6% by weight of one or more surfactants;
d. about 0.6% by weight of a polymeric agent;
e. optionally, about 2% by weight of a foam adjuvant; and f. a propellant at a concentration of about 3% to about 45% by weight of the total composition.
The composition is stored in an aerosol container and upon release expands to form a short term stable foam. According to some embodiments, the warming agent includes ginger oil. According to some embodiments the surfactant includes steareth 2, steareth 21, polysorbate 80, glyceryl monostearate, PEG-40 stearate, or a mixture thereof.
According to some embodiments, the polymeric agent includes xanthan gum, Methocell K100M, or a mixture thereof. According to some embodiments, the foam adjuvant includes cetostearyl alcohol.
a. about 10% by weight of a warming agent comprising ginger;
b. about 81 % to about 85% by weight of water;
c. about 4.5% to about 6% by weight of one or more surfactants;
d. about 0.6% by weight of a polymeric agent;
e. optionally, about 2% by weight of a foam adjuvant; and f. a propellant at a concentration of about 3% to about 45% by weight of the total composition.
The composition is stored in an aerosol container and upon release expands to form a short term stable foam. According to some embodiments, the warming agent includes ginger oil. According to some embodiments the surfactant includes steareth 2, steareth 21, polysorbate 80, glyceryl monostearate, PEG-40 stearate, or a mixture thereof.
According to some embodiments, the polymeric agent includes xanthan gum, Methocell K100M, or a mixture thereof. According to some embodiments, the foam adjuvant includes cetostearyl alcohol.
[0056] There is further provided according to some embodiments of the present invention, a composition for providing a subject with at least one sensation at a delivery site for a sustained period of time. The composition includes:
a. about 2% by weight of aloe vera;
b. about 90% to about 94% by weight of a polar solvent;
c. about 2% to about 4% by weight of one or more surfactants; and d. about 2% to about 4% by weight of a polymeric agent.
According to some embodiments, the composition further includes a propellant at a concentration of about 3% to about 45% by weight of the total composition;
wherein the composition is stored in an aerosol container and upon release expands to form a short term stable foam. According to some embodiments, the polar solvent includes water, diethylene glycol monoethyl ether, or a mixture thereof. According to some embodiments, the surfactant includes polysorbate. According to some embodiments, the polymeric agent includes Avicel RC581.
a. about 2% by weight of aloe vera;
b. about 90% to about 94% by weight of a polar solvent;
c. about 2% to about 4% by weight of one or more surfactants; and d. about 2% to about 4% by weight of a polymeric agent.
According to some embodiments, the composition further includes a propellant at a concentration of about 3% to about 45% by weight of the total composition;
wherein the composition is stored in an aerosol container and upon release expands to form a short term stable foam. According to some embodiments, the polar solvent includes water, diethylene glycol monoethyl ether, or a mixture thereof. According to some embodiments, the surfactant includes polysorbate. According to some embodiments, the polymeric agent includes Avicel RC581.
[0057] There is further provided according to some embodiments of the present invention, a composition for providing a subject with at least one sensation at a delivery site for a sustained period of time. The composition includes:
a. about 2% by weight of aloe vera;
b. about 77% by weight of a polar solvent;
c. about 11 % by weight of a hydrophobic carrier;
d. about 7% by weight of one or more surfactants;
e. about 2% by weight of a foam adjuvant;
f. about 0.6% of a polymeric agent; and g. a propellant at a concentration of about 3% to about 45% by weight of the total composition.
The composition is stored in an aerosol container and upon release expands to form a short term stable foam. According to some embodiments, the surfactant includes steareth 2, steareth 21, or a mixture thereof. According to some embodiments, the polar solvent includes water. According to some embodiments, the polymeric agent includes xanthan gum, Methocell K100M, or a mixture thereof. According to some embodiments, the foam adjuvant includes cetostearyl alcohol.
a. about 2% by weight of aloe vera;
b. about 77% by weight of a polar solvent;
c. about 11 % by weight of a hydrophobic carrier;
d. about 7% by weight of one or more surfactants;
e. about 2% by weight of a foam adjuvant;
f. about 0.6% of a polymeric agent; and g. a propellant at a concentration of about 3% to about 45% by weight of the total composition.
The composition is stored in an aerosol container and upon release expands to form a short term stable foam. According to some embodiments, the surfactant includes steareth 2, steareth 21, or a mixture thereof. According to some embodiments, the polar solvent includes water. According to some embodiments, the polymeric agent includes xanthan gum, Methocell K100M, or a mixture thereof. According to some embodiments, the foam adjuvant includes cetostearyl alcohol.
[0058] According to some embodiments, the compositions described herein further include a hydrophobic solvent, wherein the combination of the additional hydrophobic solvent and silicone oil, the combination of the additional hydrophobic solvent and triglyceride, or the combination of the additional hydrophobic solvent, silicone oil, and triglyceride, is present in the composition at about 6% to about 22% by weight of the composition.
[0059] There is thus provided according to some embodiments of the present invention, a composition for providing a subject with at least one sensation at a delivery site for a sustained period of time, the composition including:
at least one sensation or sensation modifying agent, selected from the group of a cooling agent;
a warming agent;
a relaxing or soothing agent; and a stimulating or refreshing agent;
or mixtures thereof;
a foamable carrier resistant to aging suitable for delivery of at least one sensation or sensation modifying agent; and a propellant at a concentration of about 3% to about 45% by weight of the total composition, wherein the composition is stored in an aerosol container and upon release expands to form a non-crackling short term stable foam; and wherein upon contact with a surface at the delivery site the prolonged sensation is not primarily due to the propellant or an exothermic reaction.
at least one sensation or sensation modifying agent, selected from the group of a cooling agent;
a warming agent;
a relaxing or soothing agent; and a stimulating or refreshing agent;
or mixtures thereof;
a foamable carrier resistant to aging suitable for delivery of at least one sensation or sensation modifying agent; and a propellant at a concentration of about 3% to about 45% by weight of the total composition, wherein the composition is stored in an aerosol container and upon release expands to form a non-crackling short term stable foam; and wherein upon contact with a surface at the delivery site the prolonged sensation is not primarily due to the propellant or an exothermic reaction.
[0060] According to some embodiments, the composition does not effect a substantial temperature change to the surface.
[0061] According to some further embodiments, the cooling agent is selected from menthol; an isomer of menthol, a menthol derivative; 4-Methyl-3-(1-pyrrolidinyl)-2[5H]-furanone; WS-23, Icilin, Icilin Unilever Analog, 5-methyl-4-(1-pyrrolidinyl)-3-[2H]-furanone;
4,5-dimethyl-3-(1-pyrrolidinyl)-2[5H]-furanone; isopulegol, 3-(I-menthoxy)propane-1,2-diol, 3-(I-menthoxy)-2-methylpropane-1,2-diol, p-menthane-2,3-diol, p-menthane-3,8-diol, 6-isopropyl-9-methyl-1,4-dioxas- piro[4,5]decane-2-methanol, menthyl succinate and its alkaline earth metal salts, trimethylcyclohexanol, N-ethyl-2-isopropyl-5-methylcyclohexanecarb-oxamide, Japanese mint (Mentha arvensis) oil, peppermint oil, menthone, menthone glycerol ketal, menthyl lactate, 3-(I-menthoxy)ethan-1-ol, 3-(1-menthoxy)propan-1-ol, 3-(1-menthoxy)butan-1-ol, 1-menthylacetic acid N-ethylamide, I-menthyl-4-hydroxypentanoate, I-menthyl-3-hydroxybutyrate, N,2,3-trimethyl-2-(1-methylethyl)-butanamide and spearmint oil.
4,5-dimethyl-3-(1-pyrrolidinyl)-2[5H]-furanone; isopulegol, 3-(I-menthoxy)propane-1,2-diol, 3-(I-menthoxy)-2-methylpropane-1,2-diol, p-menthane-2,3-diol, p-menthane-3,8-diol, 6-isopropyl-9-methyl-1,4-dioxas- piro[4,5]decane-2-methanol, menthyl succinate and its alkaline earth metal salts, trimethylcyclohexanol, N-ethyl-2-isopropyl-5-methylcyclohexanecarb-oxamide, Japanese mint (Mentha arvensis) oil, peppermint oil, menthone, menthone glycerol ketal, menthyl lactate, 3-(I-menthoxy)ethan-1-ol, 3-(1-menthoxy)propan-1-ol, 3-(1-menthoxy)butan-1-ol, 1-menthylacetic acid N-ethylamide, I-menthyl-4-hydroxypentanoate, I-menthyl-3-hydroxybutyrate, N,2,3-trimethyl-2-(1-methylethyl)-butanamide and spearmint oil.
[0062] According to some embodiments, the menthol derivative is selected from the group consisting of: menthol ethylene glycol carbonate, which is now known as Frescolat type MGC, menthol Propylene Glycol Carbonate (Frescolat type MPC), menthyl lactate (Frescolat ML ) and Menthone Glycerin Acetal (Frescolat MGA ) and 3-(/-Menthoxy)-1,2-propanediol.
[0063] According to some further embodiments, the warming agent is selected from polyhydric alcohols, capsaicin, capsicum powder, a capsicum tincture, capsicum extract, capsaicin, hamamalis, homocapsaicin, homodihydrocapsaicin, nonanoyl vanillyl amide, nonanoic acid vanillyl ether, vanillyl alcohol alkyl ether derivatives, such as vanillyl ethyl ether, vanillyl butyl ether, vanillyl pentyl ether, and vanillyl hexyl ether, isovanillyl alcohol alkyl ethers, ethylvanillyl alcohol alkyl ethers, veratryl alcohol derivatives, substituted benzyl alcohol derivatives, substituted benzyl alcohol alkyl ethers, vanillin propylene glycol acetal, ethylvanillin propylene glycol acetal, ginger extract, ginger oil, gingeol and gingeron.
[0064] According to some additional embodiments, the relaxing or soothing agent is selected from a herb extracts, selected from the group consisting of aloe vera, alpha bisabolol, D-panthenol, allantoin, hamamelis, chamomile, yarrow; calendula, comfrey, witch hazel and other astringents, sea weed, and oat extracts; oils, selected from the group consisting of: almond oil, avocado oil, and comfrey; and essential oils, selected from the group consisting of: cardamone, eucalyptus, mentha piperita (peppermint), hyssop, and rosemary; waxy or unctuous substances selected from the group consisting of: lanolin or vaselline jelly, minerals, selected from the group consisting of: zinc oxide, calamine and selenium; vitamins, selected from the group consisting of:
tocopheryl acetate (vitamin E), and pharmaceutical agents selected from the group consisting of:
analgesics, anesthetics, anti-inflammatory agents, and anti-histamines, and muscle relaxants; menthol, camphor, eugenol, eucalyptol, safrol, methyl salicylate, menthyl lactate, menthyl ethoxyacetate, menthone glycerinacetal, 3-1-menthoxypropane-1,2-diol, ethyl 1-menthyl carbonate, (1S,3S,4R)-p-menth-8-en-3-ol, menthyl pyrrolidone carboxylate, N-substituted-p-menthane-3-carboxamides hamamelis extract and ginger oil.
tocopheryl acetate (vitamin E), and pharmaceutical agents selected from the group consisting of:
analgesics, anesthetics, anti-inflammatory agents, and anti-histamines, and muscle relaxants; menthol, camphor, eugenol, eucalyptol, safrol, methyl salicylate, menthyl lactate, menthyl ethoxyacetate, menthone glycerinacetal, 3-1-menthoxypropane-1,2-diol, ethyl 1-menthyl carbonate, (1S,3S,4R)-p-menth-8-en-3-ol, menthyl pyrrolidone carboxylate, N-substituted-p-menthane-3-carboxamides hamamelis extract and ginger oil.
[0065] Further provided, according to some embodiments, are compositions wherein the stimulating or refreshing agent is selected from an alcohol, L-menthol, camphor, menthe oil, capsicum extract, capsaicin, benzyl nicotinate, salicylate, glycol salicylate ,acetyl choline, serotonin, histamine, a prostaglandin, a neurotransmitter; a CNS
stimulant, caffeine and quinine.
stimulant, caffeine and quinine.
[0066] In some cases, the short term stable foam is stable at the delivery site for at least one minute. In some further cases, the short term stable foam is stable at the delivery site for at least five minutes.
[0067] According to some embodiments, the sustained period of time is at least minutes. According to some further embodiments, the sustained period of time is at least 30 minutes. In some further cases, the sustained period of time is at least one hour.
[0068] Further provided, according to some embodiments, are compositions, wherein the foamable carrier is at a concentration of about 40% to about 99% by weight of the total composition excluding propellant and is selected from the group consisting of an aqueous emulsion, and aqueous gel and a non aqueous carrier wherein the carrier includes:
at least one surface active agent at a concentration of about 0.1 % to about 10%
by weight of the carrier;
at least one polymeric agent at a concentration of about 0.1 % to about 5% by weight of the total composition; and at least one non aqueous solvent.
at least one surface active agent at a concentration of about 0.1 % to about 10%
by weight of the carrier;
at least one polymeric agent at a concentration of about 0.1 % to about 5% by weight of the total composition; and at least one non aqueous solvent.
[0069] According to some embodiments, the non aqueous solvent is in the case of the aqueous emulsion, a hydrophobic emollient; in the case of the aqueous gel, a penetration enhancer; and in the case of the non aqueous carrier, a polyol.
[0070] Further provided, according to some embodiments, are compositions, wherein the at least one emollient is selected from the group consisting of: avocado oil, isopropyl myristate, mineral oil; capric triglyceride, capryllic triglyceride mineral oil, isopropyl palmitate, isopropyl isostearate, diisopropyl adipate, diisopropyl dimerate, maleated soybean oil, octyl palmitate, cetyl lactate, cetyl ricinoleate, tocopheryl acetate, acetylated lanolin alcohol, cetyl acetate, phenyl trimethicone, glyceryl oleate, tocopheryl linoleate, wheat germ glycerides, arachidyl propionate, myristyl lactate, decyl oleate, ricinoleate, isopropyl lanolate, pentaerythrityl tetrastearate, neopentylglycol dicaprylate/dicaprate, isononyl isononanoate, isotridecyl isononanoate, myristyl myristate, triisocetyl citrate, octyl dodecanol, unsaturated or polyunsaturated oils, such as olive oil, corn oil, soybean oil, canola oil, cottonseed oil, coconut oil, sesame oil, sunflower oil, borage seed oil, syzigium aromaticum oil, hempseed oil, herring oil, cod-liver oil, salmon oil, flaxseed oil, wheat germ oil, evening primrose oils; essential oils; and silicone oils, such as dimethicone, cyclomethicone, polyalkyl siloxane, polyaryl siloxane, polyalkylaryl siloxane, a polyether siloxane copolymer and a poly(dimethylsiloxane)-(diphenyl-siloxane).
[0071] According to some embodiments, the at least one stabilizing surface active agent is selected from the group consisting of: stearyl alcohol; steareth-2, steareth-21;
polysorbate 80, PEG-40 stearate, glyceryl monostearate, cetostearyl alcohol, laureth 4, and Ceteareth-20, or is a combination of at least two surfactants selected from the group consisting of combinations of polyoxyethylene alkyl ethers, particularly Brij 59 / Brij10; Brij 52 / Brij 10; Steareth 2 / Steareth 20; Steareth 2 / Steareth 21 (Brij 72 /
BRIJ 721); Myrj 52 / Myrj 59; combinations of sucrose esters, particularly Surphope 1816 /Surphope 1807;
combinations of sorbitan esters, particularly Span 20 / Span 80; Span 20 /
Span 60;
combinations of sucrose esters and sorbitan esters, particularly Surphope 1811 and Span 60; combinations of liquid polysorbate detergents and PEG compounds, particularly Twin 80 / PEG-40 stearate / methyl glucaso sequistearate.
polysorbate 80, PEG-40 stearate, glyceryl monostearate, cetostearyl alcohol, laureth 4, and Ceteareth-20, or is a combination of at least two surfactants selected from the group consisting of combinations of polyoxyethylene alkyl ethers, particularly Brij 59 / Brij10; Brij 52 / Brij 10; Steareth 2 / Steareth 20; Steareth 2 / Steareth 21 (Brij 72 /
BRIJ 721); Myrj 52 / Myrj 59; combinations of sucrose esters, particularly Surphope 1816 /Surphope 1807;
combinations of sorbitan esters, particularly Span 20 / Span 80; Span 20 /
Span 60;
combinations of sucrose esters and sorbitan esters, particularly Surphope 1811 and Span 60; combinations of liquid polysorbate detergents and PEG compounds, particularly Twin 80 / PEG-40 stearate / methyl glucaso sequistearate.
[0072] Further provided, according to some embodiments, the at least one polymeric agent is selected from the group consisting of: locust bean gum, sodium alginate, sodium caseinate, egg albumin, gelatin agar, carrageenin gum, sodium alginate, xanthan gum, quince seed extract, tragacanth gum, guar gum, cationic guars, hydroxypropyl guar gum, starch, an amine-bearing polymer, chitosan, alginic acid, hyaluronic acid, a chemically modified starch, a carboxyvinyl polymer, polyvinylpyrrolidone, polyvinyl alcohol, a polyacrylic acid polymer, a polymethacrylic acid polymer, polyvinyl acetate, a polyvinyl chloride polymer, a polyvinylidene chloride polymer, methylcellulose, hypromellose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxyethyl cellulose, hydroxy propylmethyl cellulose, methylhydroxyethylcellulose, methylhydroxypropylcellulose, hydroxyethylcarboxymethylcellulose, carboxymethyl cellulose, carboxymethylcellulose carboxymethylhydroxyethylcellulose, a cationic cellulose, methocel K100M, PEG
1000, PEG 4000, PEG 6000 and PEG 8000 xanthan gum; sodium carboxymethyl-cellulose, hydroxypropyl-cellulose, microcrystalline-cellulose, Avicel RC581, aluminum starch octyl succinate and a polyacrylate.
1000, PEG 4000, PEG 6000 and PEG 8000 xanthan gum; sodium carboxymethyl-cellulose, hydroxypropyl-cellulose, microcrystalline-cellulose, Avicel RC581, aluminum starch octyl succinate and a polyacrylate.
[0073] Additionally, according to some embodiments, the foamable carrier further includes one or more of the following:
a co-emulsifier or foam stabilizer at a concentration of about 0.1 % to about 5% by weight of the total composition;
a wax, viscosity, bulking or firming agent at a concentration of about 0.1 %
to about 15% by weight of the total composition;
a co-solvent at a concentration of about 0.1 % to about 20% by weight of the total composition;
a penetration enhancer or potent solvent at a concentration of about 0.1 % to about 25% by weight of the total composition;
a foam adjuvant agent, selected from the group consisting of a fatty alcohol having 15 or more carbons in their carbon chain; a fatty acid having 16 or more carbons in their carbon chain at a concentration of about 0.1 % to about 25% by weight of the total composition;
a stabilizer at a concentration of about 5% to about 30% by weight of the total composition; and an agent capable of having an occlusive effect at a concentration of about 5%
to about 30% by weight of the total composition.
a co-emulsifier or foam stabilizer at a concentration of about 0.1 % to about 5% by weight of the total composition;
a wax, viscosity, bulking or firming agent at a concentration of about 0.1 %
to about 15% by weight of the total composition;
a co-solvent at a concentration of about 0.1 % to about 20% by weight of the total composition;
a penetration enhancer or potent solvent at a concentration of about 0.1 % to about 25% by weight of the total composition;
a foam adjuvant agent, selected from the group consisting of a fatty alcohol having 15 or more carbons in their carbon chain; a fatty acid having 16 or more carbons in their carbon chain at a concentration of about 0.1 % to about 25% by weight of the total composition;
a stabilizer at a concentration of about 5% to about 30% by weight of the total composition; and an agent capable of having an occlusive effect at a concentration of about 5%
to about 30% by weight of the total composition.
[0074] In some cases, the propellant is a cooling agent.
[0075] According to some embodiments, the composition further includes at least one additional active agent. The at least one additional active agent includes, according to some embodiments, a cosmetic active agent or a pharmaceutical active agent having a cosmetic or pharmaceutical effect other than a sensation or sensation modifying effect.
[0076] Additionally, according to some further embodiments, the at least one additional active agent is selected from the group consisting of active herbal extracts, acaricides, age spot and keratose removing agents, allergen, analgesics, local anesthetics, antiacne agents, antiallergic agents, antiaging agents, antibacterials, antibiotics, antiburn agents, anticancer agents, antidandruff agents, antidepressants, antidermatitis agents, antiedemics, antihistamines, antihelminths, antihyperkeratolyte agents, anti inflammatory agents, antiirritants, antilipemics, antimicrobials, antimycotics, antiproliferative agents, antioxidants, anti-wrinkle agents, antipruritics, antipsoriatic agents, antirosacea agents antiseborrheic agents, antiseptic, antiswelling agents, antiviral agents, anti-yeast agents, astringents, topical cardiovascular agents, chemotherapeutic agents, cal tar, corticosteroids, dicarboxylic acids, disinfectants, fungicides, hair growth regulators, hormones, hydroxy acids, immunosuppressants, immunoregulating agents, insecticides, insect repellents, keratolytic agents, lactams, metals, metal oxides, mitocides, neuropeptides, non-steroidal anti-inflammatory agents, oxidizing agents, pediculicides, photodynamic therapy agents, retinoids, sanatives, scabicides, self tanning agents, skin whitening agents, vasoconstrictors, vasodilators, vitamins, vitamin derivatives, vitamin A and derivatives, vitamin D and derivatives, wound healing agents and wart removers.
[0077] Further provided, according to some embodiments, are compositions, wherein the foamable carrier includes at least one carrier medium, selected from the group consisting of water, an oil, a silicone oil, an alcohol, a polyol, a polyethylene glycol (PEG), a propylene glycol, and a solvent or combinations thereof.
[0078] According to some embodiments, the foamable carrier further includes a polar solvent.
[0079] Further provided, according to some embodiments, are compositions further including an additional component selected from the group consisting of an anti-perspirant, an anti-static agent, a buffering agent, a bulking agent, a chelating agent, a colorant, a conditioner, a deodorant, a diluent, a dye, an emollient, fragrance, a humectant, moisturizer, an occlusive agent, a penetration enhancer, a perfuming agent, a permeation enhancer, a pH-adjusting agent, a preservative, a skin penetration enhancer, a sunscreen, a sun blocking agent, a sunless tanning agent, and a vitamin.
[0080] Further provided, according to some embodiments, are compositions, wherein the sensation or sensation modifying is selected from the group consisting of:
a combination of a cooling and a warming agent;
a combination of a cooling and a soothing or relaxing agent;
a combination of a cooling and a stimulating or refreshing agent;
a combination of a warming and a stimulating or refreshing agent;
a combination of a warming and a soothing or relaxing agent;
a combination of a cooling; a warming and a soothing or relaxing agent; and a combination of a cooling; a warming and stimulating or refreshing agent.
a combination of a cooling and a warming agent;
a combination of a cooling and a soothing or relaxing agent;
a combination of a cooling and a stimulating or refreshing agent;
a combination of a warming and a stimulating or refreshing agent;
a combination of a warming and a soothing or relaxing agent;
a combination of a cooling; a warming and a soothing or relaxing agent; and a combination of a cooling; a warming and stimulating or refreshing agent.
[0081] Further provided, according to some embodiments, are compositions, wherein the propellant provides an initial cooling sensation combined with a sensation agent to provide a prolonged sensation.
[0082] Additionally, according to some embodiments, the foamable carrier further contains a foam adjuvant agent, selected from the group consisting of a fatty alcohol having 15 or more carbons in their carbon chain; a fatty acid having 16 or more carbons in their carbon chain.
[0083] Further provided, according to some embodiments, the composition includes:
the at least one sensation or sensation modifying agent including menthol in a concentration of 0.5 to about 3% by weight;
the at least one active agent includes:
coal tar extract in a concentration of around 2% up to around 20% by weight;
and at least one other active agent selected from salicylic acid and hydrocortisone in a concentration of around 0.5% up to around 10% by weight; and the menthol is adapted to provide an improved sensation by ameliorating a negative sensation effect of the coal tar extract.
the at least one sensation or sensation modifying agent including menthol in a concentration of 0.5 to about 3% by weight;
the at least one active agent includes:
coal tar extract in a concentration of around 2% up to around 20% by weight;
and at least one other active agent selected from salicylic acid and hydrocortisone in a concentration of around 0.5% up to around 10% by weight; and the menthol is adapted to provide an improved sensation by ameliorating a negative sensation effect of the coal tar extract.
[0084] Further provided, according to some embodiments, are compositions, wherein:
the at least one sensation or sensation modifying agent includes menthol crystals in a concentration of 0.5 to about 3% by weight;
the at least one active agent includes:
coal tar in a concentration of around 2% up to around 20% by weight; and hydrocortisone butyrate in a concentration of around 0.5% up to around 10% by weight; and the menthol crystals are adapted to provide an improved sensation by ameliorating a negative sensation effect of the coal tar.
the at least one sensation or sensation modifying agent includes menthol crystals in a concentration of 0.5 to about 3% by weight;
the at least one active agent includes:
coal tar in a concentration of around 2% up to around 20% by weight; and hydrocortisone butyrate in a concentration of around 0.5% up to around 10% by weight; and the menthol crystals are adapted to provide an improved sensation by ameliorating a negative sensation effect of the coal tar.
[0085] Additionally, there is thus provided according to some further embodiments of the present invention, a method for providing a subject with at least one sensation at a delivery site, the method including administering to the delivery site of the subject a composition including:
at least one sensation or sensation modifying agent, selected from the group of i. a cooling agent;
ii. a warming agent;
iii. a relaxing or soothing agent; and iv. a stimulating or refreshing agent;
or mixtures thereof;
a foamable carrier resistant to aging suitable for delivery of at least one sensation or sensation modifying agent; and a propellant at a concentration of about 3% to about 45% by weight of the total composition, wherein the composition is stored in an aerosol container and upon release expands to form a non-crackling short term stable foam; and wherein upon contact with a surface at the delivery site the prolonged sensation is not primarily due to the propellant or an exothermic reaction, so as to provide the subject with the at least one sensation for the sustained period of time.
at least one sensation or sensation modifying agent, selected from the group of i. a cooling agent;
ii. a warming agent;
iii. a relaxing or soothing agent; and iv. a stimulating or refreshing agent;
or mixtures thereof;
a foamable carrier resistant to aging suitable for delivery of at least one sensation or sensation modifying agent; and a propellant at a concentration of about 3% to about 45% by weight of the total composition, wherein the composition is stored in an aerosol container and upon release expands to form a non-crackling short term stable foam; and wherein upon contact with a surface at the delivery site the prolonged sensation is not primarily due to the propellant or an exothermic reaction, so as to provide the subject with the at least one sensation for the sustained period of time.
[0086] According to some embodiments, the method allows for the foam being stable at the delivery site for at least one minute. In some cases, the foam is stable at the delivery site for at least five minutes.
[0087] Additionally, according to some further embodiments, the method allows for the subject to sense the at least one sensation at the delivery site for at least at least 15 minutes. In some cases, the subject senses the at least one sensation at the delivery site for at least 30 minutes. In some further cases, the subject senses the at least one sensation at the delivery site for at least one hour. In yet some further cases, the subject senses the at least one sensation as increasing, peaking and decreasing over the sustained period of time.
[0088] According to some embodiments, the method allows for the subject to sense at least one sensation at the delivery site selected from a cooling sensation, a warming sensation, a heating sensation, a soothing sensation, a relaxing sensation, a stimulating sensation and a refreshing sensation.
[0089] According to some further embodiments, the administration step further includes spreading the foam over a surface at the delivery site.
[0090] According to yet some further embodiments, the delivery site is selected from the group consisting of the skin, a body cavity, a mucosal surface, the nose, the mouth, the eye, the ear canal, the respiratory system, the vagina and the rectum.
[0091] According to some embodiments, the method includes administering compositions further including at least one additional active agent. In some cases, the at least one additional active agent includes a cosmetic active agent or a pharmaceutical active agent having a cosmetic or pharmaceutical effect other than a sensation or sensation modifying effect.
[0092] According to yet some further embodiments, the at least one additional active agent is selected from the group consisting of active herbal extracts, acaricides, age spot and keratose removing agents, allergen, analgesics, local anesthetics, antiacne agents, antiallergic agents, antiaging agents, antibacterials, antibiotics, antiburn agents, anticancer agents, antidandruff agents, antidepressants, antidermatitis agents, antiedemics, antihistamines, antihelminths, antihyperkeratolyte agents, anti inflammatory agents, antiirritants, antilipemics, antimicrobials, antimycotics, anti proliferative agents, antioxidants, anti-wrinkle agents, antipruritics, antipsoriatic agents, antirosacea agents antiseborrheic agents, antiseptic, antiswelling agents, antiviral agents, anti-yeast agents, astringents, topical cardiovascular agents, chemotherapeutic agents, cal tar, corticosteroids, dicarboxylic acids, disinfectants, fungicides, hair growth regulators, hormones, hydroxy acids, immunosuppressants, immunoregulating agents, insecticides, insect repellents, keratolytic agents, lactams, metals, metal oxides, mitocides, neuropeptides, non-steroidal anti-inflammatory agents, oxidizing agents, pediculicides, photodynamic therapy agents, retinoids, sanatives, scabicides, self tanning agents, skin whitening agents, vasoconstrictors, vasodilators, vitamins, vitamin derivatives, vitamin A
and derivatives, vitamin D and derivatives, wound healing agents and wart removers.
and derivatives, vitamin D and derivatives, wound healing agents and wart removers.
[0093] The method, according to some embodiments, further includes treating a disorder selected from the group consisting of dermatological pain, dermatological inflammation, acne, acne vulgaris, inflammatory acne, non-inflammatory acne, acne fulminans, nodular papulopustular acne, acne conglobata, dermatitis, bacterial skin infections, fungal skin infections, viral skin infections, parasitic skin infections, skin neoplasia, skin neoplasms, pruritis, cellulitis, acute lymphangitis, lymphadenitis, erysipelas, cutaneous abscesses, necrotizing subcutaneous infections, scalded skin syndrome, folliculitis, furuncles, hidradenitis suppurativa, carbuncles, paronychial infections, rashes, erythrasma, impetigo, ecthyma, yeast skin infections, warts, molluscum contagiosum, trauma or injury to the skin, post-operative or post-surgical skin conditions, scabies, pediculosis, creeping eruption, eczemas, psoriasis, pityriasis rosea, lichen planus, pityriasis rubra pilaris, edematous, erythema multiforme, erythema nodosum, grannuloma annulare, epidermal necrolysis, sunburn, photosensitivity, pemphigus, bullous pemphigoid, dermatitis herpetiformis, keratosis pilaris, callouses, corns, ichthyosis, skin ulcers, ischemic necrosis, miliaria, hyperhidrosis, moles, Kaposi's sarcoma, melanoma, malignant melanoma, basal cell carcinoma, squamous cell carcinoma, poison ivy, poison oak, contact dermatitis, atopic dermatitis, rosacea, purpura, moniliasis, candidiasis, baldness, alopecia, Behcet's syndrome, cholesteatoma, Dercum disease, ectodermal dysplasia, gustatory sweating, nail patella syndrome, lupus, hives, hair loss, Hailey-Hailey disease, chemical or thermal skin burns, scleroderma, aging skin, wrinkles, sun spots, necrotizing fasciitis, necrotizing myositis, gangrene, scarring, and vitiligo, chlamydia infection, gonorrhea infection, hepatitis B, herpes, HIV/AIDS, human papillomavirus (HPV), genital warts, bacterial vaginosis, candidiasis, chancroid, granuloma Inguinale, lymphogranloma venereum, mucopurulent cervicitis (MPC), molluscum contagiosum, nongonococcal urethritis (NGU), trichomoniasis, vulvar disorders, vulvodynia, vulvar pain, yeast infection, vulvar dystrophy, vulvar intraepithelial neoplasia (VIN), contact dermatitis, pelvic inflammation, endometritis, salpingitis, oophoritis, genital cancer, cancer of the cervix, cancer of the vulva, cancer of the vagina, vaginal dryness, dyspareunia, anal and rectal disease, anal abscess/fistula, anal cancer, anal fissure, anal warts, Crohn's disease, hemorrhoids, anal itch, pruritus ani, fecal incontinence, constipation, polyps of the colon and rectum; and wherein the at least one active agent is suitable for treating the disorder.
[0094] Thus, according to one or more embodiments, the foamable composition, includes:
a. a foamable carrier;
b. at least one sensation or sensation modifying agent, selected from the group of i. a cooling agent;
ii. a warming agent;
iii. a relaxing or soothing agent;
iv. stimulating or refreshing agent;
or mixtures thereof;
c. a propellant at a concentration of about 3% to about 45% by weight of the total composition wherein the composition is stored in an aerosol container and upon release expands to form a foam.
a. a foamable carrier;
b. at least one sensation or sensation modifying agent, selected from the group of i. a cooling agent;
ii. a warming agent;
iii. a relaxing or soothing agent;
iv. stimulating or refreshing agent;
or mixtures thereof;
c. a propellant at a concentration of about 3% to about 45% by weight of the total composition wherein the composition is stored in an aerosol container and upon release expands to form a foam.
[0095] In accordance with one or more embodiments, there is provided a foamable base composition for use with a sensation or sensation modifying agent comprising i. a foamable carrier; and ii. a propellant at a concentration of about 3% to about 45% by weight of the total composition;
wherein the composition is stored in an aerosol container and upon release expands to form a foam.
wherein the composition is stored in an aerosol container and upon release expands to form a foam.
[0096] In accordance with one or more embodiments, the foamable composition further comprises at least one component, selected from the group consisting of:
a. a surface active agent; and b. a polymeric agent;
wherein a destabilizing foam effect of the sensation or sensation modifying agent is capable of being reduced, ameliorated or countered to some extent by the introduction of a stabilizing polymer and wherein the composition is stored in an aerosol container and upon release expands to form a breakable foam.
a. a surface active agent; and b. a polymeric agent;
wherein a destabilizing foam effect of the sensation or sensation modifying agent is capable of being reduced, ameliorated or countered to some extent by the introduction of a stabilizing polymer and wherein the composition is stored in an aerosol container and upon release expands to form a breakable foam.
[0097] In accordance with one or more embodiments, the foamable composition further comprises at least one component, selected from the group consisting of:
a. a co-emulsifier and foam stabilizer;
b. a viscosity, bulking or firming agent;
c. a stabilizer;
d. a co-solvent;
e. a penetration enhancer; and f. an agent capable of having an occlusive effect.
a. a co-emulsifier and foam stabilizer;
b. a viscosity, bulking or firming agent;
c. a stabilizer;
d. a co-solvent;
e. a penetration enhancer; and f. an agent capable of having an occlusive effect.
[0098] In accordance with one or more embodiments the foamable emollient emulsion carrier composition comprises:
a. an aqueous carrier;
b. an emollient; and c. a surfactant; or polymeric agent and optionally d. a co-emulsifier and foam stabilizer; a viscosity, bulking or firming agent; a stabilizer; a co-solvent; a penetration enhancer and or an agent capable of having an occlusive effect wherein a destabilizing foam effect of the sensation or sensation modifying agent is capable of being reduced, ameliorated or countered to some extent by the introduction of a stabilizing polymer and wherein the composition is stored in an aerosol container and upon release expands to form a breakable foam.
a. an aqueous carrier;
b. an emollient; and c. a surfactant; or polymeric agent and optionally d. a co-emulsifier and foam stabilizer; a viscosity, bulking or firming agent; a stabilizer; a co-solvent; a penetration enhancer and or an agent capable of having an occlusive effect wherein a destabilizing foam effect of the sensation or sensation modifying agent is capable of being reduced, ameliorated or countered to some extent by the introduction of a stabilizing polymer and wherein the composition is stored in an aerosol container and upon release expands to form a breakable foam.
[0099] In accordance with one or more embodiments, the foamable waterless carrier composition comprises:
a. a non-aqueous carrier;
b. a surfactant; and or a polymeric agent and optionally c. a co-emulsifier and foam stabilizer; and a viscosity, bulking or firming agent wherein a destabilizing foam effect of the sensation or sensation modifying agent is capable of being reduced, ameliorated or countered to some extent by the introduction of a stabilizing polymer and wherein the composition is stored in an aerosol container and upon release expands to form a breakable foam.
DETAILED DESCRIPTION
a. a non-aqueous carrier;
b. a surfactant; and or a polymeric agent and optionally c. a co-emulsifier and foam stabilizer; and a viscosity, bulking or firming agent wherein a destabilizing foam effect of the sensation or sensation modifying agent is capable of being reduced, ameliorated or countered to some extent by the introduction of a stabilizing polymer and wherein the composition is stored in an aerosol container and upon release expands to form a breakable foam.
DETAILED DESCRIPTION
[0100] In the detailed description, numerous specific details are set forth in order to provide a thorough understanding of the invention. However, it will be understood by those skilled in the art that these are specific embodiments and that the present invention may be practiced also in different ways that embody the characterizing features of the invention as described and claimed herein.
[0101] There is provided a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface.
[0102] There is further provided in one or more embodiments, a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, where the sensation is primarily a cooling or warming sensation.
[0103] There is further provided in one or more embodiments, a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, where the sensation is primarily a relaxing or soothing sensation.
[0104] There is further provided in one or more embodiments, a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, where the sensation is primarily a relaxing, soothing, stimulating or refreshing sensation.
[0105] There is further provided in one or more embodiments, a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, where the sensation is a combination of two or more sensations.
[0106] There is further provided in one or more embodiments, a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, in which the sensation is caused by a sensation agent and the sensation is further modulated, potentiated, increased, reduced, or ameliorated by the presence of a sensation modifying agent.
[0107] There is further provided in one or more embodiments, a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, in which the sensation is caused by a sensation agent and the sensation is complementary, supplementary or in addition to or superimposed on a cosmetic, therapeutic or pharmaceutical effect.
[0108] There is further provided in one or more embodiments, a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, wherein the foamable composition comprises a substantially non-aqueous carrier.
[0109] There is further provided in one or more embodiments, a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, wherein the foamable composition comprises a substantially aqueous emollient carrier.
[0110] There is further provided in one or more embodiments, a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, wherein the formulation is adapted so that the sensation or sensation modifying effect is of short, medium or long term duration or grades thereof.
[0111] There is further provided in one or more embodiments, a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, wherein the formulation is adapted so that onset of sensation or sensation modifying effect is of a quick, medium or slow onset or grades thereof.
[0112] There is further provided in one or more embodiments, a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, wherein the formulation is adapted so that the relative overall magnitude of sensation or sensation modifying effect is of a mild, medium or strong magnitude or grades thereof.
[0113] There is further provided in one or more embodiments, a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, wherein the sensation or sensation modifying effect increases peaks and then decreases.
[0114] There is further provided in one or more embodiments, a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, wherein the sensation or sensation modifying effect is with no or little skin irritation.
[0115] There is further provided in one or more embodiments, a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, wherein the sensation or sensation modifying effect comprises a fragrance.
[0116] There is further provided in one or more embodiments , a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, wherein the sensation or sensation modifying effect can be useful, beneficial or therapeutic in cosmetic, toiletry, bath additive, and pharmaceutical compositions.
[0117] In one or more embodiments, the composition further contains a compatible fragrance so as for example to provide in addition aromatherapy on application of the sensation foam.
[0118] In one or more embodiments, the composition further contains a compatible washable pigment so as to provide an attractive color to the dispensed foam.
[0119] In one or more embodiments, the composition is a waterless composition with hygroscopic ingredients, which upon absorbing water present on a body surface give an initial warming sensation in addition to the prolonged sensation of the sensation agent.
[0120] It was discovered that incorporating a sensation or sensation modifying agent in a foamable composition results in a product that, when compared with the composition which is not foamed provides an improved effect.
[0121] While not wishing to be limited to any particular theory, it is presently believed that the expansion of the formulations caused by the presence of a propellant causes the product to spread in the form of a thin film on the skin or delivery site, thereby giving a soft, silky, and cosmetically elegant feel. The observed effect is analogous to a comparison between whipped cream and butter. While both of these products are produced from cream, butter is a dense, greasy water in oil emulsion, whereas whipped cream is a light air in oil emulsion in which the oil is extended over a much greater volume, thereby masking its greasy properties to a substantial extent. In the present invention, by foaming the oils with a propellant to produce a low density aerated foam, the greasy property of the oil in the formulation is ameliorated or minimized.
[0122] Moreover it was further discovered that it is possible to prepare such foamable compositions using more than one different foamable platforms or carriers.
More specifically it was discovered, for example, that effective foamable compositions can be produced with a sensation or sensation modifying effect with a substantially waterless carrier and can also be produced with a substantially aqueous carrier. The ability to produce sensation or sensation modifying foam in waterless and aqueous environments allows the production of foams to suit, benefit or improve a wide variety of skin, mucosa and body cavity conditions. Based on this discovery it is possible to develop and create a multitude of foams, which provide a sensation or sensation modifying feeling with the following advantages:
1. Improvement of user compliance especially in children or sensitive patients;
2. Enhancement of user comfort;
3. Improvement of skin absorption, due to the foam texture;
4. Improvement of skin appearance due to the non-shiny appearance thereof, after administration of the composition;
5. Easier spreading on the body surface, without the need of extensive rubbing;
6. Remains substantially intact for a sufficient period to facilitate convenience of application;
7. Sensation agent may mask, neutralize, ameliorate or hide one or more undesired properties of other ingredients of the composition;
8. Improvement in absorption through skin of one or more active agents;
9. The evaporation of the propellant from newly released foam that has been applied to a body surface can, depending on the nature of the foam and the type and amount of propellant provide a cooling effect.
More specifically it was discovered, for example, that effective foamable compositions can be produced with a sensation or sensation modifying effect with a substantially waterless carrier and can also be produced with a substantially aqueous carrier. The ability to produce sensation or sensation modifying foam in waterless and aqueous environments allows the production of foams to suit, benefit or improve a wide variety of skin, mucosa and body cavity conditions. Based on this discovery it is possible to develop and create a multitude of foams, which provide a sensation or sensation modifying feeling with the following advantages:
1. Improvement of user compliance especially in children or sensitive patients;
2. Enhancement of user comfort;
3. Improvement of skin absorption, due to the foam texture;
4. Improvement of skin appearance due to the non-shiny appearance thereof, after administration of the composition;
5. Easier spreading on the body surface, without the need of extensive rubbing;
6. Remains substantially intact for a sufficient period to facilitate convenience of application;
7. Sensation agent may mask, neutralize, ameliorate or hide one or more undesired properties of other ingredients of the composition;
8. Improvement in absorption through skin of one or more active agents;
9. The evaporation of the propellant from newly released foam that has been applied to a body surface can, depending on the nature of the foam and the type and amount of propellant provide a cooling effect.
[0123] In accordance with one or more further embodiments, the propellant is at a concentration from about 3% to about 25% by weight of the total composition.
[0124] In accordance with one or more further embodiments, the propellant is at a concentration from about 25% to about 45% by weight of the total composition.
[0125] In accordance with one or more embodiments, the foamable base composition is flowable.
[0126] In accordance with one or more embodiments, the main carrier solvent is at a concentration of about 40% to about 90% by weight of the total composition.
[0127] In accordance with one or more embodiments, the foamable composition further comprises at least one component, selected from the group consisting of:
a. a surface active agent;
b. a polymeric agent wherein a destabilizing foam effect of the sensation or sensation modifying agent is capable of being reduced, ameliorated or countered to some extent by the introduction of a stabilizing polymer and wherein the composition is stored in an aerosol container and upon release expands to form a breakable foam.
a. a surface active agent;
b. a polymeric agent wherein a destabilizing foam effect of the sensation or sensation modifying agent is capable of being reduced, ameliorated or countered to some extent by the introduction of a stabilizing polymer and wherein the composition is stored in an aerosol container and upon release expands to form a breakable foam.
[0128] In accordance with one or more embodiments, the surface active agent is a stabilizing combination of at least two surface active agents.
[0129] In accordance with one or more embodiments, the surface active agent is at a concentration of about 0.1 % to about 10% by weight of the total composition.
[0130] In accordance with one or more embodiments, the polymeric agent is at a concentration of about 0.05% to about 5% by weight of the total composition.
[0131] In accordance with one or more embodiments, the surface active agent is combination of at least two surfactants.
[0132] In accordance with one or more embodiments, where the composition is an emollient emulsion the polymeric agent is preferably a combination of hydroxy propylmethyl cellulose and xantham gum. In certain other embodiments the polymeric agent is sodium carboxymethyl-cellulose, hydroxyethyl-cellulose, microcrystalline-cellulose, aluminum starch octyl succinate, and polyacrylates such as carbopol.
[0133] In accordance with one or more embodiments, wherein the composition is an emollient emulsion, the polymeric agent is preferably a hydroxypropyl-cellulose such as Klucel EF, aluminum starch octyl succinate, and polyacrylates such as carbopol.
[0134] In accordance with one or more embodiments, the co-emulsifier is at a concentration of about 0.05% to about 10% by weight of the total composition.
[0135] In accordance with one or more embodiments, the viscosity, bulking or firming agent is at a concentration of about 0.1 % to about 15% by weight of the total composition.
[0136] In accordance with one or more embodiments, the stabilizer is at a concentration of about 0.1 % to about 10% by weight of the total composition.
[0137] In accordance with one or more embodiments, the co-solvent is at a concentration of about 0.1 % to about 30% by weight of the total composition.
[0138] In accordance with one or more embodiments, the penetration enhancer is at a concentration of about 0.1 % to about 30% by weight of the total composition.
[0139] In accordance with one or more embodiments, the agent capable of having an occlusive effect is at a concentration of about 0.1 % to about 30% by weight of the total composition.
[0140] In accordance with one or more embodiments, there is also provided a sensation or sensation modifying topical composition wherein the resultant foam has a density of about 0.01 to about 0.2 g/ml.
[0141] In accordance with one or more embodiments, there is also provided a sensation or sensation modifying topical composition wherein the resultant foam is a breakable foam, which if not subjected to mechanical shear break, is capable of remaining substantially intact without substantial foam collapse for about 60 seconds or more.
[0142] In accordance with one or more embodiments, there is also provided a sensation or sensation modifying topical composition wherein the resultant foam is a breakable foam, which if not subjected to mechanical shear break, is capable of remaining substantially intact without substantial foam collapse for about 120 seconds or more.
[0143] In accordance with one or more embodiments, there is also provided a sensation or sensation modifying topical composition wherein the resultant foam is a breakable foam, which if not subjected to mechanical shear break, is capable of remaining substantially intact without substantial foam collapse for about 300 seconds or more.
[0144] In an exemplary embodiment, the foamable sensation modifying topical composition is an aqueous composition, containing water and further comprises a surface active agent.
[0145] In an exemplary embodiment, the foamable sensation modifying topical composition comprises an aliphatic alcohol, water, a fatty alcohol and a surface active agent.
[0146] In an exemplary embodiment, the foamable sensation modifying topical composition is an emulsion, comprising water, a hydrophobic solvent, a surface-active agent and a polymeric agent.
[0147] Optionally, in one or more embodiments the emulsion-type foamable composition further contains a foam adjuvant agent, selected from the group consisting of a fatty alcohol having 15 or more carbons in their carbon chain; a fatty acid having 16 or more carbons in their carbon chain.
[0148] In certain embodiments, the emulsion is an oil in water emulsion, while in additional embodiments the emulsion is a water in oil emulsion.
[0149] In certain embodiments the hydrophobic carrier is an oil. Exemplary oils include mineral oil, silicone oil, a triglyceride and an ester of a fatty acid. In certain embodiments, the hydrophobic solvent is occlusive, such as petrolatum, while in other embodiments the hydrophobic carrier in non-occlusive.
[0150] In an exemplary embodiment, the foamable sensation modifying topical composition is an oleaginous foamable composition, including at least one solvent selected from a hydrophobic solvent, a silicone oil, an emollient, a polar solvent and mixtures thereof, wherein the solvent is present at a concentration of about 70% to about 96.5% by weight of the total composition, at least a non-ionic surface-active agent and at least one polymeric agent.
[0151] In an exemplary embodiment, the foamable sensation modifying topical composition includes more than 50% of a polar solvent (as used herein, the term "polar solvent" shall mean a material that produces a uniform, clear or hazy, mixture when combined with at least a weight equivalent of water), a surface-active agent and a polymeric agent.
[0152] In certain embodiments the foamable composition contains up to 80%
water, while in additional embodiments the foamable composition contains up to 25%
water.
water, while in additional embodiments the foamable composition contains up to 25%
water.
[0153] In one or more embodiments, the composition is substantially alcohol free [0154] In one or more embodiments, the composition is substantially non-aqueous.
[0155] In accordance with one or more embodiments, there is provided a method of treating, alleviating or preventing a dermatological reaction, sensation or disorder of a mammalian subject, comprising:
a. administering an effective amount of a sensation or sensation modifying topical emollient emulsion carrier composition to a target site on a mammalian subject, comprising:
i. an aqueous carrier at a concentration of about 40% to about 90%
by weight of the total composition;
ii. an emollient at a concentration of about 5% to about 15% by weight of the total composition;
iii. a surfactant at a concentration of about 0.1 % to about 10% by weight of the total composition;
iv. a polymeric agent at a concentration of about 0.1 % to about 5% by weight of the total composition;
v. a propellant at a concentration of about 3% to about 45% by weight of the total composition;
vi. at least one active agent in an effective amount which is intended to prevent, alleviate, treat or cure said reaction, sensation or disorder; and optionally;
vii. a co-emulsifier and foam stabilizer at a concentration of about 0.1 %
to about 5% by weight of the total composition; a viscosity, bulking or firming agent at a concentration of about 0.1 % to about 15% by weight of the total composition; a stabilizer; a co-solvent at a concentration of about 0.1 % to about 20% by weight of the total composition; a penetration enhancer at a concentration of about 0.1 % to about 20% by weight of the total composition; and or an agent capable of having an occlusive effect at a concentration of about 5% to about 30% by weight of the total composition;
wherein a destabilizing foam effect of the sensation or sensation modifying agent is capable of being reduced, ameliorated or countered to some extent by the introduction of a stabilizing polymer and wherein the composition is stored in an aerosol container and upon release expands to form a breakable foam.
b. applying mechanical shear break to the applied foam such that it is spread at, about and within the target site.
a. administering an effective amount of a sensation or sensation modifying topical emollient emulsion carrier composition to a target site on a mammalian subject, comprising:
i. an aqueous carrier at a concentration of about 40% to about 90%
by weight of the total composition;
ii. an emollient at a concentration of about 5% to about 15% by weight of the total composition;
iii. a surfactant at a concentration of about 0.1 % to about 10% by weight of the total composition;
iv. a polymeric agent at a concentration of about 0.1 % to about 5% by weight of the total composition;
v. a propellant at a concentration of about 3% to about 45% by weight of the total composition;
vi. at least one active agent in an effective amount which is intended to prevent, alleviate, treat or cure said reaction, sensation or disorder; and optionally;
vii. a co-emulsifier and foam stabilizer at a concentration of about 0.1 %
to about 5% by weight of the total composition; a viscosity, bulking or firming agent at a concentration of about 0.1 % to about 15% by weight of the total composition; a stabilizer; a co-solvent at a concentration of about 0.1 % to about 20% by weight of the total composition; a penetration enhancer at a concentration of about 0.1 % to about 20% by weight of the total composition; and or an agent capable of having an occlusive effect at a concentration of about 5% to about 30% by weight of the total composition;
wherein a destabilizing foam effect of the sensation or sensation modifying agent is capable of being reduced, ameliorated or countered to some extent by the introduction of a stabilizing polymer and wherein the composition is stored in an aerosol container and upon release expands to form a breakable foam.
b. applying mechanical shear break to the applied foam such that it is spread at, about and within the target site.
[0156] In accordance with one or more embodiments, there is provided a method of treating, alleviating or preventing a dermatological reaction, sensation or disorder of a mammalian subject, comprising:
a. administering an effective amount of a sensation or sensation modifying topical substantially waterless foamable composition to a target site on a mammalian subject, comprising:
aa. a non-aqueous carrier at a concentration of about 40% to about 90%
by weight of the total composition;
bb. a surfactant at a concentration of about 0.1 % to about 10% by weight of the total composition; and or a polymeric agent at a concentration of about 0.1 % to about 5% by weight of the total composition;
cc. at least one active agent in an effective amount which is intended to prevent, alleviate, treat or cure said reaction, sensation or disorder;
dd. a propellant at a concentration of about 3% to about 25% by weight of the total composition and optionally;
ee. a co-emulsifier and foam stabilizer at a concentration of about 0.1 %
to about 5% by weight of the total composition; and a viscosity, bulking or firming agent at a concentration of about 0.1 % to about 15% by weight of the total composition.
wherein a destabilizing foam effect of the sensation or sensation modifying agent is capable of being reduced, ameliorated or countered to some extent by the introduction of a stabilizing polymer and wherein the composition is stored in an aerosol container and upon release expands to form a breakable foam.
b. applying mechanical shear break to the applied foam such that it is spread at, about and within the target site.
Hydrophobic carrier [0157] A "hydrophobic solvent" as used herein refers to a material having solubility in distilled water at ambient temperature of less than about 1 gm per 100 mL, more preferable less than about 0.5 gm per 100 mL, and most preferably less than about 0.1 gm per 100 mL.
a. administering an effective amount of a sensation or sensation modifying topical substantially waterless foamable composition to a target site on a mammalian subject, comprising:
aa. a non-aqueous carrier at a concentration of about 40% to about 90%
by weight of the total composition;
bb. a surfactant at a concentration of about 0.1 % to about 10% by weight of the total composition; and or a polymeric agent at a concentration of about 0.1 % to about 5% by weight of the total composition;
cc. at least one active agent in an effective amount which is intended to prevent, alleviate, treat or cure said reaction, sensation or disorder;
dd. a propellant at a concentration of about 3% to about 25% by weight of the total composition and optionally;
ee. a co-emulsifier and foam stabilizer at a concentration of about 0.1 %
to about 5% by weight of the total composition; and a viscosity, bulking or firming agent at a concentration of about 0.1 % to about 15% by weight of the total composition.
wherein a destabilizing foam effect of the sensation or sensation modifying agent is capable of being reduced, ameliorated or countered to some extent by the introduction of a stabilizing polymer and wherein the composition is stored in an aerosol container and upon release expands to form a breakable foam.
b. applying mechanical shear break to the applied foam such that it is spread at, about and within the target site.
Hydrophobic carrier [0157] A "hydrophobic solvent" as used herein refers to a material having solubility in distilled water at ambient temperature of less than about 1 gm per 100 mL, more preferable less than about 0.5 gm per 100 mL, and most preferably less than about 0.1 gm per 100 mL.
[0158] In one or more embodiments, the hydrophobic organic carrier is an oil, such as mineral oil, isopropyl palmitate, isopropyl isostearate, diisopropyl adipate, diisopropyl dimerate, maleated soybean oil, octyl palmitate, cetyl lactate, cetyl ricinoleate, tocopheryl acetate, acetylated lanolin alcohol, cetyl acetate, phenyl trimethicone, glyceryl oleate, tocopheryl linoleate, wheat germ glycerides, arachidyl propionate, myristyl lactate, decyl oleate, ricinoleate, isopropyl lanolate, pentaerythrityl tetrastearate, neopentylglycol dicaprylate/dicaprate, isononyl isononanoate, isotridecyl isononanoate, myristyl myristate, triisocetyl citrate, octyl dodecanol, unsaturated or polyunsaturated oils, such as olive oil, corn oil, soybean oil, canola oil, cottonseed oil, coconut oil, sesame oil, sunflower oil, borage seed oil, syzigium aromaticum oil, hempseed oil, herring oil, cod-liver oil, salmon oil, flaxseed oil, wheat germ oil, evening primrose oils; essential oils; and silicone oils, such as dimethicone, cyclomethicone, polyalkyl siloxane, polyaryl siloxane, polyalkylaryl siloxane, a polyether siloxane copolymer and a poly(dimethylsiloxane)-(diphenyl-siloxane) copolymer.
Polar Solvent [0159] A "polar solvent" is an organic solvent, typically soluble both in water and oil but is not intended to characterize the solubilization capabilities of the solvent for any specific active agent or any other component of the foamable composition. The emollient emulsion and waterless formulations may contain polar solvents, which may contribute to the penetration of an active or therapeutic agent including a sensation or sensation modifying agent.
Polymeric agent [0160] A polymeric agent can be selected from the group consisting of locust bean gum, sodium alginate, sodium caseinate, egg albumin, gelatin agar, carrageenin gum, sodium alginate, xanthan gum, quince seed extract, tragacanth gum, guar gum, cationic guars, hydroxypropyl guar gum, starch, an amine-bearing polymer, chitosan, alginic acid, hyaluronic acid, a chemically modified starch, a carboxyvinyl polymer, polyvinylpyrrolidone, polyvinyl alcohol, a polyacrylic acid polymer, a polymethacrylic acid polymer, polyvinyl acetate, a polyvinyl chloride polymer, a polyvinylidene chloride polymer, methylcellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxyethyl cellulose, hydroxy propylmethyl cellulose, methylhydroxyethylcellulose, methylhydroxypropylcellulose, hydroxyethylcarboxymethylcellulose, carboxymethyl cellulose, carboxymethylcellulose, carboxymethylhydroxyethylcellulose, a cationic cellulose PEG 1000, PEG1500, PEG2000, PEG 4000, PEG 6000 and PEG 8000.
Polyol [0161] In an embodiment of the present invention, the solvent is a polyol. A
polyol is an organic substance that contains at least two hydroxy groups in its molecular structure.
Polar Solvent [0159] A "polar solvent" is an organic solvent, typically soluble both in water and oil but is not intended to characterize the solubilization capabilities of the solvent for any specific active agent or any other component of the foamable composition. The emollient emulsion and waterless formulations may contain polar solvents, which may contribute to the penetration of an active or therapeutic agent including a sensation or sensation modifying agent.
Polymeric agent [0160] A polymeric agent can be selected from the group consisting of locust bean gum, sodium alginate, sodium caseinate, egg albumin, gelatin agar, carrageenin gum, sodium alginate, xanthan gum, quince seed extract, tragacanth gum, guar gum, cationic guars, hydroxypropyl guar gum, starch, an amine-bearing polymer, chitosan, alginic acid, hyaluronic acid, a chemically modified starch, a carboxyvinyl polymer, polyvinylpyrrolidone, polyvinyl alcohol, a polyacrylic acid polymer, a polymethacrylic acid polymer, polyvinyl acetate, a polyvinyl chloride polymer, a polyvinylidene chloride polymer, methylcellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxyethyl cellulose, hydroxy propylmethyl cellulose, methylhydroxyethylcellulose, methylhydroxypropylcellulose, hydroxyethylcarboxymethylcellulose, carboxymethyl cellulose, carboxymethylcellulose, carboxymethylhydroxyethylcellulose, a cationic cellulose PEG 1000, PEG1500, PEG2000, PEG 4000, PEG 6000 and PEG 8000.
Polyol [0161] In an embodiment of the present invention, the solvent is a polyol. A
polyol is an organic substance that contains at least two hydroxy groups in its molecular structure.
[0162] In one or more embodiments, the foamable carrier contains at least one diol (a compound that contains two hydroxy groups in its molecular structure).
Examples of diols include propylene glycol (e.g., 1,2-propylene glycol and 1,3-propylene glycol), butanediol (e.g., 1,2-butanediol, 1,3-butanediol, 2,3-butanediol and 1,4-butanediol), butanediol (e.g., 1,3-butanediol and 1,4-butenediol), butynediol, pentanediol (e.g., pentane-1,2-diol, pentane-1,3-diol, pentane-1,4-diol, pentane-1,5-diol, pentane-2,3-diol and pentane-2,4-diol), hexanediol (e.g., hexane-1,6-diol hexane-2,3-diol and hexane-2,56-diol), octanediol (e.g., 1,8-octanediol), neopentyl glycol, 2-methyl-1,3-propanediol, diethylene glycol, triethylene glycol, tetraethylene glycol, dipropylene glycol and dibutylene glycol.
Examples of diols include propylene glycol (e.g., 1,2-propylene glycol and 1,3-propylene glycol), butanediol (e.g., 1,2-butanediol, 1,3-butanediol, 2,3-butanediol and 1,4-butanediol), butanediol (e.g., 1,3-butanediol and 1,4-butenediol), butynediol, pentanediol (e.g., pentane-1,2-diol, pentane-1,3-diol, pentane-1,4-diol, pentane-1,5-diol, pentane-2,3-diol and pentane-2,4-diol), hexanediol (e.g., hexane-1,6-diol hexane-2,3-diol and hexane-2,56-diol), octanediol (e.g., 1,8-octanediol), neopentyl glycol, 2-methyl-1,3-propanediol, diethylene glycol, triethylene glycol, tetraethylene glycol, dipropylene glycol and dibutylene glycol.
[0163] In one or more embodiments, the foamable carrier contains at least one triol (a compound that contains three hydroxy groups in its molecular structure), such as glycerin, butane-1,2,3-triol, butane-1,2,4-triol and hexane-1,2,6-triol.
[0164] In one or more embodiments, the polyol is a mixture of polyols. In one or more embodiments, the mixture of polyols contains at least one diol and at least one triol.
According to certain embodiments the ratio between the diol and triol is between 9:1 and 1:1.
According to certain embodiments the ratio between the diol and triol is between 9:1 and 1:1.
[0165] In one or more embodiments, part of mixture of polyols is a saccharide.
Exemplary saccharides include, but are not limited to monosaccharide, disaccharides, oligosaccha rides and sugar alcohols.
Exemplary saccharides include, but are not limited to monosaccharide, disaccharides, oligosaccha rides and sugar alcohols.
[0166] A monosaccharide is a simple sugar that cannot be hydrolysed to smaller units. Empirical formula is (CH2O)n and range in size from trioses (n=3) to heptoses (n=7).
Exemplary monosaccharide compounds are ribose, glucose, fructose and galactose.
Exemplary monosaccharide compounds are ribose, glucose, fructose and galactose.
[0167] Disaccharides are made up of two monosaccharides joined together, such as sucrose, maltose and lactose.
[0168] A sugar alcohol (also known as a polyol, polyhydric alcohol, or polyalcohol) is a hydrogenated form of saccharide, whose carbonyl group (aldehyde or ketone, reducing sugar) has been reduced to a primary or secondary hydroxyl group. They are commonly used for replacing sucrose in foodstuffs, often in combination with high intensity artificial sweeteners to counter the low sweetness. Some exemplary sugar alcohols, which are suitable for use according to the present invention are mannitol, sorbitol, xylitol, maltitol, lactitol. (Maltitol and lactitol are not completely hydrogenated compounds -they are a monosaccharide combined with a polyhydric alcohol). Mixtures of polyols, including (1) at least one polyol selected from a diol and a triol; and (2) a saccharide are contemplated within the scope of the present invention.
Polyethylene glycol [0169] In an embodiment of the present invention, the solvent consists of a polymerized ethylene glycol, namely polyethylene glycol, which is also termed "PEG".
Exemplary PEGs are provided in the following table.
Composition Av. Molecular weight Appearance Melting point ( C) PEG 200 190 - 210 Oily liquid ?
PEG 300 285 - 315 Oily liquid PEG 400 380 - 420 Oily liquid ?
PEG 600 570 - 630 Oily liquid 17 - 22 PEG 1000 950 - 1050 Solid 35 - 40 PEG 4000 3800 -4400 Solid 53 - 58 PEG 6000 5600 -6400 Solid 55 - 60 PEG 8000 7500 -8500 Solid 58 - 65 [0170] Thus, in an embodiment of the present invention, the PEG is selected from the group consisting of PEG 200, PEG 300, PEG 400, PEG 600, PEG 1000, PEG 4000, PEG
6000 and PEG 8000. The foamable carrier according to the present invention can contain a single PEG or a mixture of two or more PEGs. PEGs having molecular weight of more that about 1000 possess gelling properties; i.e., they increase the viscosity of a composition. Therefore, by combining PEGs with different molecular weights/melting points, one can attain varying levels of flowability as desirable for the treatment of a given target site. The concentration of the PEG should be in a level that results in viscosity, prior to filling of the composition into aerosol canisters, of less than 12,000 CPs, and more preferably, less than 10,000 CPs.
Secondary polar solvent [0171] Optionally, a secondary solvent is added to the foamable composition of the present invention. The secondary solvent is selected from a variety of organic solvents that are typically miscible on both water and oil. Examples of solvent that can be contained in the foamable carrier of the present invention include dimethyl isosorbide, tetrahydrofurfuryl alcohol polyethyleneglycol ether (glycofurol), DMSO, pyrrolidones, (such as N-Methyl-2-pyrrolidone and 1-Methyl-2-pyrrolidinone), ethyl proxitol, dimethylacetamide (DMAc), PEG-type surfactants and alpha hydroxy acids, such as lactic acid and glycolic acid.
Solubilization and penetration enhancement [0172] A "skin penetration enhancer", also termed herein "penetration enhancer," is an organic solvent, typically soluble in both water and oil. Examples of penetration enhancer include polyols, such as glycerol (glycerin), propylene glycol, hexylene glycol, diethylene glycol, propylene glycol n-alkanols, terpenes, di-terpenes, tri-terpenes, terpen-ols, limonene, terpene-ol, 1-menthol, dioxolane, ethylene glycol, hexylene glycol, other glycols, sulfoxides, such as dimethylsulfoxide (DMSO), dimethylformanide, methyl dodecyl sulfoxide, dimethylacetamide, dimethylisosorbide, monooleate of ethoxylated glycerides (with 8 to 10 ethylene oxide units), azone (1-dodecylazacycloheptan-2-one), 2-(n-nonyl)-1,3-dioxolane, esters, such as isopropyl myristate/palmitate, ethyl acetate, butyl acetate, methyl proprionate, capric/caprylic triglycerides, octylmyristate, dodecyl-myristate; myristyl alcohol, lauryl alcohol, lauric acid, lauryl lactate ketones; amides, such as acetamide oleates such as triolein; various alkanoic acids such as caprylic acid;
lactam compounds, such as azone; alkanols, such as dialkylamino acetates, and admixtures thereof.
Polyethylene glycol [0169] In an embodiment of the present invention, the solvent consists of a polymerized ethylene glycol, namely polyethylene glycol, which is also termed "PEG".
Exemplary PEGs are provided in the following table.
Composition Av. Molecular weight Appearance Melting point ( C) PEG 200 190 - 210 Oily liquid ?
PEG 300 285 - 315 Oily liquid PEG 400 380 - 420 Oily liquid ?
PEG 600 570 - 630 Oily liquid 17 - 22 PEG 1000 950 - 1050 Solid 35 - 40 PEG 4000 3800 -4400 Solid 53 - 58 PEG 6000 5600 -6400 Solid 55 - 60 PEG 8000 7500 -8500 Solid 58 - 65 [0170] Thus, in an embodiment of the present invention, the PEG is selected from the group consisting of PEG 200, PEG 300, PEG 400, PEG 600, PEG 1000, PEG 4000, PEG
6000 and PEG 8000. The foamable carrier according to the present invention can contain a single PEG or a mixture of two or more PEGs. PEGs having molecular weight of more that about 1000 possess gelling properties; i.e., they increase the viscosity of a composition. Therefore, by combining PEGs with different molecular weights/melting points, one can attain varying levels of flowability as desirable for the treatment of a given target site. The concentration of the PEG should be in a level that results in viscosity, prior to filling of the composition into aerosol canisters, of less than 12,000 CPs, and more preferably, less than 10,000 CPs.
Secondary polar solvent [0171] Optionally, a secondary solvent is added to the foamable composition of the present invention. The secondary solvent is selected from a variety of organic solvents that are typically miscible on both water and oil. Examples of solvent that can be contained in the foamable carrier of the present invention include dimethyl isosorbide, tetrahydrofurfuryl alcohol polyethyleneglycol ether (glycofurol), DMSO, pyrrolidones, (such as N-Methyl-2-pyrrolidone and 1-Methyl-2-pyrrolidinone), ethyl proxitol, dimethylacetamide (DMAc), PEG-type surfactants and alpha hydroxy acids, such as lactic acid and glycolic acid.
Solubilization and penetration enhancement [0172] A "skin penetration enhancer", also termed herein "penetration enhancer," is an organic solvent, typically soluble in both water and oil. Examples of penetration enhancer include polyols, such as glycerol (glycerin), propylene glycol, hexylene glycol, diethylene glycol, propylene glycol n-alkanols, terpenes, di-terpenes, tri-terpenes, terpen-ols, limonene, terpene-ol, 1-menthol, dioxolane, ethylene glycol, hexylene glycol, other glycols, sulfoxides, such as dimethylsulfoxide (DMSO), dimethylformanide, methyl dodecyl sulfoxide, dimethylacetamide, dimethylisosorbide, monooleate of ethoxylated glycerides (with 8 to 10 ethylene oxide units), azone (1-dodecylazacycloheptan-2-one), 2-(n-nonyl)-1,3-dioxolane, esters, such as isopropyl myristate/palmitate, ethyl acetate, butyl acetate, methyl proprionate, capric/caprylic triglycerides, octylmyristate, dodecyl-myristate; myristyl alcohol, lauryl alcohol, lauric acid, lauryl lactate ketones; amides, such as acetamide oleates such as triolein; various alkanoic acids such as caprylic acid;
lactam compounds, such as azone; alkanols, such as dialkylamino acetates, and admixtures thereof.
[0173] According to one or more embodiments, the penetration enhancer is a polyethylene glycol (PEG) or PEG derivative that is liquid at ambient temperature [0174] In many cases, polyols, PEGs and solvents possess a high solubilizing power and thus, they can enable increased concentrations of a pharmaceutical active agent.
Polyols, PEGs and solvents are also known for their skin penetration enhancement properties. These properties enable high drug bioavailability in the target area of treatment, resulting in an enhanced therapeutic effect. Occasionally, combinations of a polyol, PEGs and a secondary solvent, exhibit an increased permeability across the skin, as suggested, for example, in Eur. J. Pharm. Biopharm. 1998 Nov. 46(3):265-71.
Polyols, PEGs and solvents are also known for their skin penetration enhancement properties. These properties enable high drug bioavailability in the target area of treatment, resulting in an enhanced therapeutic effect. Occasionally, combinations of a polyol, PEGs and a secondary solvent, exhibit an increased permeability across the skin, as suggested, for example, in Eur. J. Pharm. Biopharm. 1998 Nov. 46(3):265-71.
[0175] Thus, in one or more embodiments, the foamable carrier contains (1) at least one solvent, selected from a polyol (selected from a diol and a triol) and PEG; and (2) at least one secondary solvent.
[0176] In one or more embodiments, the foamable carrier contains (1) a mixture of at least two polyols; and (2) at least one secondary solvent. In additional embodiments, the foamable carrier contains a mixture of at least one polyol and at least one PEG; yet in other embodiments the foamable carrier contains (1) a mixture of at least one polyol and at least one PEG and (2) at least one secondary solvent.
[0177] According to certain embodiments the ratio between the polyol and/or PEG
and the secondary solvent is between 9:1 and 1:1.
and the secondary solvent is between 9:1 and 1:1.
[0178] In certain embodiments, the polyol is selected from the group consisting of propylene glycol, hexylene glycol and glycerin (and mixtures thereof); and the secondary solvent is selected from the group consisting of dimethyl isosorbide, diethylene glycol monoethyl ether, a liquid polyethylene glycol and glycofurol.
[0179] In certain embodiments, the foamable carrier contains (1) at least one polyol;
and (2) dimethyl isosorbide.
Potent Solvent [0180] In one or more embodiments of the present invention, the foamable composition includes a potent solvent, in addition to, or in place, of one of the hydrophobic solvents, polar solvents or emollients of the composition. A
potent solvent is a solvent other than mineral oil that solubilizes a specific active agent substantially better than a hydrocarbon solvent such as mineral oil or petrolatum. For example, a potent solvent solubilizes the active agent 5 fold better than a hydrocarbon solvent;
or even solubilizes the active agent 10-fold better than a hydrocarbon solvent.
and (2) dimethyl isosorbide.
Potent Solvent [0180] In one or more embodiments of the present invention, the foamable composition includes a potent solvent, in addition to, or in place, of one of the hydrophobic solvents, polar solvents or emollients of the composition. A
potent solvent is a solvent other than mineral oil that solubilizes a specific active agent substantially better than a hydrocarbon solvent such as mineral oil or petrolatum. For example, a potent solvent solubilizes the active agent 5 fold better than a hydrocarbon solvent;
or even solubilizes the active agent 10-fold better than a hydrocarbon solvent.
[0181] In one or more embodiments of the present invention, the composition includes at least one active agent in a therapeutically effective concentration; and at least one potent solvent in a sufficient amount to substantially solubilize the at least one active agent in the composition. The term "substantially soluble" means that at least 95% of the active agent has been solubilized, i.e., 5% or less of the active agent is present in a solid state. In one or more embodiments, the concentration of the at least one potent solvent is more than about 40% of the at least one solvent of the composition of the present invention; or even more than about 60%.
[0182] Non-limiting examples of pairs of active agent and potent solvent include:
Betamethasone valerate: Practically insoluble in mineral oil (<0.01 %);
soluble more than 1 % in glycofurol; Hydrocortisone butyrate: Practically insoluble in mineral oil (<0.01 %);
soluble more than 1 % in glycofurol; Metronidazole: Practically insoluble in mineral oil (<0.01 %); soluble more than 1 % in dimethyl isosrbide; Ketoconazole:
Practically insoluble in mineral oil (<0.01 %); soluble more than 1 % in glycofurol, propylene glycol and dimethyl isosrbide; Mupirocin: Practically insoluble in mineral oil (<0.01%); soluble more than 1 % in glycofurol, hexylene glycol, dimethyl isosorbide, propylene glycol and polyethylene glycol 400 (PEG 400); Meloxicam, a nonsteroidal anti-inflammatory agent:
Practically insoluble in mineral oil (<0.001 %); soluble in propylene glycol:
0.3 mg/mL; and in PEG 400: 3.7 mg/mL; and Progesterone: Practically insoluble in mineral oil (<0.001 %); soluble in PEG 400: 15.3 mg/mL.
Betamethasone valerate: Practically insoluble in mineral oil (<0.01 %);
soluble more than 1 % in glycofurol; Hydrocortisone butyrate: Practically insoluble in mineral oil (<0.01 %);
soluble more than 1 % in glycofurol; Metronidazole: Practically insoluble in mineral oil (<0.01 %); soluble more than 1 % in dimethyl isosrbide; Ketoconazole:
Practically insoluble in mineral oil (<0.01 %); soluble more than 1 % in glycofurol, propylene glycol and dimethyl isosrbide; Mupirocin: Practically insoluble in mineral oil (<0.01%); soluble more than 1 % in glycofurol, hexylene glycol, dimethyl isosorbide, propylene glycol and polyethylene glycol 400 (PEG 400); Meloxicam, a nonsteroidal anti-inflammatory agent:
Practically insoluble in mineral oil (<0.001 %); soluble in propylene glycol:
0.3 mg/mL; and in PEG 400: 3.7 mg/mL; and Progesterone: Practically insoluble in mineral oil (<0.001 %); soluble in PEG 400: 15.3 mg/mL.
[0183] A non-limiting exemplary list of solvents that can be considered as potent solvents includes polyethylene glycol, propylene glycol, hexylene glycol, butaneediols and isomers thereof, glycerol, benzyl alcohol, DMSO, ethyl oleate, ethyl caprylate, diisopropyl adipate, dimethylacetamide, N-methylpyrrolidone, N-hydroxyethylpyrrolidone, polyvinylpyrrolidone, isosorbide derivatives, such as dimethyl isosorbide, glycofurol and ethoxydiglycol (transcutol) and laurocapram .
[0184] The use of a potent solvent in a foam composition provides an improved method of delivering poorly soluble therapeutic agents to a target area. It is known that low drug solubility results in poor bioavailability, leading to decreased effectiveness of treatment. Foam compositions of the present invention, for which the solvent includes a potent solvent, increase the levels of the active agent in solution and thus, provide high delivery and improved therapy.
[0185] Potent solvents, as defined herein, are usually liquid. Formulations comprising potent solvents and active agents are generally disadvantageous as therapeutics, since their usage involves unwanted dripping and inconvenient method of application;
resulting in inadequate dosing. Surprisingly, the foams of the present invention, which are drip-free, provide a superior vehicle for such active agents, enabling convenient usage and accurate effective dosing.
resulting in inadequate dosing. Surprisingly, the foams of the present invention, which are drip-free, provide a superior vehicle for such active agents, enabling convenient usage and accurate effective dosing.
[0186] In one or more embodiments of the present invention the present invention the foamable pharmaceutical composition may additionally include a mixture of two or more of the solvents selected from the group of hydrophobic solvents, silicone oils, emollients, polar solvents and potent solvents in an appropriate proportion as would be appreciated to a person skilled in the art.
[0187] In one or more embodiments of the present invention, the PPG alkyl ether may act as a potent solvent.
Surface active agent [0188] The composition further contains a surface-active agent. Surface-active agents (also termed "surfactants") include any agent linking oil and water in the composition, in the form of emulsion. A surfactant's hydrophilic/lipophilic balance (HLB) describes the emulsifier's affinity toward water or oil. HLB is defined for non-ionic surfactants. The HLB scale ranges from 1 (totally lipophilic) to 20 (totally hydrophilic), with 10 representing an equal balance of both characteristics. Lipophilic emulsifiers form water-in-oil (w/o) emulsions; hydrophilic surfactants form oil-in-water (o/w) emulsions.
The HLB of a blend of two emulsifiers equals the weight fraction of emulsifier A times its HLB value plus the weight fraction of emulsifier B times its HLB value (weighted average).
In many cases a single surfactant may suffice. In other cases a combination of two or more surfactants is desired. Reference to a surfactant in the specification can also apply to a combination of surfactants or a surfactant system. As will be appreciated by a person skilled in the art which surfactant or surfactant system is more appropriate is related to the vehicle and intended purpose. In general terms a combination of surfactants can be significant in producing breakable forms of good quality.
It has been further discovered that the generally thought considerations for HLB values for selecting a surfactant or surfactant combination are not always binding for emulsions and moreover for waterless and substantially non aqueous carriers the usual guidelines are less applicable . Surfactants also play a significant role in foam formation where the foamable formulation is a single phase composition.
Surface active agent [0188] The composition further contains a surface-active agent. Surface-active agents (also termed "surfactants") include any agent linking oil and water in the composition, in the form of emulsion. A surfactant's hydrophilic/lipophilic balance (HLB) describes the emulsifier's affinity toward water or oil. HLB is defined for non-ionic surfactants. The HLB scale ranges from 1 (totally lipophilic) to 20 (totally hydrophilic), with 10 representing an equal balance of both characteristics. Lipophilic emulsifiers form water-in-oil (w/o) emulsions; hydrophilic surfactants form oil-in-water (o/w) emulsions.
The HLB of a blend of two emulsifiers equals the weight fraction of emulsifier A times its HLB value plus the weight fraction of emulsifier B times its HLB value (weighted average).
In many cases a single surfactant may suffice. In other cases a combination of two or more surfactants is desired. Reference to a surfactant in the specification can also apply to a combination of surfactants or a surfactant system. As will be appreciated by a person skilled in the art which surfactant or surfactant system is more appropriate is related to the vehicle and intended purpose. In general terms a combination of surfactants can be significant in producing breakable forms of good quality.
It has been further discovered that the generally thought considerations for HLB values for selecting a surfactant or surfactant combination are not always binding for emulsions and moreover for waterless and substantially non aqueous carriers the usual guidelines are less applicable . Surfactants also play a significant role in foam formation where the foamable formulation is a single phase composition.
[0189] According to one or more embodiments the composition contains a single surface active agent having an HLB value between about 2 and 9, or more than one surface active agent and the weighted average of their HLB values is between about 2 and about 9.
[0190] According to one or more embodiments the composition contains a single surface active agent having an HLB value between about 7 and 14, (preferably about 7 to about 12) or more than one surface active agent and the weighted average of their HLB
values is between about 7 and about 14 (preferably about 7 to about 12).
values is between about 7 and about 14 (preferably about 7 to about 12).
[0191] According to one or more other embodiments the composition contains a single surface active agent having an HLB value between about 9 and about 19, or more than one surface active agent and the weighted average of their HLB values is between about 9 and about 19.
[0192] In a waterless or substantially waterless environment a wide range of HLB
values may be suitable.
values may be suitable.
[0193] Preferably, the composition contains a non-ionic surfactant.
Nonlimiting examples of possible non-ionic surfactants include a polysorbate, polyoxyethylene (20) sorbitan monostearate, polyoxyethylene (20) sorbitan monooleate, a polyoxyethylene fatty acid ester, Myrj 45, Myrj 49, Myrj 52 and Myrj 59; a polyoxyethylene alkyl ether, polyoxyethylene cetyl ether, polyoxyethylene palmityl ether, polyethylene oxide hexadecyl ether, polyethylene glycol cetyl ether, steareths such as steareth 2, brij 21, brij 721, brij 38, brij 52, brij 56 and brij W1, a sucrose ester, a partial ester of sorbitol and its anhydrides, sorbitan monolaurate, sorbitan monolaurate, a monoglyceride, a diglyceride, isoceteth-20 and mono-, di- and tri-esters of sucrose with fatty acids. In certain embdiments, suitable sucrose esters include those having high monoester content, which have higher HLB values.
Nonlimiting examples of possible non-ionic surfactants include a polysorbate, polyoxyethylene (20) sorbitan monostearate, polyoxyethylene (20) sorbitan monooleate, a polyoxyethylene fatty acid ester, Myrj 45, Myrj 49, Myrj 52 and Myrj 59; a polyoxyethylene alkyl ether, polyoxyethylene cetyl ether, polyoxyethylene palmityl ether, polyethylene oxide hexadecyl ether, polyethylene glycol cetyl ether, steareths such as steareth 2, brij 21, brij 721, brij 38, brij 52, brij 56 and brij W1, a sucrose ester, a partial ester of sorbitol and its anhydrides, sorbitan monolaurate, sorbitan monolaurate, a monoglyceride, a diglyceride, isoceteth-20 and mono-, di- and tri-esters of sucrose with fatty acids. In certain embdiments, suitable sucrose esters include those having high monoester content, which have higher HLB values.
[0194] In an embodiment the surfactant is an ether for example polyoxyethylene (26) glycerol ether.
[0195] In certain embodiments, surfactants are selected which can provide a close packed surfactant layer. To achieve such objectives combinations of at least two surfactants are selected. Preferably, they should be complex emulgators and more preferably they should both be of a similar molecular type; for example, a pair of ethers, like steareth 2 and steareth 21, or a pair of esters, for example, PEG-40 stearate and polysorbate 80. Ideally, the surfactants can be ethers. In certain circumstances POE
esters cannot be used and a combination of sorbitan laurate and sorbitan stearate or a combination of sucrose stearic acid ester mixtures and sodium laurate may be used. All these combinations due to their versatility and strength may also be used satisfactorily and effectively with ether formulations, although the amounts and proportion may be varied according to the formulation and its objectives as will be appreciated by a man of the art.
esters cannot be used and a combination of sorbitan laurate and sorbitan stearate or a combination of sucrose stearic acid ester mixtures and sodium laurate may be used. All these combinations due to their versatility and strength may also be used satisfactorily and effectively with ether formulations, although the amounts and proportion may be varied according to the formulation and its objectives as will be appreciated by a man of the art.
[0196] It has been discovered also that by using a derivatized hydrophilic polymer with hydrophobic alkyl moieties as a polymeric emulsifier such as pemulen it is possible to stabilize the emulsion better about or at the region of phase reversal tension. Other types of derivatized polymers like silicone copolymers, derivatized starch [Aluminum Starch Octenylsuccinate (ASOS)] / [DRY-FLO AF Starch], and derivatized dexrin may also a similar stabilizing effect.
[0197] A series of dextrin derivative surfactants prepared by the reaction of the propylene glycol polyglucosides with a hydrophobic oxirane-containing material of the glycidyl ether are highly biodegradable. [Hong-Rong Wang and Keng-Ming Chen, Colloids and Surfaces A: Physicochemical and Engineering Aspects Volume 281, Issues 1-3, 15 June 2006, Pages 190-193] .
[0198] Non-limiting examples of non-ionic surfactants that have HLB of about 7 to about 12 include steareth 2 (HLB-4.9); glyceryl monostearate/PEG 100 stearate (Av HLB-1 1.2); stearate Laureth 4 (HLB-9.7) and cetomacrogol ether (e.g., polyethylene glycol 1000 monocetyl ether).
[0199] Non-limiting examples of preferred surfactants, which have a HLB of 4-19 are set out in the Table below:
Surfactant HLB
steareth 2 -4.9 glyceryl monostearate/PEG 100 stearate Av -11.2 Glyceryl Stearate -4 Steareth-21 -15.5 peg 40 stearate -16.9 polysorbate 80 -15 sorbitan stearate -4.7 laureth 4 -9.7 Sorbitan monooleate (span 80) -4.3 ceteareth 20 -15.7 steareth 20 -15.3 ceteth 20 -15.7 Macrogol Cetostearyl Ether -15.7 ceteth 2 (Lipocol C-2) -5.3 PEG-30 Dipolyhydroxystearate -5.5 sucrose distearate (Sisterna SP30) -6 polyoxyethylene (100) stearate -18.8 [0200] Another component of the formulations of the present invention is a compound used in the present invention is Sepigel 305. Sepigel 305 comprises Polyacrylamide and C13-14 Isoparaffin and Laureth-7. It acts as a surfactant and as a thickening and emulsifying agent, and comes in a liquid, very easy to handle form. It requires neither premixing, nor high rate of shear nor neutralisation. Sepigel 305 can be used to emulsify all types of oil phase without heating, producing gel-cream with a rich, silky texture that are easy to apply and rapidly absorbed by the skin.
Surfactant HLB
steareth 2 -4.9 glyceryl monostearate/PEG 100 stearate Av -11.2 Glyceryl Stearate -4 Steareth-21 -15.5 peg 40 stearate -16.9 polysorbate 80 -15 sorbitan stearate -4.7 laureth 4 -9.7 Sorbitan monooleate (span 80) -4.3 ceteareth 20 -15.7 steareth 20 -15.3 ceteth 20 -15.7 Macrogol Cetostearyl Ether -15.7 ceteth 2 (Lipocol C-2) -5.3 PEG-30 Dipolyhydroxystearate -5.5 sucrose distearate (Sisterna SP30) -6 polyoxyethylene (100) stearate -18.8 [0200] Another component of the formulations of the present invention is a compound used in the present invention is Sepigel 305. Sepigel 305 comprises Polyacrylamide and C13-14 Isoparaffin and Laureth-7. It acts as a surfactant and as a thickening and emulsifying agent, and comes in a liquid, very easy to handle form. It requires neither premixing, nor high rate of shear nor neutralisation. Sepigel 305 can be used to emulsify all types of oil phase without heating, producing gel-cream with a rich, silky texture that are easy to apply and rapidly absorbed by the skin.
[0201] More exemplary stabilizing surfactants which may be suitable for use in the present invention are found below.
[0202] PEG-Fatty Acid Monoester Surfactants, such as:
Chemical name Product example name HLB
PEG-30 stearate Myrj 51 >10 PEG-40 laurate Crodet L40 (Croda) 17.9 PEG-40 oleate Crodet 040 (Croda) 17.4 PEG-45 stearate Nikkol MYS-45 (Nikko) 18 PEG-50 stearate Myrj 53 >10 PEG-100 stearate Myrj 59, Arlacel 165 (ICI) 19 [0203] PEG-Fatty Acid Diester Surfactants, such as:
Chemical name Product example name HLB
PEG-4 dilaurate Mapeg® 200 DL (PPG), 7 Kessco®PEG 200 DL
(Stepan), LIPOPEG 2-DL (Lipo Chem.) PEG-4 distearate Kessco RTM. 200 DS 5 Ste an.sub PEG-32 dioleate Kessco® PEG 1540 DO 15 (Stepan) PEG-400 dioleate Cithrol 4DO series (Croda) >10 PEG-400 disterate Cithrol 4DS series (Croda) >10 PEG-20 glyceryl oleate Tagat® 0 (Goldschmidt) >10 [0204] Transesterification Products of Oils and Alcohols, such as:
Chemical name Product example name HLB
PEG-30 castor oil Emalex C-30 (Nihon Emulsion) 11 PEG-40 hydrogenated castor Cremophor RH 40 (BASF), 13 oil Croduret (Croda), Emulgin HRE
40 (Henkel) [0205] Polyglycerized Fatty Acids, such as:
Chemical name Product example name LB
Polyglyceryl-6 dioleate Caprol® 6G20 (ABITEC); 8.5 PGO-62 (Calgene), PLUROL
Gattefosse Hoda [0206] PEG-Sorbitan Fatty Acid Esters, such as:
Chemical name Product example name HLB
Tween-20 (Atlas/ICI), Crillet 1 PEG-20 sorbitan monolaurate (Croda), DACOL MLS 20 17 (Condea) PEG-20 sorbitan Tween 40 (Atlas/ICI), Crillet 2 16 Monopalmitate (Croda) PEG-20 sorbitan Tween-60 (Atlas/ICI), Crillet 3 15 monostearate (Croda) PEG-20 sorbitan monooleate Tween-80 (Atlas/ICI), Crillet 4 15 (Croda) [0207] Polyethylene Glycol Alkyl Ethers, such as:
Chemical name Product example name HLB
PEG-2 oleyl ether oleth-2 Brij 92/93 (Atlas/ICI) 4.9 PEG-3 oleyl ether oleth-3 Volpo 3 (Croda) <10 PEG-5 oleyl ether oleth-5 Volpo 5 (Croda) <10 PEG-10 oleyl ether oleth-10 Volpo 10 (Croda), Brij 12 96/97 (Atlas/ICI) PEG-20 oleyl ether oleth-20 Volpo 20 (Croda), Brij 15 98/99 (Atlas/ICI) PEG-4 lauryl ether laureth-4Brij 30 (Atlas/ICI) 9.7 PEG-23 lauryl ether laureth-23Brij 35 (Atlas/ICI) 17 PEG-10 stearyl ether Brij 76 (ICI) 12 PEG-2 cetyl ether Brij 52 (ICI) 5.3 [0208] Sugar Ester Surfactants, such as:
Chemical name Product example name HLB
Sucrose distearate Sisterna SP50, Surfope 1811 11 [0209] Sorbitan Fatty Acid Ester Surfactants, such as:
Chemical name Product example name HLB
Sorbitan monolaurate Span-20 (Atlas/ICI), Crill 1 8.6 (Croda), Arlacel 20 (ICI) Sorbitan monopalmitate Span-40 (Atlas/ICI), Crill 2 6.7 (Croda), Nikkol SP-10 (Nikko) Sorbitan monooleate Span-80 (Atlas/ICI), Crill 4 4.3 (Croda), Crill 50 (Croda) Sorbitan monostearate Span-60 (Atlas/ICI), Crill 3 4.7 (Croda), Nikkol SS-10 (Nikko) [0210] In one or more embodiments the surface active agent is a complex emulgator in which the combination of two or more surface active agents can be more effective than a single surfactant and provides a more stable formulation or improved foam quality than a single surfactant. For example and by way of non-limiting explanation it has been found that by choosing say two surfactants, one hydrophobic and the other hydrophilic the combination can produce a more stable emulsion than a single surfactant.
Preferably, the complex emulgator comprises a combination of surfactants wherein there is a difference of about 4 or more units between the HLB values of the two surfactants or there is a significant difference in the chemical nature or structure of the two or more surfactants.
Chemical name Product example name HLB
PEG-30 stearate Myrj 51 >10 PEG-40 laurate Crodet L40 (Croda) 17.9 PEG-40 oleate Crodet 040 (Croda) 17.4 PEG-45 stearate Nikkol MYS-45 (Nikko) 18 PEG-50 stearate Myrj 53 >10 PEG-100 stearate Myrj 59, Arlacel 165 (ICI) 19 [0203] PEG-Fatty Acid Diester Surfactants, such as:
Chemical name Product example name HLB
PEG-4 dilaurate Mapeg® 200 DL (PPG), 7 Kessco®PEG 200 DL
(Stepan), LIPOPEG 2-DL (Lipo Chem.) PEG-4 distearate Kessco RTM. 200 DS 5 Ste an.sub PEG-32 dioleate Kessco® PEG 1540 DO 15 (Stepan) PEG-400 dioleate Cithrol 4DO series (Croda) >10 PEG-400 disterate Cithrol 4DS series (Croda) >10 PEG-20 glyceryl oleate Tagat® 0 (Goldschmidt) >10 [0204] Transesterification Products of Oils and Alcohols, such as:
Chemical name Product example name HLB
PEG-30 castor oil Emalex C-30 (Nihon Emulsion) 11 PEG-40 hydrogenated castor Cremophor RH 40 (BASF), 13 oil Croduret (Croda), Emulgin HRE
40 (Henkel) [0205] Polyglycerized Fatty Acids, such as:
Chemical name Product example name LB
Polyglyceryl-6 dioleate Caprol® 6G20 (ABITEC); 8.5 PGO-62 (Calgene), PLUROL
Gattefosse Hoda [0206] PEG-Sorbitan Fatty Acid Esters, such as:
Chemical name Product example name HLB
Tween-20 (Atlas/ICI), Crillet 1 PEG-20 sorbitan monolaurate (Croda), DACOL MLS 20 17 (Condea) PEG-20 sorbitan Tween 40 (Atlas/ICI), Crillet 2 16 Monopalmitate (Croda) PEG-20 sorbitan Tween-60 (Atlas/ICI), Crillet 3 15 monostearate (Croda) PEG-20 sorbitan monooleate Tween-80 (Atlas/ICI), Crillet 4 15 (Croda) [0207] Polyethylene Glycol Alkyl Ethers, such as:
Chemical name Product example name HLB
PEG-2 oleyl ether oleth-2 Brij 92/93 (Atlas/ICI) 4.9 PEG-3 oleyl ether oleth-3 Volpo 3 (Croda) <10 PEG-5 oleyl ether oleth-5 Volpo 5 (Croda) <10 PEG-10 oleyl ether oleth-10 Volpo 10 (Croda), Brij 12 96/97 (Atlas/ICI) PEG-20 oleyl ether oleth-20 Volpo 20 (Croda), Brij 15 98/99 (Atlas/ICI) PEG-4 lauryl ether laureth-4Brij 30 (Atlas/ICI) 9.7 PEG-23 lauryl ether laureth-23Brij 35 (Atlas/ICI) 17 PEG-10 stearyl ether Brij 76 (ICI) 12 PEG-2 cetyl ether Brij 52 (ICI) 5.3 [0208] Sugar Ester Surfactants, such as:
Chemical name Product example name HLB
Sucrose distearate Sisterna SP50, Surfope 1811 11 [0209] Sorbitan Fatty Acid Ester Surfactants, such as:
Chemical name Product example name HLB
Sorbitan monolaurate Span-20 (Atlas/ICI), Crill 1 8.6 (Croda), Arlacel 20 (ICI) Sorbitan monopalmitate Span-40 (Atlas/ICI), Crill 2 6.7 (Croda), Nikkol SP-10 (Nikko) Sorbitan monooleate Span-80 (Atlas/ICI), Crill 4 4.3 (Croda), Crill 50 (Croda) Sorbitan monostearate Span-60 (Atlas/ICI), Crill 3 4.7 (Croda), Nikkol SS-10 (Nikko) [0210] In one or more embodiments the surface active agent is a complex emulgator in which the combination of two or more surface active agents can be more effective than a single surfactant and provides a more stable formulation or improved foam quality than a single surfactant. For example and by way of non-limiting explanation it has been found that by choosing say two surfactants, one hydrophobic and the other hydrophilic the combination can produce a more stable emulsion than a single surfactant.
Preferably, the complex emulgator comprises a combination of surfactants wherein there is a difference of about 4 or more units between the HLB values of the two surfactants or there is a significant difference in the chemical nature or structure of the two or more surfactants.
[0211] Specific non limiting examples of surfactant systems are, combinations of polyoxyethylene alkyl ethers, such as Brij 59 / Brij10; Brij 52 / Brij 10;
Steareth 2 /
Steareth 20; Steareth 2 / Steareth 21 (Brij 72 / Brij 721); combinations of polyoxyethylene stearates such as Myrj 52 / Myrj 59; combinations of sucrose esters, such as Surphope 1816 / Surphope 1807; combinations of sorbitan esters, such as Span 20 / Span 80;
Span 20 / Span 60; combinations of sucrose esters and sorbitan esters, such as Surphope 1811 and Span 60; combinations of liquid polysorbate detergents and PEG
compounds, such as Tween 80 / PEG-40 stearate; methyl glucaso sequistearate;
polymeric emulsifiers, such as Permulen (TRI or TR2); liquid crystal systems, such as Arlatone (2121), Stepan (Mild RM1), Nikomulese (41) and Montanov (68) and the like.
Steareth 2 /
Steareth 20; Steareth 2 / Steareth 21 (Brij 72 / Brij 721); combinations of polyoxyethylene stearates such as Myrj 52 / Myrj 59; combinations of sucrose esters, such as Surphope 1816 / Surphope 1807; combinations of sorbitan esters, such as Span 20 / Span 80;
Span 20 / Span 60; combinations of sucrose esters and sorbitan esters, such as Surphope 1811 and Span 60; combinations of liquid polysorbate detergents and PEG
compounds, such as Tween 80 / PEG-40 stearate; methyl glucaso sequistearate;
polymeric emulsifiers, such as Permulen (TRI or TR2); liquid crystal systems, such as Arlatone (2121), Stepan (Mild RM1), Nikomulese (41) and Montanov (68) and the like.
[0212] In certain embodiments the surfactant is preferably one or more of the following: a combination of steareth-2 and steareth-21 on their own or in combination with glyceryl monostearate (GMS); in certain other embodiments the surfactant is a combination of polysorbate 80 and PEG-40 stearate. In certain other embodiments the surfactant is a combination of glyceryl monostearate/PEG 100 stearate. In certain other embodiments the surfactant is a combination of two or more of stearate 21, PEG
stearate, and polysorbate 80. In certain other embodiments the surfactant is a combination of two or more of laureth 4, span80, and polysorbate 80. In certain other embodiments the surfactant is a combination of two or more of GMS and ceteareth. In certain other embodiments the surfactant is a combination of two or more of steareth 21, ceteareth 20, ceteth 2 and laureth 4 In certain other embodiments the surfactant is a combination of ceteareth 20 and polysorbate 40 stearate. In certain other embodiments the surfactant is a combination of span 60 and GMS. In certain other embodiments the surfactant is a combination of two or all of PEG 40 stearate, sorbitan stearate and polysorbate 60 [0213] In certain other embodiments the surfactant is one or more of sucrose stearic acid esters, sorbitan laureth, and sorbitan stearate.
stearate, and polysorbate 80. In certain other embodiments the surfactant is a combination of two or more of laureth 4, span80, and polysorbate 80. In certain other embodiments the surfactant is a combination of two or more of GMS and ceteareth. In certain other embodiments the surfactant is a combination of two or more of steareth 21, ceteareth 20, ceteth 2 and laureth 4 In certain other embodiments the surfactant is a combination of ceteareth 20 and polysorbate 40 stearate. In certain other embodiments the surfactant is a combination of span 60 and GMS. In certain other embodiments the surfactant is a combination of two or all of PEG 40 stearate, sorbitan stearate and polysorbate 60 [0213] In certain other embodiments the surfactant is one or more of sucrose stearic acid esters, sorbitan laureth, and sorbitan stearate.
[0214] Without being bound by any particular theory or mode of operation, it is believed that the use of non-ionic surfactants with significant hydrophobic and hydrophilic components, increase the emulsifier or foam stabilization characteristics of the composition. Similarly, without being bound by any particular theory or mode of operation, using combinations of surfactants with high and low HLB's to provide a relatively close packed surfactant layer may strengthen the formulation.
[0215] In one or more embodiments the stability of the composition can be improved when a combination of at least one non-ionic surfactant having HLB of less than 9 and at least one non-ionic surfactant having HLB of equal or more than 9 is employed.
The ratio between the at least one non-ionic surfactant having HLB of less than 9 and the at least one non-ionic surfactant having HLB of equal or more than 9, is between 1:8 and 8:1, or at a ratio of 4:1 to 1:4. The resultant HLB of such a blend of at least two emulsifiers is preferably between about 9 and about 14.
The ratio between the at least one non-ionic surfactant having HLB of less than 9 and the at least one non-ionic surfactant having HLB of equal or more than 9, is between 1:8 and 8:1, or at a ratio of 4:1 to 1:4. The resultant HLB of such a blend of at least two emulsifiers is preferably between about 9 and about 14.
[0216] Thus, in an exemplary embodiment, a combination of at least one non-ionic surfactant having HLB of less than 9 and at least one non-ionic surfactant having HLB of equal or more than 9 is employed, at a ratio of between 1:8 and 8:1, or at a ratio of 4:1 to 1:4, wherein the HLB of the combination of emulsifiers is preferably between about 5 and about 18.
[0217] In certain cases, the surface active agent is selected from the group of cationic, zwitterionic, amphoteric and ampholytic surfactants, such as sodium methyl cocoyl taurate, sodium methyl oleoyl taurate, sodium lauryl sulfate, triethanolamine lauryl sulfate and betaines.
[0218] Many amphiphilic molecules can show lyotropic liquid-crystalline phase sequences depending on the volume balances between the hydrophilic part and hydrophobic part. These structures are formed through the micro-phase segregation of two Many amphiphilic molecules can show lyotropic liquid-crystalline phase sequences depending on the volume balances between the hydrophilic part and hydrophobic part.
These structures are formed through the micro-phase segregation of two incompatible components on a nanometer scale. Soap is an everyday example of a lyotropic liquid crystal. Certain types of surfactants tend to form lyotropic liquid crystals in emulsions interface (oil-in-water) and exert a stabilizing effect [0219] In one or more embodiments the surfactant is a surfactant or surfactant combination is capable of or which tends to form liquid crystals. Surfactants which tend to form liquid crystals may improve the quality of foams. Non limiting examples of surfactants with postulated tendency to form interfacial liquid crystals are:
phospholipids, alkyl glucosides, sucrose esters, sorbitan esters.
These structures are formed through the micro-phase segregation of two incompatible components on a nanometer scale. Soap is an everyday example of a lyotropic liquid crystal. Certain types of surfactants tend to form lyotropic liquid crystals in emulsions interface (oil-in-water) and exert a stabilizing effect [0219] In one or more embodiments the surfactant is a surfactant or surfactant combination is capable of or which tends to form liquid crystals. Surfactants which tend to form liquid crystals may improve the quality of foams. Non limiting examples of surfactants with postulated tendency to form interfacial liquid crystals are:
phospholipids, alkyl glucosides, sucrose esters, sorbitan esters.
[0220] In one or more embodiments the at least one surface active agent is liquid.
Moreover for the purposes of formulating with liquid ethers a liquid surfactant is preferred.
Moreover for the purposes of formulating with liquid ethers a liquid surfactant is preferred.
[0221] In one or more embodiments the liquid surfactant is a polysorbate, preferably polysorbate 80 or 60.
[0222] In one or more embodiments the at least one surface active agent is solid, semi solid or waxy. In a further embodiment they are soluble in oil and in another embodiment have a HLB of less than about 12.
[0223] It should be noted that HLB values may not be so applicable to non ionic surfactants, for example, with liquid crystals or with silicones. Also HLB
values may be of lesser significance in a waterless or substantially non-aqueous environment.
values may be of lesser significance in a waterless or substantially non-aqueous environment.
[0224] In one or more embodiments the surfactant can be, a surfactant system comprising of a surfactant and a co surfactant, a waxy emulsifier, a liquid crystal emulsifier, an emulsifier which is solid or semi solid at room temperature and pressure, or combinations of two or more agents in an appropriate proportion as will be appreciated a person skilled in the art. Where a solid or semi solid emulsifier combination is used it can also comprise a solid or semi solid emulsifier and a liquid emulsifier. In a preferred embodiment at least one surfactant is a liquid.
[0225] In one or more embodiments, the surface-active agent includes at least one non-ionic surfactant. Ionic surfactants are known to be irritants. Therefore, non-ionic surfactants are preferred in applications including sensitive tissue such as found in most mucosal tissues, especially when they are infected or inflamed. Non-ionic surfactants alone can provide formulations and foams of good or excellent quality in the carriers and compositions of the present invention.
[0226] Thus, in a preferred embodiment, the surface active agent, the composition contains a non-ionic surfactant. In another preferred embodiment the composition includes a mixture of non-ionic surfactants as the sole surface active agent.
Yet, in additional embodiments, the foamable composition includes a mixture of at least one non-ionic surfactant and at least one ionic surfactant in a ratio in the range of about 100:1 to 6:1. In one or more embodiments, the non-ionic to ionic surfactant ratio is greater than about 6:1, or greater than about 8:1; or greater than about 14:1, or greater than about 16:1, or greater than about 20:1. In further embodiments, surface active agent comprises a combination of a non-ionic surfactant and an ionic surfactant, at a ratio of between 1:1 and 20:1.
Yet, in additional embodiments, the foamable composition includes a mixture of at least one non-ionic surfactant and at least one ionic surfactant in a ratio in the range of about 100:1 to 6:1. In one or more embodiments, the non-ionic to ionic surfactant ratio is greater than about 6:1, or greater than about 8:1; or greater than about 14:1, or greater than about 16:1, or greater than about 20:1. In further embodiments, surface active agent comprises a combination of a non-ionic surfactant and an ionic surfactant, at a ratio of between 1:1 and 20:1.
[0227] In one or more embodiments , a combination of a non-ionic surfactant and an ionic surfactant (such as sodium lauryl sulphate and cocamidopropylbetaine) is employed, at a ratio of between 1:1 and 20:1, or at a ratio of 4:1 to 10:1;
for example, about 1:1, about 4:1, about 8:1, about 12:1, about 16:1 and about 20:1 or at a ratio of 4:1 to 10:1, for example, about 4:1, about 6:1, about 8:1 and about 10:1.
for example, about 1:1, about 4:1, about 8:1, about 12:1, about 16:1 and about 20:1 or at a ratio of 4:1 to 10:1, for example, about 4:1, about 6:1, about 8:1 and about 10:1.
[0228] For foams in selecting a suitable surfactant or combination thereof it should be borne in mind that the upper amount of surfactant that may be used may be limited by the shakability of the composition. If the surfactant is non liquid, it can make the formulation to viscous or solid. Subject to its miscibility, solid surfactants may be added first, and may require gentle warming and then cooling before being combined with the other ingredients. In general terms, as the amount of non-liquid surfactant is increased the shakability of the formulation reduces until a limitation point is reached where the formulation can become non shakable and unsuitable. Thus in one embodiment, any effective amount of surfactant may be used provided the formulation remains shakable. In other certain limited embodiments the upper limit for foamable formulations may be determined by flowability such that any effective amount can be used provided the formulation is sufficiently flowable to be able to flow through an actuator valve and be released and still expand to form a good quality foam. This may be due without being bound by any theory to one or more of a number of factors such as the viscosity, the softness, the lack of crystals, the pseudoplastic or semi pseudo plastic nature of the composition and the dissolution of the propellant into the composition.
[0229] In certain embodiments the amount of surfactant or combination of surfactants is between about 0.05% to about 20%; between about 0.05% to about 15%.
or between about 0.05% to about 10%. Ina preferred embodiment the concentration of surface active agent is between about 0.2% and about 8%. In a more preferred embodiments the concentration of surface active agent is between about 1 % and about 6% or between about 1 % and about 4%.
or between about 0.05% to about 10%. Ina preferred embodiment the concentration of surface active agent is between about 0.2% and about 8%. In a more preferred embodiments the concentration of surface active agent is between about 1 % and about 6% or between about 1 % and about 4%.
[0230] In some embodiments, it is desirable that the surface active agent does not contain a polyoxyethylene (POE) moiety, such as polysorbate surfactants, POE
fatty acid esters, and POE alkyl ethers, because the active agent is incompatible with such surface active agents. For example, the active agent pimecrolimus is not stable the presence of POE moieties, yet benefits greatly from the use of dicarboxylic esters as penetration enhancers. In such cases, alternative surface active agents are employed. In an exemplary manner, POE - free surfactants include non-ethoxylated sorbitan esters, such as sorbitan monopalmitate, sorbitan monostearate, sorbitan tristearate, sorbitan monooleate, sorbitan trioleate, sorbitan monolaurate and sorbitan sesquioleate; glycerol fatty acid esters, such as glycerol monostearate and glycerol monooleate; mono-, di- and tri-esters of sucrose with fatty acids (sucrose esters), sucrose stearate, sucrose distearate sucrose palmitate and sucrose laurate; and alkyl polyglycosides, such as lauryl diglucoside.
Humectant [0231] A humectant is a substance that helps retain moisture and also prevents rapid evaporation. Non limiting examples are propylene glycol, propylene glycol derivatives, glycerin, hydrogenated starch hydrosylate, hydrogenated lanolin, lanolin wax, D manitol, sorbitol, sodium 2-pyrrolidone-5-carboxylate, sodium lactate, sodium PCA, soluble collagen, dibutyl phthalate, and gelatin. Other examples may be found in the Handbook of Pharmaceutical Additives published by Gower.
Moisturizers [0232] A moisturizer, is a substance that helps retain moisture or add back moisture to the skin. Examples are allantoin, petrolatum, urea, lactic acid, sodium PCV, glycerin, shea butter, caprylic/capric/stearic triglyceride, candelilla wax, propylene glycol, lanolin, hydrogenated oils, squalene, sodium hyaluronate and lysine PCA. Other examples may be found in the Handbook of Pharmaceutical Additives published by Gower.
fatty acid esters, and POE alkyl ethers, because the active agent is incompatible with such surface active agents. For example, the active agent pimecrolimus is not stable the presence of POE moieties, yet benefits greatly from the use of dicarboxylic esters as penetration enhancers. In such cases, alternative surface active agents are employed. In an exemplary manner, POE - free surfactants include non-ethoxylated sorbitan esters, such as sorbitan monopalmitate, sorbitan monostearate, sorbitan tristearate, sorbitan monooleate, sorbitan trioleate, sorbitan monolaurate and sorbitan sesquioleate; glycerol fatty acid esters, such as glycerol monostearate and glycerol monooleate; mono-, di- and tri-esters of sucrose with fatty acids (sucrose esters), sucrose stearate, sucrose distearate sucrose palmitate and sucrose laurate; and alkyl polyglycosides, such as lauryl diglucoside.
Humectant [0231] A humectant is a substance that helps retain moisture and also prevents rapid evaporation. Non limiting examples are propylene glycol, propylene glycol derivatives, glycerin, hydrogenated starch hydrosylate, hydrogenated lanolin, lanolin wax, D manitol, sorbitol, sodium 2-pyrrolidone-5-carboxylate, sodium lactate, sodium PCA, soluble collagen, dibutyl phthalate, and gelatin. Other examples may be found in the Handbook of Pharmaceutical Additives published by Gower.
Moisturizers [0232] A moisturizer, is a substance that helps retain moisture or add back moisture to the skin. Examples are allantoin, petrolatum, urea, lactic acid, sodium PCV, glycerin, shea butter, caprylic/capric/stearic triglyceride, candelilla wax, propylene glycol, lanolin, hydrogenated oils, squalene, sodium hyaluronate and lysine PCA. Other examples may be found in the Handbook of Pharmaceutical Additives published by Gower.
[0233] Pharmaceutical compositions of the present invention may in one or more embodiments usefully comprise in addition a heumectant or a moisturizer or combinations thereof.
Modulating Agent [0234] The term modulating agent is used to describe an agent which can improve the stability of or stabilize a carrier or a foamable composition and or an active agent by modulating the effect of a substance or residue present in the carrier or composition. The substance or residue may for example be acidic or basic and potentially alter an artificial pH in a waterless or substantially non aqueous environment or it may be one or more metal ions which may act as a potential catalyst in a waterless or substantially non aqueous environment or it may be an ionisation agent or it may be an oxidizing agent.
Modulating Agent [0234] The term modulating agent is used to describe an agent which can improve the stability of or stabilize a carrier or a foamable composition and or an active agent by modulating the effect of a substance or residue present in the carrier or composition. The substance or residue may for example be acidic or basic and potentially alter an artificial pH in a waterless or substantially non aqueous environment or it may be one or more metal ions which may act as a potential catalyst in a waterless or substantially non aqueous environment or it may be an ionisation agent or it may be an oxidizing agent.
[0235] In one or more other embodiments the modulating agent is used in a waterless composition. In one or more embodiments the modulating agent is used to describe an agent which can affect pH in an aqueous solution.
[0236] The agent can be any of the known buffering systems used in pharmaceutical or cosmetic formulations as would be appreciated by a man of the art. It can also be an organic acid, a carboxylic acid, a fatty acid an amino acid, an aromatic acid, an alpha or beta hydroxyl acid an organic base or a nitrogen containing compound.
[0237] In one or more further embodiments the modulating agent is used to describe an agent, which is a chelating or sequestering or complexing agent that is sufficiently soluble or functional in the waterless solvent to enable it to "mop up" or "lock" metal ions.
[0238] In the embodiment modulating agent is used to describe an agent which can effect pH in an aqueous solution the term modulating agent more particularly means an acid or base or buffer system or combinations thereof, which is introduced into or is present in and acts to modulate the ionic or polar characteristics and any acidity or basisity balance of a waterless or substantially non aqueous carrier, composition, foamable carrier or foamable composition or resultant foam described herein.
[0239] The terms pH, pKa, and pKb, buffers such measurements and terms are artificial in a waterless environment. In an embodiment of the present invention sufficient modulating agent is added to achieve an artificial pH in which the active agent is preferably stable. Such artificial pH may be acidic, maybe basic or may be neutral.
[0240] In an embodiment of the present invention, the modulating or additional component is a pH adjusting agent or a buffering agent.
[0241] In one or more preferred embodiments of the present invention the chelating agent is selected from the group consisting of ethylenediaminetetraacetic acid ("EDTA") and salts thereof such as disodium EDTA, tetrasodium EDTA and calsium disodium EDTA; diethylenetriaminepentaacetic acid ("DTPA") and salts thereof;
hydroxyethlethylenediaminetriacetic acid ("HEDTA") and salts thereof and nitrilotriacetic acid ("NTA"); more preferably EDTA, HEDTA and their salts; most preferably EDTA and its salts; citric acid buffers including, but not limited to citric acid and salts of citric acid, such as sodium citrate; an alpha hydroxyl acid; an aliphatic beta hydroxy acid; an aromatic acid; an aliphatic carboxylic acid; a dicarboxylic acid; organic acids (including, but not limited to, ascorbic acid, isoascorbic acid, ethanesulfonic acid, glycerophosphoric acid, acetohydroxamic acid, aconitic acid, alpha-ketocaproic acid, aminomalonic acid, hippuric acid, hydrochloric acid, methanesulfonic acid, oxalic acid, phosphoric acid, sorbic acid, iminodiacetic acid, carnitine, nicotinic acid and retinoids, such as retinoic acid and isotretinoin); and amino acids. Exemplary modulating agents include those described in U.S. Patent Publication No. 2008/0206159, filed November 29, 2007, entitled "Compositions With Modulating Agents," which is herein incorporated by reference in its entirety [0242] In one or more embodiments of the present invention a preferred non limiting example of the chelating agent is EDTA. Typically, the chelating and sequestering agent is present in the composition at a level of up to about 5.0%, preferably 1.0 percent, by weight, of the composition.
hydroxyethlethylenediaminetriacetic acid ("HEDTA") and salts thereof and nitrilotriacetic acid ("NTA"); more preferably EDTA, HEDTA and their salts; most preferably EDTA and its salts; citric acid buffers including, but not limited to citric acid and salts of citric acid, such as sodium citrate; an alpha hydroxyl acid; an aliphatic beta hydroxy acid; an aromatic acid; an aliphatic carboxylic acid; a dicarboxylic acid; organic acids (including, but not limited to, ascorbic acid, isoascorbic acid, ethanesulfonic acid, glycerophosphoric acid, acetohydroxamic acid, aconitic acid, alpha-ketocaproic acid, aminomalonic acid, hippuric acid, hydrochloric acid, methanesulfonic acid, oxalic acid, phosphoric acid, sorbic acid, iminodiacetic acid, carnitine, nicotinic acid and retinoids, such as retinoic acid and isotretinoin); and amino acids. Exemplary modulating agents include those described in U.S. Patent Publication No. 2008/0206159, filed November 29, 2007, entitled "Compositions With Modulating Agents," which is herein incorporated by reference in its entirety [0242] In one or more embodiments of the present invention a preferred non limiting example of the chelating agent is EDTA. Typically, the chelating and sequestering agent is present in the composition at a level of up to about 5.0%, preferably 1.0 percent, by weight, of the composition.
[0243] Combinations of Modulating Agents may be a useful for example chelating agents may be usefully used in combination with another modulating agent such as an acid, a base or a buffer system or with various combinations of modulating agents.
[0244] The modulating agent to the foamable composition of the present invention is further useful for adjusting the pH of the target area of application.
[0245] In one or more embodiments, the modulating agent may also be a preservative or an antioxidant or an ionization agent. Any preservative, antioxidant or ionization agents suitable for pharmaceutical or cosmetic application may be used. Non limiting examples of antioxidants are tocopherol succinate, propyl galate, butylated hydroxy toluene and butyl hydroxy anisol. In one or more embodiments the modulating agent is a flavonoid. Ionization agents may be positive or may be negative depending on the environment and the active agent or composition that is to be protected.
Ionization agents may for example act to protect or reduce sensitivity of active agents.
Non limiting examples of positive ionization agents are benzyl conium chloride, and cetyl pyridium chloride. Non limiting examples of negative ionization agents are sodium lauryl sulphate, sodium lauryl lactylate and phospholipids.
Ionization agents may for example act to protect or reduce sensitivity of active agents.
Non limiting examples of positive ionization agents are benzyl conium chloride, and cetyl pyridium chloride. Non limiting examples of negative ionization agents are sodium lauryl sulphate, sodium lauryl lactylate and phospholipids.
[0246] In one or more embodiments the formulations described herein may further contain a modulating agent.
Microsponges [0247] The Microsponges are rigid, porous and spongelike round microscopic particles of cross-linked polymer beads (e.g., polystyrene or copolymers thereof), each defining a substantially noncollapsible pore network. The Microsponges can be loaded with an active ingredient and can provide a controlled time release of the active ingredient to skin or to a mucosal membrane upon application of the formulation. The slow release is intended to reduce irritation by the active. Microsponge delivery technology was developed by Advanced Polymer Systems. In one or more embodiments the composition comprises one or more active agents loaded into Microponges with an aqueous carrier or with a waterless carrier described herein which may comprise a modulating agent.
Propellants [0248] Examples of suitable propellants include volatile hydrocarbons such as butane, propane, isobutane and fluorocarbon gases, or mixtures thereof.
Microsponges [0247] The Microsponges are rigid, porous and spongelike round microscopic particles of cross-linked polymer beads (e.g., polystyrene or copolymers thereof), each defining a substantially noncollapsible pore network. The Microsponges can be loaded with an active ingredient and can provide a controlled time release of the active ingredient to skin or to a mucosal membrane upon application of the formulation. The slow release is intended to reduce irritation by the active. Microsponge delivery technology was developed by Advanced Polymer Systems. In one or more embodiments the composition comprises one or more active agents loaded into Microponges with an aqueous carrier or with a waterless carrier described herein which may comprise a modulating agent.
Propellants [0248] Examples of suitable propellants include volatile hydrocarbons such as butane, propane, isobutane and fluorocarbon gases, or mixtures thereof.
[0249] In an embodiment the propellant is1681, which is a mixture of propane, isobutene and butane. In another embodiment it is AP 70, which is a mixture of propane, isobutene and butane with a higher pressure.
[0250] The propellant makes up about 5-25 wt% of the foamable composition. In some circumstances the propellant may be up to 35%. The propellants are used to generate and administer the foamable composition as a foam. The total composition including propellant, foamable compositions and optional ingredients is referred to as the foamable composition.
[0251] Alcohol and organic solvents render foams inflammable. It has been surprisingly discovered that fluorohydrocarbon propellants, other than chloro-fluoro carbons (CMCs), which are non-ozone-depleting propellants, are particularly useful in the production of a non-flammable foamable composition. A test according to European Standard prEN 14851, titled "Aerosol containers - Aerosol foam flammability test"
revealed that compositions containing an organic carrier that contains a hydrophobic organic carrier and/or a solvent, which are detected as inflammable when a hydrocarbon propellant is used, become non-flammable, while the propellant is an HFC
propellant.
revealed that compositions containing an organic carrier that contains a hydrophobic organic carrier and/or a solvent, which are detected as inflammable when a hydrocarbon propellant is used, become non-flammable, while the propellant is an HFC
propellant.
[0252] Such propellants include, but are not limited to, hydrofluorocarbon (HFC) propellants, which contain no chlorine atoms, and as such, fall completely outside concerns about stratospheric ozone destruction by chlorofluorocarbons or other chlorinated hydrocarbons. Exemplary non-flammable propellants according to this aspect of the invention include propellants made by DuPont under the registered trademark Dymel, such as 1,1,1,2 tetrafluorethane (Dymel 134), and 1,1,1,2,3,3,3 heptafluoropropane (Dymel 227) 1,1, difluoro ethane (Dymel 152) and 1,1,1,3,3,3 hexafluoropropane HFCs possess Ozone Depletion Potential of 0.00 and thus, they are allowed for use as propellant in aerosol products.
[0253] In one or more embodiments, the non inflammbale propellants are used in combination with the more traditional hydrocarbon propellants.
[0254] In one or more embodiments, where Dymel is used, it is used in such levels that the sensation effect is not primarily due to the propellant.
[0255] Notably, the stability of foamable emulsions including HFC as the propellant can be improved in comparison with the same composition made with a hydrocarbon propellant.
[0256] In one or more embodiments foamable compositions comprise a combination of a HFC and a hydrocarbon propellant such as n-butane or mixtures of hydrocarbon propellants such as propane, isobutane and butane.
[0257] Some propellants may have a cooling effect. The evaporation of the propellant from newly released foam that has been applied to a body surface can, depending on the nature of the foam and the type and amount of propellant provide a cooling effect. In some cases the sensation is mild and in other cases the propellant can actually produce physical cooling on the skin surface. As will be appreciated such cooling effect may increase relative to the ability of the formulation to deliver increasing levels of propellant in contact with the skin.
[0258] Dimethyl ether is a product which evaporates very rapidly to produce a cooling effect and in one or more embodiments is used as part of the propellant system.
[0259] In one or more embodiments the propellant is a mixture of propane, butane and isobutene.
[0260] In one or more embodiments the propellant is a mixture of propane, butane and isobutene together with dimethyl ether.
[0261] In one or more embodiments the propellant makes up about 5-25 wt% of the foamable composition.
[0262] In certain other embodiments the amount of propellant can be increased to up to less than half of the composition, for example, where it is desired to produce a cooling effect in addition to a cooling sensation or where it is sought to produce an initial cooling effect followed by a cooling or other sensation .
Additional components [0263] Additional component selected from the group consisting of an anti perspirant, an anti-static agent, a buffering agent, a bulking agent, a chelating agent, a colorant, a conditioner, a deodorant, a diluent, a dye, an emollient, fragrance, a humectant, an occlusive agent, a penetration enhancer, a perfuming agent, a permeation enhancer, a pH-adjusting agent, a preservative, a skin penetration enhancer, a sunscreen, a sun blocking agent, a sunless tanning agent, and a vitamin or derivative thereof.
Additional components [0263] Additional component selected from the group consisting of an anti perspirant, an anti-static agent, a buffering agent, a bulking agent, a chelating agent, a colorant, a conditioner, a deodorant, a diluent, a dye, an emollient, fragrance, a humectant, an occlusive agent, a penetration enhancer, a perfuming agent, a permeation enhancer, a pH-adjusting agent, a preservative, a skin penetration enhancer, a sunscreen, a sun blocking agent, a sunless tanning agent, and a vitamin or derivative thereof.
[0264] In addition to the sensations and sensation agents and sensation modifying effects described herein it is possible to enhance the sensation of the user and to increase compliance, by for example making the product visually attractive.
Thus, in certain further embodiments the additional component is one or more of a colored active agent, a colored excipient, a pigment, a dye, a colorant and a coloring agent.
Similarly, in other certain embodiments the additional component is a fragrance or fragrance masking agent Sensation or sensation modifying agent [0265] The sensation modifying agent is selected from a cooling agent, a warming agent a relaxing or soothing agent; a stimulating agent; a refreshing agent;
or mixtures thereof.
Thus, in certain further embodiments the additional component is one or more of a colored active agent, a colored excipient, a pigment, a dye, a colorant and a coloring agent.
Similarly, in other certain embodiments the additional component is a fragrance or fragrance masking agent Sensation or sensation modifying agent [0265] The sensation modifying agent is selected from a cooling agent, a warming agent a relaxing or soothing agent; a stimulating agent; a refreshing agent;
or mixtures thereof.
[0266] As will be appreciated by someone in the art two or more soothing, relaxing, cooling, stimulating, refreshing, and warming agents may be effectively combined in order to produce a combined, staggered, consecutive, overlapping, reduced or increased effect or sensation, as is appropriate.
Cooling agents [0267] In the context and without degradating from explanations given elsewhere, substances, which are known to provide a "cool" sensation or cooling effect on or following application to a body surface; and substances that, on or following topical application can ameliorate a hot sensation or a heating effect are called "cooling agents".
Any agent which, when incorporated in the foamable composition in a concentration sufficient to exert a cooling sensation or effect or to ameliorate a hot sensation or heating effect, is suitable for use a cooling agent in accordance with the present invention. The cooling agent may be an excipient, an active ingredient or pharmaceutical, therapeutic or cosmetic agent or a propellant or combinations of two or more agents.
Cooling agents [0267] In the context and without degradating from explanations given elsewhere, substances, which are known to provide a "cool" sensation or cooling effect on or following application to a body surface; and substances that, on or following topical application can ameliorate a hot sensation or a heating effect are called "cooling agents".
Any agent which, when incorporated in the foamable composition in a concentration sufficient to exert a cooling sensation or effect or to ameliorate a hot sensation or heating effect, is suitable for use a cooling agent in accordance with the present invention. The cooling agent may be an excipient, an active ingredient or pharmaceutical, therapeutic or cosmetic agent or a propellant or combinations of two or more agents.
[0268] Hence, non limiting examples of cooling agents, which are all incorporated herein by reference are provided in US Patents No. 3,419,543, 4,020,153, 4,032,661, 4,033,994, 4,034,109, 4,059,118, 4,060,091, 4,070,449, 4,070,496, 4,136,163, 4,150,052, 4, 4,153,679, 157,384, 4,178,459, 4,193,936, 4,226,988, 4,230,688, 4,296,255, 4,459,425, 5,266,592, 5,608,119, 5,725,865, 5,773,410, 5,843,466, 5,959,161, 6,214,788, 6,267,974, 6,303,817, 6,328,982, 6,359,168, 6,482,983, 6,592,884, 6,884,906 and7,030,273 US Patent Application 20040067970, DE
2,202,535, DE 2,205,255, DE 2,503,555, DE 2,608,226, DE 4,226,043, GB 1,351,761, GB
1,351,762, GB 1,421,744, JP 2004059474 and WO 2005049553; and in Watson et al, J.
Soc. Cosmet. Chem. 29, 185-200 (1978); and Ottinger et al in J. Agric. Food Chem., 49, 5383-5390 (2001).
2,202,535, DE 2,205,255, DE 2,503,555, DE 2,608,226, DE 4,226,043, GB 1,351,761, GB
1,351,762, GB 1,421,744, JP 2004059474 and WO 2005049553; and in Watson et al, J.
Soc. Cosmet. Chem. 29, 185-200 (1978); and Ottinger et al in J. Agric. Food Chem., 49, 5383-5390 (2001).
[0269] In an embodiment, the cooling agent has a further sensation or sensation modifying feeling or effect.
[0270] In an embodiment, the cooling agent is menthol. In additional embodiment, the cooling agent is an isomer or a derivative of menthol, as exemplifies in the following schemes:
OH
OH HO OH HC` Or O
1-menthol d-menthol (+)-neo (-)-neo Thymol Carvomenthol 1-Menthone (mild cooling) OH HO Of-I HO`' `../õ
1,8-Cineol d-camphor (+)-neoiso (-)-neoiso (+)-iso (-)-iso (mild cooling) ,=~^,, 1-carvone (cooling) [0271] Additional examples of menthol derivatives are monomenthyl esters of di-and polycarboxylic acids:
LO OI O
OY0H `~=..~' `~.~' o oH
.
OAOSugar O- O---,---OH OH OH
OH
0 /-isopulegol p-Menthane-3,8-diol t,0,,,, , OH
Menthol ethylene glycol carbonate [0272] Some derivatives have been developed to be substantially without smell.
OH
OH HO OH HC` Or O
1-menthol d-menthol (+)-neo (-)-neo Thymol Carvomenthol 1-Menthone (mild cooling) OH HO Of-I HO`' `../õ
1,8-Cineol d-camphor (+)-neoiso (-)-neoiso (+)-iso (-)-iso (mild cooling) ,=~^,, 1-carvone (cooling) [0271] Additional examples of menthol derivatives are monomenthyl esters of di-and polycarboxylic acids:
LO OI O
OY0H `~=..~' `~.~' o oH
.
OAOSugar O- O---,---OH OH OH
OH
0 /-isopulegol p-Menthane-3,8-diol t,0,,,, , OH
Menthol ethylene glycol carbonate [0272] Some derivatives have been developed to be substantially without smell.
[0273] Useful exemplary menthol derivatives are menthol ethylene glycol carbonate, which is now known as Frescolat type MGC, enthol Propylene Glycol Carbonate (Frescolat type MPC), menthyl lactate (Frescolat ML ) and Menthone Glycerin Acetal (Frescolat MGA ).
Q Q HO
Q~Q~,OH O~O OH L (- , O- = O
OH
Frescolat type MGC Frescolat type MPC Frescolat ML Frescolat MGA
Q Q HO
Q~Q~,OH O~O OH L (- , O- = O
OH
Frescolat type MGC Frescolat type MPC Frescolat ML Frescolat MGA
[0274] Additional widely used menthol derivatives are 3-(/-Menthoxy)-1,2-propanediol, known as Cooling Agent 10; and the same structure with an additional methyl group in the glycerin part of the molecule:
O~'OH OJOH
OH OH
Cooling Agent 10 /-Menthoxy-2-methyl 1,2-propanediol [0275] Menthoxy-coolants are additional cooling menthol derivatives:
O
Q ,.O
O O O"-Ir'OH
3748 OH 3807 3784 . OH
O Ms Q Q MMPD
MG
~oAj0H ~SO)JLOH OHOH
Q u Qi",iOH O~O OH
3805 j\ 3806 I
O~'OH OJOH
OH OH
Cooling Agent 10 /-Menthoxy-2-methyl 1,2-propanediol [0275] Menthoxy-coolants are additional cooling menthol derivatives:
O
Q ,.O
O O O"-Ir'OH
3748 OH 3807 3784 . OH
O Ms Q Q MMPD
MG
~oAj0H ~SO)JLOH OHOH
Q u Qi",iOH O~O OH
3805 j\ 3806 I
[0276] Cubebol is an example of a coolant with a C-C bond in the 3d position of p-menthane.
OH
OH
[0277] Cooling agents, which are not menthol derivatives, are also suitable for use in accordance with the present invention. Examples of such cooling agents are provided below:
0 H3C CH3 }0 C CH30 4-Methyl-3-(1-pyrrolidinyl)-2[5H]-furanone n 1,2 & R= OMe, OR OPr, O-FR, OBu I?-- N N
N I?-OH O" NH OH IN
H
Ic it in Unilever Analog Noe CHs <jN
1 1 ~N 11 5-methyl-4-(1-idinyl)-3-[2H]-furanonranone 4,5-dimethy1-3-(1 -pyrrolidinyI)- 4-methyl-3-(l -pyrrolidinyI)-2[5H]-furanone 2[5H]-furanone [0278] Exemplary cooling agents which can be used in the invention include, but are not limited to, menthol, isopulegol, 3-(I-menthoxy)propane-1,2-diol, 3-(I-menthoxy)-2-methylpropane- 1,2-diol, p-menthane-2,3-diol, p-menthane-3,8-diol, 6-isopropyl-9-methyl-1,4-dioxas- piro[4,5]decane-2-methanol, menthyl succinate and its alkaline earth metal salts, trimethylcyclohexanol, N-ethyl-2-isopropyl-5-m ethylcyclohexanecarb-oxamide, Japanese mint (Mentha arvensis) oil, peppermint oil, menthone, menthone glycerol ketal, menthyl lactate, 3-(I-menthoxy)ethan-1-ol, 3-(I-menthoxy)propan-1-ol, 3-(l-menthoxy)butan-1-ol, 1-menthylacetic acid N-ethylamide, I-menthyl-4-hydroxypentanoate, 1-menthyl-3-hydroxybutyrate, N,2,3-trimethyl-2-(1-methylethyl)-butanamide, and spearmint oil.
0 H3C CH3 }0 C CH30 4-Methyl-3-(1-pyrrolidinyl)-2[5H]-furanone n 1,2 & R= OMe, OR OPr, O-FR, OBu I?-- N N
N I?-OH O" NH OH IN
H
Ic it in Unilever Analog Noe CHs <jN
1 1 ~N 11 5-methyl-4-(1-idinyl)-3-[2H]-furanonranone 4,5-dimethy1-3-(1 -pyrrolidinyI)- 4-methyl-3-(l -pyrrolidinyI)-2[5H]-furanone 2[5H]-furanone [0278] Exemplary cooling agents which can be used in the invention include, but are not limited to, menthol, isopulegol, 3-(I-menthoxy)propane-1,2-diol, 3-(I-menthoxy)-2-methylpropane- 1,2-diol, p-menthane-2,3-diol, p-menthane-3,8-diol, 6-isopropyl-9-methyl-1,4-dioxas- piro[4,5]decane-2-methanol, menthyl succinate and its alkaline earth metal salts, trimethylcyclohexanol, N-ethyl-2-isopropyl-5-m ethylcyclohexanecarb-oxamide, Japanese mint (Mentha arvensis) oil, peppermint oil, menthone, menthone glycerol ketal, menthyl lactate, 3-(I-menthoxy)ethan-1-ol, 3-(I-menthoxy)propan-1-ol, 3-(l-menthoxy)butan-1-ol, 1-menthylacetic acid N-ethylamide, I-menthyl-4-hydroxypentanoate, 1-menthyl-3-hydroxybutyrate, N,2,3-trimethyl-2-(1-methylethyl)-butanamide, and spearmint oil.
[0279] The cooling agent is incorporated in the composition in a concentration which, on one side is safe and on the other side provides a cooling sensation or cooling effect upon application of the cooling foamable composition onto a body surface.
[0280] In an embodiment, the cooling agent also possesses therapeutic properties.
For example, menthol is being used in the therapy of psoriasis; relief of nasal complaints and sore throats; and WS-3 (N-Ethyl-p-menthane-3-carboxamide) and related N-substituted p-menthane carboxamides, as well as p-Menthane-3,8-diols are known insect repellents Warming agents [0281] In the context and without degradating from explanations given elsewhere, substances, which are known to provide a warming sensation or warming effect on or following application to a body surface; and substances that, upon or following topical application can ameliorate a cold sensation or a cooling effect are called "warming agents". Any agent which, when incorporated in the foamable composition in a concentration sufficient to exert a warming sensation or warming effect or to ameliorate a cold sensation or cooling effect, is suitable for use a warming agent in accordance with the present invention. The warming agent may be an excipient, an active ingredient or pharmaceutical, therapeutic or cosmetic agent or combinations of two or more agents.
For example, menthol is being used in the therapy of psoriasis; relief of nasal complaints and sore throats; and WS-3 (N-Ethyl-p-menthane-3-carboxamide) and related N-substituted p-menthane carboxamides, as well as p-Menthane-3,8-diols are known insect repellents Warming agents [0281] In the context and without degradating from explanations given elsewhere, substances, which are known to provide a warming sensation or warming effect on or following application to a body surface; and substances that, upon or following topical application can ameliorate a cold sensation or a cooling effect are called "warming agents". Any agent which, when incorporated in the foamable composition in a concentration sufficient to exert a warming sensation or warming effect or to ameliorate a cold sensation or cooling effect, is suitable for use a warming agent in accordance with the present invention. The warming agent may be an excipient, an active ingredient or pharmaceutical, therapeutic or cosmetic agent or combinations of two or more agents.
[0282] Exemplary substances, which are known to provide a sensation of warmth on application and called "warming agents". include polyhydric alcohols, capsicum (red pepper) powder, a capsicum tincture, capsicum extract, capsaicin, homocapsaicin, homodihydrocapsaicin, nonanoyl vanillyl amide, nonanoic acid vanillyl ether, vanillyl alcohol alkyl ether derivatives (JP-A-57-9729), such as vanillyl ethyl ether, vanillyl butyl ether, vanillyl pentyl ether, and vanillyl hexyl ether, isovanillyl alcohol alkyl ethers, ethylvanillyl alcohol alkyl ethers, veratryl alcohol derivatives, substituted benzyl alcohol derivatives, substituted benzyl alcohol alkyl ethers, vanillin propylene glycol acetal, ethylvanillin propylene glycol acetal, ginger extract, ginger oil, gingeol, and gingeron.
[0283] The warming agent is incorporated in the composition in a concentration which, on one side is safe and on the other side provides a warming sensation or warming effect upon application of the warming foamable composition onto a body surface.
[0284] In an embodiment , the warming agent also possesses therapeutic properties.
For example, capsicum powder, capsicum tincture and extract, as well as capsaicin and homocapsaicin are used for topically treating muscle and joint pain.
Combination of a cooling agent and a warming agent [0285] It is also possible to modulate, potentate, increase, reduce, or ameliorate the sensation effect by introducing into the composition a sensation modifying agent. Thus, the sensation effect or sensation induced by a first sensation or sensation modifying agent maybe reduced by addition of a second sensation or sensation modifying agent in the composition. For example, the cooling sensation of a cooling formulation may be reduced by the presence of a warming or warming modifying agent. Likewise, the warming sensation of a warming formulation may be reduced by the presence of a cooling or cooling modifying agent. Thus in one exemplary embodiment the composition comprises an effective amount of cooling peppermint oil and a lesser effective amount of capsaicin warming agent such that the cooling sensation is the predominant sensation. In another exemplary embodiment the composition comprises an effective amount capsaicin of and a lesser effective amount of peppermint oil cooling agent such that the warming sensation is the predominant sensation. In another embodiment the cooling and warming agents are selected so that the cooling and warming effects or sensations are staggered.
For example, in one exemplary embodiment the composition comprises an effective amount capsaicin of and an effective amount of dimethyl ether cooling agent such that the cooling sensation is the initial predominant sensation and the warming sensation follows on as the subsequent predominant sensation. Other cooling and warming agents may be effectively combined as will be appreciated by someone in the art in order to produce a combined, staggered, consecutive, overlapping, reduced or increased effect or sensation, as is appropriate.
Soothing or Relaxing Agents [0286] There are many different categories of agents which have a soothing effect and which may be used in the present invention in an effective amount either on their own or in combination with an effective amount of other soothing agents or in combination with an effective amount of other sensation or sensation modifying agents as will be appreciated by someone in the art in order to produce a combined, staggered, consecutive, overlapping, reduced or increased effect or sensation, as is appropriate.
For example, capsicum powder, capsicum tincture and extract, as well as capsaicin and homocapsaicin are used for topically treating muscle and joint pain.
Combination of a cooling agent and a warming agent [0285] It is also possible to modulate, potentate, increase, reduce, or ameliorate the sensation effect by introducing into the composition a sensation modifying agent. Thus, the sensation effect or sensation induced by a first sensation or sensation modifying agent maybe reduced by addition of a second sensation or sensation modifying agent in the composition. For example, the cooling sensation of a cooling formulation may be reduced by the presence of a warming or warming modifying agent. Likewise, the warming sensation of a warming formulation may be reduced by the presence of a cooling or cooling modifying agent. Thus in one exemplary embodiment the composition comprises an effective amount of cooling peppermint oil and a lesser effective amount of capsaicin warming agent such that the cooling sensation is the predominant sensation. In another exemplary embodiment the composition comprises an effective amount capsaicin of and a lesser effective amount of peppermint oil cooling agent such that the warming sensation is the predominant sensation. In another embodiment the cooling and warming agents are selected so that the cooling and warming effects or sensations are staggered.
For example, in one exemplary embodiment the composition comprises an effective amount capsaicin of and an effective amount of dimethyl ether cooling agent such that the cooling sensation is the initial predominant sensation and the warming sensation follows on as the subsequent predominant sensation. Other cooling and warming agents may be effectively combined as will be appreciated by someone in the art in order to produce a combined, staggered, consecutive, overlapping, reduced or increased effect or sensation, as is appropriate.
Soothing or Relaxing Agents [0286] There are many different categories of agents which have a soothing effect and which may be used in the present invention in an effective amount either on their own or in combination with an effective amount of other soothing agents or in combination with an effective amount of other sensation or sensation modifying agents as will be appreciated by someone in the art in order to produce a combined, staggered, consecutive, overlapping, reduced or increased effect or sensation, as is appropriate.
[0287] Non limiting examples of soothing agents are herb extracts, such as, aloe vera, alpha bisabolol, D-panthenol, allantoin, hamamelis, chamomile, yarrow;
calendula, comfrey, witch hazel and other astringents, sea weed, and oat extracts; oils, such as, almond oil, avocado oil, and comfrey; and essential oils, such as, cardamone, eucalyptus, mentha piperita (peppermint), hyssop, and rosemary; waxy or unctuous substances such as lanolin or vaselline jelly, minerals, such as, zinc oxide, calamine and selenium;
vitamins, such as, tocopheryl acetate (vitamin E), and drugs, such as, analgesics, anesthetics, anti-inflammatory agents, and anti-histamines, muscle relaxants and the like.
calendula, comfrey, witch hazel and other astringents, sea weed, and oat extracts; oils, such as, almond oil, avocado oil, and comfrey; and essential oils, such as, cardamone, eucalyptus, mentha piperita (peppermint), hyssop, and rosemary; waxy or unctuous substances such as lanolin or vaselline jelly, minerals, such as, zinc oxide, calamine and selenium;
vitamins, such as, tocopheryl acetate (vitamin E), and drugs, such as, analgesics, anesthetics, anti-inflammatory agents, and anti-histamines, muscle relaxants and the like.
[0288] Other non limiting examples are menthol, camphor, eugenol, eucalyptol, safrol, methyl salicylate, menthyl lactate, menthyl ethoxyacetate, menthone glycerinacetal, 3-I-menthoxypropane-1,2-diol, ethyl I-menthyl carbonate, (1 S,3S,4R)-p-menth-8-en-3-ol, menthyl pyrrolidone carboxylate, N-substituted-p-menthane-3-carboxamides (as described in U.S. Pat. No. 4,136,163, which is incorporated herein by reference) and ketal coolants (as described in WO 93/23005, which is also incorporated herein by reference) including, for example, I-menthon-Id-isomenthon glycerin ketal.
[0289] In one exemplary embodiment the composition comprises an effective amount of soothing hamamelis and a lesser effective amount of frescolate cooling agent such that the soothing sensation is the predominant sensation. In another exemplary embodiment the composition comprises an effective amount capsaicin of and a lesser effective amount of hamamelis soothing agent such that the warming sensation is the predominant sensation. In another embodiment, the soothing and warming agents are selected so that the soothing and warming effects or sensations are staggered or partially overlapping. In another embodiment, the soothing and cooling agents are selected so that the soothing and cooling effects or sensations are staggered or partially overlapping.
Stimulating or Refreshing Agents [0290] There are many different categories of agents which have a stimulating or refreshing sensation or effect and which may be used in the present invention in an effective amount either on their own or in combination with an effective amount of other stimulating or refreshing agents or in combination with an effective amount of other sensation or sensation modifying agents as will be appreciated by someone in the art in order to produce a combined, staggered, consecutive, overlapping, reduced or increased effect or sensation, as is appropriate.
Stimulating or Refreshing Agents [0290] There are many different categories of agents which have a stimulating or refreshing sensation or effect and which may be used in the present invention in an effective amount either on their own or in combination with an effective amount of other stimulating or refreshing agents or in combination with an effective amount of other sensation or sensation modifying agents as will be appreciated by someone in the art in order to produce a combined, staggered, consecutive, overlapping, reduced or increased effect or sensation, as is appropriate.
[0291] Non limiting examples are alcohols, L-menthol, camphor, menthe oil, capsicum extract, capsaicin, benzyl nicotinate, salicylate, glycol salicylate acetyl choline, serotonin, histamine , prostaglandins, other neurotransmitters; CNS
stimulants; caffeine, quinine, and the like might be suitable stimulants in dosages or delivery systems where they essentially or primarily have a local or topical as opposed to systemic effect.
Specific Agents Ginger [0292] Ginger is said to have several pharmacological activities, including anti-emetic, antithrombotic, antimicrobial, anticancer, antioxidant and anti-inflammatory properties.
Also, ginger has been reported to have hypoglycaemic, hypo- and hypertensive, cardiac, prostaglandin and platelet aggregation inhibition, antihypercholesterolaemic, cholagogic and stomachic properties. Ginger has carminative properties and has also been tried for the prophylaxis of motion sickness and nausea and vomiting in pregnancy. In vitro studies have demonstrated that constituents of ginger, such as 6-, 8- and 1 0-gingerols and galanolactone, have antiserotonergic activity. Ginger oil is used in aromatherapy.
Capsicum [0293] The capsaicinoids are principally responsible for the biological activity of capsicum. These pungent principles are thought to stimulate and aid digestion and to act as a counter-irritant when applied externally. Capsaicin has also been used as a neurochemical tool for studying sensory neurotransmission. Topical creams containing capsaicin 0.025% and 0.075% are used for symptomatic relief of osteoarthritis, and post-herpetic neuralgia, respectively. Capsicum oleoresin and capsaicin are ingredients of a number of over-the-counter topical preparations for relief of pain in muscle, tendon and joints. Capsaicin has effects on nervous, cardiovascular, respiratory, thermoregulatory and gastrointestinal systems. Capsaicin has been used as a neurochemical tool for studying sensory neurotransmission.
Hamamelis [0294] Witch hazel is characterized by its tannin constituents and astringent properties. It is also said to have haemostatic properties. The documented herbal uses are related to these astringent properties. It has been used topically in the treatment of haemorrhoids, eczema and dermatitis. Vasoconstriction was reduced in the hindquarters of rabbits. A fraction of an aqueous ethanolic bark extract was significantly active against herpes simplex virus type 1 (HSV-1). Topical applications of a hydroglycolic extract of witch hazel leaf reduced skin temperature perhaps due to a vasoconstrictor effect. After-sun lotion containing 10% hamamelis was reported to have suppressed erythema.
Peppermint oil [0295] Peppermint oil is an aromatic carminative that relaxes gastrointestinal smooth muscle and relieves flatulence and colic. Peppermint oil is also used with other volatile agents in preparations for respiratory-tract disorders. It is also used in aromatherapy.
Menthol [0296] Menthol is chiefly used to relieve symptoms of bronchitis, sinusitis, and similar conditions. For this purpose it may be used as an inhalation, usually with benzoin or eucalyptus oil, as pastilles, or as an ointment with camphor and eucalyptus oil for application to the chest or. When applied to the skin menthol dilates the blood vessels, causing a sensation of coldness followed by an analgesic effect. It relieves itching and is used in creams, lotions, or ointments in pruritus and urticaria. It has also been applied to the forehead, presumably as a counter-irritant, for the relief of headache.
Menthol has a carminative action.
(Sources: Matindale and Herbal Extracts Electronic Edition 2008) Additional active agent [0297] The foamable carrier is an ideal vehicle for active pharmaceutical ingredients and active cosmetic ingredients. In the context herein, active pharmaceutical ingredients and active cosmetic ingredients are collectively termed "additional active agent" or "additional active agents".
stimulants; caffeine, quinine, and the like might be suitable stimulants in dosages or delivery systems where they essentially or primarily have a local or topical as opposed to systemic effect.
Specific Agents Ginger [0292] Ginger is said to have several pharmacological activities, including anti-emetic, antithrombotic, antimicrobial, anticancer, antioxidant and anti-inflammatory properties.
Also, ginger has been reported to have hypoglycaemic, hypo- and hypertensive, cardiac, prostaglandin and platelet aggregation inhibition, antihypercholesterolaemic, cholagogic and stomachic properties. Ginger has carminative properties and has also been tried for the prophylaxis of motion sickness and nausea and vomiting in pregnancy. In vitro studies have demonstrated that constituents of ginger, such as 6-, 8- and 1 0-gingerols and galanolactone, have antiserotonergic activity. Ginger oil is used in aromatherapy.
Capsicum [0293] The capsaicinoids are principally responsible for the biological activity of capsicum. These pungent principles are thought to stimulate and aid digestion and to act as a counter-irritant when applied externally. Capsaicin has also been used as a neurochemical tool for studying sensory neurotransmission. Topical creams containing capsaicin 0.025% and 0.075% are used for symptomatic relief of osteoarthritis, and post-herpetic neuralgia, respectively. Capsicum oleoresin and capsaicin are ingredients of a number of over-the-counter topical preparations for relief of pain in muscle, tendon and joints. Capsaicin has effects on nervous, cardiovascular, respiratory, thermoregulatory and gastrointestinal systems. Capsaicin has been used as a neurochemical tool for studying sensory neurotransmission.
Hamamelis [0294] Witch hazel is characterized by its tannin constituents and astringent properties. It is also said to have haemostatic properties. The documented herbal uses are related to these astringent properties. It has been used topically in the treatment of haemorrhoids, eczema and dermatitis. Vasoconstriction was reduced in the hindquarters of rabbits. A fraction of an aqueous ethanolic bark extract was significantly active against herpes simplex virus type 1 (HSV-1). Topical applications of a hydroglycolic extract of witch hazel leaf reduced skin temperature perhaps due to a vasoconstrictor effect. After-sun lotion containing 10% hamamelis was reported to have suppressed erythema.
Peppermint oil [0295] Peppermint oil is an aromatic carminative that relaxes gastrointestinal smooth muscle and relieves flatulence and colic. Peppermint oil is also used with other volatile agents in preparations for respiratory-tract disorders. It is also used in aromatherapy.
Menthol [0296] Menthol is chiefly used to relieve symptoms of bronchitis, sinusitis, and similar conditions. For this purpose it may be used as an inhalation, usually with benzoin or eucalyptus oil, as pastilles, or as an ointment with camphor and eucalyptus oil for application to the chest or. When applied to the skin menthol dilates the blood vessels, causing a sensation of coldness followed by an analgesic effect. It relieves itching and is used in creams, lotions, or ointments in pruritus and urticaria. It has also been applied to the forehead, presumably as a counter-irritant, for the relief of headache.
Menthol has a carminative action.
(Sources: Matindale and Herbal Extracts Electronic Edition 2008) Additional active agent [0297] The foamable carrier is an ideal vehicle for active pharmaceutical ingredients and active cosmetic ingredients. In the context herein, active pharmaceutical ingredients and active cosmetic ingredients are collectively termed "additional active agent" or "additional active agents".
[0298] Suitable additional active agents include but are not limited to active herbal extracts, acaricides, age spot and keratose removing agents, allergen, analgesics, local anesthetics, antiacne agents, antiallergic agents, antiaging agents, antibacterials, antibiotics, antiburn agents, anticancer agents, antidandruff agents, antidepressants, antidermatitis agents, antiedemics, antihistamines, antihelminths, antihyperkeratolyte agents, anti inflammatory agents, antiirritants, antilipemics, antimicrobials, antimycotics, antiproliferative agents, antioxidants, anti-wrinkle agents, antipruritics, antipsoriatic agents, antirosacea agents antiseborrheic agents, antiseptic, antiswelling agents, antiviral agents, antiyeast agents, astringents, topical cardiovascular agents, chemotherapeutic agents, corticosteroids, dicarboxylic acids, disinfectants, fungicides, hair growth regulators, hormones, hydroxy acids, immunosuppressants, immunoregulating agents, insecticides, insect repellents, keratolytic agents, lactams, metals, metal oxides, mitocides, neuropeptides, non-steroidal anti-inflammatory agents, oxidizing agents, pediculicides, photodynamic therapy agents, retinoids, sanatives, scabicides, self tanning agents, skin whitening agents, asoconstrictors, vasodilators, vitamins, vitamin derivatives, vitamin A, vitamin A derivatives, vitamin D, vitamin D derivatives, flavanoids, wound healing agents and wart removers. As is known to one skilled in the art, in some instances a specific active agent may have more than one activity, function or effect.
Fields of Applications [0299] The foamable composition is suitable for treating any inflicted surface. In one or more embodiments, foamable carrier is suitable for administration to the skin, a body surface, a body cavity or mucosal surface, e.g., the cavity and/or the mucosa of the nose, mouth, eye, ear, respiratory system, vagina or rectum (severally and interchangeably termed herein "target site").
Fields of Applications [0299] The foamable composition is suitable for treating any inflicted surface. In one or more embodiments, foamable carrier is suitable for administration to the skin, a body surface, a body cavity or mucosal surface, e.g., the cavity and/or the mucosa of the nose, mouth, eye, ear, respiratory system, vagina or rectum (severally and interchangeably termed herein "target site").
[0300] A sensation modifying foamable composition can be used in any condition that can benefit from the modification of a cold or warm sensation, and in any condition that can benefit from stabilizing a cold or warm sensation, by applying a cooling or a warming foam on the target site.
[0301] Examples of uses of a cooling foam composition include:
- Treatment of over-heated body surface;
- Treatment of the skin after sun-burn;
- Treatment of the skin after blistering;
- Treatment of the skin after radiation treatment, burn or injury;
- Treatment of the skin after friction burn;
- Treatment of the skin after inflammation;
- Treatment of the skin after insect bite or sting;
- Treatment of the skin after shaving;
- Treatment of the skin after hair removal;
- Treatment of the skin after laser treatment, burn or injury;
- Treatment or preparation of the skin prior to radiation, laser, or heat treatment or hair removal;
- Treatment of the skin after, during or before acupuncture;
- Treatment of the skin after or during stress;
- Treatment of the skin upon pain.
- Treatment of over-heated body surface;
- Treatment of the skin after sun-burn;
- Treatment of the skin after blistering;
- Treatment of the skin after radiation treatment, burn or injury;
- Treatment of the skin after friction burn;
- Treatment of the skin after inflammation;
- Treatment of the skin after insect bite or sting;
- Treatment of the skin after shaving;
- Treatment of the skin after hair removal;
- Treatment of the skin after laser treatment, burn or injury;
- Treatment or preparation of the skin prior to radiation, laser, or heat treatment or hair removal;
- Treatment of the skin after, during or before acupuncture;
- Treatment of the skin after or during stress;
- Treatment of the skin upon pain.
[0302] Examples of uses of a warming foam composition include:
- Treatment of over-cooled body surface;
- Treatment of the skin after exposure to cold environment;
- Treatment of the skin with inadequate circulation;
- Treatment of the skin after wind exposure;
- Treatment of the skin after liquid gas treatment, burn, or injury;
- Treatment or preparation of the skin prior to liquid gas treatment;
- Treatment of the skin after, during or before massage;
- Treatment of the skin after or during stress.
- Treatment of over-cooled body surface;
- Treatment of the skin after exposure to cold environment;
- Treatment of the skin with inadequate circulation;
- Treatment of the skin after wind exposure;
- Treatment of the skin after liquid gas treatment, burn, or injury;
- Treatment or preparation of the skin prior to liquid gas treatment;
- Treatment of the skin after, during or before massage;
- Treatment of the skin after or during stress.
[0303] By selecting a suitable sensation modifying agent, or a combination of at least two sensation modifying agents, or a combination of at lease one sensation modifying agent and at least one additional therapeutic agent, the foamable composition is useful in treating an animal or a human patient having any one of a variety of dermatological disorders, including dermatological pain, dermatological inflammation, acne, acne vulgaris, inflammatory acne, non-inflammatory acne, acne fulminans, nodular papulopustular acne, acne conglobata, dermatitis, bacterial skin infections, fungal skin infections, viral skin infections, parasitic skin infections, skin neoplasia, skin neoplasms, pruritis, cellulitis, acute lymphangitis, lymphadenitis, erysipelas, cutaneous abscesses, necrotizing subcutaneous infections, scalded skin syndrome, folliculitis, furuncles, hidradenitis suppurativa, carbuncles, paronychial infections, rashes, erythrasma, impetigo, ecthyma, yeast skin infections, warts, molluscum contagiosum, trauma or injury to the skin, post-operative or post-surgical skin conditions, scabies, pediculosis, creeping eruption, eczemas, psoriasis, pityriasis rosea, lichen planus, pityriasis rubra pilaris, edematous, erythema multiforme, erythema nodosum, grannuloma annulare, epidermal necrolysis, sunburn, photosensitivity, pemphigus, bullous pemphigoid, dermatitis herpetiformis, keratosis pilaris, callouses, corns, ichthyosis, skin ulcers, ischemic necrosis, miliaria, hyperhidrosis, moles, Kaposi's sarcoma, melanoma, malignant melanoma, basal cell carcinoma, squamous cell carcinoma, poison ivy, poison oak, contact dermatitis, atopic dermatitis, rosacea, purpura, moniliasis, candidiasis, baldness, alopecia, Behcet's syndrome, cholesteatoma, Dercum disease, ectodermal dysplasia, gustatory sweating, nail patella syndrome, lupus, hives, hair loss, Hailey-Hailey disease, chemical or thermal skin burns, scleroderma, aging skin, wrinkles, sun spots, necrotizing fasciitis, necrotizing myositis, gangrene, scarring, and vitiligo.
[0304] Likewise, the foamable composition is suitable for treating a disorder of a body cavity or mucosal surface, e.g., the mucosa of the nose, mouth, eye, ear, respiratory system, vagina or rectum. Non limiting examples of such conditions include chlamydia infection, gonorrhea infection, hepatitis B, herpes, HIV/AIDS, human papillomavirus (HPV), genital warts, bacterial vaginosis, candidiasis, chancroid, granuloma Inguinale, lymphogranloma venereum, mucopurulent cervicitis (MPC), molluscum contagiosum, nongonococcal urethritis (NGU), trichomoniasis, vulvar disorders, vulvodynia, vulvar pain, yeast infection, vulvar dystrophy, vulvar intraepithelial neoplasia (VIN), contact dermatitis, pelvic inflammation, endometritis, salpingitis, oophoritis, genital cancer, cancer of the cervix, cancer of the vulva, cancer of the vagina, vaginal dryness, dyspareunia, anal and rectal disease, anal abscess/fistula, anal cancer, anal fissure, anal warts, Crohn's disease, hemorrhoids, anal itch, pruritus ani, fecal incontinence, constipation, polyps of the colon and rectum.
[0305] In an embodiment , the composition is useful for the treatment of an infection.
In one or more embodiments, the composition is suitable for the treatment of an infection, selected from the group of a bacterial infection, a fungal infection, a yeast infection, a viral infection and a parasitic infection.
In one or more embodiments, the composition is suitable for the treatment of an infection, selected from the group of a bacterial infection, a fungal infection, a yeast infection, a viral infection and a parasitic infection.
[0306] In an embodiment, the composition is useful for the treatment of wound, ulcer and burn.
[0307] The composition is also suitable for administering a hormone to the skin or to a mucosal membrane or to a body cavity, in order to deliver the hormone into the tissue of the target organ, in any disorder that responds to treatment with a hormone.
Higher (Fatty) Alcohols [0308] In some embodiments of the present invention, the compositions and carriers comprise one or more higher alcohols. These generally exclude "lower alcohols". The fatty alcohols are typically liquid at ambient temperature.
Higher (Fatty) Alcohols [0308] In some embodiments of the present invention, the compositions and carriers comprise one or more higher alcohols. These generally exclude "lower alcohols". The fatty alcohols are typically liquid at ambient temperature.
[0309] Fatty alcohols may defined as follows:
The fatty alcohols hereof have a melting point of 30 C. or less, preferably about 25 C. or less, more preferably about 22 C. or less.
The fatty alcohols hereof have a melting point of 30 C. or less, preferably about 25 C. or less, more preferably about 22 C. or less.
[0310] The unsaturated fatty alcohols hereof are also nonvolatile. By nonvolatile what is meant is they have a boiling point at 1.0 atmospheres of at least about 260 C., preferably at least about 275 C., more preferably at least about 300 C.
[0311] Suitable fatty alcohols include unsaturated monohydric straight chain fatty alcohols, saturated branched chain fatty alcohols, saturated C8 -C12 straight chain fatty alcohols, and mixtures thereof. The unsaturated straight chain fatty alcohols will typically have one degree of unsaturation. Di- and tri- unsaturated alkenyl chains may be present at low levels, preferably less than about 5% by total weight of the unsaturated straight chain fatty alcohol, more preferably less than about 2%, most preferably less than about 1%.
[0312] Preferably, the unsaturated straight chain fatty alcohols will have an aliphatic chain size of from C12 -C22, more preferably from C12 -C18, most preferably from C16 -C18. Especially preferred alcohols of this type include oleyl alcohol and palmitoleic alcohol.
[0313] The branched chain alcohols will typically have aliphatic chain sizes of from C12 -C22, preferably C14 -C20, more preferably C16 -C18. Exemplary branched chain alcohols for use herein include isostearyl alcohol, octyl dodecanol, and octyl decanol.
Examples of saturated C8 -C12 straight chain alcohols include octyl alcohol, caprylic alcohol, decyl alcohol, and lauryl alcohol. Furthermore, the higher alcohols may be selected from straight chain fatty alcohols, having 6 or more carbon atoms, which are liquid at ambient temperature, such as, but not limited to Hexanol, Octanol, Nonanol, Decanol; branched alcohols, such as: 2 Octanol (Capryl Alcohol), Undecanol (Undecyl Alcohol ), 2 Butyl Octanol (Isolauryl Alcohol ), Tridecyl Alcohol (Isotridecyl Alcohol), 2 Butyl Decanol, 2 Hexyl Octanol, Isomyristyl Alcohol , 2 Hexyl Decanol, Isocetyl Alcohol , 2 Octyl Decanol, 2 Hexyl Dodecanol, Isostearyl Alcohol , Isooctadecanol, Isooleyl Alcohol (unsaturated and branched), Isoarachidyl Alcohol , 2 Decyl Tetradecanol, Isolignoceryl Alcohol, 2 Decyl Tetradecanol , 2 Tetradecyl Octadecanol, 2 Tetradecyl Eicosanol, 2 Hexadecyl Octadecanol , 2 Hexadecyl Eicosanol; additionally unsaturated alcohols, such as Erucyl Alcohol, Linoleyl Alcohol, oleyl alcohol may be employed.
Substantially Alcohol-Free [0314] According to one or more embodiments, the foamable composition is substantially alcohol-free, i.e., free of short chain alcohols. Short chain alcohols, having up to 5 carbon atoms in their carbon chain skeleton and one hydroxyl group, such as ethanol, propanol, isopropanol, butaneol, iso-butaneol, t-butaneol and pentanol, are considered less desirable solvents or solvents due to their skin-irritating effect. Thus, the composition is substantially alcohol-free and includes less than about 5%
final concentration of lower alcohols, preferably less than about 2%, more preferably less than about 1 %.
Examples of saturated C8 -C12 straight chain alcohols include octyl alcohol, caprylic alcohol, decyl alcohol, and lauryl alcohol. Furthermore, the higher alcohols may be selected from straight chain fatty alcohols, having 6 or more carbon atoms, which are liquid at ambient temperature, such as, but not limited to Hexanol, Octanol, Nonanol, Decanol; branched alcohols, such as: 2 Octanol (Capryl Alcohol), Undecanol (Undecyl Alcohol ), 2 Butyl Octanol (Isolauryl Alcohol ), Tridecyl Alcohol (Isotridecyl Alcohol), 2 Butyl Decanol, 2 Hexyl Octanol, Isomyristyl Alcohol , 2 Hexyl Decanol, Isocetyl Alcohol , 2 Octyl Decanol, 2 Hexyl Dodecanol, Isostearyl Alcohol , Isooctadecanol, Isooleyl Alcohol (unsaturated and branched), Isoarachidyl Alcohol , 2 Decyl Tetradecanol, Isolignoceryl Alcohol, 2 Decyl Tetradecanol , 2 Tetradecyl Octadecanol, 2 Tetradecyl Eicosanol, 2 Hexadecyl Octadecanol , 2 Hexadecyl Eicosanol; additionally unsaturated alcohols, such as Erucyl Alcohol, Linoleyl Alcohol, oleyl alcohol may be employed.
Substantially Alcohol-Free [0314] According to one or more embodiments, the foamable composition is substantially alcohol-free, i.e., free of short chain alcohols. Short chain alcohols, having up to 5 carbon atoms in their carbon chain skeleton and one hydroxyl group, such as ethanol, propanol, isopropanol, butaneol, iso-butaneol, t-butaneol and pentanol, are considered less desirable solvents or solvents due to their skin-irritating effect. Thus, the composition is substantially alcohol-free and includes less than about 5%
final concentration of lower alcohols, preferably less than about 2%, more preferably less than about 1 %.
[0315] Other foamable compositions are described in: U.S. Publication No. 05-0232869, published on October 20, 2005, entitled NONSTEROIDAL
IMMUNOMODULATING KIT AND COMPOSITION AND USES THEREOF; U.S.
Publication No. 05-0205086, published on September 22, 2005, entitled RETINOID
IMMUNOMODULATING KIT AND COMPOSITION AND USES THEREOF; U.S.
Publication No. 06-0018937, published on January 26, 2006, entitled STEROID
KIT AND
FOAMABLE COMPOSITION AND USES THEREOF; U.S. Publication No. 05-0271596, published on December 8, 2005, entitled VASOACTIVE KIT AND COMPOSITION AND
USES THEREOF; U.S. Publication No. 06-0269485, published on November 30, 2006, entitled ANTIBIOTIC KIT AND COMPOSITION AND USES THEREOF; U.S. Publication No. 07-0020304, published on January 25, 2007, entitled NON-FLAMMABLE
INSECTICIDE COMPOSITION AND USES THEREOF; U.S. Publication No. 06-0193789, published on August 31, 2006, entitled FILM FORMING FOAMABLE COMPOSITION;
U.S. Patent Application No. 11/732547, filed on April 4, 2007, entitled ANTI-INFECTION
AUGMENTATION OF FOAMABLE COMPOSITIONS AND KIT AND USES THEREOF;
U.S. Patent Application No. 11/732547, filed on April 4, 2007, KERATOLYTIC
ANTIFUNGAL FOAM; U.S. Patent Application No. 11/767,442, filed on June 22, 2007, entitled FOAMABLE COMPOSITIONS AND KITS COMPRISING ONE OR MORE OF A
CHANNEL AGENT, A CHOLINERGIC AGENT, A NITRIC OXIDE DONOR, AND
RELATED AGENTS AND THEIR USES; U.S. Patent Application No. 11/825,406, filed on July 5, 2007, entitled DICARBOXYLIC ACID FOAMABLE VEHICLE AND
PHARMACEUTICAL COMPOSITIONS THEREOF; U.S. Patent Application No.
11/900072, filed on September 10, 2006, entitled FOAMABLE VEHICLE AND VITAMIN
AND FLAVONOID PHARMACEUTICAL COMPOSITIONS THEREOF; and U.S. Patent Application No. 11/947751, filed November 29, 2007, entitled COMPOSITIONS WITH
MODULATING AGENTS, all of which are incorporated herein by reference in their entirety. More particularly any of the active ingredients; the solvents; the surfactants;
foam adjuvants; polymeric agents, penetration enhancers; preservatives, humectants;
moisturizers; and other excipients as well as the propellants and methods listed therein can be applied herein and are incorporated by reference.
IMMUNOMODULATING KIT AND COMPOSITION AND USES THEREOF; U.S.
Publication No. 05-0205086, published on September 22, 2005, entitled RETINOID
IMMUNOMODULATING KIT AND COMPOSITION AND USES THEREOF; U.S.
Publication No. 06-0018937, published on January 26, 2006, entitled STEROID
KIT AND
FOAMABLE COMPOSITION AND USES THEREOF; U.S. Publication No. 05-0271596, published on December 8, 2005, entitled VASOACTIVE KIT AND COMPOSITION AND
USES THEREOF; U.S. Publication No. 06-0269485, published on November 30, 2006, entitled ANTIBIOTIC KIT AND COMPOSITION AND USES THEREOF; U.S. Publication No. 07-0020304, published on January 25, 2007, entitled NON-FLAMMABLE
INSECTICIDE COMPOSITION AND USES THEREOF; U.S. Publication No. 06-0193789, published on August 31, 2006, entitled FILM FORMING FOAMABLE COMPOSITION;
U.S. Patent Application No. 11/732547, filed on April 4, 2007, entitled ANTI-INFECTION
AUGMENTATION OF FOAMABLE COMPOSITIONS AND KIT AND USES THEREOF;
U.S. Patent Application No. 11/732547, filed on April 4, 2007, KERATOLYTIC
ANTIFUNGAL FOAM; U.S. Patent Application No. 11/767,442, filed on June 22, 2007, entitled FOAMABLE COMPOSITIONS AND KITS COMPRISING ONE OR MORE OF A
CHANNEL AGENT, A CHOLINERGIC AGENT, A NITRIC OXIDE DONOR, AND
RELATED AGENTS AND THEIR USES; U.S. Patent Application No. 11/825,406, filed on July 5, 2007, entitled DICARBOXYLIC ACID FOAMABLE VEHICLE AND
PHARMACEUTICAL COMPOSITIONS THEREOF; U.S. Patent Application No.
11/900072, filed on September 10, 2006, entitled FOAMABLE VEHICLE AND VITAMIN
AND FLAVONOID PHARMACEUTICAL COMPOSITIONS THEREOF; and U.S. Patent Application No. 11/947751, filed November 29, 2007, entitled COMPOSITIONS WITH
MODULATING AGENTS, all of which are incorporated herein by reference in their entirety. More particularly any of the active ingredients; the solvents; the surfactants;
foam adjuvants; polymeric agents, penetration enhancers; preservatives, humectants;
moisturizers; and other excipients as well as the propellants and methods listed therein can be applied herein and are incorporated by reference.
[0316] The invention is described with reference to the following examples.
This invention is not limited to these examples and experiments. Many variations will suggest themselves and are within the full intended scope of the appended claims.
Methodology [0317] The formulas of the present invention may be made in the following general way with appropriate adjustments for each formulation as will be appreciated by someone skilled in the art. Polymers, if any, are mixed, swelled and solubilized in the waterless medium, when necessary, with appropriate heat until it forms a clear solution.
Stabilizing surfactants added usually with heat, until a homogeneous mixture is obtained, the mixture is then allowed to cool. The remainder of the ingredients, are then added with mixing until they have dissolved in the medium. The active agent is usually added at the end once the modulating agent, if present, has been incorporated. For foam the canisters are then filled with the above waterless formula, sealed and crimped with a valve and pressurized with the propellant.
This invention is not limited to these examples and experiments. Many variations will suggest themselves and are within the full intended scope of the appended claims.
Methodology [0317] The formulas of the present invention may be made in the following general way with appropriate adjustments for each formulation as will be appreciated by someone skilled in the art. Polymers, if any, are mixed, swelled and solubilized in the waterless medium, when necessary, with appropriate heat until it forms a clear solution.
Stabilizing surfactants added usually with heat, until a homogeneous mixture is obtained, the mixture is then allowed to cool. The remainder of the ingredients, are then added with mixing until they have dissolved in the medium. The active agent is usually added at the end once the modulating agent, if present, has been incorporated. For foam the canisters are then filled with the above waterless formula, sealed and crimped with a valve and pressurized with the propellant.
[0318] A general procedure for preparing foamable compositions is set out in WO
2004/037225, which is incorporated herein by reference.
Composition and Foam Physical Characteristics and Advantages [0319] A pharmaceutical or cosmetic composition manufactured using the foamable carrier of the present invention is very easy to use. When applied onto the body surface of mammals, i.e., humans or animals, it is in a foam state, allowing free application without spillage. Upon further application of a mechanical force, e.g., by rubbing the composition onto the body surface, it freely spreads on the surface and is rapidly absorbed.
2004/037225, which is incorporated herein by reference.
Composition and Foam Physical Characteristics and Advantages [0319] A pharmaceutical or cosmetic composition manufactured using the foamable carrier of the present invention is very easy to use. When applied onto the body surface of mammals, i.e., humans or animals, it is in a foam state, allowing free application without spillage. Upon further application of a mechanical force, e.g., by rubbing the composition onto the body surface, it freely spreads on the surface and is rapidly absorbed.
[0320] The foamable composition of the present invention is stable, having an acceptable shelf-life of at least one year, or preferably, at least two years at ambient temperature, as revealed in accelerated stability tests or aging tests. In certain embodiments a product may satisfy stability tests if upon light shaking a homogenous formulation is restored and remains stable until well after dispensing.
Organic carriers and propellants tend to impair the stability of emulsions and to interfere with the formation of stable foam upon release from a pressurized container. It has been observed, however, that the foamable compositions according to the present invention are surprisingly stable.
Following accelerated stability studies, they demonstrate desirable texture;
they form fine bubble structures that do not break immediately upon contact with a surface, spread easily on the treated area and absorb quickly.
Organic carriers and propellants tend to impair the stability of emulsions and to interfere with the formation of stable foam upon release from a pressurized container. It has been observed, however, that the foamable compositions according to the present invention are surprisingly stable.
Following accelerated stability studies, they demonstrate desirable texture;
they form fine bubble structures that do not break immediately upon contact with a surface, spread easily on the treated area and absorb quickly.
[0321] The composition should also be free flowing, to allow it to flow through the aperture of the container, e.g., and aerosol container, and create an acceptable foam.
Quantitative and Qualitative Tests Foam Quality [0322] Foam quality can be graded as follows:
Grade E (excellent): very rich and creamy in appearance, does not show any bubble structure or shows a very fine (small) bubble structure; does not rapidly become dull; upon spreading on the skin, the foam retains the creaminess property and does not appear watery.
Grade G (good): rich and creamy in appearance, very small bubble size, "dulls"
more rapidly than an excellent foam, retains creaminess upon spreading on the skin, and does not become watery.
Grade FG (fairly good): a moderate amount of creaminess noticeable, bubble structure is noticeable; upon spreading on the skin the product dulls rapidly and becomes somewhat lower in apparent viscosity.
Grade F (fair): very little creaminess noticeable, larger bubble structure than a "fairly good" foam, upon spreading on the skin it becomes thin in appearance and watery.
Grade P (poor): no creaminess noticeable, large bubble structure, and when spread on the skin it becomes very thin and watery in appearance.
Grade VP (very poor): dry foam, large very dull bubbles, difficult to spread on the skin.
Quantitative and Qualitative Tests Foam Quality [0322] Foam quality can be graded as follows:
Grade E (excellent): very rich and creamy in appearance, does not show any bubble structure or shows a very fine (small) bubble structure; does not rapidly become dull; upon spreading on the skin, the foam retains the creaminess property and does not appear watery.
Grade G (good): rich and creamy in appearance, very small bubble size, "dulls"
more rapidly than an excellent foam, retains creaminess upon spreading on the skin, and does not become watery.
Grade FG (fairly good): a moderate amount of creaminess noticeable, bubble structure is noticeable; upon spreading on the skin the product dulls rapidly and becomes somewhat lower in apparent viscosity.
Grade F (fair): very little creaminess noticeable, larger bubble structure than a "fairly good" foam, upon spreading on the skin it becomes thin in appearance and watery.
Grade P (poor): no creaminess noticeable, large bubble structure, and when spread on the skin it becomes very thin and watery in appearance.
Grade VP (very poor): dry foam, large very dull bubbles, difficult to spread on the skin.
[0323] Topically administrable foams are typically of quality grade E or G, or occasionally FG, when released from the aerosol container. Smaller bubbles are indicative of more stable foam, which does not collapse spontaneously immediately upon discharge from the container. The finer foam structure looks and feels smoother, thus increasing its usability and appeal.
Foam Physical Characteristics [0324] In terms of foam consistency and texture an acceptable foam is one, that exhibits the following characteristics:
Foam Physical Characteristics [0324] In terms of foam consistency and texture an acceptable foam is one, that exhibits the following characteristics:
[0325] A "stable foam" is defined herein as a composition, which upon release from an aerosol can, creates a foam mass, which is sustained on a surface for at least one minute, more preferably at least two minutes, and yet more preferably for at least 5 minutes. A period of minutes is regarded as a short term, but nevertheless it allows a good and more than sufficient period of time for a subject to receive foam dispensed on a body surface and to spread it or to transfer it to another region and to spread it.
[0326] Foam texture should vary from a very fine creamy foam to a fine bubble structure.
[0327] Foam has to have specific gravity in the range of about 0.02 gr/mL to about 0.5 gr/mL, more preferably between about 0.04 gr/mL and about 0.2 gr/mL.
[0328] In terms of spreadability and absorption an acceptable foam is one, that does not readily collapse upon dispensing on the skin; spreads easily on a skin surface; at least partially absorbed following rubbing onto the skin, and more preferably, substantially absorbed following rubbing on the skin.
[0329] In terms of tactile properties an acceptable foam is one, that: creates a pleasant feeling after application; leaves minimal oily residue; and leaves minimal shiny residual look.
Shakability [0330] `Shakability' means that the composition contains some or sufficient flow to allow the composition to be mixed or remixed on shaking. That is, it has fluid or semi fluid properties. In some very limited cases it may still be possible to have a foamable composition which is flowable but not apparently shakable.
Breakability [0331] A breakable foam is thermally stable or substantially so, yet breaks under sheer force. The breakable foam of the present invention is not "quick breaking", i.e., it does not readily collapse upon exposure to body temperature environment. Sheer-force breakability of the foam is clearly advantageous over thermally induced breakability, (due to, for example, the presence of alcohol) since it allows comfortable application and well directed administration to the target area.
Foam Collapse [0332] A further aspect of the foam is breakability. Thermally sensitive foams immediately collapse upon exposure to skin temperature and, therefore, cannot be applied on the hand and afterwards delivered to the afflicted area.
Shakability [0330] `Shakability' means that the composition contains some or sufficient flow to allow the composition to be mixed or remixed on shaking. That is, it has fluid or semi fluid properties. In some very limited cases it may still be possible to have a foamable composition which is flowable but not apparently shakable.
Breakability [0331] A breakable foam is thermally stable or substantially so, yet breaks under sheer force. The breakable foam of the present invention is not "quick breaking", i.e., it does not readily collapse upon exposure to body temperature environment. Sheer-force breakability of the foam is clearly advantageous over thermally induced breakability, (due to, for example, the presence of alcohol) since it allows comfortable application and well directed administration to the target area.
Foam Collapse [0332] A further aspect of the foam is breakability. Thermally sensitive foams immediately collapse upon exposure to skin temperature and, therefore, cannot be applied on the hand and afterwards delivered to the afflicted area.
[0333] The foam of the present invention has several notable advantages, when compared with hydroalcoholic foam compositions, such as Breakability. The foam of the present invention is thermally stable and breakable under sheer force but is not "quick breaking which allows comfortable application and well directed administration to the target area.
Skin drying and skin barrier function. Short chain alcohols are known to dry the skin and impair the integrity of the skin barrier. By contrast, including a film forming agent in the composition of the present invention foes not cause unwanted skin barrier damage.
Irritability. Due to the lack of lower alcohols (C1-C5) and improvement in skin barrier function, skin irritability is eliminated.
Skin drying and skin barrier function. Short chain alcohols are known to dry the skin and impair the integrity of the skin barrier. By contrast, including a film forming agent in the composition of the present invention foes not cause unwanted skin barrier damage.
Irritability. Due to the lack of lower alcohols (C1-C5) and improvement in skin barrier function, skin irritability is eliminated.
[0334] Another property of the foam is specific gravity, as measured upon release from the aerosol can. Typically, foams have specific gravity of less than 0.12 g/mL; or less than 0.10 g/mL; or less than 0.08 g/mL, depending on their composition and on the propellant concentration.
Examples [0335] The invention is described with reference to the following examples.
This invention is not limited to these examples and experiments. Many variations will suggest themselves and are within the full intended scope of the appended claims [0336] All % values are provided on a weight (w/w) basis.
Examples [0335] The invention is described with reference to the following examples.
This invention is not limited to these examples and experiments. Many variations will suggest themselves and are within the full intended scope of the appended claims [0336] All % values are provided on a weight (w/w) basis.
[0337] In some cases the formulations are expressed in amounts up to 100%
including the propellant. In other cases the formulations are expressed in amounts up to 100% not including the propellant, which is then added to the composition.
GENERAL METHODOLOGY
including the propellant. In other cases the formulations are expressed in amounts up to 100% not including the propellant, which is then added to the composition.
GENERAL METHODOLOGY
[0338] In one or more various embodiments the sensation or sensation modifying topical compositions can be prepared according to the general methodology set out below with appropriate changes as would be well appreciated by a man of the art.
Emulsion Foam 1. Mix oily phase ingredients and heat to 75 C to melt all ingredients and obtain homogeneous mixture.
2. Mix polymers in water with heating or cooling as appropriate for specific polymer.
3. Add all other water soluble ingredients to water-polymer solution and heat to 75 C.
4. Add slowly internal phase to external phase at 75 C under vigorous mixing and homogenize to obtain fine emulsion.
5. Cool to below 40 C and add sensitive ingredients with mild mixing.
6. Cool to room temperature.
This methodology is suitable, for example, for the preparation of the hamamelis, and also for the capsaicin emollient emulsion compositions exemplified below.
Waterless Foam 1. Dissolve the polymers in the main solvent with heating or cooling as appropriate for specific polymer. Add the all other ingredients and heat to 75 C to melt and dissolve the various ingredients.
2. Cool to below 40 C and add sensitive ingredients with mild mixing.
3. Cool to room temperature.
This methodology is suitable, for example, for the preparation of the capsaicin waterless compositions exemplified below.
Emulsion: Mint oil 1. Mix oily phase ingredients and heat to 75 C to melt all ingredients and obtain homogeneous mixture.
2. Mix polymers in water with heating or cooling as appropriate for specific polymer.
3. Add all other water soluble ingredients to water-polymer solution and heat to 75 C.
4. Add internal phase to external phase at 75 C under vigorous mixing and homogenize to obtain fine emulsion.
5. Cool to below 40 C.
6. Add sensitizing agents and any other active ingredient with mild mixing.
7. Cool to room temperature.
8. In case of Pemulene stabilizer, dissolve the Pemulene in the Mint oil and add to the emulsion.
Waterless: Mint oil 1. Dissolve the polymers in the main solvent with heating or cooling as appropriate for specific polymer. Add the all other ingredients and heat to 75 C to melt and dissolve the various ingredients.
2. Cool to below 40 C
3. Add sensitizing agents and any other active ingredient with mild mixing.
4. Cool to room temperature.
Production under vacuum [0339] Optionally, the foamable formulation may be produced under nitrogen and under vacuum. Whilst the whole process can be carried out under an oxygen free environment, it can be sufficient to apply a vacuum after heating and mixing all the ingredients to obtain an emulsion or homogenous liquid. Preferably the production chamber is equipped to apply a vacuum but if not the formulation can be for example placed in a dessicator to remove oxygen prior to filing and crimping.
Canisters Filling and Crimping [0340] Each aerosol canister is filled with PFF and crimped with valve using vacuum crimping machine. The process of applying a vacuum will cause most of the oxygen present to be eliminated. Addition of hydrocarbon propellant may without being bound by any theory further help to reduce the likelihood of any remaining oxygen reacting with the active ingredient. It may do so, without being bound by any theory, by one or more of dissolving in the oil or hydrophobic phase of the formulation, by dissolving to a very limited extent in the aqueous phase, by competing with some oxygen from the formulation, by diluting out any oxygen, by a tendency of oxygen to occupy the dead space, and by oxygen occupying part of the space created by the vacuum being the unfilled volume of the canister or that remaining oxygen is rendered substantially ineffective in the formulation.
Pressurizing Propellant Filling [0341] Pressurizing is carried out using a hydrocarbon gas or gas mixture.
Canisters are filled and then warmed for 30 sec in a warm bath at 50oC and well shaken immediately thereafter.
Closure Integrity Test.
Emulsion Foam 1. Mix oily phase ingredients and heat to 75 C to melt all ingredients and obtain homogeneous mixture.
2. Mix polymers in water with heating or cooling as appropriate for specific polymer.
3. Add all other water soluble ingredients to water-polymer solution and heat to 75 C.
4. Add slowly internal phase to external phase at 75 C under vigorous mixing and homogenize to obtain fine emulsion.
5. Cool to below 40 C and add sensitive ingredients with mild mixing.
6. Cool to room temperature.
This methodology is suitable, for example, for the preparation of the hamamelis, and also for the capsaicin emollient emulsion compositions exemplified below.
Waterless Foam 1. Dissolve the polymers in the main solvent with heating or cooling as appropriate for specific polymer. Add the all other ingredients and heat to 75 C to melt and dissolve the various ingredients.
2. Cool to below 40 C and add sensitive ingredients with mild mixing.
3. Cool to room temperature.
This methodology is suitable, for example, for the preparation of the capsaicin waterless compositions exemplified below.
Emulsion: Mint oil 1. Mix oily phase ingredients and heat to 75 C to melt all ingredients and obtain homogeneous mixture.
2. Mix polymers in water with heating or cooling as appropriate for specific polymer.
3. Add all other water soluble ingredients to water-polymer solution and heat to 75 C.
4. Add internal phase to external phase at 75 C under vigorous mixing and homogenize to obtain fine emulsion.
5. Cool to below 40 C.
6. Add sensitizing agents and any other active ingredient with mild mixing.
7. Cool to room temperature.
8. In case of Pemulene stabilizer, dissolve the Pemulene in the Mint oil and add to the emulsion.
Waterless: Mint oil 1. Dissolve the polymers in the main solvent with heating or cooling as appropriate for specific polymer. Add the all other ingredients and heat to 75 C to melt and dissolve the various ingredients.
2. Cool to below 40 C
3. Add sensitizing agents and any other active ingredient with mild mixing.
4. Cool to room temperature.
Production under vacuum [0339] Optionally, the foamable formulation may be produced under nitrogen and under vacuum. Whilst the whole process can be carried out under an oxygen free environment, it can be sufficient to apply a vacuum after heating and mixing all the ingredients to obtain an emulsion or homogenous liquid. Preferably the production chamber is equipped to apply a vacuum but if not the formulation can be for example placed in a dessicator to remove oxygen prior to filing and crimping.
Canisters Filling and Crimping [0340] Each aerosol canister is filled with PFF and crimped with valve using vacuum crimping machine. The process of applying a vacuum will cause most of the oxygen present to be eliminated. Addition of hydrocarbon propellant may without being bound by any theory further help to reduce the likelihood of any remaining oxygen reacting with the active ingredient. It may do so, without being bound by any theory, by one or more of dissolving in the oil or hydrophobic phase of the formulation, by dissolving to a very limited extent in the aqueous phase, by competing with some oxygen from the formulation, by diluting out any oxygen, by a tendency of oxygen to occupy the dead space, and by oxygen occupying part of the space created by the vacuum being the unfilled volume of the canister or that remaining oxygen is rendered substantially ineffective in the formulation.
Pressurizing Propellant Filling [0341] Pressurizing is carried out using a hydrocarbon gas or gas mixture.
Canisters are filled and then warmed for 30 sec in a warm bath at 50oC and well shaken immediately thereafter.
Closure Integrity Test.
[0342] Each pressurized canister is subjected to bubble and crimping integrity testing by immersing the canister in a 60 C water bath for 2 minutes. Canisters are observed for leakage as determined by the generation of bubbles. Canisters releasing bubbles are rejected.
FOAM TESTS
FOAM TESTS
[0343] By way of non limiting example the objectives of hardness, collapse time and FTC stability tests are briefly set out below as would be appreciated by a person of the art.
Hardness [0344] LFRA100 instrument is used to characterize hardness. A probe is inserted into the test material. The resistance of the material to compression is measured by a calibrated load cell and reported in units of grams on the texture analyzer instrument display. Preferably at least three repeat tests are made. The textural characteristics of a dispensed foam can affect the degree of dermal penetration, efficacy, spreadability and acceptability to the user. The results can also be looked at as an indicator of softness.
Note: the foam sample is dispensed into an aluminum sample holder and filled to the top of the holder.
Collapse Time [0345] Collapse time (CT) is examined by dispensing a given quantity of foam and photographing sequentially its appearance with time during incubation at 36 C.
It is useful for evaluating foam products, which maintain structural stability at skin temperature for at least 1 min.
Viscosity [0346] Viscosity is measured with Brookfield LVDV-II + PRO with spindle SC4-25 at ambient temperature and 10, 5 and 1 RPM. Viscosity is usually measured at 10RPM.
However, at about the apparent upper limit for the spindle of ->50,000CP, the viscosity at 1 RPM may be measured, although the figures are of a higher magnitude.
FTC (Freeze Thaw Cycles) [0347] To check the foam appearance under extreme conditions of repeated cycles of cooling, heating, (first cycle) cooling, heating (second cycle) etc., commencing with -100 C (24hours) followed by +400 C (24hours) measuring the appearance and again repeating the cycle for up to three times.
Chemical Stability [0348] The amount of active agent present is analyzed in foam expelled from various pressurized canisters containing foam formulations using HPLC. Analysis is carried out at zero time and at appropriate time intervals thereafter. The canisters are stored in controlled temperature incubators at 5 C, at 25 C, at, 40 C and at 50 C. At appropriate time intervals canisters are removed and the amount of active agent in the foam sample is measured.
Creaming by centrifugation Principle of test [0349] The centrifugation used in this procedure serves as a stress condition simulating the aging of the liquid dispersion under investigation. Under these conditions, the centrifugal force applied facilitates the coalescence of dispersed globules or sedimentation of dispersed solids, resulting in loss of the desired properties of the formulated dispersion.
Procedure [0350] Following preparation of the experimental formulation/s, allow to stand at room temperature for >_ 24 h. Handle pentane in the chemical hood. Add to each experimental formulation in a 20-mL glass vial a quantity of pentane equivalent to the specified quantity of propellant for that formulation, mix and allow formulation to stand for at least 1 h and not more than 24 h.
Hardness [0344] LFRA100 instrument is used to characterize hardness. A probe is inserted into the test material. The resistance of the material to compression is measured by a calibrated load cell and reported in units of grams on the texture analyzer instrument display. Preferably at least three repeat tests are made. The textural characteristics of a dispensed foam can affect the degree of dermal penetration, efficacy, spreadability and acceptability to the user. The results can also be looked at as an indicator of softness.
Note: the foam sample is dispensed into an aluminum sample holder and filled to the top of the holder.
Collapse Time [0345] Collapse time (CT) is examined by dispensing a given quantity of foam and photographing sequentially its appearance with time during incubation at 36 C.
It is useful for evaluating foam products, which maintain structural stability at skin temperature for at least 1 min.
Viscosity [0346] Viscosity is measured with Brookfield LVDV-II + PRO with spindle SC4-25 at ambient temperature and 10, 5 and 1 RPM. Viscosity is usually measured at 10RPM.
However, at about the apparent upper limit for the spindle of ->50,000CP, the viscosity at 1 RPM may be measured, although the figures are of a higher magnitude.
FTC (Freeze Thaw Cycles) [0347] To check the foam appearance under extreme conditions of repeated cycles of cooling, heating, (first cycle) cooling, heating (second cycle) etc., commencing with -100 C (24hours) followed by +400 C (24hours) measuring the appearance and again repeating the cycle for up to three times.
Chemical Stability [0348] The amount of active agent present is analyzed in foam expelled from various pressurized canisters containing foam formulations using HPLC. Analysis is carried out at zero time and at appropriate time intervals thereafter. The canisters are stored in controlled temperature incubators at 5 C, at 25 C, at, 40 C and at 50 C. At appropriate time intervals canisters are removed and the amount of active agent in the foam sample is measured.
Creaming by centrifugation Principle of test [0349] The centrifugation used in this procedure serves as a stress condition simulating the aging of the liquid dispersion under investigation. Under these conditions, the centrifugal force applied facilitates the coalescence of dispersed globules or sedimentation of dispersed solids, resulting in loss of the desired properties of the formulated dispersion.
Procedure [0350] Following preparation of the experimental formulation/s, allow to stand at room temperature for >_ 24 h. Handle pentane in the chemical hood. Add to each experimental formulation in a 20-mL glass vial a quantity of pentane equivalent to the specified quantity of propellant for that formulation, mix and allow formulation to stand for at least 1 h and not more than 24 h.
[0351] Transfer each mixture to 1.5 mL microtubes. Tap each microtube on the table surface to remove entrapped air bubbles.
[0352] Place visually balanced microtubes in the centrifuge rotor and operate the centrifuge at one or more of 10,000 rpm for 10 min, 3,000 rpm for 10 min or at 1,000 rpm for 10 min.
Bubble Size [0353] Foams are made of gas bubbles entrapped in liquid. The bubble size and distribution reflects in the visual texture and smoothness of the foam. Foam bubbles size is determined by dispensing a foam sample on a glass slide, taking a picture of the foam surface with a digital camera equipped with a macro lens. The diameter of about 30 bubbles is measured manually relatively to calibration standard template.
Statistical parameters such as mean bubble diameter, standard deviation and quartiles are then determined. Measuring diameter may also be undertaken with image analysis software.
The camera used was a Nikon D40X Camera (resolution 10MP) equipped with Sigma Macro Lens (ref: APO MACRO 150mm F2.8 EX DG HSM). Pictures obtained are cropped to keep a squared region of 400 pixels x 400 pixels.
Foam Satisfaction Tests [0354] Compositions of the present invention were separately applied to clean skin of a group of human subjects. After 5 minutes tested subjects were asked to provide a gauge of their satisfaction relating to the following parameters: Ease of application, skin absorption, stickiness, odor, oily residue, skin surface shiny appearance, composition stability; overall satisfaction; sensation change, such as cooling, relaxing, heating etc.
The subjects gauged their response according to the following scoring system:
1 - very bad feeling 2 - Bad feeling 3 - feels "OK"
4 - Feels good - Feels excellent, want more The scores assigned by the subjects were added and an average result was recorded.
Sensation quantification tests [0355] In cases where a sensation agent was added to the composition, the above test was repeated after 15, 30, 60, 120 minutes and after washing off the composition from the skin surface (after 120 minutes). The subjects were asked to gauge their feeling of a sensation, such as sensation change, such as cooling, relaxing, heating etc. The scores assigned by the subjects were added and an average result was recorded.
In some cases, as exemplified below, the sensation was observed over a prolonged or sustained period of time.
Bubble Size [0353] Foams are made of gas bubbles entrapped in liquid. The bubble size and distribution reflects in the visual texture and smoothness of the foam. Foam bubbles size is determined by dispensing a foam sample on a glass slide, taking a picture of the foam surface with a digital camera equipped with a macro lens. The diameter of about 30 bubbles is measured manually relatively to calibration standard template.
Statistical parameters such as mean bubble diameter, standard deviation and quartiles are then determined. Measuring diameter may also be undertaken with image analysis software.
The camera used was a Nikon D40X Camera (resolution 10MP) equipped with Sigma Macro Lens (ref: APO MACRO 150mm F2.8 EX DG HSM). Pictures obtained are cropped to keep a squared region of 400 pixels x 400 pixels.
Foam Satisfaction Tests [0354] Compositions of the present invention were separately applied to clean skin of a group of human subjects. After 5 minutes tested subjects were asked to provide a gauge of their satisfaction relating to the following parameters: Ease of application, skin absorption, stickiness, odor, oily residue, skin surface shiny appearance, composition stability; overall satisfaction; sensation change, such as cooling, relaxing, heating etc.
The subjects gauged their response according to the following scoring system:
1 - very bad feeling 2 - Bad feeling 3 - feels "OK"
4 - Feels good - Feels excellent, want more The scores assigned by the subjects were added and an average result was recorded.
Sensation quantification tests [0355] In cases where a sensation agent was added to the composition, the above test was repeated after 15, 30, 60, 120 minutes and after washing off the composition from the skin surface (after 120 minutes). The subjects were asked to gauge their feeling of a sensation, such as sensation change, such as cooling, relaxing, heating etc. The scores assigned by the subjects were added and an average result was recorded.
In some cases, as exemplified below, the sensation was observed over a prolonged or sustained period of time.
[0356] By "prolonged period of time" or "sustained period of time" or "substantial period of time" (used interchangeably herein), is meant a period of time of about five or more minutes, more typically, at least 15 minutes in which the subject senses a sensation pertaining to a sensation agent applied to a target or delivery site on/in the subject.
Foam Temperature Effects [0357] In the Examples hereinbelow, the following test was performed to see if there were any temperature changes to a surface onto which a foam was placed:
1. Place a thermometer in a clean glass vial and allow it to come to equilibrium.
2. Measure and record the temperature.
3. Release foam about 5gm onto the thermometer.
4. Observe temperature for 300 sec.
The procedure was performed on regular; different cooling and heating foam formulations (per examples below).
Results: For all foams tested by the above method as seen in the examples hereinbelow, no detectable significant temperature difference was noted between the surface temperature, foam temperature and ambient initial temperature. This is indicative that the foams produced in the examples below did not exhibit a measurable exothermic or endothermic reaction. Thus, the foams tested should not induce a significant temperature effect at the target site primarily due to the cooling effect of the propellant. In certain embodiments, it may be possible for there to be an interaction between chemicals in the skin or other target site and the foam composition, particularly for the non-aqueous compositions. For example, by moisture in the skin being absorbed by hygroscopic pharmaceutical recipients, like glycols. Nevertheless, a main aim is to deliver a sensation via a foam vehicle, where the prime sensation is due to pharmaceutical stimulation rather than an actual physical effect. In one or more embodiments, the sensation may be a combination of pharmaceutical stimulation and physical effect. For example, where an excess of propellant may provide an initial physical cooling and the sensation agent provides a prolonged sensation, without further cooling. The vehicles disclosed herein are adapted to provide the main sensation with or without an initial physical cooling sensation.
SECTION A
COOLING
Example 1- Emollient Emulsion Foamable Composition with 10% Menthol Crystals and Avocado Oil a) Formulation Ingredient Name Function % w/w Avocado oil emollient and solvent 10 PEG 40 Stearate Stabilizing emulsifier 2.31 Stearyl Alcohol Co-emulsifier and foam stabilizer 0.77 Isopropyl myristate emollient 4.62 Mineral Oil Emollient 4.62 Hypromellose Stabilizing polymers 0.23 Xanthan gum Stabilizing polymers 0.23 Polysorbate 80 Stabilizing emulsifier 0.77 GMS Co-emulsifier foam stabilizer 0.39 Menthol Cooling agent 10 Water Solvent to 100 Propane/butane/isobutane 8 Foam quality Excellent Color White Odor Menthol Density /cm3 0.045 Shakability Good pH 6.63 Collapse time [seconds] >300 b) Emollient + avocado oil +10% menthol crystals: Mean cooling effect on three subjects over time is 12.7 Time Score 0 2.00 5' 1.33 15' 2.33 30' 2.00 60' 2.00 120' 1.33 after washing 1.67 Sum total of points for this formulation for all subjects is: 38 c) Emollient + avocado oil +10% menthol crystals: Foam satisfaction Parameters Ease of skin stickiness odor oily residue foam Shiny overall application absorption stability Look satisfaction 3.3 2.7 4.0 3.0 3.7 3.3 3.3 3.7 Sum total of points for this formulation for all subjects is: 107 [0358] Comments: Emollient emulsion foam provided a reasonable and prolonged cooling sensation; excellent foam quality; moisturizing; Comprises an oil phase, a water phase, a surfactant combination supported by co emulsifiers and a combination of polymeric agents. The co emulsifiers are non essential and can be omitted although some adjustment may be needed to the surfactant combination as will be appreciated by someone skilled in the art.
Note: The propellant can be added at a concentration of about 3% to about 25%
or more.
Example 2- Emollient Emulsion Foamable Composition with 10% Menthol Crystals and Avocado Oil and 15% Ethanol a) Emollient +10% menthol crystals +15% ethanol: Formulation Ingredient Name Function % w/w Avocado oil emollient and solvent 10 PEG 40 Stearate Stabilizing emulsifier 2.31 Stearyl Alcohol Co-emulsifier and foam stabilizer 0.77 Isopropyl myristate emollient 4.62 Mineral Oil Emollient 4.62 hypromellose Stabilizing polymers 0.23 xanthan gum Stabilizing polymers 0.23 Polysorbate 80 Stabilizing emulsifier 0.77 GMS Co-emulsifier foam stabilizer 0.39 Menthol Cooling agent 10 ETHANOL Solvent - penetration enhancer 15 Water Solvent to 100 Propane/butane/isobutane 8 Foam quality Good Color White Odor Menthol Density /cm 0.044 Shakability Moderate pH 5.89 Collapse time [seconds] 300 b) Emollient + avocado oil +10% menthol crystals + 15% ethanol: Mean cooling effect on four subjects over time is 13.34 Time Score 0 1.75 5' 1.875 15' 2.5 30' 2.75 60' 2.25 120' 1.25 after washing 1 Sum total of points for this formulation for all subjects is: 53.5 c) Emollient + avocado oil +10% menthol crystals + 15% ethanol: Foam satisfaction Parameters Ease of skin stickiness odor oily foam Shiny overall application absorption residue stability Look satisfaction 4.25 3.75 5 4 4.25 3.75 2 4 Sum total of points for this formulation for all subjects is: 124 [0359] Comments: Emollient foam provided reasonable and prolonged cooling sensation; good foam quality; moisturizing; Comprises an oil phase, water phase, surfactant combination supported by co emulsifiers and a combination of polymeric agents plus a polar solvent as a penetration enhancer. Menthol in the above formulation achieves good penetration on its own so the presence of 15% ethanol is of only marginal effect. Ethanol is not essential and may be omitted or replaced by other penetrating agents such as transcutol; DMI; and the like. See section on penetration agents.
Note: The propellant can be added at a concentration of about 3% to about 25%
or more.
Example 3- Emollient Emulsion Foamable Composition with 15% Menthol Crystals a) Formulation Ingredient Name Function % w/w Capric/caprilic triglyceride Emollient and solvent 6 Stearic acid Co-emulsifier and foam stabilizer 2 hypromellose Stabilizing polymers 0.3 xanthan gum Stabilizing polymers 0.3 Steareth-2 Stabilizing emulsifier 2.5 Steareth-21 Stabilizing emulsifier 3 Menthol Cooling agent 15 Propylene Glycol Solvent; moisturizer; penetration 3 enhancer Ingredient Name Function % w/w Water solvent To 100 Propane/butane/isobutane 8 Foam quality Good Color White Odor Menthol -Density /cm3 0.025 Shakabilit Moderate H 6.26 -Collapse time [seconds] >300 b) Emollient +15% menthol crystals: Mean cooling effect on four subjects over time is 13.88 Time Score 0 1.375 5' 2 15' 3.25 30' 3.5 60' 2.5 120' 1.25 after washing 1.25 Sum total of points for this formulation for all subjects is 60.5 c) Emollient +15% menthol crystals: Foam satisfaction Parameters Ease of skin stickiness odor oily foam Shiny overall application absorption residue stability Look satisfaction 4 4 3.5 3.75 3.5 4.5 2.75 3.75 Sum total of points for this formulation for all subjects is: 119 [0360] Comments: Emollient foam provided excellent and prolonged cooling sensation; good foam quality; moisturizing. Comprises an oil phase, a water phase, a surfactant combination supported by a co-emulsifier and a combination of polymeric agents. The propylene glycol is non essential.
Note: The propellant can be added at a concentration of about 3% to about 25%
or more.
Example 4- Emollient Emulsion Foamable Composition with 15% Peppermint Oil a) Formulation CTFA Name Function % w/w Ca ric/ca rilic Tri I ceride Emollient and solvent 6 Stearic acid Co-emulsifier and foam stabilizer 2 hypromellose Stabilizing polymers 0.3 xanthan gum Stabilizing polymers 0.3 Steareth-2 Stabilizing emulsifier 2.5 Steareth-21 Stabilizing emulsifier 3 PEPPERMINT OIL Cooling agent 15 Propylene Glycol Solvent / moisturizer / penetration 3 enhancer Permulen 0.1 TEA To pH 7 Water solvent To 100 Propane/butane/isobutane 8 Foam quality Good Color White Odor Menthol Density /cm 0.028 Shakability Low pH 6.17 Collapse time [seconds] >300 b) Emollient +15% peppermint oil: Mean cooling effect on four subjects over time is 11.75 Time Score 0 1.75 5' 1.5 15' 2.25 30' 2.5 60' 1.75 120' 1 after washing 1 Sum total of points for this formulation for all subjects is: 47 c) Emollient +15% peppermint oil Foam satisfaction Parameters Ease of skin stickiness odor oily foam Shiny overall application absorption residue stability Look satisfaction 4 3.75 4 3.25 3.75 4.5 3.25 3.75 Sum total of points for this formulation for all subjects is: 121 [0361] Comments: Emollient foam provided reasonable and prolonged cooling sensation; good foam quality; moisturizing; Comprises an oil phase, a water phase, a surfactant combination supported by a co-emulsifier and a combination of polymeric agents. The propylene glycol is non-essential. The peppermint oil reduces the viscosity of the emulsion and is matrix destabilizing.
Note: The propellant can be added at a concentration of about 3% to about 25%
or more.
Example 5- Emollient Emulsion Foamable Composition with 15% Menthol Crystals and 25% propellant a) Formulation Ingredient name Function % w/w Stearic acid * Co-emulsifier and foam 3 stabilizer Steareth-2 * Stabilizing emulsifier 2 Steareth-21 * Stabilizing emulsifier 3 Methylcellulose * Co-emulsifier and foam 0.3 stabilizer Xanthan gum * Co-emulsifier and foam 0.3 stabilizer Menthol crystal Cooling agent 15 Water * Solvent To 100 Glyceryl monostearete Co-emulsifier foam stabilizer 2 Propellant 25 Pro ane/Butane/Isobutane b) Emollient +25% propellant + Menthol crystals: Mean cooling effect on four subjects over time Time Score 0 1.7 5' 1.0 15' 2.3 30' 2.7 60' 1.7 120' 1.3 after washing 1.0 Sum total of points for this formulation for all subjects is: 37 c) Emollient +25% propellant + Menthol crystals: Foam satisfaction Parameters Ease of skin stickiness odor oily foam Shiny overall application absorption residue stability Look satisfaction 4.0 3.3 3.0 3.0 3.0 3.0 4.0 3.7 Sum total of points for this formulation for all subjects is: 76 [0362] Comments: Emollient foam provided good cooling sensation; good foam quality; doesn't require preservative.
Note: The propellant can be added at a concentration of about 3% to about 25%
or more.
Example 6- Waterless Foamable Composition with 15% Menthol Crystals (Formula number - 28) a) Formulation Ingredient Name Function % w/w PEG 4000 Firming wax 7.5 Stearic acid Co-emulsifier and foam stabilizer 2 H droxuprop l cellulose Stabilizing polymers 2 Steareth-2 Stabilizing emulsifier 2.5 Steareth-21 Stabilizing emulsifier 3 Menthol Cooling agent 15 Propylene Glycol Solvent / moisturizer / penetration 68 enhancer Propane/butane/isobutane 8 Foam quality Fairly good Color White Odor Menthol b) Mean cooling effect on four subjects over time Time Score 5' 1.125 15' 1.375 30' 2 60' 2.5 120' 1.5 after washing 1 Sum total of points for this formulation for all subjects is: 42 c) Foam satisfaction Parameters Ease of skin stickiness odor oily foam Shiny overall application absorption residue stability Look satisfaction 4 2.5 3.25 3.75 2 1 1.75 2.25 Sum total of points for this formulation for all subjects is: 82 [0363] Comments: Waterless foam provided reasonable and prolonged cooling sensation with a delayed onset; fairly good foam quality; moisturizing;
doesn't require preservative. Any high molecular weight PEG (for example 1500, 2000, 4000, 6000 or 8000) or combinations of high molecular weight PEG with lower molecular weight PEG
(for example 200, 400, 600) may be used.
Note: The propellant can be added at a concentration of about 3% to about 25%
or more.
Example 7- Waterless Foamable Composition with 10% Peppermint Oil (Formula number - 32) a) Formulation Ingredient Name Function % w/w PEG 4000 Firming wax 7.5 Stearic acid Co-emulsifier and foam stabilizer 2 Hydroxypropyl cellulose Stabilizing polymers 2 Steareth-2 Stabilizing emulsifier 2.5 Steareth-21 Stabilizing emulsifier 3 PEPPERMINT OIL Cooling agent 10 Propylene Glycol Solvent / moisturizer - penetration 73 enhancer Propane/butane/isobutane 8 Foam quality Fairy good Color White Odor Menthol Cooling score 7- of total points for this formulation from all people) 36 a) Mean cooling effect on Four subjects over time is 9 Time Score 5' 1 15' 1.75 30' 2 60' 1.25 120' 1 after washing 1 Sum total of points for this formulation for all subjects is: 36 c) Foam satisfaction Parameters Ease of skin stickiness odor oily foam Shiny overall application absorption residue stability Look satisfaction 4 3 3.25 3.5 2.25 3.5 2.5 3 Sum total of points for this formulation for all subjects is: 100 [0364] Comments: Waterless foam provided reasonable and medium term cooling sensation with delayed onset; fairly good foam quality; moisturizing; doesn't require preservative. Any high molecular weight PEG (for example 1500, 2000, 4000, 6000 or 8000) or combinations of high molecular weight PEG with lower molecular weight PEG
(for example 200, 400, 600) may be used. The peppermint oil has a thinning effect on the composition, which is to some extent counterbalanced or ameliorated by the high molecular weight PEG.
Note: The propellant can be added at a concentration of about 3% to about 25%
or more.
RELAXING OR SOOTHING
Example 8- Emollient Emulsion Foamable Relaxing or Soothing Composition with Hamamelis w/w Mineral oil 6.00 Isopropyl myristate 6.00 GI cer l monostearate 0.50 Stearyl alcohol 1.00 Xanthan gum 0.30 Methocel K100M 0.30 Polysorbate 80 1.00 PEG-40 stearate 3.00 Hamamelis glycerin fluid extract (Alban Muller, France) 10.00 EDTA disodium 0.20 Phenonip 0.30 Water pure to 100.0 Propellant (propane and butane 20:80) 8.0 Foam quality Excellent Density /cm3 0.04 Collapse time >120 Shakability Yes Odor slight [0365] Comments: Emollient foam capable of providing a soothing sensation;
excellent foam quality; moisturizing. It comprises an oil phase, water phase, a surfactant combination supported by co emulsifiers and a combination of polymeric agents, plus a preservative and a chelating agent. The chelating agent is non essential. The co emulsifiers are non essential and can be omitted although some adjustment may be needed to the surfactant combination as will be appreciated by someone skilled in the art.
Note: The propellant can be added at a concentration of about 3% to about 25%
or more.
WARMING
Example 9- Prophetic Emollient Emulsion Foamable Warming Composition with Capsaicin and Mineral Oil Ingredient name %w/w Mineral oil 4.62 Isopropyl myristate 4.62 Glyceryl monostearate 0.39 Polysorbate 80 0.77 PEG-40 stearate 2.31 Stearyl alcohol 0.77 Hydroxypropyl methylcellulose 0.23 Xanthan 0.23 Water TO 100 Capsaicin 0.025 Total: 100.00 Propellant (Propane/Butane/Isobutane) 8 Example 10- Prophetic Waterless Foamable Warming Composition with Capsaicin Ingredient name %w/w PEG 4000 7.5 Capsaicin 0.025 H drox ro l cellulose 2 Stearic acid 2 Steareth-2 2.5 Steareth-21 3 Propylene glycol To 100 ,Propellant Pro ane/Butane/Isobutane 8 Example 11- Prophetic Emollient Emulsion Foamable Warming Composition with Capsaicin and MCT
Ingredient name %w/w Stearic acid 2 Steareth 2 2.5 Steareth-21 3 Capsaicin 0.025 Propylene Glycol 3 Xanthan gum 0.3 Hypromellose 0.3 Water To 100 Propellant Pro ane/Butane/Isobutane 8 [0366] Comments:
- It is possible to use any of the above exemplary warming formulations with other warming agents, for example, methyl salicylate. Apart from its warming effect methyl salicylate is an analgesic and counter irritant. Lists of applicable warming agents are described in the specification. An effective amount of the warming agent is introduced into the formulation in place of capsaicin and the amount of the main carrier is adjusted to bring the formulation to 100%, which in the case of the waterless composition is propylene glycol and in the case of the emollient emulsion composition is water. The amount of methyl salicylate is of the order of 5 to 10%.
- It is also possible to use combinations of warming agents. The combination of capsaicin with methyl salicylate, for example, may be useful. Methyl salicylate has a quick onset whilst capsaicin does not so a combination may be helpful in cases where pain relief is sought.
- It is also possible to modulate, potentate, increase, reduce, or ameliorate the warming effect by introducing into the composition a sensation modifying agent. I an embodiment the warming effect or sensation maybe reduced by addition of a cooling agent in the composition.
- The formulations may contain polar solvents, which contribute to skin penetration of an active agent FOAM WITH ADDITIONAL THERAPEUTIC AGENTS
Example 12 -Foamable Oil In Water Emulsion Foamable Compositions, Containing Menthol As Cooling Agent And Coal Tar Extract And Salicylic Acid As Additional Therapeutic Agents Ingredient name CTR005 CTR006 %W/W %W/W
Menthol (Sensation modifying agent) 1 1 Coal tar extract (Additional therapeutic agent) 10 10 Salicylic acid (Additional therapeutic agent) 5 Hydrocortisone (Additional therapeutic agent) 1 PPG-15 Stearyl ether -- 3 Isopropyl Myristate 10 5 Octyldodecanol 12 12 Stearyl Alcohol 2 1 Glycerin -- 3 Lanolin -- 2 Laureth-4 -- 2 Emulgin B2 -- 1.5 Glyceryl Stearate 1.5 --Ingredient name CTR005 CTR006 %W/W %W/W
PEG-40 Stearate 3 --CMC -- 0.5 Methocel K100M 0.28 --Xanthan gum 0.28 --Propylene Glycol -- 5 Polysorbate 60 1 --Water, purified To 100 To 100 Propellant 8 8 [0367] Comments: The above formulations provided excellent moisturizing emollient foams with improved sensation by ameliorating the negative sensation effect of coal tar.
Section B
Cooling Example 13 A) Waterless propylene glycol formulation containing peppermint oil as cooling agent Steareth 2 2.00 polysorbate 80 2.00 GI cer l monostearate 2.00 H drox ro l cellulose 1.00 peppermint oil 10.00 Propylene Glycol 83.00 Total: 100.00 Propellant (AP-70) 8.00 Results PFF
Viscosity 148.97 Centrifgation 1 K stable Centrifgation 3K stable FOAM
Quality G-E
Color White Collapse time (sec.) 95/F
Density (gr/ml) 0.070 Bubble size (pm) 180 Bubble size (%-above 500 pm) 6.30 temperature change T-0 MINUTES=13 C
T-5 MINUTES=12 C
*G-E =Good to Excellent [0368] Comments: This waterless single phase formulation provides a stable vehicle for peppermint oil that can generate good quality foam and which can withstand 3000rpm.
The surfactants and a polymeric agent provide viscosity support and aid foaming. On forming foam there is no significant temperature change when measured on a glass surface. When the formulation is applied to the skin, however, the peppermint oil provides a sensation of cooling, which may be potentiated by the evaporation of propellant and the lower temperature of the foam compared to the skin.
B) A waterless PG formulation and two oil in water emulsion formulations containing menthol crystals as cooling agent cf example 3 cf example 12 MCT 6.00 Isopropyl myristate 10.00 Octyldodecanol 10.00 Stearic acid 2.00 Stearyl alcohol 2.00 Cetostearyl alcohol 2.00 Steareth 2 2.00 4.20 Steareth-21 1.40 polysorbate 80 2.00 Glyceryl monostearate 2.00 1.40 PEG-40 stearate 3.10 Polysorbate 60 1.20 Xanthan gum 0.30 0.28 Methocell k100M 0.30 0.28 Hydroxypropyl cellulose 1.00 Water 67.80 59.74 menthol crystals 10.00 15.00 1.00 Propylene Glycol 81.00 3.00 Coal tar 10.00 Hydrocortisone butyrate 1.00 Total: 100.00 100.00 100.00 Propellant (AP-70) 8.00 8.00 8.00 Results PFF
Viscosity 4447.05 4527.04 2037.57 Centrifgation 1 K stable Stable stable Centrifgation 3K stable Stable stable FOAM
Quality G-E G-E G-E
Color White White Slightly Yellow Collapse time (sec.) >300/G >300/FG >300/FG
Density (gr/ml) 0.060 0.043 0.039 Bubble size (pm) 62 99 112 Bubble size (%-above 500 pm) 0.00 0.00 0.00 [0369] Comments: Formulation 5 is a single phase composition that provides a stable vehicle for menthol crystals that can generate good quality foam capable of withstanding 3000rpm and having a collapse time in excess of 5 minutes. The surfactants, adjuvant and a polymeric agent provide viscosity support and aid foaming. The other two formulations 6 and 7 are stable oil in water emulsions that can generate good quality foam, are resistant to centrifugation at 3000rpm and have a collapse time in excess of 5 minutes. All the formulations can accommodate substantial amounts of cooling sensation agent. In an embodiment the cooling agent is a combination of at least two cooling agents. In a further embodiment the cooling agent may be used in combination with a soothing agent. The coal tar formulation is yellow prior to addition of the propellant but upon discharge from the canister and release as a foam the color is dissipated such that the foam is only slightly yellow, which may be an advantage for its use.
Warming Example 14 - A waterless PG formulation and two oil in water emulsion formulations containing capsaicin as warming agent cf example 11 cf example 9 MCT 8.00 Mineral oil 5.00 Isopropyl myristate 5.00 Stearic acid 2.00 Stearyl alcohol 1.00 Cetostearyl alcohol Steareth 2 6.70 2.00 Steareth-21 1.80 Glyceryl monostearate 1.80 PEG-40 stearate 1.50 Xanthan gum 0.30 0.23 Methocell k1 00M 0.30 0.23 Water 77.87 82.21 Capsaicin 0.03 0.03 0.03 Propylene Glycol 3.00 3.00 97.97 Total: 100.00 100.00 100.00 Propellant (AP-70) 8.00 8.00 8.00 Results PFF
Viscosity 18636.03 1085.77 4367.07 Centrifgation 1 K stable Stable stable Centrifgation 3K stable Stable stable FOAM
Quality G-E G-E G-E
Color White White White Collapse time (sec.) >300/FG >300/FG >300/G
Density (gr/ml) 0.078 0.036 0.048 Bubble size (pm) 78 96 85 Bubble size (%-above 500 pm) 0.00 0.00 0.00 temperature MINUTES=13C
change T-5 MINUTES=14C
Foam Temperature Effects [0357] In the Examples hereinbelow, the following test was performed to see if there were any temperature changes to a surface onto which a foam was placed:
1. Place a thermometer in a clean glass vial and allow it to come to equilibrium.
2. Measure and record the temperature.
3. Release foam about 5gm onto the thermometer.
4. Observe temperature for 300 sec.
The procedure was performed on regular; different cooling and heating foam formulations (per examples below).
Results: For all foams tested by the above method as seen in the examples hereinbelow, no detectable significant temperature difference was noted between the surface temperature, foam temperature and ambient initial temperature. This is indicative that the foams produced in the examples below did not exhibit a measurable exothermic or endothermic reaction. Thus, the foams tested should not induce a significant temperature effect at the target site primarily due to the cooling effect of the propellant. In certain embodiments, it may be possible for there to be an interaction between chemicals in the skin or other target site and the foam composition, particularly for the non-aqueous compositions. For example, by moisture in the skin being absorbed by hygroscopic pharmaceutical recipients, like glycols. Nevertheless, a main aim is to deliver a sensation via a foam vehicle, where the prime sensation is due to pharmaceutical stimulation rather than an actual physical effect. In one or more embodiments, the sensation may be a combination of pharmaceutical stimulation and physical effect. For example, where an excess of propellant may provide an initial physical cooling and the sensation agent provides a prolonged sensation, without further cooling. The vehicles disclosed herein are adapted to provide the main sensation with or without an initial physical cooling sensation.
SECTION A
COOLING
Example 1- Emollient Emulsion Foamable Composition with 10% Menthol Crystals and Avocado Oil a) Formulation Ingredient Name Function % w/w Avocado oil emollient and solvent 10 PEG 40 Stearate Stabilizing emulsifier 2.31 Stearyl Alcohol Co-emulsifier and foam stabilizer 0.77 Isopropyl myristate emollient 4.62 Mineral Oil Emollient 4.62 Hypromellose Stabilizing polymers 0.23 Xanthan gum Stabilizing polymers 0.23 Polysorbate 80 Stabilizing emulsifier 0.77 GMS Co-emulsifier foam stabilizer 0.39 Menthol Cooling agent 10 Water Solvent to 100 Propane/butane/isobutane 8 Foam quality Excellent Color White Odor Menthol Density /cm3 0.045 Shakability Good pH 6.63 Collapse time [seconds] >300 b) Emollient + avocado oil +10% menthol crystals: Mean cooling effect on three subjects over time is 12.7 Time Score 0 2.00 5' 1.33 15' 2.33 30' 2.00 60' 2.00 120' 1.33 after washing 1.67 Sum total of points for this formulation for all subjects is: 38 c) Emollient + avocado oil +10% menthol crystals: Foam satisfaction Parameters Ease of skin stickiness odor oily residue foam Shiny overall application absorption stability Look satisfaction 3.3 2.7 4.0 3.0 3.7 3.3 3.3 3.7 Sum total of points for this formulation for all subjects is: 107 [0358] Comments: Emollient emulsion foam provided a reasonable and prolonged cooling sensation; excellent foam quality; moisturizing; Comprises an oil phase, a water phase, a surfactant combination supported by co emulsifiers and a combination of polymeric agents. The co emulsifiers are non essential and can be omitted although some adjustment may be needed to the surfactant combination as will be appreciated by someone skilled in the art.
Note: The propellant can be added at a concentration of about 3% to about 25%
or more.
Example 2- Emollient Emulsion Foamable Composition with 10% Menthol Crystals and Avocado Oil and 15% Ethanol a) Emollient +10% menthol crystals +15% ethanol: Formulation Ingredient Name Function % w/w Avocado oil emollient and solvent 10 PEG 40 Stearate Stabilizing emulsifier 2.31 Stearyl Alcohol Co-emulsifier and foam stabilizer 0.77 Isopropyl myristate emollient 4.62 Mineral Oil Emollient 4.62 hypromellose Stabilizing polymers 0.23 xanthan gum Stabilizing polymers 0.23 Polysorbate 80 Stabilizing emulsifier 0.77 GMS Co-emulsifier foam stabilizer 0.39 Menthol Cooling agent 10 ETHANOL Solvent - penetration enhancer 15 Water Solvent to 100 Propane/butane/isobutane 8 Foam quality Good Color White Odor Menthol Density /cm 0.044 Shakability Moderate pH 5.89 Collapse time [seconds] 300 b) Emollient + avocado oil +10% menthol crystals + 15% ethanol: Mean cooling effect on four subjects over time is 13.34 Time Score 0 1.75 5' 1.875 15' 2.5 30' 2.75 60' 2.25 120' 1.25 after washing 1 Sum total of points for this formulation for all subjects is: 53.5 c) Emollient + avocado oil +10% menthol crystals + 15% ethanol: Foam satisfaction Parameters Ease of skin stickiness odor oily foam Shiny overall application absorption residue stability Look satisfaction 4.25 3.75 5 4 4.25 3.75 2 4 Sum total of points for this formulation for all subjects is: 124 [0359] Comments: Emollient foam provided reasonable and prolonged cooling sensation; good foam quality; moisturizing; Comprises an oil phase, water phase, surfactant combination supported by co emulsifiers and a combination of polymeric agents plus a polar solvent as a penetration enhancer. Menthol in the above formulation achieves good penetration on its own so the presence of 15% ethanol is of only marginal effect. Ethanol is not essential and may be omitted or replaced by other penetrating agents such as transcutol; DMI; and the like. See section on penetration agents.
Note: The propellant can be added at a concentration of about 3% to about 25%
or more.
Example 3- Emollient Emulsion Foamable Composition with 15% Menthol Crystals a) Formulation Ingredient Name Function % w/w Capric/caprilic triglyceride Emollient and solvent 6 Stearic acid Co-emulsifier and foam stabilizer 2 hypromellose Stabilizing polymers 0.3 xanthan gum Stabilizing polymers 0.3 Steareth-2 Stabilizing emulsifier 2.5 Steareth-21 Stabilizing emulsifier 3 Menthol Cooling agent 15 Propylene Glycol Solvent; moisturizer; penetration 3 enhancer Ingredient Name Function % w/w Water solvent To 100 Propane/butane/isobutane 8 Foam quality Good Color White Odor Menthol -Density /cm3 0.025 Shakabilit Moderate H 6.26 -Collapse time [seconds] >300 b) Emollient +15% menthol crystals: Mean cooling effect on four subjects over time is 13.88 Time Score 0 1.375 5' 2 15' 3.25 30' 3.5 60' 2.5 120' 1.25 after washing 1.25 Sum total of points for this formulation for all subjects is 60.5 c) Emollient +15% menthol crystals: Foam satisfaction Parameters Ease of skin stickiness odor oily foam Shiny overall application absorption residue stability Look satisfaction 4 4 3.5 3.75 3.5 4.5 2.75 3.75 Sum total of points for this formulation for all subjects is: 119 [0360] Comments: Emollient foam provided excellent and prolonged cooling sensation; good foam quality; moisturizing. Comprises an oil phase, a water phase, a surfactant combination supported by a co-emulsifier and a combination of polymeric agents. The propylene glycol is non essential.
Note: The propellant can be added at a concentration of about 3% to about 25%
or more.
Example 4- Emollient Emulsion Foamable Composition with 15% Peppermint Oil a) Formulation CTFA Name Function % w/w Ca ric/ca rilic Tri I ceride Emollient and solvent 6 Stearic acid Co-emulsifier and foam stabilizer 2 hypromellose Stabilizing polymers 0.3 xanthan gum Stabilizing polymers 0.3 Steareth-2 Stabilizing emulsifier 2.5 Steareth-21 Stabilizing emulsifier 3 PEPPERMINT OIL Cooling agent 15 Propylene Glycol Solvent / moisturizer / penetration 3 enhancer Permulen 0.1 TEA To pH 7 Water solvent To 100 Propane/butane/isobutane 8 Foam quality Good Color White Odor Menthol Density /cm 0.028 Shakability Low pH 6.17 Collapse time [seconds] >300 b) Emollient +15% peppermint oil: Mean cooling effect on four subjects over time is 11.75 Time Score 0 1.75 5' 1.5 15' 2.25 30' 2.5 60' 1.75 120' 1 after washing 1 Sum total of points for this formulation for all subjects is: 47 c) Emollient +15% peppermint oil Foam satisfaction Parameters Ease of skin stickiness odor oily foam Shiny overall application absorption residue stability Look satisfaction 4 3.75 4 3.25 3.75 4.5 3.25 3.75 Sum total of points for this formulation for all subjects is: 121 [0361] Comments: Emollient foam provided reasonable and prolonged cooling sensation; good foam quality; moisturizing; Comprises an oil phase, a water phase, a surfactant combination supported by a co-emulsifier and a combination of polymeric agents. The propylene glycol is non-essential. The peppermint oil reduces the viscosity of the emulsion and is matrix destabilizing.
Note: The propellant can be added at a concentration of about 3% to about 25%
or more.
Example 5- Emollient Emulsion Foamable Composition with 15% Menthol Crystals and 25% propellant a) Formulation Ingredient name Function % w/w Stearic acid * Co-emulsifier and foam 3 stabilizer Steareth-2 * Stabilizing emulsifier 2 Steareth-21 * Stabilizing emulsifier 3 Methylcellulose * Co-emulsifier and foam 0.3 stabilizer Xanthan gum * Co-emulsifier and foam 0.3 stabilizer Menthol crystal Cooling agent 15 Water * Solvent To 100 Glyceryl monostearete Co-emulsifier foam stabilizer 2 Propellant 25 Pro ane/Butane/Isobutane b) Emollient +25% propellant + Menthol crystals: Mean cooling effect on four subjects over time Time Score 0 1.7 5' 1.0 15' 2.3 30' 2.7 60' 1.7 120' 1.3 after washing 1.0 Sum total of points for this formulation for all subjects is: 37 c) Emollient +25% propellant + Menthol crystals: Foam satisfaction Parameters Ease of skin stickiness odor oily foam Shiny overall application absorption residue stability Look satisfaction 4.0 3.3 3.0 3.0 3.0 3.0 4.0 3.7 Sum total of points for this formulation for all subjects is: 76 [0362] Comments: Emollient foam provided good cooling sensation; good foam quality; doesn't require preservative.
Note: The propellant can be added at a concentration of about 3% to about 25%
or more.
Example 6- Waterless Foamable Composition with 15% Menthol Crystals (Formula number - 28) a) Formulation Ingredient Name Function % w/w PEG 4000 Firming wax 7.5 Stearic acid Co-emulsifier and foam stabilizer 2 H droxuprop l cellulose Stabilizing polymers 2 Steareth-2 Stabilizing emulsifier 2.5 Steareth-21 Stabilizing emulsifier 3 Menthol Cooling agent 15 Propylene Glycol Solvent / moisturizer / penetration 68 enhancer Propane/butane/isobutane 8 Foam quality Fairly good Color White Odor Menthol b) Mean cooling effect on four subjects over time Time Score 5' 1.125 15' 1.375 30' 2 60' 2.5 120' 1.5 after washing 1 Sum total of points for this formulation for all subjects is: 42 c) Foam satisfaction Parameters Ease of skin stickiness odor oily foam Shiny overall application absorption residue stability Look satisfaction 4 2.5 3.25 3.75 2 1 1.75 2.25 Sum total of points for this formulation for all subjects is: 82 [0363] Comments: Waterless foam provided reasonable and prolonged cooling sensation with a delayed onset; fairly good foam quality; moisturizing;
doesn't require preservative. Any high molecular weight PEG (for example 1500, 2000, 4000, 6000 or 8000) or combinations of high molecular weight PEG with lower molecular weight PEG
(for example 200, 400, 600) may be used.
Note: The propellant can be added at a concentration of about 3% to about 25%
or more.
Example 7- Waterless Foamable Composition with 10% Peppermint Oil (Formula number - 32) a) Formulation Ingredient Name Function % w/w PEG 4000 Firming wax 7.5 Stearic acid Co-emulsifier and foam stabilizer 2 Hydroxypropyl cellulose Stabilizing polymers 2 Steareth-2 Stabilizing emulsifier 2.5 Steareth-21 Stabilizing emulsifier 3 PEPPERMINT OIL Cooling agent 10 Propylene Glycol Solvent / moisturizer - penetration 73 enhancer Propane/butane/isobutane 8 Foam quality Fairy good Color White Odor Menthol Cooling score 7- of total points for this formulation from all people) 36 a) Mean cooling effect on Four subjects over time is 9 Time Score 5' 1 15' 1.75 30' 2 60' 1.25 120' 1 after washing 1 Sum total of points for this formulation for all subjects is: 36 c) Foam satisfaction Parameters Ease of skin stickiness odor oily foam Shiny overall application absorption residue stability Look satisfaction 4 3 3.25 3.5 2.25 3.5 2.5 3 Sum total of points for this formulation for all subjects is: 100 [0364] Comments: Waterless foam provided reasonable and medium term cooling sensation with delayed onset; fairly good foam quality; moisturizing; doesn't require preservative. Any high molecular weight PEG (for example 1500, 2000, 4000, 6000 or 8000) or combinations of high molecular weight PEG with lower molecular weight PEG
(for example 200, 400, 600) may be used. The peppermint oil has a thinning effect on the composition, which is to some extent counterbalanced or ameliorated by the high molecular weight PEG.
Note: The propellant can be added at a concentration of about 3% to about 25%
or more.
RELAXING OR SOOTHING
Example 8- Emollient Emulsion Foamable Relaxing or Soothing Composition with Hamamelis w/w Mineral oil 6.00 Isopropyl myristate 6.00 GI cer l monostearate 0.50 Stearyl alcohol 1.00 Xanthan gum 0.30 Methocel K100M 0.30 Polysorbate 80 1.00 PEG-40 stearate 3.00 Hamamelis glycerin fluid extract (Alban Muller, France) 10.00 EDTA disodium 0.20 Phenonip 0.30 Water pure to 100.0 Propellant (propane and butane 20:80) 8.0 Foam quality Excellent Density /cm3 0.04 Collapse time >120 Shakability Yes Odor slight [0365] Comments: Emollient foam capable of providing a soothing sensation;
excellent foam quality; moisturizing. It comprises an oil phase, water phase, a surfactant combination supported by co emulsifiers and a combination of polymeric agents, plus a preservative and a chelating agent. The chelating agent is non essential. The co emulsifiers are non essential and can be omitted although some adjustment may be needed to the surfactant combination as will be appreciated by someone skilled in the art.
Note: The propellant can be added at a concentration of about 3% to about 25%
or more.
WARMING
Example 9- Prophetic Emollient Emulsion Foamable Warming Composition with Capsaicin and Mineral Oil Ingredient name %w/w Mineral oil 4.62 Isopropyl myristate 4.62 Glyceryl monostearate 0.39 Polysorbate 80 0.77 PEG-40 stearate 2.31 Stearyl alcohol 0.77 Hydroxypropyl methylcellulose 0.23 Xanthan 0.23 Water TO 100 Capsaicin 0.025 Total: 100.00 Propellant (Propane/Butane/Isobutane) 8 Example 10- Prophetic Waterless Foamable Warming Composition with Capsaicin Ingredient name %w/w PEG 4000 7.5 Capsaicin 0.025 H drox ro l cellulose 2 Stearic acid 2 Steareth-2 2.5 Steareth-21 3 Propylene glycol To 100 ,Propellant Pro ane/Butane/Isobutane 8 Example 11- Prophetic Emollient Emulsion Foamable Warming Composition with Capsaicin and MCT
Ingredient name %w/w Stearic acid 2 Steareth 2 2.5 Steareth-21 3 Capsaicin 0.025 Propylene Glycol 3 Xanthan gum 0.3 Hypromellose 0.3 Water To 100 Propellant Pro ane/Butane/Isobutane 8 [0366] Comments:
- It is possible to use any of the above exemplary warming formulations with other warming agents, for example, methyl salicylate. Apart from its warming effect methyl salicylate is an analgesic and counter irritant. Lists of applicable warming agents are described in the specification. An effective amount of the warming agent is introduced into the formulation in place of capsaicin and the amount of the main carrier is adjusted to bring the formulation to 100%, which in the case of the waterless composition is propylene glycol and in the case of the emollient emulsion composition is water. The amount of methyl salicylate is of the order of 5 to 10%.
- It is also possible to use combinations of warming agents. The combination of capsaicin with methyl salicylate, for example, may be useful. Methyl salicylate has a quick onset whilst capsaicin does not so a combination may be helpful in cases where pain relief is sought.
- It is also possible to modulate, potentate, increase, reduce, or ameliorate the warming effect by introducing into the composition a sensation modifying agent. I an embodiment the warming effect or sensation maybe reduced by addition of a cooling agent in the composition.
- The formulations may contain polar solvents, which contribute to skin penetration of an active agent FOAM WITH ADDITIONAL THERAPEUTIC AGENTS
Example 12 -Foamable Oil In Water Emulsion Foamable Compositions, Containing Menthol As Cooling Agent And Coal Tar Extract And Salicylic Acid As Additional Therapeutic Agents Ingredient name CTR005 CTR006 %W/W %W/W
Menthol (Sensation modifying agent) 1 1 Coal tar extract (Additional therapeutic agent) 10 10 Salicylic acid (Additional therapeutic agent) 5 Hydrocortisone (Additional therapeutic agent) 1 PPG-15 Stearyl ether -- 3 Isopropyl Myristate 10 5 Octyldodecanol 12 12 Stearyl Alcohol 2 1 Glycerin -- 3 Lanolin -- 2 Laureth-4 -- 2 Emulgin B2 -- 1.5 Glyceryl Stearate 1.5 --Ingredient name CTR005 CTR006 %W/W %W/W
PEG-40 Stearate 3 --CMC -- 0.5 Methocel K100M 0.28 --Xanthan gum 0.28 --Propylene Glycol -- 5 Polysorbate 60 1 --Water, purified To 100 To 100 Propellant 8 8 [0367] Comments: The above formulations provided excellent moisturizing emollient foams with improved sensation by ameliorating the negative sensation effect of coal tar.
Section B
Cooling Example 13 A) Waterless propylene glycol formulation containing peppermint oil as cooling agent Steareth 2 2.00 polysorbate 80 2.00 GI cer l monostearate 2.00 H drox ro l cellulose 1.00 peppermint oil 10.00 Propylene Glycol 83.00 Total: 100.00 Propellant (AP-70) 8.00 Results PFF
Viscosity 148.97 Centrifgation 1 K stable Centrifgation 3K stable FOAM
Quality G-E
Color White Collapse time (sec.) 95/F
Density (gr/ml) 0.070 Bubble size (pm) 180 Bubble size (%-above 500 pm) 6.30 temperature change T-0 MINUTES=13 C
T-5 MINUTES=12 C
*G-E =Good to Excellent [0368] Comments: This waterless single phase formulation provides a stable vehicle for peppermint oil that can generate good quality foam and which can withstand 3000rpm.
The surfactants and a polymeric agent provide viscosity support and aid foaming. On forming foam there is no significant temperature change when measured on a glass surface. When the formulation is applied to the skin, however, the peppermint oil provides a sensation of cooling, which may be potentiated by the evaporation of propellant and the lower temperature of the foam compared to the skin.
B) A waterless PG formulation and two oil in water emulsion formulations containing menthol crystals as cooling agent cf example 3 cf example 12 MCT 6.00 Isopropyl myristate 10.00 Octyldodecanol 10.00 Stearic acid 2.00 Stearyl alcohol 2.00 Cetostearyl alcohol 2.00 Steareth 2 2.00 4.20 Steareth-21 1.40 polysorbate 80 2.00 Glyceryl monostearate 2.00 1.40 PEG-40 stearate 3.10 Polysorbate 60 1.20 Xanthan gum 0.30 0.28 Methocell k100M 0.30 0.28 Hydroxypropyl cellulose 1.00 Water 67.80 59.74 menthol crystals 10.00 15.00 1.00 Propylene Glycol 81.00 3.00 Coal tar 10.00 Hydrocortisone butyrate 1.00 Total: 100.00 100.00 100.00 Propellant (AP-70) 8.00 8.00 8.00 Results PFF
Viscosity 4447.05 4527.04 2037.57 Centrifgation 1 K stable Stable stable Centrifgation 3K stable Stable stable FOAM
Quality G-E G-E G-E
Color White White Slightly Yellow Collapse time (sec.) >300/G >300/FG >300/FG
Density (gr/ml) 0.060 0.043 0.039 Bubble size (pm) 62 99 112 Bubble size (%-above 500 pm) 0.00 0.00 0.00 [0369] Comments: Formulation 5 is a single phase composition that provides a stable vehicle for menthol crystals that can generate good quality foam capable of withstanding 3000rpm and having a collapse time in excess of 5 minutes. The surfactants, adjuvant and a polymeric agent provide viscosity support and aid foaming. The other two formulations 6 and 7 are stable oil in water emulsions that can generate good quality foam, are resistant to centrifugation at 3000rpm and have a collapse time in excess of 5 minutes. All the formulations can accommodate substantial amounts of cooling sensation agent. In an embodiment the cooling agent is a combination of at least two cooling agents. In a further embodiment the cooling agent may be used in combination with a soothing agent. The coal tar formulation is yellow prior to addition of the propellant but upon discharge from the canister and release as a foam the color is dissipated such that the foam is only slightly yellow, which may be an advantage for its use.
Warming Example 14 - A waterless PG formulation and two oil in water emulsion formulations containing capsaicin as warming agent cf example 11 cf example 9 MCT 8.00 Mineral oil 5.00 Isopropyl myristate 5.00 Stearic acid 2.00 Stearyl alcohol 1.00 Cetostearyl alcohol Steareth 2 6.70 2.00 Steareth-21 1.80 Glyceryl monostearate 1.80 PEG-40 stearate 1.50 Xanthan gum 0.30 0.23 Methocell k1 00M 0.30 0.23 Water 77.87 82.21 Capsaicin 0.03 0.03 0.03 Propylene Glycol 3.00 3.00 97.97 Total: 100.00 100.00 100.00 Propellant (AP-70) 8.00 8.00 8.00 Results PFF
Viscosity 18636.03 1085.77 4367.07 Centrifgation 1 K stable Stable stable Centrifgation 3K stable Stable stable FOAM
Quality G-E G-E G-E
Color White White White Collapse time (sec.) >300/FG >300/FG >300/G
Density (gr/ml) 0.078 0.036 0.048 Bubble size (pm) 78 96 85 Bubble size (%-above 500 pm) 0.00 0.00 0.00 temperature MINUTES=13C
change T-5 MINUTES=14C
[0370] Comments: Formulation 3 is a waterless single phase composition that provides a stable vehicle for capsaicin that can generate good quality foam capable of withstanding 3000rpm and having a collapse time in excess of 5 minutes. The surfactants, adjuvant and a polymeric agent provide viscosity support and aid foaming.
The other two formulations 1 and 2 are stable oil in water emulsions that can generate good quality foam, are resistant to centrifugation at 3000rpm and have a collapse time in excess of 5 minutes. On forming foam there is no significant temperature change when measured on a glass surface. When the formulation is applied to the skin, however, the capsaicin should provide a sensation of warming.
In an embodiment the warming agent is a combination of at least two warming agents. In a further embodiment the warming agent may be used in combination with a soothing agent.
Soothing Example 15 A) Two oil in water stable emulsion formulations containing ginger oil as soothing agent Cetostearyl alcohol 2.00 Steareth 2 1.40 Steareth-21 4.50 polysorbate 80 1.40 GI cer l monostearate 1.30 PEG-40 stearate 1.80 Xanthan gum 0.30 0.30 Methocell k1 00M 0.30 0.30 Avicel RC581 Water 84.90 81.50 ginger oil 10.00 10.00 Total: 100.00 100.00 Propellant (AP-70) 8.00 8.00 Results PFF
Viscosity 4399.06 1150.75 Centrifgation 1 K stable stable Centrifgation 3K stable stable FOAM
Quality FG G-E
Color slight yellow Off-white Collapse time (sec.) 30/F >300/G
Density (gr/ml) 0.034 Bubble size (pm) 105 Bubble size (%-above 500 pm) 0.00 temperature change T-0 MINUTES=13C
T-5 MINUTES=13C
The other two formulations 1 and 2 are stable oil in water emulsions that can generate good quality foam, are resistant to centrifugation at 3000rpm and have a collapse time in excess of 5 minutes. On forming foam there is no significant temperature change when measured on a glass surface. When the formulation is applied to the skin, however, the capsaicin should provide a sensation of warming.
In an embodiment the warming agent is a combination of at least two warming agents. In a further embodiment the warming agent may be used in combination with a soothing agent.
Soothing Example 15 A) Two oil in water stable emulsion formulations containing ginger oil as soothing agent Cetostearyl alcohol 2.00 Steareth 2 1.40 Steareth-21 4.50 polysorbate 80 1.40 GI cer l monostearate 1.30 PEG-40 stearate 1.80 Xanthan gum 0.30 0.30 Methocell k1 00M 0.30 0.30 Avicel RC581 Water 84.90 81.50 ginger oil 10.00 10.00 Total: 100.00 100.00 Propellant (AP-70) 8.00 8.00 Results PFF
Viscosity 4399.06 1150.75 Centrifgation 1 K stable stable Centrifgation 3K stable stable FOAM
Quality FG G-E
Color slight yellow Off-white Collapse time (sec.) 30/F >300/G
Density (gr/ml) 0.034 Bubble size (pm) 105 Bubble size (%-above 500 pm) 0.00 temperature change T-0 MINUTES=13C
T-5 MINUTES=13C
[0371] Comments: By altering the surfactant mix a good quality foam was generated that is resistant to centrifugation and has a collapse time in excess of 5 minutes. The vehicle is capable of supporting substantial amounts of ginger oil. On forming foam there is no significant temperature change when measured on a glass surface. When the formulation is applied to the skin, however, the ginger oil should provide a sensation of soothing.
B) Gel formulation containing aloe vera as soothing agent polysorbate 80 2.00 4.00 Avicel RC581 2.00 4.00 Water 94.00 65.00 Aloe vera 2.00 2.00 Diethylene glycol monoethyl ether 25.00 Total: 100.00 100.00 Propellant (AP-70) 8.00 Results PFF
Viscosity 39.99 2273.51 Centrifgation 1 K not stable not stable Centrifgation 3K not stable not stable FOAM
Quality G-E G-E
Color White White Collapse time (sec.) 95/F 140/F
Density (gr/ml) 0.044 0.034 Bubble size (pm) 131 113 Bubble size (%-above 500 pm) 0.00 0.00 [0372] Comments: These water gel formulations are single phase compositions that provide a vehicle for aloe vera that can generate good quality foam having a collapse time in excess of 1.5 minutes. When the formulation is applied to the skin, the aloe vera should provide a sensation of soothing. In an embodiment the soothing agent is a combination of at least two soothing agents. In a further embodiment the soothing agent may be used in combination with a cooling agent or with a warming agent.
C) Emollient emulsion formulation containing aloe vera as soothing agent Mineral oil 11.00 Cetostearyl alcohol 2.00 Steareth 2 4.30 Steareth-21 2.90 Xanthan gum 0.30 Methocell k100M 0.30 Water 77.20 Aloe vera 2.00 Total: 100.00 Propellant (AP-70) 8.00 Results PFF
Viscosity 18300.10 Centrifgation 1 K stable Centrifgation 3K Stable FOAM
Quality G-E
Color White Odor Characteris.odor Collapse time (sec.) >300/G
Density (gr/ml) 0.070 Bubble size (pm) 48 Bubble size (%-above 500 pm) 0.00 [0373] Comments: These emollient emulsion formulations provide a vehicle for aloe vera that can generate good quality foam having a collapse time in excess of 5 minutes and is stable to centrifugation. When the formulation is applied to the skin, the aloe vera should provide a sensation of soothing. In an embodiment the soothing agent is a combination of at least two soothing agents. In a further embodiment the soothing agent may be used in combination with a cooling agent or with a warming agent.
B) Gel formulation containing aloe vera as soothing agent polysorbate 80 2.00 4.00 Avicel RC581 2.00 4.00 Water 94.00 65.00 Aloe vera 2.00 2.00 Diethylene glycol monoethyl ether 25.00 Total: 100.00 100.00 Propellant (AP-70) 8.00 Results PFF
Viscosity 39.99 2273.51 Centrifgation 1 K not stable not stable Centrifgation 3K not stable not stable FOAM
Quality G-E G-E
Color White White Collapse time (sec.) 95/F 140/F
Density (gr/ml) 0.044 0.034 Bubble size (pm) 131 113 Bubble size (%-above 500 pm) 0.00 0.00 [0372] Comments: These water gel formulations are single phase compositions that provide a vehicle for aloe vera that can generate good quality foam having a collapse time in excess of 1.5 minutes. When the formulation is applied to the skin, the aloe vera should provide a sensation of soothing. In an embodiment the soothing agent is a combination of at least two soothing agents. In a further embodiment the soothing agent may be used in combination with a cooling agent or with a warming agent.
C) Emollient emulsion formulation containing aloe vera as soothing agent Mineral oil 11.00 Cetostearyl alcohol 2.00 Steareth 2 4.30 Steareth-21 2.90 Xanthan gum 0.30 Methocell k100M 0.30 Water 77.20 Aloe vera 2.00 Total: 100.00 Propellant (AP-70) 8.00 Results PFF
Viscosity 18300.10 Centrifgation 1 K stable Centrifgation 3K Stable FOAM
Quality G-E
Color White Odor Characteris.odor Collapse time (sec.) >300/G
Density (gr/ml) 0.070 Bubble size (pm) 48 Bubble size (%-above 500 pm) 0.00 [0373] Comments: These emollient emulsion formulations provide a vehicle for aloe vera that can generate good quality foam having a collapse time in excess of 5 minutes and is stable to centrifugation. When the formulation is applied to the skin, the aloe vera should provide a sensation of soothing. In an embodiment the soothing agent is a combination of at least two soothing agents. In a further embodiment the soothing agent may be used in combination with a cooling agent or with a warming agent.
[0374] The references cited herein teach many principles that are applicable to the present invention. Therefore the full contents of these publications are incorporated by reference herein where appropriate for teachings of additional or alternative details, features and/or technical background.
[0375] It is appreciated that certain features, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable subcombination. Although the invention has been described in conjunction with specific embodiments thereof, it is evident that many alternatives, modifications and variations will be apparent to those skilled in the art.
Claims (58)
1. A composition that provides to a subject at least one sensation for a sustained period of time following application to the skin, the composition comprising:
a. at least one sensation or sensation modifying agent, comprising one or more of a cooling agent, a warming agent, a relaxing or soothing agent, and a stimulating or refreshing agent;
b. a foamable carrier; and c. a propellant having a concentration about 3% to about 45% by weight of the total composition;
wherein the composition is stored in an aerosol container and upon release expands to form a non-crackling short term stable foam.
a. at least one sensation or sensation modifying agent, comprising one or more of a cooling agent, a warming agent, a relaxing or soothing agent, and a stimulating or refreshing agent;
b. a foamable carrier; and c. a propellant having a concentration about 3% to about 45% by weight of the total composition;
wherein the composition is stored in an aerosol container and upon release expands to form a non-crackling short term stable foam.
2. A composition according to claim 1, wherein the sensation is provided at a delivery site of the subject.
3. A composition according to claim 1 or claim 2, wherein upon contact at a delivery site the sustained sensation is not primarily due to the propellant or an exothermic reaction.
4. A composition according to any of claims 1 to 3, wherein the foamable carrier is resistant to aging and/or suitable for delivery of at least one sensation or sensation modifying agent.
5. A composition according to any of claims 1 to 4, wherein a relaxing or soothing agent comprises a herb extract, an astringent, a sea weed extract, an oat extract, an oil, a waxy or unctuous substance, a mineral, a vitamin, a pharmaceutical agent, menthol, camphor, eugenol, eucalyptol, safrol, methyl salicylate, menthyl lactate, menthyl ethoxyacetate, menthone glycerinacetal, 3-1-menthoxypropane-1,2-diol, ethyl I-menthyl carbonate, (1S,3S,4R)-p-menth-8-en-3-ol, menthyl pyrrolidone carboxylate, an N-substituted-p-menthane-3-carboxamide, hamamelis extract, ginger oil, or any mixture of two or more thereof.
6. A composition according to claim 5, wherein a herb extract comprises one or more of aloe vera, alpha bisabolol, D-panthenol, allantoin, hamamelis, chamomile, and yarrow.
7. A composition according to claim 5, wherein an astringent comprises one or more of calendula, comfrey, and witch hazel.
8. A composition according to claim 5, wherein an oil comprises one or more of almond oil, avocado oil, cardamone, eucalyptus, mentha piperita (peppermint), hyssop, and rosemary.
9. A composition according to claim 5, wherein a waxy or unctuous substance comprises one or more of lanolin and petrolatum (e g , vaseline jelly).
10. A composition according to claim 5, wherein a mineral comprises one or more of zinc oxide, calamine and selenium.
11. A composition according to claim 5, wherein a vitamin comprises tocopheryl acetate.
12. A composition according to claim 5, wherein a pharmaceutical agent comprises one or more of an analgesic, an anesthetic, an anti-inflammatory agent, an antihistamine, and a muscle relaxant.
13. A composition according to any of claims 1 to 4, wherein a stimulating or refreshing agent comprises an alcohol, L-menthol, camphor, menthe oil, capsicum extract, capsaicin, benzyl nicotinate, salicylate, glycol salicylate, acetyl choline, serotonin, histamine, a prostaglandin, a neurotransmitter; a CNS stimulant, caffeine, quinine, or any mixture of two or more thereof.
14. A composition according to any of claims 1 to 13, wherein said foamable carrier comprises about 40% to about 99% by weight of the total composition, excluding the propellant, and is an aqueous emulsion, an aqueous gel, or a non-aqueous carrier.
15. A composition according to any of claims 1 to 14, wherein said foamable carrier comprises a. at least one surface active agent at a concentration of about 0.1% to about 10% by weight of the carrier;
b. at least one polymeric agent at a concentration of about 0.1% to about 5%
by weight of the total composition; and c. at least one non-aqueous solvent.
b. at least one polymeric agent at a concentration of about 0.1% to about 5%
by weight of the total composition; and c. at least one non-aqueous solvent.
16. A composition according to claim 15, wherein said foamable carrier further comprises one or more of:
a. a co-emulsifier or foam stabilizer at a concentration of about 0.1% to about 5%
by weight of the total composition;
b. a wax, viscosity, bulking or firming agent at a concentration of about 0.1%
to about 15% by weight of the total composition;
c. a co-solvent at a concentration of about 0.1% to about 20% by weight of the total composition;
d. a penetration enhancer or potent solvent at a concentration of about 0.1%
to about 25% by weight of the total composition;
e. a foam adjuvant agent, comprising a fatty alcohol having 15 or more carbons in the carbon chain, or a fatty acid having 16 or more carbons in the carbon chain, at a concentration of about 0.1% to about 25% by weight of the total composition;
f. a stabilizer at a concentration of about 5% to about 30% by weight of the total composition; and g. an agent providing an occlusive effect, at a concentration of about 5% to about 30% by weight of the total composition.
a. a co-emulsifier or foam stabilizer at a concentration of about 0.1% to about 5%
by weight of the total composition;
b. a wax, viscosity, bulking or firming agent at a concentration of about 0.1%
to about 15% by weight of the total composition;
c. a co-solvent at a concentration of about 0.1% to about 20% by weight of the total composition;
d. a penetration enhancer or potent solvent at a concentration of about 0.1%
to about 25% by weight of the total composition;
e. a foam adjuvant agent, comprising a fatty alcohol having 15 or more carbons in the carbon chain, or a fatty acid having 16 or more carbons in the carbon chain, at a concentration of about 0.1% to about 25% by weight of the total composition;
f. a stabilizer at a concentration of about 5% to about 30% by weight of the total composition; and g. an agent providing an occlusive effect, at a concentration of about 5% to about 30% by weight of the total composition.
17. A composition according to any of claims 1 to 16, further comprising at least one additional active agent, which is a cosmetic active agent or a pharmaceutical active agent having a cosmetic or pharmaceutical effect other than a sensation or sensation modifying effect.
18. A composition according to claim 17, wherein the at least one additional active agent comprises at least one of an active herbal extract, an acaricide, an age spot and keratosis removing agent, an allergen, an analgesic, a local anesthetic, an antiacne agent, an antiallergic agent, an antiaging agent, an antibacterial, an antibiotic, an antiburn agent, an anticancer agent, an antidandruff agent, an antidepressant, an antidermatitis agent, an antiedemic, an antihistamine, an antihelminth, an antihyperkeratolytic agent, an antiinflammatory agent, an antiirritant, an antilipemic, an antimicrobial, an antimycotic, an antiproliferative agent, an antioxidant, an anti-wrinkle agent, an antipruritic, an antipsoriatic agent, an antirosacea agent, an antiseborrheic agent, an antiseptic, an antiswelling agent, an antiviral agent, an anti-yeast agent, an astringent, a topical cardiovascular agent, a chemotherapeutic agent, coal tar or an extract thereof, a corticosteroid, a dicarboxylic acid, a disinfectant, a fungicide, a hair growth regulator, a hormone, a hydroxy acid, an immunosuppressant, an immunoregulating agent, an insecticide, an insect repellent, a keratolytic agent, a lactam, a metal, a metal oxide, a mitocide, a neuropeptide, a non-steroidal anti-inflammatory agent, an oxidizing agent, a pediculicide, a photodynamic therapy agent, a retinoid, a sanative, a scabicide, a self tanning agent, a skin whitening agent, a vasoconstrictor, a vasodilator, a vitamin, a vitamin derivative, vitamin A or a derivative thereof, vitamin D or a derivative thereof, a wound healing agent, and a wart remover.
19. The composition of any of claims 1 to 18, further comprising an additional component, which is an anti-perspirant, an anti-static agent, a buffering agent, a bulking agent, a chelating agent, a colorant, a conditioner, a deodorant, a diluent, a dye, an emollient, fragrance, a humectant, a moisturizer, an occlusive agent, a penetration enhancer, a perfuming agent, a permeation enhancer, a pH-adjusting agent, a preservative, a skin penetration enhancer, a sunscreen, a sun blocking agent, a sunless tanning agent, a vitamin, or a mixture of any two or more thereof.
20. A composition according to any of claims 15 to 19, wherein a polymeric agent comprises at least one of locust bean gum, sodium alginate, sodium caseinate, egg albumin, gelatin agar, carrageenin gum, sodium alginate, xanthan gum, quince seed extract, tragacanth gum, guar gum, a cationic guar, hydroxypropyl guar gum, starch, an amine-bearing polymer, chitosan, alginic acid, hyaluronic acid, a chemically modified starch, a carboxyvinyl polymer, a polyvinylpyrrolidone, a polyvinyl alcohol, a polyacrylic acid polymer, a polymethacrylic acid polymer, a polyvinyl acetate, a polyvinyl chloride polymer, a polyvinylidene chloride polymer, a methylcellulose, a hydroxypropyl cellulose, a hydroxypropyl methylcellulose, a hydroxyethyl cellulose, a hydroxypropyl methyl cellulose, a methylhydroxyethylcellulose, a methylhydroxypropylcellulose, a hydroxyethylcarboxymethylcellulose, a carboxymethyl cellulose, a carboxymethylcellulose, a carboxymethylhydroxyethylcellulose, a cationic cellulose, a ployethylene glycol, xanthan gum, a sodium carboxymethylcellulose, microcrystalline-cellulose, aluminum starch octyl succinate, and a polyacrylate.
21. The composition of any of claims 1 to 20, wherein upon dispensing as a foam, has a density of about 0.01 to about 0.2 g/ml.
22. A topical composition according to any of claims 1 to 21, containing a sensation or sensation modifying comprising at least one of:
a. a combination of a cooling and a warming agent, b. a combination of a cooling and a soothing or relaxing agent;
c. a combination of a cooling and a stimulating or refreshing agent;
d. a combination of a warming and a stimulating or refreshing agent;
e. a combination of a warming and a soothing or relaxing agent;
f. a combination of a cooling, a warming and a soothing or relaxing agent;
and g. a combination of a cooling, a warming and stimulating or refreshing agent.
a. a combination of a cooling and a warming agent, b. a combination of a cooling and a soothing or relaxing agent;
c. a combination of a cooling and a stimulating or refreshing agent;
d. a combination of a warming and a stimulating or refreshing agent;
e. a combination of a warming and a soothing or relaxing agent;
f. a combination of a cooling, a warming and a soothing or relaxing agent;
and g. a combination of a cooling, a warming and stimulating or refreshing agent.
23. A topical composition according to any of claims 1 to 17, and 19 to 22, containing:
a. a sensation or sensation modifying agent comprising menthol at a concentration of 0.5 to about 3% by weight of the composition;
b. at least one additional active agent comprising i. coal tar or coal tar extract at a concentration of about 2% to about 20% by weight of the composition; and ii. at least one other active agent comprising salicylic acid, hydrocortisone, or both, in a concentration of about 0 5% to about 10% by weight of the composition.
a. a sensation or sensation modifying agent comprising menthol at a concentration of 0.5 to about 3% by weight of the composition;
b. at least one additional active agent comprising i. coal tar or coal tar extract at a concentration of about 2% to about 20% by weight of the composition; and ii. at least one other active agent comprising salicylic acid, hydrocortisone, or both, in a concentration of about 0 5% to about 10% by weight of the composition.
24. A composition for providing a subject with at least one sensation for a sustained period of time, the composition comprising:
a. coal tar or coal tar extract;
b. a mixture of mint and peppermint oil;
c. a silicone oil;
d. a surfactant;
e. a buffering system; and f. a propellant at a concentration of about 3% to about 45% by weight of the total composition, wherein the composition is stored in an aerosol container and upon release expands to form a short term stable foam.
a. coal tar or coal tar extract;
b. a mixture of mint and peppermint oil;
c. a silicone oil;
d. a surfactant;
e. a buffering system; and f. a propellant at a concentration of about 3% to about 45% by weight of the total composition, wherein the composition is stored in an aerosol container and upon release expands to form a short term stable foam.
25. A composition for providing a subject with at least one sensation for a sustained period of time, the composition comprising:
a. coal tar or coal tar extract;
b. a mixture of mint and peppermint oil;
c. a triglyceride;
d. a surfactant;
e. a buffering system; and f. a propellant at a concentration of about 3% to about 45% by weight of the total composition, wherein the composition is stored in an aerosol container and upon release expands to form a short term stable foam.
a. coal tar or coal tar extract;
b. a mixture of mint and peppermint oil;
c. a triglyceride;
d. a surfactant;
e. a buffering system; and f. a propellant at a concentration of about 3% to about 45% by weight of the total composition, wherein the composition is stored in an aerosol container and upon release expands to form a short term stable foam.
26. A composition for providing a subject with at least one sensation for a sustained period of time, the composition comprising:
a. coal tar or coal tar extract;
b. a mixture of mint and peppermint oil;
c. a silicone oil and a triglyceride;
d. a surfactant;
e. a buffering system; and f. a propellant at a concentration of about 3% to about 45% by weight of the total composition, wherein the composition is stored in an aerosol container and upon release expands to form a short term stable foam.
a. coal tar or coal tar extract;
b. a mixture of mint and peppermint oil;
c. a silicone oil and a triglyceride;
d. a surfactant;
e. a buffering system; and f. a propellant at a concentration of about 3% to about 45% by weight of the total composition, wherein the composition is stored in an aerosol container and upon release expands to form a short term stable foam.
27. A composition according to any of claims 24 to 26, wherein the buffering system comprises an EDTA, a citrate buffer, or a mixture thereof.
28. A composition according to any of claims 24 to 27, wherein the composition further comprises a polymeric agent, a foam adjuvant, or a combination thereof.
29. A composition according to any of claims 24 to 28, wherein the composition further comprises a penetrating agent, a humectant, or a combination thereof.
30. A composition according to any of claims 24 to 29, wherein the coal tar or coal tar extract is present in the composition at a concentration of about 2% to about 20% by weight.
31. A composition according to any of claims 24 to 30, wherein the surfactant is present in the composition at a concentration of about 2% to about 8.5% by weight.
32. A waterless composition for providing a subject with at least one sensation at a delivery site for a sustained period of time, the composition comprising:
a. about 10% by weight of a cooling agent;
b. about 81 % to about 83% by weight of a glycol;
c. about 6% by weight of one or more surfactants;
d. about 1% by weight of a polymeric agent, and e. a propellant at a concentration of about 3% to about 45% by weight of the total composition, wherein the composition is stored in an aerosol container and upon release expands to form a short term stable foam.
a. about 10% by weight of a cooling agent;
b. about 81 % to about 83% by weight of a glycol;
c. about 6% by weight of one or more surfactants;
d. about 1% by weight of a polymeric agent, and e. a propellant at a concentration of about 3% to about 45% by weight of the total composition, wherein the composition is stored in an aerosol container and upon release expands to form a short term stable foam.
33. The composition of claim 32, wherein the cooling agent is peppermint oil or menthol crystals.
34. The composition of claim 32 or claim 33, wherein the glycol is propylene glycol.
35. The composition of any of claims 32 to 34, wherein the surfactant comprises steareth 2, polysorbate 80, glyceryl monostearate, or mixtures thereof.
36. The composition of any of claims 32 to 35, wherein the polymeric agent is hydroxypropyl cellulose.
37. The composition of any of claims 32 to 36, further comprising a foam adjuvant.
38. The composition of claim 37, wherein the foam adjuvant is cetostearyl alcohol.
39. A waterless composition for providing a subject with at least one sensation at a delivery site for a sustained period of time, the composition comprising a. about 0 03% by weight of a warming agent;
b. about 97 97% by weight of a glycol;
c. about 2% by weight of one or more surfactants; and d. a propellant at a concentration of about 3% to about 45% by weight of the total composition, wherein the composition is stored in an aerosol container and upon release expands to form a short term stable foam.
b. about 97 97% by weight of a glycol;
c. about 2% by weight of one or more surfactants; and d. a propellant at a concentration of about 3% to about 45% by weight of the total composition, wherein the composition is stored in an aerosol container and upon release expands to form a short term stable foam.
40. The composition of claim 39, wherein the warming agent is capsaicin.
41. The composition of claim 39 or claim 40, wherein the glycol is propylene glycol.
42. The composition of any of claims 39 to 41, wherein the surfactant is steareth 2.
43. A composition for providing a subject with at least one sensation at a delivery site for a sustained period of time, the composition comprising a. about 10% by weight of a warming agent comprising ginger;
b. about 81% to about 85% by weight of water;
c. about 4.5% to about 6% by weight of one or more surfactants;
d. about 0.6% by weight of a polymeric agent;
e. optionally, about 2% by weight of a foam adjuvant; and f. a propellant at a concentration of about 3% to about 45% by weight of the total composition, wherein the composition is stored in an aerosol container and upon release expands to form a short term stable foam.
b. about 81% to about 85% by weight of water;
c. about 4.5% to about 6% by weight of one or more surfactants;
d. about 0.6% by weight of a polymeric agent;
e. optionally, about 2% by weight of a foam adjuvant; and f. a propellant at a concentration of about 3% to about 45% by weight of the total composition, wherein the composition is stored in an aerosol container and upon release expands to form a short term stable foam.
44. The composition of claim 43, wherein the warming agent comprises ginger oil.
45. The composition of claim 43 or claim 44, wherein the surfactant comprises steareth 2, steareth 21, polysorbate 80, glyceryl monostearate, PEG-40 stearate, or a mixture thereof.
46. The composition of any of claims 43 to 45, wherein the polymeric agent comprises xanthan gum, Methocell K100M, or a mixture thereof.
47. The composition of any of claims 43 to 46, wherein the foam adjuvant comprises cetostearyl alcohol.
48. A composition for providing a subject with at least one sensation at a delivery site for a sustained period of time, the composition comprising:
a. about 2% by weight of aloe vera;
b. about 90% to about 94% by weight of a polar solvent;
c. about 2% to about 4% by weight of one or more surfactants; and d. about 2% to about 4% by weight of a polymeric agent.
a. about 2% by weight of aloe vera;
b. about 90% to about 94% by weight of a polar solvent;
c. about 2% to about 4% by weight of one or more surfactants; and d. about 2% to about 4% by weight of a polymeric agent.
49. The composition of claim 48 wherein the composition further comprises a propellant at a concentration of about 3% to about 45% by weight of the total composition, wherein the composition is stored in an aerosol container and upon release expands to form a short term stable foam.
50. The composition of claim 48 or claim 49, wherein the polar solvent comprises water, diethylene glycol monoethyl ether, or a mixture thereof.
51. The composition of any of claims 48 to 50, wherein the surfactant comprises polysorbate.
52. The composition of any of claims 48 to 51, wherein the polymeric agent comprises Avicel RC581.
53. A composition for providing a subject with at least one sensation at a delivery site for a sustained period of time, the composition comprising:
a. about 2% by weight of aloe vera;
b. about 77% by weight of a polar solvent;
c. about 11 % by weight of a hydrophobic carrier;
d. about 7% by weight of one or more surfactants;
e. about 2% by weight of a foam adjuvant;
f. about 0.6% of a polymeric agent; and g. a propellant at a concentration of about 3% to about 45% by weight of the total composition, wherein the composition is stored in an aerosol container and upon release expands to form a short term stable foam.
a. about 2% by weight of aloe vera;
b. about 77% by weight of a polar solvent;
c. about 11 % by weight of a hydrophobic carrier;
d. about 7% by weight of one or more surfactants;
e. about 2% by weight of a foam adjuvant;
f. about 0.6% of a polymeric agent; and g. a propellant at a concentration of about 3% to about 45% by weight of the total composition, wherein the composition is stored in an aerosol container and upon release expands to form a short term stable foam.
54. The composition of claim 53, wherein the surfactant comprises steareth 2, steareth 21, or a mixture thereof.
55. The composition of any of claims 53 or claim 54, wherein the polar solvent comprises water.
56. The composition of any of claims 53 to 55, wherein the polymeric agent comprises xanthan gum, Methocell K100M, or a mixture thereof.
57. The composition of any of claims 53 to 56, wherein the foam adjuvant comprises cetostearyl alcohol.
58. The composition according to any of claims 24 to 31, further comprising a hydrophobic solvent, wherein the combination of the additional hydrophobic solvent and silicone oil, the combination of the additional hydrophobic solvent and triglyceride, or the combination of the additional hydrophobic solvent, silicone oil, and triglyceride, is present in the composition at about 6% to about 22% by weight of the composition.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/971,197 US20080253973A1 (en) | 2002-10-25 | 2008-01-08 | Sensation modifying topical composition foam |
| US11/971,197 | 2008-01-08 | ||
| PCT/IB2009/005005 WO2009087578A2 (en) | 2008-01-08 | 2009-01-08 | Sensation modifying topical composition foam |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2711703A1 true CA2711703A1 (en) | 2009-07-16 |
Family
ID=40853523
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2711703A Abandoned CA2711703A1 (en) | 2008-01-08 | 2009-01-08 | Sensation modifying topical composition foam |
Country Status (3)
| Country | Link |
|---|---|
| CA (1) | CA2711703A1 (en) |
| WO (1) | WO2009087578A2 (en) |
| ZA (1) | ZA201005630B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014117265A1 (en) * | 2013-02-01 | 2014-08-07 | Ddrops Company | Liquid menthol compositions |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8512718B2 (en) | 2000-07-03 | 2013-08-20 | Foamix Ltd. | Pharmaceutical composition for topical application |
| IL152486A0 (en) | 2002-10-25 | 2003-05-29 | Meir Eini | Alcohol-free cosmetic and pharmaceutical foam carrier |
| US9265725B2 (en) | 2002-10-25 | 2016-02-23 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
| US8900554B2 (en) | 2002-10-25 | 2014-12-02 | Foamix Pharmaceuticals Ltd. | Foamable composition and uses thereof |
| US7704518B2 (en) | 2003-08-04 | 2010-04-27 | Foamix, Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
| US10117812B2 (en) | 2002-10-25 | 2018-11-06 | Foamix Pharmaceuticals Ltd. | Foamable composition combining a polar solvent and a hydrophobic carrier |
| US9211259B2 (en) | 2002-11-29 | 2015-12-15 | Foamix Pharmaceuticals Ltd. | Antibiotic kit and composition and uses thereof |
| JP2006505583A (en) | 2002-10-25 | 2006-02-16 | フォーミックス エルティーディー. | Cosmetic and pharmaceutical foam |
| US9668972B2 (en) | 2002-10-25 | 2017-06-06 | Foamix Pharmaceuticals Ltd. | Nonsteroidal immunomodulating kit and composition and uses thereof |
| US8119109B2 (en) | 2002-10-25 | 2012-02-21 | Foamix Ltd. | Foamable compositions, kits and methods for hyperhidrosis |
| US20080138296A1 (en) | 2002-10-25 | 2008-06-12 | Foamix Ltd. | Foam prepared from nanoemulsions and uses |
| US8486376B2 (en) | 2002-10-25 | 2013-07-16 | Foamix Ltd. | Moisturizing foam containing lanolin |
| US7820145B2 (en) | 2003-08-04 | 2010-10-26 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
| US8119150B2 (en) | 2002-10-25 | 2012-02-21 | Foamix Ltd. | Non-flammable insecticide composition and uses thereof |
| US7700076B2 (en) | 2002-10-25 | 2010-04-20 | Foamix, Ltd. | Penetrating pharmaceutical foam |
| US7575739B2 (en) | 2003-04-28 | 2009-08-18 | Foamix Ltd. | Foamable iodine composition |
| US8486374B2 (en) | 2003-08-04 | 2013-07-16 | Foamix Ltd. | Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses |
| US8795693B2 (en) | 2003-08-04 | 2014-08-05 | Foamix Ltd. | Compositions with modulating agents |
| WO2006100154A1 (en) | 2005-03-24 | 2006-09-28 | Nolabs Ab | Cosmetic treatment with nitric oxide, device for performing said treatment and manufacturing method therefor |
| US20080260655A1 (en) | 2006-11-14 | 2008-10-23 | Dov Tamarkin | Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses |
| US8636982B2 (en) | 2007-08-07 | 2014-01-28 | Foamix Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
| WO2009069006A2 (en) | 2007-11-30 | 2009-06-04 | Foamix Ltd. | Foam containing benzoyl peroxide |
| WO2010041141A2 (en) | 2008-10-07 | 2010-04-15 | Foamix Ltd. | Oil-based foamable carriers and formulations |
| WO2009090495A2 (en) | 2007-12-07 | 2009-07-23 | Foamix Ltd. | Oil and liquid silicone foamable carriers and formulations |
| AU2009205314A1 (en) | 2008-01-14 | 2009-07-23 | Foamix Ltd. | Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses |
| WO2010125470A2 (en) | 2009-04-28 | 2010-11-04 | Foamix Ltd. | Foamable vehicle and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
| CA2769625C (en) | 2009-07-29 | 2017-04-11 | Foamix Ltd. | Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses |
| WO2011013008A2 (en) | 2009-07-29 | 2011-02-03 | Foamix Ltd. | Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses |
| WO2011022680A2 (en) | 2009-08-21 | 2011-02-24 | Novan, Inc. | Wound dressings, methods of using the same and methods of forming the same |
| WO2011022652A1 (en) | 2009-08-21 | 2011-02-24 | Novan, Inc. | Topical gels |
| US9849142B2 (en) | 2009-10-02 | 2017-12-26 | Foamix Pharmaceuticals Ltd. | Methods for accelerated return of skin integrity and for the treatment of impetigo |
| US8945516B2 (en) | 2009-10-02 | 2015-02-03 | Foamix Pharmaceuticals Ltd. | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
| BR112012030653B1 (en) * | 2010-06-11 | 2021-10-13 | Leo Pharma A/S | TOPICAL AEROSOL COMPOSITION AND PRESSURIZED CONTAINER |
| BR112014000178A2 (en) | 2011-07-05 | 2017-02-07 | Novan Inc | topical compositions |
| WO2013006613A1 (en) | 2011-07-05 | 2013-01-10 | Novan, Inc. | Methods of manufacturing topical compositions and apparatus for same |
| CN104302175B (en) | 2012-03-14 | 2017-04-12 | 诺万公司 | Nitric oxide releasing pharmaceutical compositions |
| ES2701758T3 (en) | 2013-02-27 | 2019-02-25 | Symrise Ag | Ginger extract for the protection of stem cells |
| US9855211B2 (en) | 2013-02-28 | 2018-01-02 | Novan, Inc. | Topical compositions and methods of using the same |
| KR102428738B1 (en) | 2013-08-08 | 2022-08-02 | 노반, 인크. | Topical compositions and methods of using the same |
| EP3698775A1 (en) | 2014-07-11 | 2020-08-26 | Novan Inc. | Topical antiviral compositions and methods of using the same |
| US10322082B2 (en) | 2014-07-11 | 2019-06-18 | Novan, Inc. | Topical antiviral compositions and methods of using the same |
| US10925689B2 (en) | 2014-07-14 | 2021-02-23 | Novan, Inc. | Nitric oxide releasing nail coating compositions, nitric oxide releasing nail coatings, and methods of using the same |
| CA2919733A1 (en) | 2014-08-08 | 2016-02-08 | Novan, Inc. | Topical compositions and methods of using the same |
| EP3097905B1 (en) | 2015-05-28 | 2020-11-04 | Symrise AG | Cosmetic compositions |
| US10849864B2 (en) | 2015-07-28 | 2020-12-01 | Novan, Inc. | Combinations and methods for the treatment and/or prevention of fungal infections |
| ITUB20160058A1 (en) * | 2016-01-19 | 2017-07-19 | Farm S R L C U S | Composition of a preparation for the treatment of insect bites with vasoconstrictive, soothing, anti-inflammatory and anti-reddening activity |
| KR102319497B1 (en) | 2016-03-02 | 2021-11-01 | 노반, 인크. | Composition for treating inflammation and method for treating inflammation |
| CN116585257A (en) | 2016-04-13 | 2023-08-15 | 诺万公司 | Compositions, systems, kits and methods for treating infections |
| US20190117547A1 (en) | 2016-05-30 | 2019-04-25 | Symrise Ag | Cosmetic compositions comprising sclareolide |
| CN109641025A (en) | 2016-05-30 | 2019-04-16 | 西姆莱斯股份公司 | Drug containing race CO2 extract |
| EP3478251A1 (en) | 2016-06-30 | 2019-05-08 | Symrise AG | Medicament and cosmetic composition comprising resorcinol derivatives |
| MX377365B (en) | 2016-09-08 | 2025-03-10 | Journey Medical Corp | COMPOSITIONS AND METHODS FOR TREATING ROSACEA AND ACNE. |
| WO2018053213A1 (en) * | 2016-09-19 | 2018-03-22 | The Procter & Gamble Company | Foam compositions, aerosol products, and methods of using the same to improve sensory benefits to the skin |
| CN110149795B (en) * | 2016-12-02 | 2023-10-03 | 西姆莱斯股份公司 | cosmetic mixture |
| JP2021515807A (en) | 2018-03-01 | 2021-06-24 | ノーバン,インク. | Nitric oxide-releasing suppositories and methods of their use |
| WO2019175290A1 (en) | 2018-03-13 | 2019-09-19 | Beckley Canopy Therapeutics Limited | Cannabis or cannabis derived compositions for promoting cessation of chemical dependence |
| BR112022004141A2 (en) * | 2019-09-20 | 2022-05-31 | Unilever Ip Holdings B V | non-therapeutic use |
| WO2021204568A1 (en) | 2020-04-07 | 2021-10-14 | Universität Basel | A topical composition for treatment of pruritus |
| US20250073142A1 (en) * | 2023-09-06 | 2025-03-06 | Colgate-Palmolive Company | Personal Care Compositions |
| WO2025159776A1 (en) * | 2024-01-22 | 2025-07-31 | Chattem, Inc. | Fast acting itch relief cooling spray |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0414920T3 (en) * | 1989-03-17 | 1997-12-15 | Taisho Pharmaceutical Co Ltd | Aerosol preparations for external use |
| ATE124860T1 (en) * | 1989-07-28 | 1995-07-15 | Hisamitsu Pharmaceutical Co | FOAM AEROSOL COMPOSITION. |
| WO1992011839A1 (en) * | 1991-01-08 | 1992-07-23 | Leonard Mackles | Anhydrous aerosol |
| EP0993827A4 (en) * | 1997-06-13 | 2006-07-05 | Taisho Pharmaceutical Co Ltd | AEROSOLS |
| JP4394775B2 (en) * | 1999-09-03 | 2010-01-06 | 株式会社ダイゾー | Water-in-oil foam aerosol composition and method for producing the same |
-
2009
- 2009-01-08 WO PCT/IB2009/005005 patent/WO2009087578A2/en not_active Ceased
- 2009-01-08 CA CA2711703A patent/CA2711703A1/en not_active Abandoned
-
2010
- 2010-08-04 ZA ZA2010/05630A patent/ZA201005630B/en unknown
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014117265A1 (en) * | 2013-02-01 | 2014-08-07 | Ddrops Company | Liquid menthol compositions |
| US9999602B2 (en) | 2013-02-01 | 2018-06-19 | Ddrops Company | Liquid menthol compositions |
| AU2014211953B2 (en) * | 2013-02-01 | 2018-08-02 | Ddrops Company | Liquid menthol compositions |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009087578A2 (en) | 2009-07-16 |
| ZA201005630B (en) | 2011-08-31 |
| WO2009087578A3 (en) | 2010-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9320705B2 (en) | Sensation modifying topical composition foam | |
| CA2711703A1 (en) | Sensation modifying topical composition foam | |
| US11103454B2 (en) | Wax foamable vehicle and pharmaceutical compositions thereof | |
| US8119109B2 (en) | Foamable compositions, kits and methods for hyperhidrosis | |
| US10322085B2 (en) | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof | |
| US9439857B2 (en) | Foam containing benzoyl peroxide | |
| US20120156144A1 (en) | Foamable Compositions, Kits and Methods for Hyperhidrosis | |
| EP2494959B1 (en) | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof | |
| US7645803B2 (en) | Saccharide foamable compositions | |
| US20080152596A1 (en) | Polypropylene glycol foamable vehicle and pharmaceutical compositions thereof | |
| US20070292359A1 (en) | Polypropylene glycol foamable vehicle and pharmaceutical compositions thereof | |
| US20150025060A1 (en) | Foamable Compositions and Kits Comprising One or More of a Channel Agent, a Cholinergic Agent, A nitric Oxide Donor and Related Agents and Their Uses | |
| US20090130029A1 (en) | Glycerol ethers vehicle and pharmaceutical compositions thereof | |
| WO2008038140A2 (en) | Foamable vehicle comprising polypropylene glycol alkyl ether and pharmaceutical compositions thereof | |
| HK1175403B (en) | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20140106 |
|
| FZDE | Dead |
Effective date: 20160804 |